Novel benzopyran or thiobenzopyran derivatives

ABSTRACT

The present invention relates to a novel benzopyran or thiobenzopyran derivative represented by formula (1): pharmaceutically acceptable salt or stereoisomer thereof, in which X, R 1 , R 2 , R 3 , R 4  and A are defined as described in the specification, and to a process for preparation thereof and a pharmaceutical composition having anti-estrogenic activity which contains the compound (1) as an active component.

TECHNICAL FIELD

[0001] The present invention relates to a novel benzopyran or thiobenzopyran derivative having anti-estrogenic activity. More specifically, the present invention relates to a novel benzopyran or thiobenzopyran derivative represented by the following formula (1):

[0002] pharmaceutically acceptable salt or stereoisomer thereof, in which

[0003] X represents O or S,

[0004] R₁ represents hydrogen, hydroxy, or —OR₆ (wherein R₆ represents acyl or alkyl),

[0005] R₂ represents phenyl which is optionally substituted by one or more substituents selected from a group consisting of hydroxy, lower alkyl, halogen, nitro, hydroxymethyl, carboxy, alkoxycarbonyl, —OR₆ (wherein R₆ represents acyl or alkyl) and amino which is optionally substituted by one or two lower alkyl; or represents 5- or 6membered unsaturated heterocycle containing nitrogen, oxygen or sulfur as the hetero atom,

[0006] R₅ represents hydrogen or lower alkyl, provided that R₃ does not exist when

is a double bond (wherein

represents a single bond or a double bond),

[0007] R₄ represents hydrogen or lower alkyl,

[0008] A represents hydrogen; hydroxyalkyl; carboxyalkyl; carboxyvinylphenyl; pyrrole substituted by carboxyvinylbenzyl; or represents a group selected from the following formulae (a) to (1);

[0009] in the above formulae (a) to (1)

[0010] m₁ to m₃ independently of one another represent an integer of 0 to 15,

[0011] n₁ to n₂ independently of one another represent an integer of 0, 1 or 2,

[0012] R₅ represents cyano; alkyl; halogenoalkyl; alkoxy; hydroxy; carboxy; alkoxycarbonyl; carbamoyl; monoalkylamino; phenyl which is optionally substituted by one or more substituents selected from a group consisting of straight-chain or branched alkyl, carboxy and cyano; piperidinyl which is optionally substituted by one or more substituents selected from a group consisting of carboxy, alkyl and alkoxycarbonyl; cyclohexyl which is optionally substituted by carboxy; imidazolyl; dialkylamino; or piperidinyl oxide,

[0013] D¹ and D² independently of one another represent a direct bond, or a group selected from the following:

[0014] wherein

[0015] m, m₁ and m₂ independently of one another represent an integer of 0 to 15, and

[0016] R₅ is defined as previously described,

[0017] and to a process for preparation thereof and a pharmaceutical composition having anti-estrogenic activity which contains the compound (1) as an active component.

BACKGROUND ART

[0018] In treating diseases caused by the abnormal tissue growth depending on a certain sexual steroidal hormone such as estrogen, it is very important to significantly inhibit, if possible, to completely remove the effect induced by said sexual steroidal hormone. For this purpose, it is desirable to block the receptor site which can-be stimulated by sexual steroidal hormone and further, to reduce the level of sexual steroidal hormone capable of acting on said receptor site. For instance, as a substitution or combined therapy, administration of anti-estrogenic agents to limit the production of estrogen to the amount less than required to activate the receptor site may be used. However, prior methods for blocking the estrogen production could not sufficiently inhibit the effect induced through estrogen receptor. Practically, even when estrogen is completely absent, some of the receptors may be activated. Accordingly, it was considered that antagonists for estrogen can provide better therapeutic effect in comparison to the method for blocking only the production of sexual steroidal hormone. Thus, numerous anti-estrogenic compounds have been developed. For example, many patent publications including U.S. Pat. Nos. 4,760,061, 4,732,912, 4,904,661, 5,395,842 and WO 96/22092, etc. disclose various anti-estrogenic compounds. However, prior antagonists have sometimes insufficient affinity to the receptors. In some cases, moreover, they can combine to the receptor but act themselves as agonists, and therefore, activate rather than block the receptor. For example, Tamoxifen has been most widely used as an anti-estrogenic agent. However, it has a disadvantage that it exhibits estrogenic activity in some organs (see, M. Harper and A. Walpole, J. Reprod. Fertil., 1967, 13, 101). Therefore, it is required to develop the anti-estrogenic compound which has substantially or completely no agonistic effect and can effectively block the estrogenic receptor.

[0019] In addition, it has been known that 7 a -substituted derivatives of estradiol, for example, 7α4-(CH₂)₁₀CONMeBu derivative, exhibit anti-estrogenic activity (see, EP Appl. 0138504, U.S. Pat. No. 4,659,516). Further, estradiol derivative having —(CH₂)₉SOC₅H₆F₅ substituent has also been disclosed (see, Wakeling et al., Cancer Res., 1991, 51, 3867) as steroidal anti-estrogenic agent without agonistic effect.

[0020] Non-steroidal anti-estrogenic drug without agonistic effect has been first reported by Wakeling et al. in 1987 (see, A. Wakeling and J. Bowler, J. Endocrinol., 1987, 112, R₇). Meanwhile, U.S. Pat. No. 4,904,661 (ICI, Great Britain) discloses a phenol derivative having anti-estrogenic activity. This phenol derivative generally has a tetrahydronaphthalene structure and includes, typically, the following compounds:

[0021] As other non-steroidal anti-estrogenic compounds, WO 93/10741 discloses a benzopyran derivative having aminoethoxyphenyl substituent (Endorecherche), of which the typical compound is EM-343 having the following structure:

[0022] Accordingly, the present inventors have researched the anti-estrogenic activity of compounds having various structures. As a result, we have identified that the benzopyran or thiobenzopyran derivatives represented by formula (1), as defined above, can exhibit a good anti-estrogenic activity without agonistic activity, to be expected no undesirable side effect and thus, completed the present invention.

DISCLOSURE OF THE INVENTION

[0023] Therefore, the present invention relates to a novel benzopyran or thiobenzopyran derivative represented by the following formula (1):

[0024] pharmaceutically acceptable salt or stereoisomer thereof, in which

[0025] X represents O or S,

[0026] R₁ represents hydrogen, hydroxy, or —OR₆ (wherein R₆ represents acyl or alkyl),

[0027] R₂ represents phenyl which is optionally substituted by one or more substituents selected from a group consisting of hydroxy, lower alkyl, halogen, nitro, hydroxymethyl, carboxy, alkoxycarbonyl, —OR₆ (wherein R₆ represents acyl or alkyl) and amino which is optionally substituted by one or two lower alkyl; or represents 5- or 6-membered unsaturated heterocycle containing nitrogen, oxygen or sulfur as the hetero atom,

[0028] R₃ represents hydrogen or lower alkyl, provided that R₃ does not exist when

is a double bond (wherein

represents a single bond or a double bond),

[0029] R₄ represents hydrogen or lower alkyl,

[0030] A represents hydrogen; hydroxyalkyl; carboxyalkyl; carboxyvinylphenyl; pyrrole substituted by carboxyvinylbenzyl; or represents a group selected from the following formulae (a) to (1);

[0031] in the above formulae (a) to (1)

[0032] m₁ to m₃ independently of one another represent an integer of 0 to 15,

[0033] n₁ to n₂ independently of one another represent an integer of 0, 1 or 2,

[0034] R₅ represents cyano; alkyl; halogenoalkyl; alkoxy; hydroxy; carboxy; alkoxycarbonyl; carbamoyl; monoalkylamino; phenyl which is optionally substituted by one or more substituents selected from a group consisting of straight-chain or branched alkyl, carboxy and cyano; piperidinyl which is optionally substituted by one or more substituents selected from a group consisting of carboxy, alkyl and alkoxycarbonyl; cyclohexyl which is optionally substituted by carboxy; imidazolyl; dialkylamino; or piperidinyl oxide,

[0035] D¹ and D² independently of one another represent a direct bond, or a group selected from the following:

[0036] wherein

[0037] m, m₁ and m₂ independently of one another represent an integer of 0 to 15. and

[0038] R₅ is defined as previously described.

[0039] In addition, the present invention also relates to processes for preparing the benzopyran or thiobenzopyran derivative of formula (1).

[0040] Further, the present invention relates to a pharmaceutical composition having anti-estrogenic activity, which contains the compound of formula (1) as an active component.

BEST MODE FOR CARRYING OUT THE INVENTION

[0041] In the present specification, the term “lower alkyl” denotes straight-chain or branched saturated hydrocarbon radicals having 1 to 6, preferable 1 to 4, carbon aoms; the term “halogenoalkyl” denotes straight-chain or branched saturated hydrocarbon radicals having halogen atoms such as fluorine, chlorine, bromine, etc., preferably fluorine atom; and the term “alkyl” denotes straight-chain or branched saturated hydrocarbon radicals having 1 to 12 carbon atoms including lower alkyl as defined above.

[0042] The compound of formula (1) according to the present invention can form a pharmaceutically acceptable salt. Such salt includes a salt with pharmaceutically acceptable acids such as asparagic acid, gluconic acid, hydrochloric acid, p-toluenesulfonic acid or citric acid, etc., a salt with bases such as pyridine or ammonia, etc., and a salt with acids or bases which are generally known and conventionally used in the technical field to which the benzopyran or thiobenzopyran derivative pertains. These pharmaceutically acceptable salts can be prepared according to a conventional conversion method.

[0043] In the compound of formula (1) wherein the bond between 3- and 4-positions of benzopyran or thiobenzopyran ring is a single bond, the two carbon atoms of 3- and 4-positions of the ring can be asymmetric, and thus the compound of formula (1) can exist as a pure stereoisomer such as enantiomer of R or S, diastereomer, etc., or a mixture thereof including racemate. Therefore, the present invention also includes each of these stereoisomers and their mixtures.

[0044] Among the novel compound of formula (1) according to the present invention, the preferred compounds include those wherein

[0045] X represents O or S,

[0046] R₁ represents hydroxy,

[0047] R₂ represents phenyl which is optionally substituted by one or more substituents selected from a group consisting of hydroxy, lower alkyl and halogen; or represents 6-membered unsaturated heterocycle containing nitrogen as the hetero atom,

[0048] R₃ represents lower alkyl, provided that R₃ does not exist when

is a double bond,

[0049] R₄ represents hydrogen,

[0050] A represents a group selected from the following formulae (a) to (e), (k) and (1);

[0051] in the above formulae (a) to (e), (k) and (1)

[0052] m₁ to m₃ independently of one another represent an integer of 0 to 15,

[0053] n₁ to n₂ independently of one another represent an integer of 0, 1 or 2,

[0054] R₅ represents alkyl; halogenoalkyl; alkoxy; hydroxy; carboxy; phenyl which is optionally substituted by one or two straight-chain or branched alkyl; or dialkylamino,

[0055] D¹ and D² independently of one another represent a direct bond, or a group selected from the following:

[0056] wherein

[0057] m₁ and m₂ independently of one another represent an integer of 0 to 15, and

[0058] R₅ is defined as previously described.

[0059] As specific example of the compound of formula (1) according to the present invention, the following compounds can be mentioned.

[0060] 7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-{9-[4-(4,4,5,5,5-pentafluoro pentyl)piperazinyl]nonyl}chroman;

[0061] (3RS,4RS)-7-hydroxy-4-[(11-imino-11-N-butylamino)undecyl]-3-(4-hydroxy phenyl)-3-methylchroman;

[0062] (3RS,4RS)-7-hydroxy-4-[(11-N-butylimino-11-N-butylamino)undecyl]-3-(4-hydroxyphenyl)-3-methylchroman;

[0063] (3RS,4SR)-7-hydroxy-4-{4-{2-{4-{[3,5-bis(t-butyl)phenyl]methyl}piperaziny l}ethoxy}-phenyl}-3-(4-hydroxyphenyl)-3-methylchroman;

[0064] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-{5-[N-methyl-N-3-4,4,5,5,5-pentafluoropentylthio)-propylamino]pentyl}-3-methylchroman;

[0065] 4-{4-{2-[2-(4,4,5,5,5-pentafluoropentylsulfinyl)ethoxy]ethoxy phenyl}-7-hydroxy-3-(4-hydroxyphenyl)-2H-chromene;

[0066] (3RS,4RS)-4-[9-(3 dimethylaminopropylsulfinyl)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman;

[0067] (3RS,4RS)-4-[9-(N-4,4,5,5,5-pentafluoropentylaminosulfonylamino)nonyl)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman;

[0068] (3RS,4RS)-{9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]nonylsulfinyl}hexanoic acid;

[0069] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2-methoxy ethoxy)ethylsulfinyl]nonyl}thiochroman;

[0070] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2-hydroxy ethoxy)ethylsulfinyl]nonyl}thiochroman;

[0071] (3RS,4RS)-7-hydroxy-3-(2-methylphenyl)-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentyl)sulfinylnonyl]thiochroman;

[0072] (3RS,4RS)-7-hydroxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-3-4pyridyl)chroman;

[0073] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentyl)sulfonylamino)nonyl]thiochroman;

[0074] (3RS,4RS)-3-(4-fluorophenyl)-7-hydroxy-3-methyl-4-[9-4,4,5,5,5-penta fluoropentylsulfinyl)nonyl]thiochroman;

[0075] (3RS,4RS)-3-(3-fluorophenyl)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentylsulfinyl)nonyl)thiochroman;

[0076] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[N-5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentylamino]propyl}chroman;

[0077] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(N-methyl-N-4,4,5,5,5-pentafluoropentyl)aminononyl]chroman;

[0078] N-methyl-N-(4,4,5,5,5-pentafluoropentyl)-9-[(3RS,4RS)-7-hydroxy-3-4-hydroxyphenyl)-3-methylchroman-4-yl]nonylamine N-oxide;

[0079] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-{4-[2-(4,4,5,5,5-pentafluoropentylsulfinyl)ethoxy]phenoxy}propyl}thiochroman;

[0080] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman;

[0081] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentylaminosulfonyl)nonyl]chroman;

[0082] (3RS,4RS)— 10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid;

[0083] (3′RS,4′RS)-{8-[7-hydroxy-3-(4-hyroxyphenyl)-3-methylthiochroman-4-yl]octyl}-(4,4,5,5,5-pentafluoropentyl)methane-1, -dicarboxylic acid;

[0084] methyl-(3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroma n-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoate;

[0085] (3′RS,4′RS)-2-{8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4yl]octyl}-2-4,4,5,5,5-pentafluoropentyl)propane-1,3-diol;

[0086] (3RS,4RS)-7-hydroxy-3-(4hydroxyphenyl)-3-methyl-4A9-2-aza-2-carbonyl]-(4,4,5,5,5-pentafluoropentylamino)ethenyl)aminononyl)thiochroman;

[0087] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3;methyl-4 (9-(11-(4,4,5,5,5-pentafluoropentyl)amino)-2-nitroethenyl)amino)nonyl)thiochroman;

[0088] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4[8-4,4,5,5,5-penta fluoropentylsulfonylamino)octyl]chroman;

[0089] (3RS,4RS)-7-hydroxy-3-(4-(hydroxyphenyl)-3-methyl-4-[4-4-piperidyl-butyl oxy)phenyl]chroman;

[0090] (3RS,4RS)-7-hydroxy-3-methyl-3-{-4-hydroxyphenyl)-44 (3-(2-4,4,5,5,5-pentafluoropentyl sulfinyl)ethoxy)-(R)-2-hydroxypropyloxy)phenyl)chroman;

[0091] (3RS,4RS)-7-hydroxy-3-(4-hydroxypheny])-3-methyl-4-{[4-(4,4,5,5,5-penta fluoropentylsulfinyl)butyloxy]butyl}chroman;

[0092] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{5-{N-methyl-N-[3{4,4,5,5,5-pentafluoropentyl)sulfiny]propyl) aminopentyl}chroman;

[0093] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{5-{N-methyl-N- oxo-N-[3-(4,4,5,5,5-pentafluoropentyl)sulfiny]propyl}aminopentyl) chroman;

[0094] (3′RS,4′RS)-2-4-(7-hydroxy)-3-(4-hydroxyphenyl)-3-methylchroman-4-yl) butyl-6-(4-(4,4,5,5,5-pentafluoropentyi)sulfinyl)hexanoic acid;

[0095] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(N-cyano-N-pentylcarbonyl)aminononyl]thiochroman;

[0096] (3RS,4RS)-7-hydroxy-344-(hydroxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]chroman;

[0097] (3′RS,4′RS)-6,6,7,7,7-pentafluoro-2-(2-4-(4-(7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl)butyl)phenyloxy)ethyl)heptanoic acid;

[0098] (3RS,4RS)-4-allyl-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman;

[0099] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2,2,2-trifluoro ethoxy)ethylsulfinyl]nonyl) thiochroman;

[0100] (3′RS,4′RS)-8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl] octanoic acid;

[0101] (3′RS,4′RS)—[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl-3 hexanoic acid;

[0102] (3′RS,4′RS)-7-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochrom an-4-yl) heptanoic acid;

[0103] (3RS,4RS)-4-[4,7-dioxa-9-4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman;

[0104] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[6-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman;

[0105] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4f-7-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman;

[0106] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-5-oxa-9-4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman; (3′RS,4′RS)-9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl] nonanoic acid;

[0107] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl] decanoic acid;

[0108] (E)-3-[7-hydroxy-3-(4-hydoxyphenyl)-2H-chromen-4-yl]phenylacrylic acid;

[0109] (3′RS,4′RS)-(E)-3-[7-hydroxy-3-(4-hydoxyphenyl)thiochroman-4-yl]phenyl acrylic acid;

[0110] (3RS,4RS)-4-[9-(4-cyanobutylsulfinyl)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman;

[0111] (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]chroman-3-yl}benzoic acid;

[0112] (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]chroman-3-yl}benzyl alcohol;

[0113] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[3-(4,4,5,5,5-penta fluoropentylsulfinyl)propylphenoxy]-1-propyl) chroman;

[0114] (3RS,4RS)-7-hydroxy-3-{-4-hydroxyphenyl)-3-methyl -4-{3-[3-(4,4,5,5,5-penta fluoropentylsulfonyl)propylphenoxy]-1-propyl}chroman;

[0115] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[4-(4,4,5,5,5-penta fluoropentylsulfinylethyloxy)phenyl]-1-butyl) chroman;

[0116] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[4-4,4,5,5,5-penta fluoropentylsulfonyl-ethyloxy)phenyl]-1-butyl}chroman;

[0117] (3′RS,4′RS)-1-[7-hydroxy-4-(4-hydroxyphenyl)-3-methylchroman-4yl]-14,14,15,15,15-pentafluoropentadecan-10-ol;

[0118] (3RS,4RS)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)- nonyl]-3-(3-pyridyl)chroman;

[0119] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-[9-(4,4,5,5,5-pentafluoropentyl sulfinyl)nonyl]chroman;

[0120] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-(9-oxo-14,14,15,15,15-penta fluoro)pentadecyl-3-methylchroman;

[0121] (3RS,4RS)-7-hydroxy-3-{-4-hydroxyphenyl)-4-{-9-hydroxy-10-hydroxy carbonyl-14,14,15,15,15-pentafluoro)pentadecyl-3-methylchroman;

[0122] (3RS,4RS)-7-hydroxy-4[(10-ethoxycarbonyl-14,14,15,15,15-pentafluoro) pentadec-9-enyl]-3-(4-hydroxyphenyl)-3-methyl chroman;

[0123] 1,1,1,2,2-pentafluoro- 14-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-5-pentadecanone;

[0124] (E)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]nonyl}-2-heptenoic acid;

[0125] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentylsulfonylamino)nonyl]chroman;

[0126] (3RS,4RS)-(E3-{4-[7-hydroxy-3-(4-hydroxyphenyl)thiochromen-4-yl]pheny l}propeneoic acid;

[0127] (3RS,4RS)-(E)-3-{4-[7-hydroxy-3-(4-hydroxyphenyl)thiochroman-4-yl)pheny l}propeneoic acid;

[0128] (3′RS,4′RS)-E)-3-{4-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]phenyl} propeneoic acid;

[0129] (3′RS,4′RS)-N-[2-(4,4,5,5,5-pentafluoropentylsulfinyl)]ethyl-4-{4-[7-hydroxy-3-(4-hydryoxyphenyl)-3-methylchroman-4-yl]butyl}phenyl-N-methylamin;

[0130] 6-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phe noxy}-2-(4,4,5,5,5-pentafluoropentyl)hexanoic acid;

[0131] 7-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phe noxy}-2-4,4,5,5,5-pentafluoropentyl)heptanoic acid;

[0132] 8-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl chroman-4-yl]phe noxy)}-2-(4,4,5,5,5-pentafluoropentyl)octanoic acid;

[0133] 9-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phe noxy}-2-(4,4,5,5,5-pentafluoropentyl)nonanoic acid;

[0134] (3RS,4RS)-9-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4yl-2-(4,4,5,5,5-pentafluoropentyl)nonanoic acid;

[0135] (3RS,4RS)-9-7-hydroxy-3-(4-hydroxyphenyl)-3-thiochroman-4-yl-2-(4,4,5,5,5-pentafluoropentyl)nonanoic acid;

[0136] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-{[11-carboxyl-11-(4A4,5,5,5-pentafluoropentyl)]undecyl}-3-methylthiochroman;

[0137] (3RS,4RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid;

[0138] 9-4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)nonanoic acid;

[0139] 8-[4-[(3RS,4RS)-7-hydroxy-3-(4-hydrdxyphenyl)-3-methylthiochroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)octanoic acid;

[0140] 7-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)heptanoic acid;

[0141] 6-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]phenoxy 3-2-(4,4,5,5,5-pentafluoropentyl)hexanoic acid;

[0142] 5-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phe noxy}-2-(4,4,5,5,5-pentafluoropentyl)pentanoic acid;

[0143] 5-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]phenoxy)-2-(4,4,5,5,5-pentafluoropentyl)pentanoic acid;

[0144] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-4,4,5,5,5-pentafluoropentyl)undecanoic acid;

[0145] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)undecanoic acid;

[0146] (3′RS,4′RS)-12-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-4,4,5,5,5-pentafluoropentyl)dodecanoic acid;

[0147] (3′RS,4′RS)-12-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)dodecanoic acid;

[0148] (3′RS,4′RS)-9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)nonanoic acid;

[0149] (3′RS,4′RS)-9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)nonanoic acid;

[0150] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid;

[0151] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-4,4,5,5,5-pentafluoropentyl)decanoic acid;

[0152] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(3,3,4,4,4-pentafluorobutyl)decanoic acid;

[0153] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-3,3,4,4,4-pentafluorobutyl)decanoic acid;

[0154] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid;

[0155] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid;

[0156] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid;

[0157] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-6,6,7,7,7-pentafluoroheptyl)decanoic acid;

[0158] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(3,3,4,4,4-pentafluorobutyl)undecanoic acid;

[0159] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(3,3,4,4,4-pentafluorobutyl)undecanoic acid;

[0160] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(5,5,6,6,6-pentafluorobexyl)undecanoic acid;

[0161] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid;

[0162] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid;

[0163] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid;

[0164] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-methyl-2-(4,4,5,5,5-pentafluoropentyl)undecanoic acid;

[0165] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-(4,4,5,5,5-pentafluoropentyl)undecanoic acid;

[0166] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-methyl-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid;

[0167] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-(4,4,5,5,S-pentafluoropentyl)decanoic acid;

[0168] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(4,4,5,5,5-pentafluoropentyl)undecanoic acid;

[0169] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(4,4,5,5,5-pentafluoropentyl)undecanoic acid;

[0170] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid;

[0171] (3′RS,4′RS)-10-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-4,4,5,5,5-pentafluoropentyl)decanoic acid;

[0172] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid;

[0173] (3′RS,4′RS)-11-7-hydroxy-344-hydroxyphenyl)-3-methylthiochroman-4--yl)-2-methyl-2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid;

[0174] (3′RS,4′RS)-1-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2 (6,6,7,7,7-pentafluoroheptyl)undecanoic acid;

[0175] (3′RS,4′RS)-1-[7-hydroxy-3-(4hydroxyphenyl)-3-methylthiochroman-4-yl]-2-methyl-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid;

[0176] (3′RS,4′RS)-11-[7-hydroxy-3-{-4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-5,5,6,6,6-pentafluorohexyl)undecanoic acid;

[0177] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid;

[0178] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid;

[0179] (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid;

[0180] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid;

[0181] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-methyl-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid;

[0182] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid;

[0183] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-methyl-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid;

[0184] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid;

[0185] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4yl]-2-ethyl-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid;

[0186] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid; or

[0187] (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid.

[0188] The present invention also provides the following processes I to V for preparing the compound of formula (1) as defined above.

[0189] [Process I]

[0190] First, the compound of formula (1) wherein A represents hydrogen, that is a compound of formula (2):

[0191] wherein X, R₁, R₂, R₃ and R₄ are defined as previously described, can be prepared by the reduction of the ketone of formula (3):

[0192] wherein X, R₃ and R₄ are defined as previously described, and P represents a hydroxy-protecting group.

[0193] In the following processes for preparing the compound of formula (1) according to the present invention including the process for preparing the compound of formula (1) wherein A represents hydrogen, suitable hydroxy-protecting groups and leaving groups which have been conventionally used in the technical field to which the present invention pertains or which can be easily selected by a person skilled in the art may be used. Preferably, methoxymethyl or t-butyldimethylsilyl as the hydroxy-protecting group and tosyloxy, mesyloxy, halo or acetyi as the leaving group can be mentioned.

[0194] Further, if not specifically mentioned, any organic solvents which do not adversely affect the reaction can be used as the solvent in the processes according to the present invention. These solvents may be used under anhydrous condition if such a condition is required due to the nature of the reaction, Only the solvents particularly appropriate are mentioned for the respective reaction steps in the present specification, The reactions. may be carried out under cooling to warming or heating, and the reaction temperature and time are organically combined together to contribute to the reaction completion.

[0195] [Process II]

[0196] The compound of formula (1) wherein A represents hydroxyalkyl, that is a compound of formula (4):

[0197] wherein X, R₁, R₂, R₃, R₄ and; m₁ are defined as previously described, can be prepared using the same procedure described in International Patent Appln No. PCT/KR97/00265.

[0198] [Process III]

[0199] The compound of formula (1) wherein A represents carboxyalkyl, that is a compound of formula (5):

[0200] wherein X, R₁, R₂, R₃, R₄ and ml are defined as previously described, can be prepared by a process characterized in that

[0201] (a) the compound of formula (6):

[0202] wherein X, R₃, R₄, m₁ and P are defined as previously described, is oxidized and deprotected to produce a compound of formula (5a):

[0203] wherein X, R₃, R₄ and m₁ are defined as previously described, or

[0204] (b) the compound of formula (7):

[0205] wherein X, R₃, R₄, m₂ and P are defined as previously described, is reacted with a Wittig reagent and the resulting compound is hydrogenated and deprotected to produce a compound of formula (5a):

[0206] wherein X, Ra, R and m, are defined as previously described.

[0207] [Process IV]

[0208] The compound of formula (1) wherein A represents carboxyvinylphenyl, that is a compound of formula (8):

[0209] wherein X, R₁, R₂, R₃ and R₄ are defined as previously described, can be prepared by a process characterized in that a compound of formula (9):

[0210] wherein X, R₃, R₄ and P are defined as previously described, is reacted with a compound of formula (10).

[0211] wherein L represents acetal or nitrile or protected-hydroxymethyl group, and the resulting compound is deprotected or hydrogenated or dehydrated or oxidized to produce a compound of formula (11):

[0212] wherein X, R₃, R₄ and P are defined as previously described, and the resulting compound of formula (11) is reacted with malonic acid derivative and is deprotected to produce a compound of formula (12):

[0213] wherein X, R₃ and R₄ are defined as previously described.

[0214] [Process V]

[0215] (Method A)

[0216] The compound of formula (1) wherein A represents group (a), that is a compound of formula (Ia):

[0217] wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂ and D¹ are defined as previously be prepared by a process characterized in that of formula (13):

[0218] wherein X, R₃, R₄, m₁ and P are defined as previously described, and W⁴ represents a leaving group, is reacted with a compound of formula (14):

D¹H₂  (14)

[0219] defined as previously described, to produce a compound of formula (15):

[0220] wherein X, R₃, R₄, D¹, m₁ and P are defined as previously described, the resulting compound of formula (15) is reacted with a compound of formula (16):

W²—(CH₂)_(m) ₂ —R₃  (16)

[0221] wherein R₅ and m₂ are defined as previously described, and W² represents a leaving group such as acyl, hydrogen, etc., and then deprotected to produce a compound of formula (1aa):

[0222] wherein X, R₃, R₄, R₅, m₁, m₂ and D¹ are defined as previously described, or (b) the compound of formula (13) is reacted with sodium cyanide to produce a compound of formula (17):

[0223] wherein X, R₅, R₄, m₁ and P are defined as previously described, the resulting compound of formula (17) is reacted with a compound of formula (18):

H₂N—(CH₂)_(m) ₂ —R₅  (18)

[0224] wherein R₅ and m₂ are defined as previously described, in the presence of a Lewis acid to produce a compound of formula (1ab) or (1ac):

[0225] wherein X, R₃, R₄, R₅, m₁ and m₂ are defined as previously described.

[0226] In the method A (a) for preparing the compound of formula (Ia), the coupling step of the compound (13) and (14) may be carried out in a solvent. As the preferable solvent, one or more selected from a group consisting of dioxane, methanol, ethanol, diethylether, tetrahydrofuran, dimethylsulfoxide, methylene chloride, dimethylformamide, chloroform, ethyl acetate, acetonitrile and acetone can be used. This reaction may be carried out optionally in the presence of one or more inorganic or organic bases selected from a group consisting of potassium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, triethylamine and cesium carbonate. The reaction may be suitably proceeded under the reflux temperature of the solvent used or room temperature. if appropriate, under ice-cooling.

[0227] The compound of formula (15) resulted from the coupling of compounds (13) and (14) is reacted with the compound of formula (16) and then deprotected to produce the compound of formula (1aa). This reaction can be carried out in one or more solvents selected from a group consisting of acetone, toluene, dimethylformamide, acetonitrile, dimethylsulfoxide and methylene chloride, optionally in the presence of a base such as potassium carbonate, triethylamine, sodium ethoxide, etc. The deprotection reaction may be carried out according to a conventional method such as hydrolysis in the presence of acid or base, and reduction, etc. Preferably, the deprotection is achieved in the presence of one or more hydrolyzing agents selected from a group consisting of borontribromide, hydrochloric acid, hydrobromic acid, hydrofluoric acid, pyridinium-p-toluenesulfonate and sulfuric acid, or in the presence of one or more reducing agents selected from a group consisting of Pd(OH)₂/C under hydrogen, Pd/C and diisobutylaluminum hydride(DIBAL). This reaction can be carried out under a low temperature to warming, preferably carried out by starting at a low temperature of −78° C. and then warming to room temperature. While, the compound of formula (1aa) thus produced may be further oxidized using metachloroperbenzoic acid (mCPBA) in a solvent such as chloroform.

[0228] In the method A(b), the compound of formula (13) is first reacted with sodium cyanide to produce the compound of formula (17). In this reaction, one or more solvents selected from dimethylsulfoxide, acetonitrile and dimethylformamide can be used. The compound (17) thus produced is reacted with the compound of formula (18) in the presence of a Lewis acid to give the compound of formula (1ab) or (1ac). As the Lewis acid which can be used, AlCl₃, BF₃.Et₂O, SnCl₄, Znl₂ or FeCl₃ can be mentioned, and as the solvent one or more selected from xylene, benzene and toluene can be mentioned. Preferably, the reaction is proceeded at the reflux temperature of the solvent used for 1 to 20 hours.

[0229] (Method A-1)

[0230] The compound of formula (Ia) wherein R₁, R₂, R₃, R and D¹ represent —OH, —C₆H₄ (OH), —Me, H and (—CH(CO₂H)—) respectively may typically be synthesized by the following methods.

[0231] Method A-1a

[0232] wherein X, R₅, m₁, and m₂ are defined as previously described; A₁₀ and A₁₁ are protecting _group such as t-butyldimethylsilyl, triisopropylsilyl, triethylsilyl, t-buthyldiphenylmethylsilyl, methoxymethyl, tertahydropyranyl, methyl, etc.; L₁₀ is a leaving group such as methansulfonyl, p-toluenesulfonyl, etc.; M is a methal such as Li, Na, K, etc.; Y₁₀ is a halogen such as Cl, Br, I, etc.; R₂₀ is alkyl group such as methyl, ethyl, etc.; and mio is an integer of 0 to 12.

[0233] The compound (12aa) may be synthesized in the following manner.

[0234] The compund represented by the formula (26aa) is reacted with acetylene (13aa) in the presence of base such as n-buthyllithium, sec-buthyllithium, sodium hydride, in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, chloroform, preferably in tetrahydrfuran or dioxane, at the temperature between −78° C. and the boiling point of the reaction mixture, preferably at −78° C. through room temperature, to yield the compound represented by the formula (2aa).

[0235] The compound represented by the formula (2aa) is reduced by sodium cyanoborohydride in the presence of Lewis acid such as zinc iodide, in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in dichloroethane at the temperature between −78° C. and the boiling point of the reaction mixture, preferably at 0° C. through room temperature, to yield the compound represented by the formula (3aa).

[0236] The compound represented by the formula (3aa) is hydrogenated with a catalyst such as palladium on activated carbon, palladium hydroxide, platinum oxide, in a solvent inert to the reaction such as methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, dichloroethane, chloroform, preferably in tetrahydrofuran, ethyl acetate at the temperature between room temperature and the boiling point of the reaction mixture, preferably at room temperature, optionally in the presence of sodium hydrogen carbonate, to yield the compound represented by the formula (4aa). The compound represented by the formula (4aa) is also obtained from the compound represented by the formula (2aa) directly by hydrogenation reaction with a catalyst such as palladium on activated carbon, palladium hydroxide or platinum oxide, in a solvent inert to the reaction such as methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in tetrahydrofuran, ethyl acetate at the temperature between room temperature and the boiling point of the reaction mixture, preferably at room temperature.

[0237] The compound represented by the formula (4aa) is treated with tetrabuthylammonium fluoride or cesium fluoride or hydrogen fluoride-pyridine in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in tetrahydrofuran, at the temperature between room temperature and the boiling point of the reaction mixture, preferably at room temperature to yield the compound represented by the formula (5aa).

[0238] The compound represented by the formula (5aa) is treated with methanesulfonyl chloride or p-toluenesulfonylchloride in the presence of an organic base such as triethylamine or pyridine in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in dichloromethane, at the temperature between room temperature and the boiling point of the reaction mixture, preferably at room temperature to yield the compound represented by the formula (6aa).

[0239] The compound represented by the formula (6aa) is treated with metalhalide such as sodium iodide or potassium iodide in a solvent inert to the reaction such as acetone, tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in dichloromethane, at the temperature between room temperature and the boiling point of the reaction mixture, preferably at the boiling point of the reaction mixture, to yield the compound represented by the formula (7aa).

[0240] The compound represented by the formula (7aa) is reacted with malonate such as diethyl malonate or dimethyl malonate in the presence of a base such as sodium hydride, sodium hydroxide or potassium t-butoxide, in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in tetrahydrofuran, at the temperature between room temperature and the boiling point of the reaction mixture to yield the compound represented by the formula (8aa). The compound represented by the formula (8aa) is also obtained from the compound represented by the formula (6aa) directly by the reaction with malonate such as diethyl malonate or dimethyl malonate in the presence of a base such as sodium hydride, sodium hydroxide or potassium t-butoxide, in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in tetrahydrofuran, at the temperature between room temperature and the boiling point of the reaction mixture.

[0241] The compound represented by the formula (8aa) is reacted with alkylhalide as the compound represented by the fomula (14aa) in the presence of a base such as sodium hydride, sodium hydroxide or potassium t-butoxide in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in tetrahydrofuran, at the temperature between room temperature and the boiling point of the reaction mixture to yield the compound represented by the formula (9aa).

[0242] The compound represented by the formula (9aa) is treated with sodium hydroxide or potassium hydroxide in a solvent such as water, ethanol, methanol, a mixture of water-ethanol or a mixture of water-methanol at the temperature between room temperature and the boiling point of the reaction mixture, preferably at the boiling point of the reaction mixture to yield the compound represented by the formula (10aa).

[0243] The compound represented by the formula (10aa) is heated at 50° C. to the boiling point of the reaction mixture in a solvent such as dimethylsulfoxide, dimethylformamide, benzene, toluene, xylene, dioxane or tetrahydrofuran, optionally in the presence of an acid such as hydrogen chloride, sulfuric acid or p-toluenesulfonic acid, to yield the compound represented by the formula (11aa).

[0244] The compound represented by the formula (11aa) is treated with an acid, such as hydrogen chloride, sulfuric acid, hydrogen bromide, hydrogen pyridinium chloride, boron tribromide at the temperature between −78° C. and the boiling point of the reaction mixture to yield the compound represented by the formula (12aa).

[0245] Method A-1b

[0246] wherein X, R₅, m₁, m₂ and A₁₁ are defined as previously described.

[0247] The compound (12aa) may be synthesized in the following manner.

[0248] The compound represented by the formula (10aa) is treated with an acid, such as hydrogen chloride, sulfuric acid, hydrogen bromide, hydrogen pyridinium chloride or boron tribromide at the temperature between −78° C. and the boiling point of the reaction mixture to yield the compound represented by the formula (16aa).

[0249] The compound represented by the formula (16aa) is heated at 50° C. to the boiling point of the reaction mixture in a solvent such as dimethylsulfoxide, dimethylformamide, benzene, toluene, xylene, dioxane or tetrahydrofuran, optionally in the presence of an acid such as hydrogen chloride, sulfuric acid or p-toluenesulfonic acid, to yield the compound represented by the formula (12aa).

[0250] Method A-1c

[0251] wherein X, R₅, R₂₀, Y₁₀, A₁₁, m₁ and m₂ are defined as previously described.

[0252] The compound represented by the formula (25aa) is reacted with malonate such as diethyl malonate or dimethyl malonate in the presence of a base such as sodium hydride, sodium hydroxide or potassium t-butoxide, in a solvent inert to the reaction such as tetrahydroftiran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in tetrahydrofuran, at the temperature between −78° C. and the boiling point of the reaction mixture to yield the compound represented by the formula (15aa).

[0253] The compound represented by the formula (15aa) is reacted with the compound represented by the formula (7aa) in the presence of a base such as sodium hydride, sodium hydroxide or potassium t-butoxide in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in tetrahydrofuran, at the temperature between −78° C. and the boiling point of the reaction mixture to yield the compound represented by the formula (9aa).

[0254] The compound represented by the formula (9aa) is converted to the compound represented by the formula (12aa) according to the previously described method.

[0255] Method A-1d

[0256] wherein X, R₅, R₂₀, A₁₁, m₁ and m₂ are defined as previously described; m₁₁ and m₁₂ are an integer of 0 to 10.

[0257] The compound (12aa) may be synthesized in the following manner.

[0258] The compound represented by the formula (17aa) is reacted with the compound represented by the formula (18aa) in the presence of a catalyst such as benzylidene-bis(tricyclohexylphosphine)dichlororuthenium in a solvent such as methylene chloride, chloroform, benzene, toluene, xylene, dioxane, tetrahydrofuran, dimethylsulfoxide or dimethylformamide at the temperature between −78° C. and the boiling point of the reaction mixture to, preferably at the boiling point of the reaction mixture, yield the compound represented by the formula (19aa)

[0259] The compound represented by the formula (19aa) is hydrogenated with a catalyst such as palladium on activated carbon, palladium hydroxide, platinum oxide or Wilkinson's catalyst in a solvent inert to the reaction such as methanol, ethanol, ethyl acetate, tetrahydrofuran, dioxane, dichloromethane, dichloroethane, chloroform or benzene at the temperature between room temperature and the boiling point of the reaction mixture, preferably at room temperature to yield the compound represented by the formula (20aa).

[0260] The compound represented by the formula (20aa) is treated with sodium hydroxide or potassium hydroxide in a solvent such as water, ethanol, methanol, a mixture of water-ethanol or a mixture of water-methanol at the temperature between room temperature and the boiling point of the reaction mixture, preferably at the boiling point of the reaction mixture to yield the compound represented by the formula (11aa).

[0261] The compound represented by the formula (11aa) is converted to the compound represented by the formula (12aa) according to the previously described method.

[0262] (Method A-2)

[0263] The compound of formula (17aa) may typically be synthesized by the following methods.

[0264] Method A-2a

[0265] wherein X, A₁₁, m₁₁, and Y₁₀ are defined as previously described.

[0266] The compound (17aa) may be synthesized in the following manner.

[0267] The compound represented by the formula (21aa) is reacted with the Grignard reagent represented by the formula (23aa) in a solvent inert to the reaction such as diethyl ether, benzene, toluene, xylene, dioxane or tetrahydrofuran at the temperature between −78° C. and the boiling point of the reaction mixture, to yield the compound represented by the formula (22aa).

[0268] The compund represented by the formula (22aa) is reduced by sodium cyanoborohydride in the presence of Lewis acid such as zinc iodide, or by triethylsilane in the presence of an acid such as trifluoroacetic acid, in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane or chloroform, preferably in dichloroethane at the temperature between −78° C. and the boiling point of the reaction mixture, preferably at 0° C. through room temperature, to yield the compound represented by the formula (17aa).

[0269] Method A-2b

[0270] wherein X, A₁₁ and m₁₁ are defined as previously described.

[0271] The compound (17aa) may be synthesized in the following manner.

[0272] The compound represented by the formula (21aa) is reduced by a reagent such as sodium borohydride or lithium aluminum hydride in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane, or chloroform at the temperature between −78° C. and the boiling point of the reaction mixture, preferably at the temperature between 0° C. and room temperature, to yield the compound represented by the formula (24aa).

[0273] The compound represented by the formula (24aa) is reacted with the compound represented by the formula (25aa) in the presence of a Lewis acid such as zinc iodide or boron trifluoride diethyl etherate in a solvent inert to the reaction such as tetrahydrofuran, dioxane, dichloromethane, dichloroethane, or chloroform at the temperature between −78° C. and the boiling point of the reaction mixture to yield the compound represented by the formula (17aa).

[0274] The above compound (17aa) is novel.

[0275] (Method B)

[0276] The compound of formula (1) wherein A represents group (b), that is a compound of formula (Ib):

[0277] wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂ and D¹ are defined as previously described, can be prepared by a process characterized in that a compound of formula (19):

[0278] wherein X, R₃, R₄, m₁, W¹ and P are defined as previously described, is reacted with a compound of formula (20):

HD¹—(CH₂)_(m) ₂ —R₅  (20)

[0279] wherein R₅, m₂ and D¹ are defined as previously described, and then deprotected to produce a compound of formula (1ba):

[0280] wherein X, R₃, R₄, R₅, m₁, m₂ and D¹ are defined as previously described.

[0281] The reaction of the compound (19) with (20) is preferably carried out in one or more solvents selected from acetone, dimethylformamide, methylene chloride and chloroform at the reflux temperature of the solvent used. In addition, a base such as potassium carbonate, tetra-n-butylammonium iodide, tetra-n-butylammonium fluoride, tetra-n-butylammonium bromide, etc. may be used to more facilitate the reaction.

[0282] (Method C)

[0283] The compound of formula (1) wherein A represents group (c), that is a compound of formula (Ic):

[0284] wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂, m₃, n₁ and D¹ are defined as previously described, can be prepared by a process characterized in that a compound of formula (21):

[0285] wherein X, R, m₁, m₂, D¹, W¹ and P are defined as previously described, is reacted with a compound of formula (22):

W²—S—(CH₂)_(m) ₃ —R₅  (22)

[0286] wherein R₅, m₃ and W² are defined as previously described, to produce a compound of formula (23):

[0287] wherein X, R₄, R₅, m₁, m₂, m₃, D¹ and P are defined as previously described, the resulting compound of formula (23) is deprotected and dehydrated to produce a compound of formula (24):

[0288] wherein X, R₄, R₅, m₁, m₂, ans and D¹ are defined as previously described, which is then oxidized to produce a compound of formula (Ica):

[0289] wherein X, R₄, R₅, m₁, m₂, m₃ and D¹ are defined as previously described, and n₁′ represents 1 or 2.

[0290] The compound of formula (21) is reacted with the compound of formula (22) in one or more solvents selected from methanol, ethanol and acetonitrile and optionally in the presence of one or more bases selected from sodium hydroxide, sodium ethoxide and sodium methoxide under warming for 1 to 20 hours to produce the coupling product of formula (23). Deprotection and dehydration reactions are subjected to the resulting compound of formula (23) to prepare the compound of formula (24). The deprotection and dehydration reaction may be carried out by applying the reaction conditions which are generally used for this purpose. This reaction is preferably carried out by refluxing under argon in the presence of a salt such as pyridinium p-toluenesulfonate.

[0291] The desired compound of formula (1ca) is produced by oxidizing the compound of formula (24). The oxidation reaction can be carried out under the condition selected from the various possible conditions based on the structure and nature of the compound to be oxidized. Generally, the oxidation is carried out in one or more solvents selected from methanol, water, chloroform, tetrahydrofuran, dioxane, ethanol and methylene chloride in the presence of one or more oxidizing agents selected from sodium periodate(NaIO₄), metachloroperbenzoic acid, hydrogen peroxide and Oxone^(R) (monopersulfate compound; DuPont product). Hereinafter, the oxidation reactions for the other compounds having different structures can be explained in the same manner.

[0292] (Method D)

[0293] The compound of formula (1) wherein A represents group (d), that is a compound of formula (1d):

[0294] wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂, m₃, n₁, D¹ and D² are defined as previously described, can be preparedt by a process characterized in that

[0295] (a) the compound of formula (13):

[0296] wherein X, R₃, R₄, m₁, P and W′ are defined as previously described, is reacted with a compound of formula (25):

HD¹—(CH₂)_(m) ₂ —S(O)_(m) ₃ —R₅  (25)

[0297] wherein R₅, m₂, m₃, n₁ and D¹ are defined as previously described, and then deprotected to produce a compound of formula (1da):

[0298] wherein X R₃, R₄, R₅, m₁, m₂, m₃, n₁ and D¹ are defined as previously described,

[0299] (b) the compound of formula (15):

[0300] wherein X, R₃, R₄, D¹, m₁ and P are defined as previously described, is reacted with a compound of formula (26):

[0301] wherein n₁ and W² are defined as previously described, P⁴ represents a hydroxy-protecting group, and D^(2′) is the same with D², provided that 1 or 2 hydrogen atoms are excluded therefrom, to produce a compound. of formula (27):

[0302] wherein X, R₃, R₄, m₁, n₁, D¹, D^(2′), P and P′ are defined as previously described, the resulting compound of formula (27) is condensed with a compound of formula (28):

HO—(CH₂)_(m) ₂ —R₅  (28)

[0303] wherein R₅ and m₂ are defined as previously described, and then deprotected to produce a compound of formula (1db):

[0304] wherein X, R₃, R₃, R₅, m₁, m₂, n₁, D¹ and D² are defined as previously described,

[0305] (c) the compound of formula (13) is reacted with a compound of formula (29):

W²—S—D²—(CH2)_(m) ₃ —R₅  (29)

[0306] wherein R₅, m₃, D² and W² are defined as previously described, to produce a compound of formula (30):

[0307] wherein X, R₃, P₄, R₅, m₁, m₃, D² and P are defined as previously described, the resulting compound of formula (30) is then deprotected and oxidized to produce a compound of formula (1dc):

[0308] wherein X, R₃, R₄, R₅, m₁, m₃, n₁′ and D² are defined as previously described,

[0309] (d) the compound of formula (13) is reacted with a compound of formula (29a):

W²—S—D²—(CH₂)_(m) ₃ —R₅′—P′  (29a)

[0310] wherein m₃, D², P′and W² are defined as previously described, and R₅′ is the same with R₅, provided that 1 or 2 hydrogen atoms are excluded therefrom, to produce a compound of formula (30a):

[0311] wherein X, R₃, R₄, R₅′, m₁, m₃, D², P and P′ are defined as previously described, the resulting compound of formula (30a) is then deprotected and oxidized to produce the compound of formula (1dc),

[0312] (e) the compound of formula (13) is reacted with sodium azide and then reduced to produce a compound of formula (31):

[0313] wherein X, R₃, R₄, m₁ and P are defined as previously described, the resulting compound of formula (31) is reacted with a compound of formula (32):

W²—SO₂—(CH₂)_(m) ₃ —R₅  (32)

[0314] wherein R₅, m₃ and W² are defined as previously described, and then deprotected to produce a compound of formula (1dd):

[0315] wherein X, R₃, R₄, R₅, m₁ and m₃ are defined as previously described,

[0316] (f) the compound of formula (31) is reacted with a compound of formula (32a):

OHC(CH₂)_(m) ₂ —S(O)_(n) ₁ —(CH₂)_(m) ₃ —R₅  (32a)

[0317] wherein R₅, m₃ and n₁ are defined as previously described, and m_(2′) equals m₂−1, and then deprotected to produce a compound of formula (1de):

[0318] wherein X, R₃, R₄, R₅, m₁, m₂, m₃ and n₁ are defined as previously described,

[0319] (g) a compound of formula (33):

[0320] wherein X, R₃, R₄, m₁, m₂, D¹, W¹ and P are defined as previously described, is reacted with the. compound of formula (22):

W²—S—(CH₂)_(m) ₃ —R₅  (22)

[0321] wherein R₅, m₃ and W² are defined as previously described, to produce a compound of formula (34):

[0322] wherein X, R₃, R₄, R₅, m₁, m₂, m₃, D¹ and P are defined as previously described, the resulting compound of formula (34) is then deprotected and oxidized to produce a compound of formula (1df):

[0323] wherein X, R₃, R₄, R₅, m₁, m₂, m₃ and D¹ are defined as previously described, or

[0324] (h) a compound of formula (35):

[0325] wherein X, R₃, R₄, m₁, n₁, W¹ and P are defined as previously described, is reacted with a compound of formula (36):

P′—D²—(CH₁)_(m) ₂ —R₅  (36)

[0326] wherein R₅, m₃, D² and P⁴ are defined as previously described, and then deprotected to produce a compound of formula (1dg):

[0327] wherein X, R₃, R₄, R₅, m₁, m₃, n₁ and D² are defined as previously described.

[0328] The above methods D(a) to D(h) will be explained more in detail in due order hereinafter.

[0329] In the method D(a), the compound of formula (13) is coupled with the compound of formula (25) and then deprotected to produce the compound of formula (1da). The reaction conditions explained for the preparation of the compound of formula (1aa) can be referred to in this coupling and deprotection reaction.

[0330] In the method D(b), the compound of formula (27) is prepared by reacting the compound of formula (15) with the compound of formula (26) in a solvent such as methylene chloride in the presence of one or more organic bases selected from triethylamine, pyridine, diisopropylamine and dimethylethylamine under a low temperature. The compound of formula (27) thus prepared -is condensed with the compound of formula (28) and then deprotected to produce the desired compound of formula (1 db). The condensation reaction may be carried out optionally in one or more solvents selected from methylene chloride, tetrahydrofuran, acetonitrile and dimethylformamide, and in the presence of a condensing agent such as triphenylphosphine, diethylazodicarboxylate, etc.

[0331] In the methods D(c) and D(d), the compound of formula (13) is coupled with the compound of formula (29) or (29a), respectively, to produce the compound of formula (30) or (30a), and the resulting compound (30) or (30a) is then deprotected and oxidized to produce the desired compound of formula (1dc). The optimum reaction condition for the structure of the compound to be reacted can be established by referring to the process for preparing the compound of formula (1aa) for the coupling and deprotection reaction, and referring to the process for preparing the compound of formula (1ca) for the oxidation reaction, respectively.

[0332] In the method D(e), the compound of formula (13) is first reacted with sodium azide, and then reduced to produce the amine compound of formula (31). The reaction with sodium azide is preferably carried out in one or more solvents selected from dimethylformamide, acetonitrile, methylene chloride, chloroform and tetrahydrofuran and optionally under nitrogen. The reduction is also carried out using a reducing agent such as Pd/C or Pd(OH)₂C under hydrogen in one or more solvents selected from methanol, ethanol, ethyl acetate and methylene chloride. The amine compound of formula (31) thus obtained is coupled with the compound of formula (32) and then deprotected to produce the desired compound of formula (1dd). The reaction conditions explained for the preparation of the compound of formula (1aa) can be referred to in this coupling and deprotection reaction.

[0333] In the method D(f) for preparing the compound of formula (1de), the compound of formula (31) prepared in the above method D(e) is used as the starting material. That is, the compound of formula (31) is coupled with the aldehyde compound of formula (32a) and then deprotected to produce the compound of formula (Ide). Here, the coupling reaction with the aldehyde compound is preferably carried out in the presence of a reducing agent such as sodium cyanoborohydride in one or more solvents selected from methanol, methylene chloride, diethylether and dichloroethane. Also, the reaction conditions explained for the preparation of the compound of formula (1aa) can be referred to in this deprotection reaction. In the method D(g), the compound of formula (33) is first coupled with the compound of formula (22) to produce the compound of formula (34), and the resulting compound (34) is subjected to deprotection and oxidation reaction to produce the desired compound of formula (1df). Here, the optimum reaction condition for the compound to be reacted can be established by referring to the process for preparing the compound of formula (1aa) for the coupling and deprotection reaction, and referring to the process for preparing the compound of formula (1ca) for the oxidation reaction, respectively.

[0334] In the method D(h), the compound of formula (35) is first coupled with the compound of formula (36) and then deprotected to produce the desired compound of formula (1dg). Here, the optimum reaction condition for the compound to be reacted can be established by referring to the process for preparing the compound of formula (1aa) for the coupling and deprotection reaction.

[0335] (Method E)

[0336] The compound of formula (1) wherein A represents group (e), that is a compound of formula (Ie):

[0337] wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂, m₁, n₁ and n₂ are defined as previously described, can be prepared by a process characterized in that a compound of formula (13):

[0338] wherein X, R₃, R₄, m₁, P and W¹ are defined as previously described, is reacted with a compound of formula (37):

W³S—(CH₂)_(m) ₂ —S(O)_(n) ₂ —(CH₂)_(m) ₃ —R₄  (37)

[0339] wherein R₅, M₂, m₃ and n₂ are defined as previously described and W³ represents acyl group, and the resulting compound is then deprotected and oxidized to produce a compound of formula (1ea):

[0340] wherein X, R₃, R₄, R₅, m₁, m₂, m₃, no and n₂ are defined as previously described.

[0341] The reaction of the compound (13) and (37) can be carried out in one or more solvents selected from methanol, ethanol and acetonitrile and optically in the presence of one or more bases selected from sodium hydroxide, sodium ethoxide and sodium methoxide under warming for 1 to 20 hours. The deprotection can be carried out using a conventional method such as hydrolysis in the presence of acid or base. Preferably, the deprotection is achieved in the presence of one or more hydrolyzing agents selected from a group consisting of borontribromide, hydrochloric acid, hydrobromic acid and spyridinium-p-toluenesulfonate The oxidation can be carried out under the condition selected from the various conditions based on the structure and nature of the compound. Generally, the oxidation is carried out in one or more solvents selected from methanol, water, chloroform, tetrahydrofuran, dioxane, ethanol and methylene chloride in the presence of one or more oxidizing agents selected from sodium periodate, metachloroperbenzoic acid, hydrogen peroxide and Oxone^(R) (monopersulfate compound; DuPont product).

[0342] (Method F)

[0343] The compound of formula (1) wherein A represents group (f), that is a compound of formula (If):

[0344] wherein X, R₁R₂, R₃, R_(a), R₅, m₁, m₂, n₁ and n₂ are defined as previously described, can be prepared by a process characterized in that a compound of formula (38):

[0345] wherein X, R₃, R₄, m₁, P and W¹ are defined as previously described, is reacted with a compound of formula (39):

W³—S(O)_(n) ₂ —(CH₂)_(m) ₂ R₅  (39)

[0346] wherein R₅, m₂ and W³ are defined as previously described, and the resulting compound is then deprotected and oxidized to produce a compound of formula (1fa):

[0347] wherein X, R₃, R₄, R₅, m₁, m₂, n₁, and n₂ are defined as previously described.

[0348] The reaction of the compound (38) and (39) can be carried out in one or more solvents selected from methanol, ethanol and acetonitrile and optically in the presence of one or more bases selected from sodium hydroxide, sodium ethoxide and sodium methoxide under wanning for 1 to 20 hours. The deprotection can be carried out using a conventional method such as hydrolysis in the presence of acid or base. Preferably, the deprotection is achieved in the presence of one or more hydrolyzing agents selected from a group consisting of borontribromide, hydrochloric acid, hydrobromic acid and pyridinium-p-toluenesulfonate. The oxidation can be carried out under the condition selected from the various conditions based on the structure and nature of the compound. Generally, the oxidation is carried out in one or more solvents selected from methanol, water, chloroform, tetrahydrofuran, dioxane, ethanol and methylene chloride in the presence of one or more oxidizing agents selected from sodium periodate, metachloroperbenzoic acid, hydrogen peroxide and Oxone^(R) (monopersulfate compound; DuPont product).

[0349] (Meth d G)

[0350] The compound of formula (1) wherein A represents group (g), that is a compound of formula (Ig):

[0351] wherein X, R₁, R₂, R₃, R₄, R₅, m₁ and n₁ are defined as previously described, can be prepared by a process characterized in that a compound of formula (38):

[0352] wherein X, R₃, R₄, m₁, P, and W¹ are defined as previously described, is reacted with a compound of formula (40):

W⁴—R₅  (40)

[0353] wherein R₅ is defined as previously described, W⁴ represents hydrogen, and the resulting compound is then deprotected to produce a compound of formula (1ga):

[0354] wherein X, R₅, R₄, R₅, m₁, and n₁ are defined as previously described.

[0355] The reaction of the compound (38) and (40) can be carried out in one or more solvents selected from methanol, ethanol and acetonitrile under refluxing for 1 to 48 hours. The deprotection can be carried out using a conventional method such as hydrolysis in the presence of acid or base. Preferably, the deprotection is achieved in the presence of one or more hydrolyzing agents selected from a group consisting of borontribromide, hydrochloric acid, hydrobromic acid and pyridinium-p-toluenesulfonate.

[0356] (Method H)

[0357] The compound of formula (1) wherein A represents group (h), that is a compound of formula (1h):

[0358] wherein X, R₁, R₂, R₃, R₄ and m₁ are defined as- previously described, can be prepared by a process characterized in that a compound of formula (41):

[0359] wherein X, R₃, R₄, m₁, P and W¹ are defined as previously described, is reacted with a compound of formula (42):

[0360] wherein W⁴ is defined as previously described, and the resulting compound is then deprotected to produce a compound of formula (1ha):

[0361] wherein X, R₃, R₄ and m₁ are defined as previously described.

[0362] The reaction of the compound (41) and (42) can be carried out in one or more solvents selected from methanol, ethanol and acetonitrile under refluxing for 1 to 48 hours. The deprotection can be carried out using a conventional method such as hydrolysis in the presence of acid or base. Preferably, the deprotection is achieved in the presence of one or more hydrolyzing agents selected from a group consisting of borontribromide, hydrochloric acid, hydrobromic acid and pyridinium-ptoluenesulfonate.

[0363] (Method 1)

[0364] The compound of formula (1) wherein A represents group (1), that is a compound of formula (Ii):

[0365] wherein X, R₁, R₂, R₃, R₄, R₅, D¹, D², m₁, m₂, m₃ and n₁ are defined as previously described, can be prepared according to the similar procedure as Method D.

[0366] (Method J)

[0367] The compound of formula (1) wherein A represents group (j), that is a compound of formula (Ij):

[0368] wherein X, R₁, R₂, R₃, R₄, R₅, m₁ and n₁ are defined as previously described, can be prepared by a process characterized in that a compound of formula (41):

[0369] wherein X, R₃, R₄, m₁, P and W¹ are defined as previously described, is reacted with a compound of formula (43):

W³—S(O)_(n) ₁ —R₅  (43)

[0370] wherein R₅, n₁ and W³ are defined as previously described, and the resulting compound is then deprotected and oxidized to produce a compound of formula (1ja):

[0371] wherein X, R₃, R₄, R₅, m₁ and n₁ are defined as previously described.

[0372] The reaction of the compound (41) and (43) can be carried out in one or more solvents selected from methanol, ethanol and acetonitrile and optically in the presence of one or more bases selected from sodium hydroxide, sodium ethoxide and sodium methoxide under warming for 1 to 20 hours. The deprotection can be carried out using a conventional method such as hydrolysis in the presence of acid or base. Preferably, the deprotection is achieved in the presence of one or more hydrolyzing agents selected from a group consisting of borontribromide, hydrochloric acid, hydrobromic acid and pyridinium-p-toluenesulfonate. The oxidation can be carried out under the condition selected from the various conditions based on the structure and nature of the compound. Generally, the oxidation is carried out in one or more solvents selected from methanol, water, chloroform, tetrahydrofuran, dioxane, ethanol and methylene, chloride in the presence of one or more oxidizing agents selected from sodium periodate, metachloroperbenzoic acid, hydrogen peroxide and Oxone^(R) (monopersulfate compound; DuPont product).

[0373] (Method K)

[0374] The compound of formula (1) wherein A represents group (k), that is a compound of formula (Ik):

[0375] wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂, n₁ and and D¹ are defined as previously described, can be prepared by a process characterized in that a compound of formula (13):

[0376] wherein X, R₃, R₄, m₁, P and W¹ are defined as previously described, is reacted with a compound of formula (44):

W³S—(CH₂)_(m) ₂ —D¹—(CH₂)_(m) ₃ —R₅  (44)

[0377] wherein R₅, m₂, m₃, W³ and D¹ are defined as previously described, and the resulting compound is then deprotected and oxidized to produce a compound of formula (1ka):

[0378] wherein X, R₃, R₄, R₅, m₁, m₂, m₃, n₁ and D¹ are defined as previously described.

[0379] The reaction of the compound (13) and (44) can be carried out in one or more solvents selected from methanol, ethanol and acetonitrile and optically in the presence of one or more bases selected from sodium hydroxide, sodium ethoxide and sodium methoxide under warming for 1 to 20 hours. The deprotection can be carried out using a conventional method such as hydrolysis in the presence of acid or base. Preferably, the deprotection is achieved in the presence of one or more hydrolyzing agents selected from a group consisting of borontribromide, hydrochloric acid, hydrobromic acid and pyridinium-p-toluenesulfonate. The oxidation can be carried out under the condition selected from the various conditions based on the structure and nature of the compound. Generally, the oxidation is carried out in one or more solvents selected from methanol, water, chloroform, tetrahydrofuran, dioxane, ethanol and methylene chloride in the presence of one or more oxidizing agents selected from sodium periodate, metachloroperbenzoic acid, hydrogen peroxide and Oxone^(R) (monopersulfate compound; DuPont product).

[0380] (Method L)

[0381] The compound of formula (1) wherein A represents group (1), that is a compound of formula (1):

[0382] wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂, m₃ and D¹ are defined as previously described, can be prepared by a process characterized in that a compound of formula (45):

[0383] wherein X, R₃, R₄, m₁ and P are defined as previously described, is reacted with a compound of formula (46):

W¹ (CH₂)_(m) ₂ W²  (46)

[0384] wherein m₂, W¹ and W² are defined as previously described, to produce a compound of formula (47):

[0385] wherein X, R₃, R₄, m₁, m₂, W² and P are defined as previously described, the resulting compound of formula (47) is reacted with a compound of formula (14):

D¹H₂  (14)

[0386] wherein D¹ is defined as previously described, to produce a compound of formula (48):

[0387] wherein X, R₃, R₄, m₁, m₂, D¹ and P are defined as previously described, the resulting compound of formula (48)-is reacted with a compound of formula (16a):

W⁵—(CH₂)_(m) ₃ —R₅  (16a)

[0388] wherein R₅ and m₃ are defined as previously described, and W⁵ represents a leaving group and then deprotected to produce a compound of formula (11a):

[0389] wherein X, R₁, R., R₅, m₁, m₂, m and D¹ are defined as previously described.

[0390] The coupling step of the compound (45) and (46) may be carried out in a solvent. As the preferable solvent, one or more selected from a group consisting of dioxane, methanol, ethanol, diethylether, tetrahydrofuran, dimethylsulfoxide, methylene chloride, dimethylformamide, chloroform, ethyl acetate, acetonitrile and acetone can be used. This reaction may be carried out optionally in the presence of one or more inorganic or organic bases selected from a group consisting of potassium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, triethylamine and cesium carbonate. The reaction may be suitably proceeded under the reflux temperature of the solvent used or room temperature, if appropriate, under ice-cooling.

[0391] The coupling step of the compound (47) and (14) in a solvent. As the preferable solvent, one or more selected from a group consisting of dioxane, methanol, ethanol, diethylether, tetrahydrofuran, dimethylsulfoxide, methylene chloride, dimethylformamide, chloroform, ethyl acetate, acetonitrile and acetone can be used. This reaction may be carried out optionally in the presence of one or more inorganic or organic bases selected from a group consisting of potassium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, triethylamine and cesium carbonate. The reaction may be suitably proceeded under the reflux temperature of the solvent used or room temperature, if appropriate, under ice-cooling.

[0392] The coupling step of the compound (48) and (16a) in a solvent. As the preferable solvent, one or more selected from a group consisting of dioxane, methanol, ethanol, diethylether, tetrahydrofuran, dimethylsulfoxide, methylene chloride, dimethylformamide, chloroform, ethyl acetate, acetonitrile and acetone can be used. This reaction may be carried out optionally in the presence of one or more inorganic or organic bases selected from a group consisting of potassium carbonate, potassium hydroxide, sodium hydroxide, sodium methoxide, sodium ethoxide, triethylamine and cesium carbonate. The reaction may be suitably proceeded under the reflux temperature of the solvent used or room temperature, if appropriate, under ice-cooling.and then deprotected to produce the compound of formula (1ha). This reaction can be carried out in one or more solvents selected from a group consisting of acetone, toluene, dimethylformamide, acetonitrile, dimethylsulfoxide and methylene chloride, optionally in the presence of a base such as potassium carbonate, triethylamine, sodium ethoxide, etc. The deprotection reaction may be carried out according to a conventional method such as hydrolysis in the presence of acid. or base, reduction, etc. Preferably, the deprotection is achieved in the presence of one or more hydrolyzing agents selected from a group consisting of borontribromide, hydrochloric acid, hydrobromic acid, hydrofluoric acid, pyridinium-p-toluenesulfonate and sulfuric acid, or in the presence of one or more reducing agents selected from a group consisting of Pd(OH)₂C under hydrogen, Pd/C and diisobutylaluminum hydride(DIBAL). This reaction can be carried out under a low temperature to warmning, preferably carried out by starting at a low temperature of −78° C. and then warming to room temperature. While, the compound of formula (1aa) thus produced may be further oxidized using metachloroperbenzoic acid (mCPBA) in a solvent such as chloroform.

[0393] The desired compounds obtained in each processes may be separated and purified using the conventional methods such as column chromatography, recrystallization, etc.

[0394] The above processes I to V according to the present invention will be more specifically explained through the following examples.

[0395] As stated above, the compound of formula (1) prepared according to the process of the present invention as mentioned above has a good anti-estrogenic activity and, therefore, can be used for the treatment of estrogen-related diseases including anovular infertility, breast cancer, endometrial cancer, uterine cancer, ovarian cancer, endometriosis, endometfial fibroma, benign prostate hypertrophy, premature, menstrual disorder, etc.

[0396] Therefore, the present invention relates to an anti-estrogenic pharmaceutical composition containing the compound of formula (1) as an active component.

[0397] When the anti-estrogenic pharmaceutical composition containing the compound of the present invention as an active component is used for clinical purpose, it can be formulated into a conventional preparation in the pharmaceutical field, for example, preparation for oral administration such as tablet, capsule, troche, solution, suspension, etc., or injectable preparation such as injectable solution or suspension, ready-to-use injectable dry powder which can be reconstituted with distilled water for injection when it is injected, etc., by combining with a carrier conventionally used in the pharmaceutical field.

[0398] Suitable carrier which can be used in the composition of the present invention includes those conventionally used in the pharmaceutical field, for example, binder, lubricant, disintegrant, excipient, solubilizer, dispersing agent, stabilizing agent, suspending agent, coloring agent, perfume, etc. for oral preparation; and preservative, pain alleviating agent, solubilizing agent, stabilizing agent, etc. for injectable preparation. The pharmaceutical preparation thus prepared can be administered orally -or parenterally, for example, intravenously, subcutaneously or intraperitoneally. In addition, in order to prevent the active component from the decomposition with gastric acid, the oral preparation can be administered together with an antacid or in the enteric- coated form of the solid preparation such as tablet.

[0399] The dosage of the benzopyran or thiobenzopyran derivative of formula (1) according to the present invention for human being can be suitably determined depending on absorption, inactivation and secretion of the active ingredient in the human body, age, sex and condition of subject patient, kinds and severity of disease to be treated. It is generally suitable to administer the compound of formula (1) in an amount of 1 to 500 mg, preferably 5 to 200, per day for adult patient.

[0400] The present invention is more specifically explained by the following examples. However, it should be understood that the present invention is not limited to these examples in any manner.

EXAMPLE 1

[0401] Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-3methyl-4-{9-[4-4,4,5,5, pentafluoropentyl)piperazinyl]nonyl}chroman

[0402] Step 1) Synthesis of 7-methoxymethoxy)-3-(4-methoxymethoxyphenyl)-4-(9-piperazinylnonyl)-3-methylchroman

[0403] 9-{7-(Methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman-4-yl}nonyl 4-methylbenzenesulfonate (540 mg, 0.843 mmol) and piperazine (2.2 g, 25.5 mmol) were dissolved in dioxane and then the mixture was refluxed for 2 hours. The mixture was cooled down to room temperature, basified to pH 13 using 5N—NaOH, and then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the organic solvent was removed under reduced pressure. The concentrate was subjected to column chromatography (methanol) to give 380 mg (yield 81%, (3RS,4RS):(3RS, 4SR)=5:4) of the title compound as a white solid.

[0404]¹H NMR (300 MHz, CDCl₃, (3RS,4RS)-compound) δ: 0.99 (s, 3H), 1.19 (brs, 14H), 1.38 (brs, 2H), 2.19 (t, 2H), 2.3 (brs, 4H), 2.79 (brs, 4H), 2.98 (m, 1H), 3.39 (s, 6H), 3.83 (d, 1H), 4.11 (d, 1H), 5.05 (d, 4H), 6.48 (d, 2H), 6.80-6.95 (m, 3H), 7.48 (d, 2H)

[0405] Step 2) Synthesis of 7-(methoxymethoxy)-3-(4-methoxymethoxyphenyl) 4-{9-[4-(4,4,5,5,5-pentafluoropentyl)piperazinyl]nonyl}-3-methylchroman

[0406] 7-(Methoxymethoxy)-3-(4-methoxymethoxyphenyl)-4-(9-piperazinyinonyl)-3-methylchroman (380 mg, 0.685 mmol), K₂CO₃ (190Mg, 1.375 mmol) and 4,4,5,5,5-pentafluoropentyl-4-methylbenzenesulfonate (460 mg, 1.384 mmol) were refluxed under acetone for 15 hours. After the mixture was cooled down to room temperature, water was added thereto, and the resulting mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and the organic solvent was removed under reduced pressure. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate=4:1j to give 238 mg (yield 48%) of the title compound as a white solid.

[0407]¹H NMR (300 MHz, CDCl₃, (3RS,4RS)-compound) δ: 0.82-1.30 (m, 19H), 1.4 (brs, 4H), 2.3 (m, 6H), 3.05 (m, 1H), 3.31 (s, 2H), 3.37 (s, 6H), 3.40 (s, 2H), 3.43 (brs, 2H), 3.86 (d, 1H), 4.134.21 (m, 1H), 5.1 (m, 4H), 6.4-6.5 (m, 2H), 6.94-6.85 (m, 3H), 7.20 (d, 2H)

[0408] Step 3) Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-[4-(4,4,5,5,5-pentafluoropentyl)piperazinyl]nonyl chroman

[0409] 7-(Methoxymethoxy)-3-(4-methoxymethoxyphenyl)-4-{9-[4-(4,4,5,5,5-penta- fluoropentyl)piperazinyl]nonyl}-3-methylchroman (210 mg, 0.294 mmol) was dissolved in 2N—HCl solution in methanol, and the mixture was stirred at 50° C. for 1 hour. The mixture was cooled down to room temperature, adjusted to pH=9 using aqueous NaHCO. solution, and then extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and the organic solvent. was removed under reduced pressure. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate=]:1) to give 162 mg (yield 88%. (3RS,4RS):(3RS,4SR)=8:5) of the title compound as a white solid.

[0410]¹H NMR(300 MHz, CDCl₃, (3RS,4RS)-compound) δ: 0.8-1.2 (brs, 19H), 1.36 (brs, 4H), 1.86-2.1 (m, 2H), 2.30 (m, 4H), 2.48 (brs, 7H), 4.12 (d, 1H), 4.39 (d, 1H), 6.23 (s, 1H), 6.26 (m, 1H), 6.64 (m, 3H), 6.69 (m, 2H)

EXAMPLE 2

[0411] Synthesis of (3RS,4RS)-7-hydroxy-4-[(111-imino-11-N-butylam ino)undecyl]-3-(4-hydroxyphenyl)-3methylchroman and (3RS,4RS)-7-hydroxy-4-[(11-N-butylimino-11-N-butylamino)undecyl]-3-(4-hydroxyphenyl)-3-methylchroman

[0412] Step 1) Synthesis of (3RS,4RS)-4-(10-cyanodecyl)-7-methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman

[0413] (3RS,4RS)-4-[1044-Methylbenzenesulfonyldecyl]-7-(methoxymethoxy)-3-[4-metho xymethoxy)phenyl]-3-methylchroman (233 mg, 0.37 mmol) and NaCN (54.7 mg, 1.1 mmol) were dissolved in DMSO (5 ml) and the resulting mixture was stirred at 80° C. for 10 hours. After the mixture was cooled down to room temperature, water was added thereto, and the reaction mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and the organic solvent was removed under reduced pressure. The concentrate was subjected to column chromatography (n-hexane:ethyl acetate=8:1) to give 128 mg (yield 68%) of the title compound as a colorless oil.

[0414]¹H NMR(300 MHz, CDCl₃) δ: 0.87-1.37 (m, 18H), 1.35 (q, 3H), 2.23 (t, 2H), 2.56 (m, 1H), 3.42 (d, 6H), 4.19 (dd, 1H), 4.46 (dd, 1H), 5.01 (d, 4H), 6.46 (m, 2H), 6.82 (dd, 1H), 6.91 (d, 2H), 7.01 (d, 2H)

[0415] Step 2) Synthesis of (3RS,4RS)-7-hydroxy-4-[(11-imino-11-N-butyl amino)undecyl]-3-(4-hydroxyphenyl)-3-methylchroman (I) and (3RS,4RS)-7-hydroxy-4-[(11-N-butylimino-11-N-butylamino)undecyl]-3-(4-hydroxyphenyl)-3-methylchroman (II)

[0416] (3RS,4RS)-4-(10-Cyanodecyl)-7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl)-3-methylchroman (70 mg, 0.14 mmol) and AlCl₃ (73.2 mg, 0.56 mmol) were dissolved in xylene (3 ml), butylamine (61.4, 0.84 mmol) was added dropwise thereto, and the resulting mixture was refluxed for 1.5 hour. The mixture was cooled down to normal temperature, water was added thereto, and the reaction mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and the organic solvent was removed under reduced pressure. The concentrate was subjected to base silica gel column chromatography (ethyl acetate:ethanol=5:1) to give the compound I(19 mg, yield 27%) and the compound II (30.8 mg, yield 40%).

[0417] <Compound I>

[0418]¹H NMR (300 MHz, CD₃OD) δ: 0.8 (t, 3H), 0.82-1.7 (m, 23H), 2.23 (t, 2H), 2:52 (m, 1H), 2.92 (broad), 3.15 (t, 2H), 4.06 (dd, —H), 4.37 (dd, 1H), 6.16 (m, 2H), 6.43-6.72 (m, 3H), 6.89 (dd, 2H)

[0419] <Compound II>

[0420]¹H NMR (300 MHz, CD₃OD) δ: 0.84 (t, 6H), 0.84-1.73 (m, 26H), 2.3 (t, 2H), 2.55 (m, 1H), 3.2 (t, 4H), 4.1 (dd, 1H), 4.39 (dd, 1H), 6.21 (m, 2H), 6.43-6.72 (m, 3H), 6.89 (dd, 2H)

EXAMPLE 3

[0421] Synthesis of (3RS,4SR)-7-hydroxy-4-{4-{2-{4-{[3,5bis(t-butyl) phenyl]methyl}piperazinyl}ethoxy}phenyl}-3-(4-hydroxyphenyl)-3-methylchrom an

[0422] Step 1) Synthesis of 3,5-bis(t-butyl)-1-(bromomethyl)benzene

[0423] 3,5-Bis(t-butyl-1-methylbenzene (200 mg, 0.98 mmol) was dissolved in carbon tetrachloride (4 ml), and then N-bromosuccinimide (192 mg, 1.08 mmhol) and AIBN (α,α′-azabisisobutyronitrile) (2 mg) were added thereto. The mixture was heated under reflux and stirred for 5 hours. The filtrate obtained from the filtration of the reaction mixture was evaporated under reduced pressure to give 170 mg (yield 61%) of a pale. yellow oil.

[0424]¹H-NMR (300 MHz CDCl₃) δ: 1.30 (s, 18H), 4.52 (s, 2H), 7.21 (s, 2H), 7.38 (s, 1H)

[0425] Step 2) Synthesis of t-butyl 4-{[3,5-bis(t-butyl)phenyl]methyl}piperazine Carboxylate

[0426] 3,5-Bis(t-butyl)-1-(bromomethyl)benzene (170 mg, 0.60 mmol), t-butyl piperazine carboxylate (102 mg, 0.55 mmol) and potassium carbonate (151 mg, 1.10 mmol) were dissolved in a solvent mixture of acetone (2 ml) and DMF (0.2 ml), and the mixture was stirred overnight while heated under reflux. The reaction mixture was extracted with ethyl acetate, dried over sodium sulfate, and then the filtrate was evaporated under reduced pressure. The concentrate was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give 120 mg (yield 56%) of the title compound as a white solid.

[0427]¹H-NMR (300 MHz, CDCl₃) δ: 1.31 (s, 18H), 1.42 (s, 9H), 2.46 (t, 4H), 3.38 (t, 4H), 3.49 (s, 2H), 7.11 (s, 2H), 7.27 (s, 1H)

[0428] Step 3) Synthesis of {[3,5-bis(t-butyl)phenyl]methyl}piperazinedihydro Chloride

[0429] t-Butyl 4-{[3,5-bis(t-butyl)phenyl]methyl}piperazinecarboxylate (1.88 g, 4.84 mmol) was dissolved in dichloromethane (20 m-9), 4N—HCl(1,4-dioxane solution) (10 ml) was added dropwise thereto at 0° C., and the mixture was stirred at room temperature for 2 hours. The reaction solution was evaporated under reduced pressure to give 2.15 g (yield 100%) of the title compound as a white solid.

[0430]¹H-NMR (300 MHz, CD₃OD) δ: 1.38 (s, 18H), 3.56-3.64 (m, 8H), 4.45 (s, 2H), 7.50 (s, 2H), 7.61 (s, 1H)

[0431] Step 4) Synthesis of (3RS,4SR)-4-[4-t-butyldimethylsilyloxy)phenyl]-7-(methoxy-methoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman

[0432] Magnesium (909 mg, 37.39 mmol) and iodine (10 mg) were introduced into a 250 ml flask saturated with argon. 2 ml of a solution wherein 1-bromo-4-(t-butyldimethylsilyloxy) benzene (8.06 g, 28.05 mmol) was dissolved in dry tetrahydrofuran (35 ml) was added portionwise thereto, and the mixture was heated. After the brown color disappeared, the remaining sblution (33 ml) was slowly added portionwise thereto again under reflux condition. After the mixture was heated under reflux for 2 hours, 7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylch roman-4-one(6.7 g, 18.69 mmol) dissolved in. dry tetrahydrofuran (35 ml) was slowly added portionwise at room temperature, and the resulting mixture was stirred under reflux for 2 hours. The reaction mixture was treated with ice water, extracted with ethyl acetate, washed with saline solution, dried over sodium sulfate, and then filtered. The filtrate was evaporated under reduced pressure and the concentrate thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=8:1) to give 7.4g of a colorless oil. This oil was dissolved in 1.2-dichloroethane (150 ml). zine iodide(6.25 g, 19.58 mmol) and sodium cyanoborohydride (5.74 g, 91.34 mmol) were added thereto at 0° C., and the resulting mixture was stirred for 10 minutes. The mixture was stirred at room temperature for further 1 hour, treated with water, and extracted with dichloromethane. The extract was washed with saline solution, dried over sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure and the concentrate thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=16:1) to give 2.19 g (yield. 21%) of a colorless oil.

[0433]¹H-NMR (300 MHz, CDCl₃) δ: 0.01 (s, 6H), 0.83 (s, 9H), 1.38 (s, 3H), 3.37 (s, 6H), 3.78 (s, 1H), 3.90 (dd, 1H), 4.48 (dd, 1H), 5.06 (s, 4H), 6.33 (m, 4H), 6.44 (dd, 1H), 6.56 (t, 1H), 6.70 (m, 5H)

[0434] Step 5) Synthesis of (3RS,4SR-4-[4-2-chloroethoxy)phenyl]-7-( methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman

[0435] (3RS,4SR)-4-[4-(t-Butyidimethylsilyloxy)phenyl]-7-(methoxymethoxy)-3-[4-(mnethox ymethoxy)phenyl]-3-methylchroman (2.19 g, 3.98 mmol) was dissolved in tetrahydrofuran (40 ml), tetrabutylammoniumfluoride (1.0M in tetrahydrofuran, 4.37 ml, 4.38 mmol) was added dropwise thereto, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was treated with water, extracted with ethyl acetate, dried over sodium sulfate, and then filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give 1.7 g of a foamy oil. (3RS,4SRy-4 (4-Hydroxyphenyl)-27-methoxyme thoxy)-3-[4{methoxymethoxy)phenyl]-3-methylchroman (140 mg, 0.32 mmol) thus obtained was dissolved in a solvent mixture of 1,4-dioxane(3 ml) and water (0.5 ml), sodium hydroxide (38 mg, 0.96 mmol) and 1-bromo-2-chloroethane (0.13 ml, 1.60 mmol) were added thereto, and the mixture was stirred while heated under reflux for 2 days. The reaction solution was extracted with ethyl acetate, dried over sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=8:1) to give 95 mg (yield 59%) of a sticky oil.

[0436]¹H-NMR (300 MHz, CDCl₃) δ: 1.51 (s, 3H), 3.46 (s, 3H), 3.51 (s, 3H), 3.74 (t, 2H), 3.91 (s, 1H), 4.02 (d, 1H), 4.03-4.13 (m, 2H), 4.58 (d, 1H), 5.12 (s, 2H), 5.15 (s, 2H), 6.506.88 (m, 11H)

[0437] Step 6) Synthesis of (3RS,4SR)-4-{4-{2-{4-{[3,5-bis(t-butyl)phenyl) methyl piperazinyl}ethoxy}phenyl}-7-(methoxymethoxy)-3-[4-(methoxymethoxy)ph enyl]-3-methylchroman

[0438] (3RS,4SR)-4-[4-(2-Chloroethoxy)phenyl]-7-methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman (210 mg, 0.42 mmol) and {(3,5-bis (t-butyl)phenyl]methyl)piperazine (243 mg, 0.84 mmol) were dissolved in a solvent mixture of acetone (4 ml) and DMF (0.4 ml). To the mixture potassium carbonate(116 mg, 0.84 mmol) and tetrabutylammonium iodide (16 mg, 0.04 mmol) added were, and the mixture was stirred while heated under reflux for 3 days. The reaction solution was extracted with ethyl acetate, dried over sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give 160 mg (yield 51%) of a white foamy solid.

[0439]¹H-NMR (300 MHz, CDCl₃) δ: 1.32 (s, 18H), 1.49 (s, 3H), 2.47-2.62 (m, 8H), 2.75 (t, 2H), 3.46 (s, 3H), 3.51 (s, 3H), 3.53 (s, 2H), 3.92 (s, 1H), 3.94-4.02 (m, 3H), 4.57 (d, 1H), 5.09 (s, 2H), 5.14 (s, 2H), 6.47-7.28 (m, 14H)

[0440] Step 7) Synthesis of (3RS,4SR)-4-{4-{2-{4-{[3,5-bis(t-butyl)phenyl]methyl}piperazinyl}ethoxy}phenyl}-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchrom an

[0441] (3RS,4SR)-4-{4-{2-{4-{[3,5-Bis(t-butyl)phenyl]methyl}piperazinyl) ethoxy}phenyl}-7-(methoxymethoxy)-3-[4-methoxymethoxy)phenyl]-3-methylchroman (150 mg, 0.21 mmol) was dissolved in methanol (1.5 ml), 6N—HCl (2 ml) was added portionwise thereto, and the mixture was stirred at 50-60° C. for 2 hours. The reaction solution was diluted with dichloromethane, which was then basified with saturated sodium bicarbonate solution. This solution was washed with water, dried over sodium sulfate, and filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel column chromatography (dichloromethane:methanol=40:1) to give 75 mg (yield 54%) of a pale yellow solid.

[0442]¹H-NMR (300 MHz, CD₃OD) δ: 1.38 (s, 18H), 1.53 (s, 3H), 2.54-2.72 (m, 8H), 2.80 (t, 2H), 3.62 (5, 2H), 3.984.07 (m. 4H), 4.62 (d, 1H), 6.82-7.44 (m, 14H)

[0443] Mass ESI): 663 (M+1)

EXAMPLE 4

[0444] Synthesis of (3RS,4RS)-7-hydroxy-3-(4hydroxyphenyl)-4-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-propylaminoopentyl)-3-methylchro man

[0445] Step 1) Synthesis of (3RS,4RS)-4-(5-hydroxypentyl)-7-methoxy-3-(4-methoxyphenyl)-3-methyl-chroman

[0446] 5-(t-Butyldimethylsilyloxy)pent-1-yne(1.15 g, 5.8 mmol) was dissolved in dry tetrahydrofuran (40 ml) under argon atmosphere, which was then cooled down to −78° C. 2.5M n-Butyllithium (n-BuLi) (2.3 ml, 5.8 mmol) was slowly added dropwise thereto, and the resulting mixture was stirred for 30 minutes. 7-Methoxy-3-(4-methoxyphenyl)-3-methyl chroinan-4-one(860 mg, 2.9 mmol) dissolved in dry tetrahydrofuran(IOInii) was added dropwise thereto, which was slowly warmed to room temperature. Water was added to the reaction solution to stop the reaction, and then the reaction solution was extracted with ethyl acetate. The organic layer thus separated was dried over magnesium sulfate and concentrated to give 2.2 g of a white solid. This solid was dissolved in ethyl acetate (60 ml), and then 10% Pd/C (0.7 g) was added dropwise thereto. The reaction solution was stirred under hydrogen for 15 hours, filtered, and concentrated. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1→1:1) to give the tide compound (430 mg, yield from the two steps 40%) as a colorless oil.

[0447] Step 2) Synthesis of (3RS,4RS)-7-methoxy-3-(4-methoxyphenyl)-4-[5-(p-toluene-sulfonyloxy)pentyl]-3-methylchroman

[0448] (3RS,4RS)-4-(5-Hydroxypentyl)-7-methoxy-3-(4-methoxyphenyl)-3-methyl chroman (430 mg, 1.2 mmol) was dissolved in a solvent mixture of pyridine (12 ml) and dichloromethane (4 ml), which was then cooled down to 0° C. p-Toluenesulfonylchloride (460 mg, 2.3 mmol) was added dropwise thereto, and the mixture was stirred at room temperature for 3 hours. Water was then added, and the organ layer was extracted with ethyl acetate. The organic extract was washed with 2N hydrochloric acid solution, dried over magnesium sulfate, and concentrated. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound (315 mg, yield 53%) as a colorless oil.

[0449]¹H-NMR (300 MHz CDCl₃) δ: 7.70 (d, 2H), 7.28 (d, 2H), 7.08 (d, 2H), 6.85 (m, 3H), 6.44 (m, 1H), 6.40 (m, 1H), 4.50 (d, 1H), 4.25 (dd, 1H), 3.87 (t, 2H), 3.82 (s, 3H), 3.75 (s, 3H), 2.58 (m, 1H), 2.41 (s, 3H), 1-05-1.55 (m, 8H)

[0450] Step 3) Synthesis of (3RS,4RS)-7-methoxy-3-(4-methoxyphenyl)-4-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-propylamino]pentyl}-3-methyl chroman

[0451] (3RS,4RS)-7-Methoxy-3-(4-methoxyphenyl)-4-[5-(p-toluenesulfonyloxy pentyl]-3-methylchroman (0.31 g, 0-6 mmol), 3-(N-methylamino)-1-(4,4,5,5,5-pentafluoropentylthio) propane (0.6 mmol) and K₂CO₃ (0.25 g, 0.18 mmol) were dissolved in DMSO (7 ml), and the mixture was stirred at 70-80° C. After 1 hour the mixture was cooled down to normal temperature, and water was added thereto to stop the reaction. The reaction solution was extracted with ethyl acetate, washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and subjected to silica gel column chromatography (n-hexane:ethyl acetate, 8:1-4:1) to give the title compound (150 mg, yield 47%) as a colorless oil.

[0452]¹H-NMR (300 MHz, CDCl₃) δ: 7.12 (d, 2H), 6.86 (m, 3H), 6.38-6.45 (m, 2H), 4.50 (d, 1H), 4.24 (dd, 1H), 3.91 (t, 2H), 3.80 (s, 3H), 3.76 (s, 3H), 3.31 (br, 2H), 2.82 (br, 3H), 2.40-2.72 (m, 5H) 2.12 (m, 2H), 1.70-1.91 (m, 4H), 1.10-1.62 (m, 9H)

[0453] Step 4) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl) 4-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-propylamino]pentyl}-3-methyl Chroman

[0454] (3RS,4RS)-7-Methoxy-3-(4-methoxyphenyl)-{5-[N-methyl-N-3,4,4,5,5,5-pentafluoropentylthio)propylamino]pentyl}-3-methylchroman (150 mg, 0.24 mmol) was dissolved in dry dichloromethane (5 ml) under argon atmosphere, which was cooled down to −78° C. Then, BBr₃ (1M methylene chloride solution, 1.75 ml, 1.44 mmol) was slowly added dropwise thereto. The resulting mixture was stirred at −50° C. for 6 hours, water was added thereto, and then the mixture was extracted with ethyl acetate. The organic layer separated after extraction was washed with water and saturated aqueous sodium chloride solution, dried over anhydrous magnesium sulfate, and subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound (68 mg, yield 49%) as a colorless oil.

[0455] Mass=655(M+2Na)

[0456]¹H-NMR (300 MHz, acetone d₆) δ: 7.20 (d, 2H), 6.96 (d, 1H), 6.84 (d, 2H), 6.41 (dd, 1H), 6.38 (d, 1H), 4.50 (d, 1H), 4.23 (dd, 1H), 3.95 (t, 2H), 3.37 (t, 2H) 2.88 (s, 3H), 2-84 (m, 1H), 2.70 (t, 2H), 2.55 (t, 2H) 2.26 (m, 2H) 1.78-2.10 (m, 4H), 1.05-1.45 (m, 9H)

EXAMPLE 5

[0457] Synthesis of 4-{4-{2-[2-(4,4,5,5,5-pentafluoropentylsulfinyl)ethoxy]ethoxy}phenyl)-7-hydroxy-3-(4-hydroxypkenyl)-2H-chromene

[0458] Step 1) Synthesis of 4-hydroxy-4-{4-[2-2-chloroethoxy)ethoxy]phenyl}-7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]chroman

[0459] 4-Hydroxy-44-hydroxyphenyl)-7-(methoxymethoxy)-3-[4-(methoxy-methoxy)phenyl]chroman (770 mg, 1.4ml), bis-(2-chloroethyl)ether (810 mg, 5.7 m), potassium carbonate (782 mg, 5.7ml) and 18-crown-6 (132 mg, 0.49 ml) were dissolved in dry N,N-dimethylforTnamide (10 ml) under argon atmosphere, which was then stirred at 100° C. for 2.5 hours. The reaction solution was cooled down to normal temperature, water was added thereto, and the mixture was extracted with ethyl acetate. The organic extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to flash column chromatography (n-hexane:ethyl acetate=2:1) to give the title compound (0.71 g, yield 35%) as a red oil.

[0460]¹H-NMR (300 MHz, CDCl₃) δ: 7.06 (d, 2H), 6.83-6.73 (m, 7H), 6.61 (d, 1H), 6.52 (dd, 1H), 5.13 (s, 2H), 5.08 (s, 2H), 4.66 (t, 1H), 4.26 (dd, 1H), 4.11 (t, 2H), 3.83 (t, 2H), 3.79 (t, 2H), 3.63 (t, 2H), 3.45 (s, 3H), 3.41 (s, 3H), 3.39 (dd, 1H)

[0461] Step 2) Synthesis of 4-{4-[2-(2-Iodoethoxy)ethoxy]phenyl}4-hydroxy-7-(methoxymethoxy)-3-(4-(methoxymethoxy)phenyl)chroman

[0462] 4-Hydroxy-4-{4-[2-(2-chloroethoxy)ethoxy]phenyl}-7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]chroman (490 mg, 0.9 mmol) was dissolved in 2-butanone (30 ml) under argon atmosphere. Then, sodium iodide (14 g, 9.3 mmol) and tetrabutylammonium iodide (1.6 g, 4-5 mmol) were added thereto, and the mixture was refluxed for 16 hours. The reaction solution was cooled down to normal temperature, concentrated, and diluted with ethyl acetate. Then, in order to eliminate the resulting NaCl and the excess sodium iodide and tetrabutylammonium iodide, the solution was filtered. The filtrate was concentrated under reduced pressure, and the residue was subjected to flash column chromatography (n-hexane:ethyl acetate=4:1→2:1) to give the title compound (527 mg, yield 90%) which is pale yellow and sticky.

Mass [M−H₂O]⁺=619

[0463] Step 3) Synthesis of 4-hydroxy-4-{4-{2-[2-4,4,5,5,5-pentafluoropentyl thio)ethoxy]ethoxy}phenyl}-7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]chr oman

[0464] 1-(4,4,5,5,5-Pentafluoropentylthio)acetate (67 mg, 4.15 mmol) was dissolved in MeOH (25 ml). 2N—NaOH (5 ml) was added thereto, and the mixture was stirred at room temperature for 30 minutes. 4-{4-[2-(2-Iodoethoxy)ethoxy]phenyl}-4-hydroxy-7-(methoxymethoxy)-3-[4-methoxymethoxyphenyl]chroman (527 mg, 0.83 mmol) dissolved in MeOH (25 ml) was added thereto, which was then stirred at 60° C. for 20 hours. The reaction solution was cooled down to room temperature, water was added, and the resulting mixture was extracted with ethyl acetate. The organic extract was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash column chromatography (n-hexane:ethyl acetate=4:1→2:1) to give the title compound (565 mg, yield 97%) as a colorless oil.

[0465]¹H-NMR (300 MHz, CDCl₃) δ: 7.05 (d, 2H), 6.82-6.71 (m, 7H), 6.61-(d, 1H), 6.49 (dd, 1H), 5-14 (s, 2H), 5.08 (s, 2H), 4.67 (t, 1H), 4.23 (dd, 1H), 4.07 (t, 2H), 3.76 (t, 2H), 3.67 (t, 2H)

[0466] Step 4) Synthesis of 7-hydroxy-4-{{2-[2-4,4,5,5,5-pentafluoro pentylthio)ethoxy]ethoxy}phenyl}-3-(4-hydroxyphenyl)-2H-chromene

[0467] 4-Hydroxy-4-{4-{2-[2-4,4,5,5,5-pentafluoropentylthio)ethoxyethoxy)}phenyl}-7-methdxymethoxy)-3-[4-methoxymethoxy)phenyl]chroman-4-ol (540 mg, 0.77 mmol) was dissolved in methanol (40 mg) under argon atmosphere. Pyridinium p-toluenesulfonate (1.94 g, 7.72 mmol) was added thereto, which was then vigorously refluxed for 10 hours. The reaction solution was cooled down to room temperature, concentrated under reduced pressure, and diluted with ethyl acetate (40 ml). This solution was stirred at room temperature for 30 minutes, filtered, and the filtrate was concentrated. The residue was subjected to flash column chromatography (n-hexane:ethyl acetate=2:1) to give the pale yellow oilic title compound (359 mg, yield 78%).

[0468]¹H-NMR (300 MHz, CDCl₃) δ: 7.01 (d, 2H), 6.82 (m, 4H), 6.68 (d, 1H), 6.59 (d, 2H), 6.40 (d, 1H), 6.28 (dd, 1H), 5.01 (s, 2H), 4.09 (t, 2H), 3.82 (t, 2H), 3.71 (t, 2H), 2.71 (t, 2H), 2.64 (t, 2H), 2.16 (m, 2H), 1.90 (m, 2H)

[0469] Step 5) Synthesis of 4-{4-{2-[2-4,4,5,5,5-pentafluoropentylthio)ethoxy]ethoxy}phenyl}-7-hydroxy-3-(4-hydroxyphenyl)-2H-chromene

[0470] 4-Hydroxy-4-{4-{2-[2-(4,4,5,5,5-pentafluoropentylthio)ethoxy]ethoxy}phenyl}-3-(4-hydroxyphenyl)-2H-chromene (359 mg, 0.06 mmol) was dissolved in MeOH (40 ml). Water (4.6 ml) and sodium periodate (193 mg, 0.90 mmol) were added thereto, and then the mixture was stirred under the atmosphere of normal temperature for 14 hours. The reaction solution was filtered, and the filtrate was concentrated. The residue was extracted with ethyl acetate, dried over anhydrous magnesium sulfate, and subjected to flash column chromatography (ethanol:ethyl acetate=1:19) to give the title compound (219 mg, yield 60%) as a yellow foamy solid.

[0471]¹H-NMR (300 MHz, CD₃OD) δ: 7.02 (d, 2H), 6.84 (m, 4H), 6.58 (d, 1H), 6.51 (d, 2H), 6.31 (d, 1H), 6.22 (dd, 1H), 4.93 (s, 2H), 4.13 (t, 2H), 3.97 (t, 2H), 3.82 (t, 2H), 3.12 (m, 1H), 3.02 (m, 1H), 2.91 (m, 2H), 2.81 (m, 2H), 2.05 (m, 2H)

EXAMPLE 6

[0472] Synthesis of (3RS,4RS)-4-]9-3-imethylaminopropylsulfinyl)non yl]-7-hydroxy-344-hydroxyphenyl)-3-methylthiochroman,

[0473] Step 1) Synthesis of 4-[9t-butyldimethylsilyloxy)-1-nonynyl]-4-hydroxy-7-methoxy-3-4methoxyphenyl)-3-methylthiochroman

[0474] To a solution of 9-(t-butyldimethylsilyloxy)-1-nonyne(12 g, 47.15 mmol) in dry tetrahydrofuran (150 ml) was added dropwise n-butyl lithium(25.5nie, 42.43 mmol, 1.66 mole/e in tetrahydrofuran) at −78° C., which was then stirred at −20° C. for 1 hour. Then, to this reaction mixture was added 7-methoxy-3-(4-methoxyphenyl)-3-methylthio chroman-4-one(3 g, 9.54 mmol) dissolved in tetrahydrofuran at the same temperature for 30 minutes, and the resulting mixture was stirred at —10° C. for 24 hours. After the reaction was completed, saturated ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to column chromatography (n-hexane:ethyl acetate=9:1) to stoichiometrically give the title compound (5.40g) as a colorless oil.

[0475]¹H-NMR (270 MHz, CDCl₃) δ: 7.86 (d, J=8.5 Hz, 1H, Ar—H), 7.59 (d, J=8.9 Hz 2H, Ar—H), 6.87 (d, J=8.9B2, 2H, Ar—H), 6.63 (m, 2H, Ar—H), 4.25 (d, J=12.6 Hz, 2H, C2-H), 3.81 (s, 3H, OCH₃), 3.77 (s, 3H, OCH₃), 3.59 (t, J=6.6 Hz, 2H, CH₂—OTBS), 2.70 (d, 12.6 Hz, 1H, C2-H), 2.18 (t, J=6.6 Hz, 3H, propargyl-CH₂ and OH), 1.48 (s, 3H, C3-CH₃), 1.36 (m, 10H, alkyl-H), 0.89 (s, 9H, t-butyl-H), 0.04 (s, 6H, 2×CH₃)

[0476] Step 2) Synthesis of 4-[9-t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0477] To a solution of 4-[9-(t-butyl dimethylsilyloxy)-1-nonynyl]-4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (5.40 g, 9.49 mmol) in 1,2dichloroethane (150 ml) were added zinc iodide(4.54 g, 14.23 mmol) and sodium cyanoborohydride(4.47 g, 71.17 mmol), which was then stirred at room temperature for 12 hours. After the reaction was completed, water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=9:1) to give the title compound (2.64 g, yield 50%, 3RS/4RS:3RS/4SR=6:1) as a colorless oil.

[0478]¹H-NMR (270 MHz, CDCl-₃, 3RS,4RS-compound) δ: 7.25 (m, 3H, Ar—H), 6.82 (d, J=8.9 Hz, 2H, Ar—H), 6.68 (m, 2H, Ar—H), 3.78 (s, 3H, OCH₃), 3.76 (s, 31H, OCH₃), 3.72 (s, 11, C4-H), 3.76 (d, J=12.2 Hz, 1H, C2-H), 3.58 (t,]=6.6 Hz, 2H, CH₂—OTBS), 2.99 (d, J=12.2 Hz, 1H, C2-H), 2.02 (m, 2H, propargyl-CH2), 1.44 (s, 3H, C3-CH₃), 1.20 (m, 10H, alkyl-H), 0.89 (s, 9H, t-butyl-H), 0.05 (s, 6H, 2×CH₃)

[0479] Step 3) Synthesis of 4-[9-t-butyldimethylsilyloxy)nonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0480] To a solution of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (2.64 g, 4.77 mmol) in methanol (15oni.e) and tetrahydrofuran (15 mg) was added 10% Pd-C (850 mg), which was then stirred at room temperature under hydrogen (atmospheric pressure) for 1 day. Ethyl acetate was added to the reaction solution. The resulting solution was filtered, extracted several times with ethyl acetate, and concentrated under reduced pressure to remove the organic solvent. Hydrogenation reaction was repeated three times under the same condition. After the organic solvent was removed, the residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=9:1) to give the title compound (2.20 g, yield 83%) as a colorless oil.

[0481]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.28 (d, J=8.9 Hz, 2H, Ar—H), 6.91 (m, 3H, Ar—H), 6.72 (d, J=2.3 Hz, 1H, C8-H), 6.58 (dd, J=8.6 and 2.3 Hz, 1H, C6-H), 3.82 (s, 3K, OCH₃), 3.78 (s, 31H, OCH₃), 3.64 (d, J=11.5SHz, 1H, C2-H), 3.56 (t, J=6.6 Hz, 2H, CH₂—OTBS), 2.98 (d, J=11.5 Hz, 1H, C2-H), 2.71 (brt, 1H, C4H), 1.48-1.17 (m, 19H, C3-CH₃ and alkyl-H), 0.88 (s, 9H, t-butyl-H), 0.03 (s, 6H, 2×CH₃)

[0482] Step 4) Synthesis of 4-(9-hydroxynonyl)-7-methoxy-3-(4-methoxy phenyl)-3-methylthiochroman

[0483] 4-[9-(t-Butyldimethylsilyloxy)nonyl]-7-methoxy-3-(4-meth oxyphenyl)-3-methylthiochroman (2.2 g, 3.95 mmol) was dissolved in tetrahydrofuran (150 ml), and 3N—HCl(11 ml) was added thereto. The reaction mixture was stirred at room temperature for 140 minutes. After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=8:2 and 1:1) to give the title compound (1.61 g, yield 92%) as a white solid.

[0484]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.29 (d, J=8.9 Hz, 2H, Ar—H), 6.91 (in, 3H, Ar—H), 6.71 (m, 1H, Ar—H), 6.58 (m, 1H, Ar—H), 3.82 (s, 3H, OCH₃), 3.78 (s, 3H, OCH₃), 3.68 (in, 4H, CH ₂—OH and C2-CH₂), 2.98 (d, J=11.6 Hz, 1H, C2-H), 2.78 (brt, 1H, C4-H), 1.56-1.08 (m, 19H, C3-CH₃ and alkyl-H).

[0485] Step 5) Synthesis of 4-(9-methanesulfonyloxynonyl)-7-methoxy-3-(4-methoxy-phenyl)-3-methylthiochroman

[0486] 4-(9-Hydroxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methyl thiochroman (882 mg, 1.99 mmol) was dissolved in dichloromethane (60 ml) and triethylamine (1.38 ml, 9.96 mmol), to which was added methanesulfonylchloride (0.77 ml, 9.96 mmol). The reaction mixture was stirred at room temperature for 40 minutes. After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, and dried over anhydrous magnesium sulfate. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=7:3) to give the title compound (0.74 g, yield 72%) as a colorless oil.

[0487]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.29 (d, J=8.9 Hz, 2H, Ar—H), 6.91 (m, 3H, Ar—H), 6.70 (d, J=2.3 Hz, 1H, C8-H), 6.58 (dd, J=8.5 and 2.3 Hz, 1H, Ar—H), 4.18 (t, J=6.6 Hz, 2H, OCH₂), 3.82 (s, 3H, OCH₃), 3.78 (s, 3H, OCH₃), 3.64 (d, J=11.3 Hz, 1H, C2-H), 2.99 (s, 3H, OSO₂CH₃), 2.97 (brd, J=not separated, 1H, C2-H), 2.78 (brs, 1H, C4-H), 1.63 (m, 3H, alkyl-H), 1.37-1.08 (m, 16H, C3-CH₃ and alkyl-H)

[0488] Step 6) Synthesis of 3-dimethylaminopropan-1-thiolacetate

[0489] To a solution of 3-dimethylaminopropyl chloride (1.77 g, 14.5 mmol) in acetone (40m) was added potassium thioacetate (3.64 g, 31.87 mmol), and the mixture was stirred at room temperature for 2 days. After the reaction was completed, the reaction mixture was filtered through a filter paper and washed three times with diethyl ether. The organic solution was combined and concentrated under reduced pressure to give the title compound (1.50 g, yield 64%) as a yellow oil. This compound thus obtained was used in the next reaction withour further purification.

[0490]¹H-NMR (270 MHz, CDCl₃) δ: 2.89 (t, J=7.2 Hz, 2H, C₁-CH₂), 2.40 (t, J=7.3, 2H, C3-CH₂), 2.32 (s, 3H, SCOCH₃), 2.27 (s, 6H, N(CH₃₂), 1.78 (quin, J=7.2 and 7.5 Hz, 2H, C2-CH₂)

[0491] Step 7) Synthesis of 4-[9-(3-dimethylaminopropylthio)nonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0492] To a solution of 3-dimethylaminopropyl-1-thiolacetate(596 mg, 3.69 mmol) in methanol (20 ml) was added 1M sodium methoxide(3.21 ml), and the resulting mixture was stirred at room temperature for 90 minutes. Then, 4-(9-methanesulfonyloxynonyl)-7-methoxy-3-(4-me thoxyphenyl)-3-methylthiochroman (290 mg, 0.566 mmol) dissolved in dry tetrahydrofuran (10 ml) was added dropwise thereto at room temperature. The reaction mixture was stirred overnight. After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, and dnred over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to give the title compound (300 mg, crude product, stoichiometfic yield) as an oil. This compound was used in the next reaction without further purification.

[0493]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.27 (d, J=8.9 Hz, 2H, Ar—H), 6.91 (m, 3H, Ar—H), 6.72 (d, J=2.3 Hz, 1H, C8-H), 6.58 (dd, J=8.2 and 2.3 Hz, 1H, C6-H), 3.82 (s, 3H, OCH₃), 3.77 (s, 3H, OCH₃), 3.64 (d, J=119 Hz, 1H. C2-H), 2.97 (d, J=11.9 Hz, 1H, C2-H), 2.72 (t, J=7.2 Hz, 2H, SCH₂), 2.50 (m. 3H, C4-H and SCH₂), 2.34 (t, 2H, J=6.6 Hz, N—CH₂), 2.22 (s, 6H, 2×NCH₃), 1.85 (m, 2H, SCH₂ CH2CH₂N), 1.75 (m, 2H, alkyl-H), 1.48-0.98 (m, 17H, C3-CH—. and alkyl-H)

[0494] Step 8) Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(3-dimethylaminopropylthio)nonyl]thiochroman

[0495] A mixture of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(3-dimethylaminopropylthio)nonyl]thiochroman (50 mg, 0.09 mmol), hydrobromic acid (0.13rmQ, 48% aqueous solution) and acetc acid (0.15 ml) was heated for 8 hours. After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate -solution and water, and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure to give the title compound (60 ml, crude product) as a colorless oil- This compound thus obtained was used in the next reaction without further purification.

[0496]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.23 (d, J=8.9 Hz, 2H, Ar—H), 6.85 (d, J=8.2 Hz, 1H, C5-H), 6.76 (d, J=8.6 Hz, 2H, Ar—H), 6.61 (d, J=2.3 Hz, 1H, C8-H), 6.50 (dd, J=8.2 and 2.3 Hz, 1H, C6-H), 4.96 (brs, 1H, OH), 4.92 (brs, 1H, OH), 3.64 (d, J=11.9 Hz, 1H, C2-H), 2.97 (d, J=11.9 Hz, 1H, C2-H), 2.71 (t, 3=6.6 Hz, 2H, SCH₂), 2.46 (m, 3H, C4-H and SCH₂), 2.34 (t, 2H, J=7.6 Hz, N—CH₂), 2.24 (s, 6H, 2×NCH₃), 1.86 (m, 2H, SCH₂ CH ₂CH₂N), 1.42-0.96 (m, 19H, C3-CH₃ and alkyl-H)

[0497] Step 9) Synthesis of (3RS,4RS)-4-[9-(3-dimethylaminopropylsulfinyl) nonyl]-7-hydroxy-3-{-4-hydroxyphenyl)-3-methylthiochroman

[0498] Methanol (7 ml) and water (1.5 ml) were added to a mixture of 7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-3dimethylaminopropylthio)nonylathi ochroman (60 mg) and sodium periodate (16 mg), and the mixture was stirred at room temperature for 4 hours. To the reaction mixture were added absolute methanol and a small quantity of anhydrous magnesium sulfate, which was then filtered through a filter paper. Then, the filtrate was concentrated under reduced pressure to remove the solvent. The cmde product thus obtained was subjected to amino silica gel plate (ethyl acetate:methanol=10:0.5) to give the title compound (26 mg, yield from the two steps 54%) as a white solid.

[0499]¹H-NMR (270 MHz, CD₃OD, 3RS,4RS-compound) δ: 7.08 (d, J=8.6 Hz, 2H, Ar—H), 6.66 (m, 3H, Ar—H), 6.43 (d, J=2.3 Hz, 1H, C8-H), 6.31 (dd, J=8.2 and 2.3H 1H, C6-H), 3.51 (d, J=11.6 Hz, 1H, C2-H), 2.83 (d, J=11.6 Hz, 1H, C2-H), 2.67 (m, 5H, C4-H and 2×S(O)CH₂), 2.42 (t, J=7.2 Hz, 2H, N—CH₂), 2.20 (s, 6H, 2×NCH;), 1.89 (m, 2H, SCH₂ CH ₂CH₂N), 1.65-0.95 (m, 19H, C3-CH₃ and alkyl-H)

EXAMPLE 7

[0500] Synthesis of (3RS,4RS)-4-]9-(N-4,4,5,5,5-pentafluoropentylamino sulfonylamino)noIIyl)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman

[0501] Step 1) Synthesis of 4-[9(t-butyldimethylsilyloxy)-1-nonynyl]-4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0502] 9-(t-Butyldimethylsilyloxy)-1-nonyne (7.1 g, 27.9 mmol) was dissolved in dry tetrahydroftiran(70 ml) under argon atmnosphere, which was then cooled down to −78° C. n-Butyllithium (15.1 l, 25.1 mmol, 1.66 mol/e solution in tetrahydrofuran) was slowly added dropwise thereto, and the mixture was stirred at −20° C. for 80 minutes. To this mixture was added dropwise 7-methoxymethoxy-3-(4-methoxymethoxy phenyl)-3 methyl chromanA-one(2.0 g, 5.58 mmol) dissolved in dry tetrahydrofuran (1 ml) at −20° C., and the resulting reaction mixture was stirred at the same temperature for 3 hours, and then stirred at −10° C. overnight. The reaction was quenched with water, and the reaction solution was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=9:1) to give the title compound (3.37 g, yield 99%) as a colorless oil.

[0503]¹H-NMR (270 MHz, CDCl₃) δ: 7.65 (d, 3-8.6 Hz, 1H, CS—H), 7.47 (d, J=8.9 Hz, 2H, Ar—H), 7.04 (d, 1=8.9 Hz, 2H, Ar—H), 6.66 (dd, 8.6 and 2.3 Hz, 1H, C6-H), 6.55 (d, J=2.3 Hz, 1H, C8-H), 5.19 (s, 2H, OCH₂OCH ₃), 4.90 (d, J=10.6 Hz, 1H, C2-H), 4.06 (d, J=10.6 Hz, 1H, C2-H), 3.60 (t, J=6.6 Hz, 2H, CH₂—OThS), 3.49 (s, 3H, OCH₂OCH ₃), 3.47 (s, 3H, OCH₂OCH ₃), 2.26 (t, J=6.9 Hz, 2H, propargyl-CH₂), 2.06 (s, 1H, OH), 1.50 (s, 3H, C3-CH₃), 1.58-1.23 (m, 10H, alkyl-H), 0.89 (s, 9H, t-butyl-H), 0.04 (s, 6H, 2×CH₃)

[0504] Step 2) Synthesis of 4-[9-(t-bttyldimethylsilyloxyk-1-nonynyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0505] To a solution of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (3.10 g, 5.06 mmol) in 1,2-dichloroethane(200 ml) were added zinc iodide (2.42 g, 7.59 mmol) and sodium cyanoborohydride(2.23 g, 35.42 mmol), which was then stirred at room temperature for 8 hours. After the reaction was completed, water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=9:1) to give the title compound (1.50 g, yield 50%, 3RS/4RS:3RS14SR=6:1) as a colorless oil.

[0506]¹H-NMR (270 MHz, Ct)Cl₃, 3RS,4RS-compound) δ: 7.27. (m, 3H, Ar—H), 6.94 (d, J=8.9 Hz, 2H, Ar—H), 6.61 (dd, J=8.3 and 2.3 Hz, 1H, C6-H), 6.51 (d, J=2.3 Hz, 1H, C8-H), 5.14 (s, 2H, OCH₂OCH₃), 5.12 (s, 2H, OCH ₂—OCH₃), 4.49 (d, J=10.6 Hz, 1H, C2-H), 4.16 (d, J=10.6 Hz, 1H, C2-H), 3.89 (brs, 1H, C4-H), 3.58 (t, J=6.6 Hz, 2H, CH110TS), 3.47 (s, 3H, OCH₂OCH ₃), 3.46 (s, 3H, OCH₂OCH ₃), 2.03 (m, 2H, propargyl-CH2), 1.37 (s, 3H, C3-CH₃), 1.42-0.93 (m, 10H, alkyl-H), 0.89 (s, 9H, t-butyl-H), 0.05 (s, 614, 2×CH₃)

[0507] Step 3) Synthesis of 4-[9-(t-butyldimethylsilyloxy)nonyl]-7-methoxy methoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0508] To a solution of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (150 g, 2.51 mmol) in methanol (100 ml) and tetrahydrofuran (10ml) was added 10% Pd-C(570 mg), which was then stirred at room temperature under hydrogen (atmospheric pressure) for 1 day. Ethyl acetate was added to the reaction solution, which was then filtered, extracted several times with ethyl acetate, and concentrated under reduced pressure to give the title compound (134 g, yield 89%, 3RS/4RS:3RS/4SR=6:1) as a colorless oil.

[0509]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.13 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.95 (dd, J=8.6 and 2.3 Hz, 1H, C6-H), 6.57 (m, 2H, Ar—H), 5.17 (s, 2H, OCH₂OCH ₃), 5.14 (s, 2H, OCH ₂OCH₃), 4.52 (d, J=10.6 Hz, 1H, C2-H), 4.25 (d, J=10.6 Hz, 1H, C2-H), 3.57 (t, J=6.6 Hz, 2H, CH₂—OTBS), 3.50 (s, 3H, OCH₂OCH ₃), 3.49 (s, 3H, OCH₂OCH ₃) 2.65 (brs, 1H, C4-H), 1.54-1.09 (m, 19H, C3-CH₃ and alkyl-H), 0.88 (s, 9H, t-butyl-H), 0.03 (s, 6H, 2×CH₃)

[0510] Step 4) Synthesis of 4-(9-hydroxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0511] 4-[9-(t-Butyldi methylsilyloxy)nonyl]-7-methoxymet hoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (1.34 g, 2.23 mmol) was dissolved in ethanol (70 ml), and pyridinium ptoluenesulfonate (426 mg, 1.70 mmol) was added thereto. The reaction mixture was stirred at room temperature for 10 hours, water was added, and the resulting mixture was extracted with ethyl acetate. The organic layer was separated, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=7:3 and 1:1) to give the title compound (831 mg, yield 77%) as a colorless oil. In this reaction, 247 mg(18%) of the unreacted starting compound was recovered.

[0512]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.12 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.95 (dd, J=8.6 and 2.3 Hz, 1H, C6-H), 6.57 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.14 (s, 2H, OCH ₂—OCH₃), 4.52 (d, J=10.6 Hz, 1H, C2-H), 4.25 (d, J=10.6 Hz, 1H, C2-H), 3.50 (s, 3H, OCH₂OCH ₃), 3.49 (s, 3H, OCH₂OCH ₃), 3.47 (t, J=not separated, 2H, CH ₂—OH), 2.63 (brs, 1H, C4-H), 1.57-1.06 (m, 19H, C3-CH₃ and alkyl-H)

[0513] Step 5) Synthesis of 4-(9-methanesulfonyloxynonyl)-7-methoxy methoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0514] 4-(9-Hydroxynonyl)-7-methoxymethoxy-3-(4-methoxyme thoxyphenyl)-3-methylchroman (435 mg, 0.89 mmol) was dissolved in dichloromethane (30 ml), to which were added triethylamine (0.62mf., 4.47 mmol) and methanesulfonyl chloride (0.34 ml, 4.47 mmol). The reaction mixture was stirred at room temperature for 30 minutes- After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate-7:3) to give the title compound (0.49 g, yield 97%) as a colorless oil.

[0515]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.12 (d, 3=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.95 (dd, J=8.6 and 2.3 Hz, 1H, C6-H), 6.58 (m. 2H, Ar—H), 5.16 (s, 2H, OCH ₂), 5.13 (s, 2H, OCH ₂OCH₃), 4.56 (d, J=10.6 Hz, 1H, C2-H), 4.23 (d, J=10.6 Hz, 1H, C2-H), 4.19 (t, J=6.6 Hz, OCH₂), 3.50 (s, 3H, OCH₂OCH ₃), 3.49 (s, 3H, OCH₂OCH ₃), 2.99 (s, 3H, OSO₂CH₃), 2.65 (brs, 1H, C4-H), 1.61 (m, 3H, alkyl-H), 1.42-1.02 (m, 16H, C3-CH₃ and alkyl-H)

[0516] Step 6) Synthesis of 4-(9-azidononyl)-7-methoxymethoxy-3-(4-methoxy methoxyphenyl)-3-methylchroman

[0517] To a solution of 4-(9-methanesulfonyloxynonyl)-7-methoxy methoxy-3-(4-methoxymehoxyphenyl-3-methylchroman (499 mg, 0.966 mmol) in N,N-dimethyl-formamide (8 ml) was added sodium azide (281 mg, 4.33 mmol), which was then stirred at 50° C. for 2 hours. After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=7:3) to give the title compound (411 mg, yield 93%) as a white solid.

[0518]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.13 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.95 (dd, J=8.6 and 2.3 Hz, 1H, C6-H), 6.56 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.14 (s, 2H, OCH ₂OCH₃), 4.52 (d, J=10.5 Hz, 1H, C2-H), 4.25 (d, J=10.6 Hz, 1H, C2-H), 3.50 (s, 3H, OCH₂OCH ₃), 3.49 (s, 3H, OCH₂OCH ₃), 3.22 (t, J=6.9 Hz, 2H, CH₂N₂), 2.62 (brs, 1H, C4-H), 1.55-1.02 (m, 19H, C3-CH₃ and alkyl-H)

[0519] Step 7) Synthesis of 4-(9-aminononyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0520] To a solution of 4-(9-azidononyl)-7-methoxymethoxy-3-(4-me thoxymethoxyphenyl)-3-methylchroman (411 mg, 0.80 mmol) in methanol (100 ml) was added 10% Pd—C (100 mg), which was then stirred overnight at room temperature under hydrogen (atmospheric pressure). The resulting mixture was filtered through cellite and concentrated under reduced pressure to give the title compound (391 mg, stoichiometric yield) as a white solid.

[0521]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.13 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.94 (m, 1H, Ar—H), 6.55 (m, 2H, Ar—H), 5.17 (s, 2H, OCH₂OCH ₃), 5.14 (s, 2H, OCH₂OCH ₃), 4.52 (d, J=10.5 Hz, 1H, C2-H), 4.25 (d, J=10.6 Hz, 1H, C2-H), 3.49 (s, 3H, OCH₂OCH ₃), 3.48 (s, 3H, OCH₂OCH ₃), 2.65 (t J=6.6 Hz, 2H, CH₂NH₂), 2.62 (brs, 1H, C4-H), 1.39-1.06 (m, 19H, C₃-CH₃ and alkyl-H).

[0522] Step 8) Synthesis of 4-[9-(N-t-butyloxycarbonylaminosulfonylamino) nonyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0523] To a solution of chlorosulfonylisocyanate (25 μl, 0.292 mmol) in dichloromethane (1 ml) was added t-butanol (27 μl, 0.292 mmol) at −38° C. for 10 minutes, which was then stirred for 2.5 hours. Then, the reaction mixture was cooled down to −78° C., 4-(9-aminononyl)-7-methoxy methoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (118 mg, 0.243 mmol) dissolved in triethylamine (50 μl, 0.364 mmol) and dichloromethane (1 ml) was slowly added thereto, and the resulting mixture was stirred overnight at room temperature. After the reaction was completed, saturated ammonium chloride solution was added to the reaction solution, and the resulting solution was extracted with ethyl acetate. The organic layer was washed with diluted hydrochloride solution, water and saturated sodium chloride solution, and dried over anhydrous magnesium sulfate. The residue was subjected to preparative TLC (chloroform:methanol=10:1) to give the title compound (57 mg, yield 36%) as a white solid.

[0524]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.13 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.94 (dd, J=8.6 and 2.3 Hz, 1H, C6-H), 6.56 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.14 (s, 2H, OCH ₂OCH₃), 4.52 (d, 3-10.3 Hz, 1H, C2-H), 4.25 (d, 3=10.3 Hz, 1H, C2-H), 3.50 (s, 3H, OCH₂OCH ₃), 3.49 (s, 3H, OCH₂OCH ₃), 3.01 (t, J=6.2 Hz, 2H, CH ₂—NHSO₂NH), 2.63 (brs, 1H, C4-H), 1.48 (s, 9H, t-butyl-H), 1.28-1.05 (m, 19H, C3-CH₃ and alkyl-H)

[0525] Step 9) Synthesis of 4-[9-(N-t-butyloxycarbonyl-N-4,4,5,5,5-penta fluoropentylaminosulfonyl amino)nonyl]-7-methoxymethoxy-3-(4-methoxymethoxyph enyl)-3-methylchroman

[0526] To a solution of 4-[9-(N-t-butyloxycarbonylaminosulfonyl amino)nonyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (5 7 mg, 0.088 mmol) in dichloromethane (2 ml) were added 4,4,5,5,5-pentafluoropentyl alcohol (15.6 mg, 0.088 mmol) and triphenylphosphine (23 mg, 0.088 mmol) at room temperature. Diethyl azodicarboxylate in dichloromethane (1 ml) was added dropwise to the reaction mixture at the same temperature until the color of the reaction solution turned to yellow, which was then stirred overnight. After the reaction was completed, the organic solvent was evaporated under reduced pressure. The crude product thus obtained was subjected to preparative TLC (n-hexane:ethyl acetate=8:2) to give the title compound (47 mg, yield 67%) as a white solid.

[0527]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.13 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.94 (m, 1H, Ar—H),, 6.56 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.14 (s, 2H, OCH ₂OCH₃), 4.52 (d, J=10.2 Hz, 1H, C2-H), 4.25 (d, J=10.2 Hz, 1H, C2-H), 3.73 (t, J=6.5 Hz, 2H, CH ₂—N-Boc), 3.50 (s, 3H, OCH₂OCH ₃), 3.49 (s, 3H, OCH₂OCH ₃), 2.91 (t, J=6.9 Hz, 2H, CH ₂—NHSO₂NH), 2.62 (brs, 1H, C4-H), 1.94 (m, 4H, alkyl-H), 1.52 (s, 9H, t-butyl-H), 1-24-1.09 (m, 19H, C3-CH, and alkyl-H)

[0528] Step 10) Synthesis of (3RS,4RS)-4-[9-(N-4,4,5,5,5-pentafluoropentyl aminosulfonylamino)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman

[0529] To a solution of 4-[9-(N-t-butyloxycarbonyl-N-4,4,5,5,5-penta fluoropentylaminosul fonyl amino)nonyl]-7-methoxymethoxy-3-(4-methoxymethoxyph enyl)-3-methylchroman (47 mg, 0.058 mmol) in isopropanol (3 ml) and tetrahydrofuran (0.5 mg) was added 5N—HCl (0.8 ml) at room temperature, which was then stirred for 1.5 day. After the reaction was completed, saturated sodium bicarbonate solution was added to the reaction solution, and the resulting solution was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. To the residue were added dichloromethane (3 mg) and trifluoroacetic acid (0.25 ml) at room temperature, which was then stirred at the same temperature for 2 hours. The solution was concentrated under reduced pressure, and the residue was subjected to preparative TLC (n-hexane:ethyl acetate=7:3) to give the title compound (16 mg, yield 43%) as a white solid.

[0530]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.07 (d, J=8.6 Hz, 2H, Ar—H), 6.90 (d, J=7.9 Hz, 1H, Ar—H), 6.38 (d, 1=8.6 Hz, 2H, Ar—H), 6.37 (m, 2H, Ar—H), 5.27 (s, 1H, OH), 5.77 (s, 1H, OH), 4.50 (d, J=10.6 Hz, 1H, C2-H), 4.21 (m, 3H, C2-H and 2×NH), 3.15 (dd, 1=6.6 Hz, 2H, CH₂—NH), 2.61 (brs, 1H, C4-H), 2.09 (m, 2H, alkyl-H), 1.87 (s, 2H, alkyl-H), 1.49-1.06 (m, 19H, C3-CH₃ and alkyl-H)

EXAMPLE 8

[0531] Synthesis of 6-[(3RS,4RS){9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthio chroman-4-yl]nonylsulfinyl}hexanoic Acid

[0532] Step 1) Synthesis of 5-ethoxycarbonylpentan-1-thio]acetate

[0533] To a solution of ethyl 6bromohexanoate acid ethylester (2.23 g, 10 mmol) in polyethyleneglycol 400 (20 ml) was added potassium thioacetate (1.14 g, 10 mmol) at room temperature, which was then stirred overnight. Water was added to the reaction solution, and the resulting solution was extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (2.17 g, yield 94%) as a yellow oil. This product thus obtained was used in the next reaction without further purification.

[0534]¹H-NMR (270 MHz, CDCl₃) δ: 4.06 (q, J=7.2 Hz, 2H, COOCH ₂CH₃). 2.82 (dd, J=7.1 and 7.4 Hz, 2H, C1-CH₂), 2.25 (s, 3H, SCOCH₃), 2.21 (t, 2H, CH₂), 1.52 (m, 4H, 2×CH₂), 1.34 (m, 2H, CH₂), 1.19 (t, J=7.2 Hz, 3H, COOCH₂ CH ₂)

[0535] Step 2) Synthesis of {9-[7-methoxy-3-(4-methoxyphenyl)-3-methyl]thiochroman-4-yl}nonylthio-6-hexanoic acid

[0536] To a solution of 5-ethoxycarbonylpentan-1-thiolacetate (807 mg, 3.47 mmol) in ethanol (20 ml) was added 2N sodium hydroxide solution at room temperature, which was then stirred for 40 minutes. Then, 4-(9-methanesul fonyloxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochrom an (362 mg, 0.695 mmol) dissolved in dry tetrahydrofuran (12 ml) was added dropwise thereto at room temperature, and the resulting mixture was stirred overnight at room temperature. After the reaction was completed, the reaction mixture was acidified with 1N—HCl and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The concentrate was subjected to preparative TLC (n-hexane:ethyl acetate=1:1) to give the title compound (350 mg, yield 88%) as a white solid.

[0537]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.29 (d, J=8.9 Hz, 2H, Ar—H), 6.91 (m, 3H, Ar—H), 6.73 (d, J=2.3 Hz, 1H, thiochroman C8-H), 6.58 (dd, J=8.2 and 2.3 Hz, 1H, thiochroman C6-H), 3.82 (s, 3H, OCH₃), 3.77 (s, 3H, OCH₃), 3.64 (d, J=11.6 Hz, 1H, thiochroman C2-H), 2.98 (d, J=11.6 Hz, 1H, thiochroman C2-H), 2.72 (brs, 1H, thiochroman C4-H), 2.47 (m, 4H, 2×SCH₂), 2.35 (t, J=7.2 Hz, 2H, CH₂CO), 1.62-0.99 (m, 25H, thiochroman C3-CH₃ and alkyl-H)

[0538] Step 3) Synthesis of (3RS,4RS)-{9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methyl]thiochroman-4-yl}nonylthio-6-hexanoic Acid

[0539] {9-[7-Methoxy-3-(4-methoxyphenyl)-3-methyl]thiochroman-4-yl}nonylthio-6-hexanoic acid (350 mg, 0.61 mmol) was dissolved in dichloromethane (30 ml), and boron tribromide (2.63m., 1.0 mol/l solution in dichloromethane) was added thereto at −78 C. The reaction mixture was stirred at the same temperature for 1 hour, and further stirred at room temperature for about 8 hours. After the reaction was completed, water was added to the reaction mixture, which was then extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The concentrate was. subjected to preparative TLC (chloroform:methanol=10:1) to give the title compound (230,ng, yield 69%) as a white solid.

[0540]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.24 (d, J=8.6 Hz, 2H, Ar—H), 6.85 (m, 3H, Ar—H), 6.67 (d, J=2.7 Hz, 1H, thiochroman C8-H), 6.50 (dd, J=8.8 and 2.7 Hz, 1H, thiochroman C6-H), 3.62 (d, J=11.5 Hz, 1H, thiochroman C2-H), 2.95 (d, J=11.5 Hz, 1H, thiochroman C2-H), 2.69 (brs, 1H, thiochroman C4-H), 2.49 (m, 4H, 2×SCH₂), 2.37 (t, J=7.2 Hz, 2H, CH₂CO), 1.69-1.05 (m, 25H, thiochroman C3-CH₃ and alkyl-H)

[0541] Step 4) Synthesis of 6-{(3RS,4RS)-{9-[7-hydroxy-3-(4-hydroxy phenyl)-3-methylthiochroman-4-yl]-nonyl sulfinyl}-hexanoic Acid

[0542] To a solution of (3RS,4RS)-{9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methyl]thiochroman-4-yl}-nonylthio-6-hexanoic acid (1.65 mg, 0.30 mmol) in methanol (10 ml) and tetrahydrofuran (30 mg) was slowly added Oxone^(R) (monopersulfate compound; DuPont product) (186 mg, 0.30 mmol) dissolved in water (1 ml), which was then stirred at the same temperature for 10 minutes. After water was added thereto, the reaction solution was extracted with ethyl acetate. The extract was concentrated under reduced pressure, and subjected to preparative TLC (chloroform:methanol=10:1) to give the title compound (94 mg, yield 55%) as a white solid.

[0543]¹H-NMR (270 MHz, CD₃OD, 3RS,4RS-compound) δ: 7.16 (d, JJ=8.9 Hz, 2H, Ar—H), 6.78 (d, J=8.2 Hz, 1H, thiochroman C5-H), 6.69 (d, J=8.9 Hz. 2H, Ar—H), 6.47 (d, J=2.3 Hz, 1H, thiochroman C8-H), 6.35 (dd, 3=8.2 and 2.3 Hz, 1H, thiochroman C6-H), 3.53 (d, J=11.5 Hz, 1H, thiochroman C2-H), 2.85 (d, J=11.5 Hz, 1H, thiochroman C2-H), 2.68 (m, 5H, thiochroman C4-H and 2×SCOCH₂), 2.12 (t, J=7-3 Hz, 2H, COCH₂), 1.81-0.99 (m, 25H, thiochroman C3-CH₃ and alkyl-H)

EXAMPLE 9

[0544] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-12-(2-methoxyethoxy)ethylsulfinyl]nonyl}thiochroman

[0545] Step 1) Synthesis of 2-(2-methoxyethoxy)ethyl p-toluenesulfonate

[0546] To a solution of diethylene glycol monomethylether (12 g, 100 mmol) in pyridine (70 ml) was added p-toluenesulfonyl chloride (22.8 g, 120 mmol) at 0° C., which was then stirred at room temperature for 2 hours. Water was added thereto, and the mixture was extracted with diethyl ether. The extracted organic layer was washed with 0.5N—HCl, water and saturated sodium bicarbonate solution, and dried over anhydrous magnesium sulfate. The organic solvent was removed under reduced pressure to give the title compound (27 g, stoichiometric yield) as a yellow oil. The compound thus obtained was used in the next reaction without further purification.

[0547]¹H-NMR (270 MHz, CDCl₃) δ: 3.54 (m, 6H, 3×OCH₂), 3.35 (s, 3H, OCH₃), 3.07 (t, J=6.2 Hz, 2H, SCH₂), 2.31 (s, 3H, SCOCH₃)

[0548] Step 2) Synthesis of 2-(2-methoxyethoxy)ethyl Thioacetate

[0549] The title compound was prepared -from 2-(2-methoxyethoxy)ethyl p-toluenesulfonate according to the same procedure as Step 1 of Example 8.

[0550]¹H-NMR (270 MHz, CDCl₃) δ: 7.78 (d, J=8.0 Hz, 2H, Ar—H), 7.32 (d, J=7.7 Hz, 2H, Ar—H), 4.15 (dd, J=5.0 and 4.1 Hz, 2H, OCH₂), 3.67 (dd, J=5.5 and 4.1 Hz, 2H, OCH₂), 3.56 (m, 2H, OCH₂), 3.46 (m, 2H, OCH₂), 3.33 (s, 3H, OCH₃), 2.43 (s, 3H, CH₃)

[0551] Step 3) Synthesis of 7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-one

[0552] To a solution of 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one(2.27 g, 7.22 mmol) in acetic acid (75 ml) was added 48% aqueous HBr solution(75 mg), which was then heated under reflux for 1 day. The reaction mixture was extracted with diethyl ether. The organic layer was washed with saturated sodium bicarbonate solution and saturated saline solution, dried over anhydrous magnesium sulfate, and concentrated. Then, the residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=7:3 and 1:1) to give the title compound (1.92 g, yield 92%).

[0553]¹H-NMR (270 MHz, CDCl₃) δ: 8.12 (d, J=8.6 Hz, 1H, C5-H), 7.07 (d, J=8.6 Hz, 2H, Ar—H), 6.75 (d, J=8.6 Hz, 2H, Ar—H), 6.63 (d, J=8.6 and 2.3 Hz, 1H, C6-H), 6.56 (d, J=2.3 Hz, 1H, C8-H), 3.41 (s, 2H, C2-CH2), 1.26 (s, 3H, C3- CH₃)

[0554] Step 4) Synthesis of 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman-4-one

[0555] To a solution of 7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-one (1.92 g, 6.7 mmol) in dry acetone (200nim) were added potassium carbonate (8.34 g, 60.42 mmol) and methpxymethyl chloride (3.04aQ, 40.28 mmol), which was then heated for 8 hours. Water was added thereto, and the resulting solution was extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:etbyl acetate=7:3 and 1:1) to give the title compound (2.50 g, yield 99%).

[0556]¹H-NMR (270 MHz, CDCl₃) δ: 8.17 (d, J=8.9 Hz, 1H, C5-H), 7.14 (d, J=8.3 Hz, 2H, Ar—H), 6.95 (d, J=8.6 Hz. 2H, Ar—H), 6.80 (d, J=8.9 and 2.6 Hz, 1H, C6-H), 6.75 (d, J=2.3 Hz, 1H, C8-H), 5.24 (s, 2H, OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 3.48 (s, 2H, C2-CH2), 3.45 (s, 3H, OCH₂OCH ₃), 3.44 (s, 3H, OCH₂OCH ₃), 1.57 (s, 3H, C3-CH₃)

[0557] Step 5) Synthesis of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman

[0558] The title compound was prepared from 7-methoxymethoxy-3-(4-methoxy-methoxyphenyl}-3-methylthiochroman-4-one according to the same procedure as

[0559] Step 1 of Example 6.

[0560]¹H-NMR (270 MHz, CDCl₃) δ: 7.86 (d, J=8.9 Hz, 1H, C5-H), 7.59 (d, J=8.9 Hz, 2H, Ar—H), 7.01 (d, J=8.9 Hz, 2H, Ar—H), 6.82 (d, J=2.3 Hz, 1H, C8-H), 6.75 (dd, J=8.9 and 2.4 Hz, 1H, C6-H), 5.18 (s, 2H, OCH ₂OCH₃), 5.14 (s, 2H, OCH ₂OCH₃), 4.25 (d, J=12.6 Hz, 1H, C2-H), 3.56 (t, 1=6.6 Hz, 2H, CH₂—OTBS), 3.48 (s, 31, OCH₂OCH ₃), 3.46 (s, 3H, OCH₂OCH ₃), 2.69 (d, J=12.6 Hz, 1H, C2-H), 2.18 (m, 3H, OH and propargyl-CH₂), 1.58 (s, 3H, C3-CH₃), 1.57-1.29 (m, 10H, alkyl-H), 0.89 (s, 9H, t-butyl-H), 0.04 (s, 6H, 2×CH₃)

[0561] Step 6) Synthesis of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman

[0562] The title compound was prepared from 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthio-chroman according to the same procedure as Step 2 of Example 6.

[0563]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.43 (m, 3H, Ar—H), 6.97 (d, J=8.9 Hz, 2H, Ar—H), 6.84 (d, J=2.3 Hz, 1H, C8-H), 6.73 (dd, J=8.9 and 2.3 Hz, 1h, C6H), 5.15 (s, 2H, OCH ₂OCH₃), 5.12 (s, 2H, OCH ₂OCH₃), 3.77 (brs, 1H, C4-H), 3.65 (d, J=12.2 Hz, 1H, C2-H), 3.59 (t, J=6.6 Hz, 2H, CH₂—OTBS), 3.52 (s, 3H, OCH₂OCH ₃), 3.51 (s, 3H, OCH₂OCH ₃), 2.99 (d, J=12.2 Hz, 1H, C2-H), 2.04 (t, J=6.6 Hz, 2H, propargyl-CH₂), 1.55 (s, 3H, C3-CH₃), 1.49-1.25 (m, 10H, alkyl-H), 0.89 (s, 9H, t-butyl-H), 0.04 (s, 6H, 2×CH₃)

[0564] Step 7) Synthesis of 4-(9-hydroxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman

[0565] 4-[9-(t-Butyldimethylsilyloxy)-1-nonynyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman (1.43 g, 2.27 mmol) was dissolved in ethanol (100 ml) and tetrahydrofuran (10ml), and 20% palladium hydroxide on carbon (500 mg) which had been washed with ethanol was added thereto. The reaction solution was stirred for 1 day under hydrogen (atrnospheric pressure). Ethyl acetate was added to the reaction mixture, which was then filtered and concentrated. The concentrate was dissolved in dichloromethane (50 ml) and 1N-sodium hydroxide (2 ml), and tetra-n-butylammonium chloride (556 mg, 2 mmol) was added thereto at room temperature. To the reaction mixture was added dropwise methoxymethyl chloride (0.22m.e, 3 mmol) at the same temperaiure, which was then stirred for 2 hours. Water was added, and the resulting solution was extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=1:1) to give the title compound (855 mg, yield 75%) as a white solid.

[0566]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.27 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.6 Hz, 2H, Ar—H), 6.92 (d, J=8.3 Hz, 1H, CS—H), 6.87 (d, J=2.3 Hz, 1H, C8-H), 6.68 (dd, J=8.3 and 2.3 Hz, 1H, C6-H), 5.18 (s, 2H, OCH ₂OCH₃), 5.13 (s, 2H, OCH ₂OCH₃), 3.60 (m, 3H, C2-H and CH ₂OH), 3.49 (s, 3H, OCH₂OCH ₃), 3.48 (s, 3H, OCH₂OCH ₃), 2.98 (d, J=12.2 Hz, 1H, C2-H), 2.78 (brs, 1H, C4-H), 1.56-1.08 (m, 19H, C3-CH₃ and alkyl-H)

[0567] Step 8) Synthesis of 4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman

[0568] The title compound was prepared from 4-(9-hydroxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman according to the same procedure as Step 5 of Example 6.

[0569]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.27 (d, J=8.9 Hz, 2H, Ar—H), 7.01 (d, J=8.6 Hz, 2H, Ar—H), 6.91 (d, J=8.2 Hz, 1H, C5-H), 6.86 (d, J=2.3 Hz, 1H, C8-H), 6.67 (dd, J=8.2 and 2.3 Hz, 1H, C6-H), 5.17 (s, 2H, OCH ₂OCH₃), 5.12 (s, 2H, OCH ₂OCH₃), 4.17 (t, J=6.6 Hz, 2H, OCH₂), 3.61 (d, J=11.5 Hz, 1H, C2-H), 3.48 (s, 3H, OCH₂ CH ₃), 3.47 (s, 3H, OCH₂OCH ₃), 2.97 (m, 4H, C2-H and OSO₂CH₃), 2.78 (brs, 1H, C4-H), 1.67 (m, 3H, alkyl-H), 1.34-1.06 (m, 16H, C3-CH₃ and alkyl-H)

[0570] Step 9) Synthesis of 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-{9-[2-(2-methoxyethoxy)ethylthio]nonyl Thiochroman

[0571] The title compound was prepared from 4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman and 2-2-methoxyethoxy)ethyl thiolacetate according to the same procedure as Step 7 of Example 6.

[0572]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.28 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.91 (d, J=8.3 Hz, 1H, C5-H), 6.87 (d, J=2.3 Hz, 1H, C8-H), 6.67 (dd, J=8.3 and 2.3 Hz, 1H, C6-H), 5.18 (s, 2H, OCH ₂OCH₃), 5.14 (s, 2H, OCH ₂OCH₃), 3.58 (m, 7H, C2-H and 3×OCH₂), 3.49 (s, 3H, OCH₂OCH ₃), 3.48 (s, 3H, OCH₂OCH ₃), 3.37 (s, 3H, OCH₃), 2.97 (d, J=11.8 Hz, 1H, C2-H), 2.70 (m, 3H, C4-H and SCH₂), 2.50 (t, J=6.6 Hz, 2H, SCH₂), 1.56 (m, 3H, alkyl-H), 1.35-1.05 (m, 16H, C3-CH₃ and alkyl-H)

[0573] Step 10) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2-methoxyethoxy)ethylthio]nonyl}thiochroman

[0574] To a solution of 7-methoxymethoxy-3-(4-methoxymethoxyphenyl}3-methyl-4-{9-[2-(2-methoxyethoxy)ethylthio]nonyl}thiochroman (68 mg, 0.109 mmol) in isopropanol (5.5 ml) and tetrahydrofuran (0.9 ml) was added 5N—HCl (1.47 ml) at room temperature, which was stirred for 2 days. Water was added thereto, and the resulting solution was extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=1:1) to give the title compound (43 mg, yield 74%) as a white solid.

[0575]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.29 (d, J=8.9 Hz, 2H, Ar—H), 6.70 (m, 3H, Ar—H), 6.72 (d, J=2.3 Hz, 1H, C8-H), 6.54 (dd, J=8.2 and 2.3H, 1H, C6-H). 5.70 (s, 1H, OH), 5.37 (s, H, OH), 3.66 (m, 7H, C2-H and 3×OCH₂), 3.44 (s, 3H, OCH₃), 2.99 (d, J=11.5 Hz, 1H, C2-H), 2.76 (m, 3H, C4-H and SCH₂), 2.56 (t, J=6.6 Hz, 2H, SCH₂), 1.53 (m, 3H, alkyl-H), 1.33-1.09 (m, 16H, C3-CH₃ and alkyl-H)

[0576] Step 11) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2-methoxyethoxy)ethylsulfinyl]nonyl}thiochroman

[0577] The title compound was prepared from (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2-methoxyethoxy)ethylthio]nonyl}thiochroman according to the same procedure as Step 4 of Exampel 8.

[0578]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.62 (s, 1H, OH, diastereomer A), 7.21 (d, J=8.9 Hz, 2H, Ar—H), 7.15 (s, 1H, OH, diastereomer A), 6.85 (m, 3H, Ar—H), 6.67 (d, J=2.3 Hz, 1H, C8-H), 6.50 (m, 1H, C6-H), 5.70 (s, 1H, OH, diastereomer B), 5.43 (s, 1H, OH, diastereomer B), 3.95 (m, 2H, OCH₂), 3.62 (m, 5H, C2-H and 2×OCH₂), 3.39 (s, 3H, OCH₃), 2.87 (m, 6H, C2-H, C4-H and 2×S(O)CH₂), 1.72 (m, 3H, alkyl-H), 1.49-1.02 (m, 16H, C3-CH₃ and alkyl-H)

EXAMPLE 10

[0579] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl-3-methyl-4-{9-[2-2-hydroxyethoxy)ethylsulfinyl]nonyl}thiochroman

[0580] Step 1) Synthesis of −2-[2-(t-butyldimethylsilyloxy)ethoxy]ethyl Chloride

[0581] To a solution of ethylene glycol mono-2chloroethyl ether (6.2 g, 50 mmol) in acetonitrile (150 mg) were added imidazole(6.77 g, 99.54 mmol) and t-butyldimethylsilyl chloride (11.25 g, 74.65 mmol) at room temperature. The reaction mixture was stirred overnight at the same temperature. After the reaction was completed, the mixture was filtered through a filter paper, and concentrated under reduced pressure. Then, the concentrate was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=9:1) to give the title compound (11.0 g, yield 912%) as a colorless oil.

[0582]¹H-NMR (270 MHz, CDCl₃) δ: 3.86 and 3.63 (m, 8H, CH₂Cl and 3×OCH₂), 0.89 (s, 9H, t-butyl-H), 0.06 (s, 6H, 2×CH₃)

[0583] Step 2) Synthesis of 2-[2-(t-butyldimethylsilyloxy)ethoxy]ethyl Thioacetate

[0584] The title compound was prepared from 2-[2-(t-butyldimethylsilyloxy) ethoxy]ethyl chloride according to the same procedure as Step 1 of Example 8.

[0585]¹H-NMR (270 MHz, CDCl₃) o: 3:74 (dd, J=5.3 and 5.0 Hz, 2H, OCH₂), 3.60 (dd, J=6.6 and 6.3 Hz, 2H, OCH₂), 3.52 (dd, J=5.3 and 4.9 Hz, 2H, OCH₂), 3.08 (dd, J=6.2 and 6.6 Hz, 2H, SCH₂), 2.33 (s, 3H, SCOCH₃), 0.89 (s, 9H, t-butyl-H), 0.06 (s, 6H, 2×CH₃)

[0586] Step 3) Synthesis of 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-{9-[2-(2-t-butyldimethylsilyl oxyethoxy)ethylthio]nonyl}thiochroman

[0587] The title compound was prepared from 4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman and 2-[2-t-butyldimethylsilyloxy)ethoxy]ethyl thioacetate according to the same procedure as Step 7 of Example 6.

[0588]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.28 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.88 (d, J=8.3 Hz, 1H, C5-H), 6.86 (d, J=2.3 Hz, 1H, C8-H), 6.66 (dd, J=8.3 and 2.3 Hz, 1H, C6-H), 5.18 (s, 2H, OCH ₂OCH₃), 5.13 (s, 2H, OCH ₂OCH₃), 3.64 (m, 7H, C2-H and 3×OCH₂), 3.49 (s, 3H, OCH₂OCH ₃), 3.48 (s, 3H, OCH₂OCH ₃), 2.98 (d, J=11.8 Hz, 1H, C2-H), 2.68 (m, 3H, C4-H and SCH₂), 2.50 (t, J=6.6 Hz, 2H, SCH₂), 1.62-1.08 (m, 19H, C3-CH₃ and alkyl-H), 0.89 (s, 9H, t-butyl-H), 0.06 (s, 6H, 2×CH₃)

[0589] Step 4) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2-hydroxyethoxy)ethylthio]nonyl}thiochroman

[0590] The title compound was prepared from 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-{9-[2-2-t-butyldimethylsilyloxyethoxy)ethylthio]nonyl}thiochroman according to the same procedure as Step 10 of Example 9.

[0591]¹H-NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.23 (d, J=8.9 Hz, 2H, Ar—H), 6.85 (m, 3H, Ar—H), 6.67 (d, J=2.3 Hz, 1H, C8-H), 6.50 (dd, J=8.2 and 2.3 Hz, 1H, C6-H), 5.83 (s, 1H, OH), 5.39 (s, 1H, OH), 3.67 (m, 7H, C2-H and 3×OCH₂), 2.94 (d, J=11.5 Hz, 1H, C2-H), 2.72 (m, 3H, C4-H and SCH₂), 2.54 (t, 3=6.6 Hz, 2H, SCH₂), 1.53 (m, 3H, alkyl-H), 1.28-1.08 (m, 16H, C3-CH₃ and alkyl-H)

[0592] Step 5) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl({9-[2-2-hydroxyethoxy)ethylsulfinyl]nonyl}thiochroman

[0593] The title compound was prepared from (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl 4-{9-[2-(2-hydroxyethoxy)ethylthio]nonyl}thiochroman according to the same procedure as Step 4 of Example 8.

[0594]¹H-NMR (270 MHz, CD₃CD, 3RS,4RS-compound) δ: 7.17 (d, J=8.9 Hz, 2H, Ar—H), 6.77 (d, J=8.2 Hz, 1H, C5-H), 6.69 (d, J=8.9 Hz, 2H, Ar—H), 6.48 (d, J=2.3 Hz, 1H, C8-H), 6.36 (dd, J=8.2 and 2.3 Hz, 1H, C6-H), 3.81 (m, 2H, OCH₂), 3.58 (m, 3H, C2-H and OCH₂), 3.49 (m, 2H, OCH₂), 2.88 (m, 6H, C2-H, C4-H and 2×S(O)CH₂), 1.63 (m, 3H, alkyl-H), 1.40-1.04 (m, 16H, C3-CH₃ and alkyl-H)

EXAMPLE 11

[0595] Synthesis of (3RS,4RS)-7-hydroxy-3-(2-methylphenyl)-3-methyl-4-[9-(4,4,5,5-pentainuoropentyl)sulfinylnonyl]thiochroman

[0596] Step 1) Synthesis of 7-methoxy-3-(2-methylphenyl)-3-methylthiochroman-4-one

[0597] The title compound was prepared using ethyl 2-methylphenylacetate according to the same procedure described in International Patent Appln. No. PCT/KR97/00265.

[0598]¹H-NMR (270 MHz, CDCl₃) δ: 8.17 (d, 1H, J=8.9 Hz, C5-H), 7.44-7.34 (m, 1H, Ar—H), 7.24-7.12 (m, 3H), 6.75 (dd, 1H, J=8.9 Hz and 2.6 Hz, Ar—H), 6.70 (d, 1H, J=2.3tHz, C8-H), 3.90 (d, 1H, J=14.2 Hz), 3.84 (3H, s, OCH₃), 2.78 (d, 1H, J=14.2 Hz), 2.22 (s, 3H, Ar—CH₃), 1.81 (s, 3H, C3-CH₃)

[0599] Step 2) Synthesis of (3RS,4RS)-7-hydroxy-3-(2-methylphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentyl)sulfinylnonyl]thiochroman

[0600] The title compound was prepared from 7-methoxy-3-(2-methylphenyl)-3-methylthiochroman-4-one according to the same procedure described in International Patent Appln. No. PCT/KR97/00265.

[0601] EI-MS 604 (M+)

[0602]¹H-NMR (270 MHz, CDCl₃) δ: 7.30-7.12 (m, 4H, Ar—H), 6.87 (d, 1H, J=8.3 Hz, Ar—H), 6.69 (dd, 1H, J=2.3, 2.3 Hz, C8-H), 6.62 (s, 1H, OH), 6.56-6.50 (m, 1H, Ar—H), 3.80 (d, 1H, J=7.9 Hz, C2-H), 3.19 (d, 1H, J=7.9 Hz), 3.10-2.92 (1H, m, C4-H), 2.86-2.68 (m, 2H), 2.62 (s, 3H, Ar—CH₃), 2.40-2.10 (m, 4H), 1.76-1.60 (m, 2H), 1.36 (s, 3H, C3-CH₃), 1.36-1.00 (m, 16H)

EXAMPLE 12

[0603] Synthesis of (3RS,4RS)-7-hydroxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentyl-sulfinyl)nonyl]-3-(4-pyridyl)chroman

[0604] Step 1) Synthesis of 2-hydroxy-4-methoxy-2-(4-pyridyl)acetophenone

[0605] To a solution of lithium diisopropylamide (LDA) (2.0 mol/l, 35.2 ml, 70.4 mmol) in tetrahydrofuran (15 ml) was added dropwise a solution of 4-picoline (3.28 g, 3.52 mmol) in tetrahydrofuran (15 ml) under ice-cooling, which was then stirred for 30 minutes. Then, a solution of methyl 4-methoxysalicylate (4.0 g, 22 mmol) in tetrahydrofuran (20m) was added dropwise thereto, and the resulting mixture was heated under reflux for 3 hours. After the reaction was completed, the reaction solution was neutralized under ice-cooling using saturated aqueous NH₄Cl solution, extracted with ethyl acetate, and washed with water and saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:2) to give 2-hydroxy-4-methoxy-2-(4-pyridyl)acetophenone (3.51 g, yield 66%).

[0606] EI-MS : 243 (M+)

[0607]¹H-NMR (270 MHz, CDCl₃) δ: 12.53 (s, 1H, ArOH), 8.58 (d, 2H, J=5.6 Hz, pyridyl), 7.68 (d, 1H, J=8.6 Hz, Ar—H), 7.21 (d, 21, J=5.6 Hz, pyridyl), 6.48 (d, 1H, J=2.3 Hz, Ar—H), 6.45 (s, 1H, Ar—H), 4.22 (s, 2H, C(O)CH ₂), 3.85 (s, 1H, OCH₃)

[0608] Step 2) Synthesis of 7-methoxy-3-(4-pyridyl)chroman-4-one

[0609] To a solution of 2-hydroxy-4-methoxy-2-(4-pyridyl)acetophenone (3.51 g, 14.4 mmol) in tetrahydrofuran (30 ml) were added under ice-cooling dry acetate (2.72nit, 28.8 mmol) and a solution of N,N,N′,N′-tetramethyl-diaminomethane(1.96 ne., 14.4 mmol) in DMF (10 ml), which was then stirred for 30 minutes. After the reaction was completed, the reaction solution was neutralized under ice-cooling using saturated aqueous NaHCO₃ solution, extracted with ethyl acetate, and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was dissolved in tetrahydrofuran (20 mg), tetta-n-butylammonium fluoride (11.0 mmol/ g, 0.144 mg, 0.144 mmol) was added thereto under ice-cooling, and the resulting mixture was stirred at room temperature for 1 hour. After the reaction was completed, saturated aqueous NH₄Cl solution was added to the reaction solution, which was then extracted with ethyl acetate and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:2) to give 7-methoxy-3-(4-pyridyl)chroman-4-one(2.02 g, yield 55%).

[0610] EI-MS: 255(M+)

[0611]¹H-NMR (270 MHz, CDCl₃) δ: 8.57 (d, 2H, J=6.3 Hz, pyridyl), 7.89 (d, 1H, J=8.9 Hz, Ar—H), 7.24 (d, 2H, J=6.3 Hz, pyridyl), 6.63 (dd, 1H, J=2.3, 6.9 Hz, Ar—H), 6.46 (d, 1H, J=2.3 Hz, C8-H), 4.69 (d, 2H, J=6.3 Hz, C2-H), 3.89 (t, 1H, J=6.3 Hz, C3-H), 3.86 (s, 3H, OCH3)

[0612] Step 3) Synthesis of 7-methoxy-3-methyl-3-(4-pyridyl)chroman-4-one

[0613] To a solution of LDA(2.0 mol/l, 0.863 ml, 1.73 mmol) in tetrahydrofuran (1.5 ml) was added at −78° C. a solution of 7-methoxy-3-(4-pyridyl)chroman-4-one (220 mg, 0.863 mmol) in tetrahydrofuran (2 ml), which was then stirred for 30 minutes. Iodomethane (0.537 ml, 8.63 mmol) was added to -the reaclion solution, which was warmed to −10° C. and stirred for 3 hours. After the reaction was completed, the reaction solution was neutralized under ice-cooling using saturated aqueous NH₄Cl solution, extracted with ethyl acetate, and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:2) to give 7-methoxy-3-methyl-3-(4-pyridyl)chroman-4-one (131 mg, yield 56%).

[0614]¹H-NMR (270 MHz, CDCl₃) δ: 8.54 (dd, 2H, J=3.3, 6.3 Hz, pyridyl), 7.87 (d, 1H, J=8.9 Hz, Ar—H), 7.33 (dd, 2H, J=3.3, 6.3 Hz, pyridyl), 6.59 (dd, 1H, J=2.3 Hz, 8.9 Hz, Ar—H), 6.35 (d, 1H, J=2.3 Hz, C8-H), 4.85 (d, 1H, J=12.2 Hz, C2-H), 4.38 (d, 1H, J=12.2 Hz, C2-H), 3.81 (s, 3H, OCH₃), 1.48 (s, 3H, C3-CH₃)

[0615] Step 4) Synthesis of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-4-hydroxy-7-methoxy-3-methyl-3-(4-pyridyl)chroman

[0616] To a solution of an acetylene (525 mg, 1.94 mmol, separately synthesized) in tetrahydrofuran (5 ml) was added at −78° C. n-BuLi (1.59 mol/l, 1.02 ml, 1.62 mmol), which was then adjusted to −50° C. and stirred for 30 minutes. A solution of 7-methoxy-3-methyl-3-(4-pyridyl)chroman-4-one (290 mg, 1.08 mmol) in tetrahydro- furan (3 ml) was added thereto, and the resulting solution was adjusted to −10° C., and then stirred for 4 hours. After the reaction was completed, the reaction solution was neutralized under ice-cooling using saturated aqueous NH₄Cl solution, extracted with ethyl acetate, and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=3:1) to give 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-4-hydroxy-7-methoxy-3-methyl-3-(4-pyridyl)chroman (509 mg, yield 87%).

[0617]¹H-NMR (270 MHz, CDCl₃) δ: 8.54 (d, 2H, J=5.3 Hz, pyridyl), -7.64 (d, 1H, J=8.9 Hz, Ar—H), 7.46 (d, 2H, J=5.3 Hz, pyridyl), 6.58 (dd, 1H, J=2.6, 8.9 Hz, Ar—H), 6.41 (d, 1H, J=2.6 Hz, C8-H), 4.92 (d, 1H, J=10.2 Hz, C2-H), 4.09 (d, 1H, J=10.2 Hz, C2-H), 3.80 (s, 3H, OCH₃), 3.60 (t, 2H, J=6.4 Hz, CH ₂OTBS), 2.29 (t, 2H, J=6.9 Hz, CH ₂-acetylene), 1.60-1.24 (m, 10H), 1.50 (s, 3H, C3-CH₃), 0.89 (s, 9H, SiBu-t), 0.04 (s, 6H, SiCH₃×2)

[0618] Step 5) Synthesis of 4-(9-hydroxynonyl)-7-methoxy-3-methyl-3-(4-pyridyl) Chroman

[0619] To a solution of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]4-hydroxy-7-methoxy-3-methyl-3-(4-pyridyl)chroman (471 mg, 0.874 mmol) in 1,2-dichloroethane (6 ml) were added under ice-cooling:ZnI₂ (558 mg, 1.75 mmol) and NaBH₃CN (384 mg, 6.12 mmol), which was then stirred at room temperature for 3 hours. After the reaction was completed, water was added, and the resulting mixture was extracted with chloroform and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=3:1) to give a mixture containing 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxy-3-methyl-3-(4-pyridyl)chroman

[0620] This mixture was dissolved in ethyl acetate (5 ml), Pd(OH)₂(150 mg) was added thereto, and the resulting mixture was stirred overnight at room temperature under hydrogen. After the reaction was completed, the solvent was removed under reduced pressure. The residue was dissolved in EtOH (5 ml), Pd(OH)₂ (150 ml) was added thereto, then the mixture was stirred at 60° C. under hydrogen atmosphere for 3 days. After the reaction was completed, the reaction solution was filtered and the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (chloroform:methanol=10:1) to give 4-(9-hydroxynonyl)-7-methoxy-3-methyl-3-(4-pyridyl)chroman (108 mg, yield 31%).

[0621]¹H-NMR (270 MHz, CDCl₃) δ: 8.59 (d, 10/9H, J=5.9 Hz, pyridyl), 8.49 (d, 8/9H, J=5.6 Hz, pyridyl), 7.31 (d, 8/9H, J=5.6 Hz, pyridyl), 7.16 (d, 10/9H, J=5.9 Hz, Ar—H), 6.96 (d, 5/9H, J=8.6 Hz, pyridyl), 6.93 (d, 4/9H, J=8.6 Hz, Ar—H), 6.48 (dd, 5/9H, J=2.6, 8.6 Hz, Ar—H), 6.43 (d, 5/9H, J=2.6 Hz, C8-H), 6.39 (dd, 4/9H, J=2.6, 8.6 Hz, Ar—H), 6.32 (d, 4/9H, J=2.6 Hz, C8-H), 4.54 (d, 5/9H, J=10.6 Hz, C2-H), 4.31 (d, 4/9H, J=10.6 Hz, C2-H), 4.27 (d, 519H, J=10.6 Hz, C2-H), 4.04 (d, 4/9H, J=10.6 Hz, C2-H), 3.79 (s, 10/3H, OCH₃), 3.73 (s, 8/3H, OCH₃), 3.64 (t, 8/9H, J=6.3 Hz, CH ₂OH), 3.62 (t, 10/9H, J=6.3 Hz, CH ₂OH), 3.04-2.96 (m, 4/9H, C3-H), 2.72-2.64 (m, 5/9H, C3-H), 1.62-1.44 (m, 2H); 1.42-1.04 (m, 16H), 1.28 (s, 5/3H, C3-CH₃), 1.25 (s, 4/3H, C3-CH₃)

[0622] Step 6) Synthesis of 4-(9-methanesulfonyloxynonyl)-7-methoxy-3-methyl-3-(4-pyridyl)chroman

[0623] To a solution of 4-(9-hydroxynonyl)-7-methoxy-3-methyl-3-(4-pyridyl) chroman (108 mg, 0.272 mmol) in methylene chloride (2 ml) were added under ice-cooling triethylamine (0.057 ml, 0-41 mmol) and methanesulfonyl chloride (0.032 ml, 0.041 mmol), which was then stirred for 30 minutes. After the reaction was completed, saturated aqueous NH₄Cl solution was added, the resulting mixture was then extracted with methylene chloride and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:1) to give 4-(9-methanesulfonyl-oxynonyl)-7-methoxy-3-methyl-3-(4-pyridyl)chroman (49.2 mg, yield 38%).

[0624] EI-MS: 475(M+)

[0625]¹H-NMR (270 MHz, CDCl₃) δ: 8.58 (d, 10/9H, J=5.9 Hz, pyridyl), 8.48 (d, 8/9H, J=5.9 Hz, pyridyl), 7.29 (d, 8/9H, J=5.9 Hz, pynidyl), 7.15 (d, 10/9H, J=5.9 Hz, pyridyl), 6.96 (d, 5/9H, J=8.6 Hz, Ar—H), 6.91 (d, 4/9H, J=8.6 Hz, Ar—H), 6.48 (dd, 5/9H, J=2.3, 8.6 Hz, Ar—H), 6.43 (d, 5/9H, J=2.3 Hz, C8-H), 6.40 (dd, 4/9H, J=2.,, 8.6 Hz, Ar—H), 6.31 (d, 4/9H, J=2.3 Hz, C8-H), 4.54 (d, 5/9H, J=10.5 Hz, C2-H), 4.31 (d, 4/9H, J=10.5 Hz, C2-H), 4.27 (d, 5/9H, 1=10.5 Hz, C2-H), 4.22 (t, 8/9H, J=6.6 Hz, CH ₂OH), 4.20 (t, 10/9H, J=6.6 Hz, CH ₂OH), 4.06 (d, 4/9H, J=10.5 Hz, C2-H), 3.79 (s, 10/3H, OCH₃), 3.72 (s, 8/3H, OCH₃), 3.00 (s, 8/3H, CH₃SO2), 2.99 (s, 10/3H, CH₃SO₂), 2.72-2.66 (m, 5/9H, C3-H), 2.62-2.56 (m, 4/9H, C3-H), 1.80-160 (m, 2H), 1.44-1.04 (m, 16H), 1.28 (s, 5/3H, C3-CH₃), 1.26 (s, 4/3H, C3-CH₃)

[0626] Step 7) Synthesis of (3RS,4RS)-7-methoxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoro pentylthio)nonyl]-3-(4-pyridyl)chroman

[0627] To a solution of 4,4,5,5,5-pentafluoropentythioacetate(47.7 mg, 0.202 mmol, separately synthesized) in tetrahydrofuran(Iml) was added under nitrogen NaOMe (0.992 mmol/l, 0.183 ml, 0.182 mmol), which was then stirred for 15 minutes. A solution of 4-(9-methanesulfonyloxynonyl)-7-methoxy-3-methyl-3-(4-pyridyl)chroman (48.0 ml, 0.101 mmol) in tetrahydrofuran (1 ml) was added to the reaction solution, and the mixture was stirred overnight. After the reaction was completed, saturated aqueous NH₄Cl solution was added, the resulting mixture was then extracted with ethyl acetate and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:1) to give (3RS,4RS)-7-methoxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-3-(4-pyridyl)chroman (15.5 mg, yield 27%).

[0628]¹H-NMR (270 MHz, CDCl₃) δ: 8.39 (d, 2H, J=5.9 Hz, pyridyl), 7.14 (d, 2H, J=5.9 Hz, pyridyl), 6.96 (d, 1H, J=8.3 Hz, Ar—H), 6.49 (dd, 1H, J=2.3, 8.3 Hz, Ar—H), 6.43 (d, 1H, J=2.3 Hz, C8-H), 4.54 (d, 1H, J=10.6 Hz, C2-H), 4.27 (dd, 1H, J=1.6, 10.6 Hz, C2-H), 3.79 (s, 3H, OCH₃), 2.74-2.66 (m, 1H, C4-H), 2.58 (t, 2H, J=6.9 Hz), 2.48 (t, 2H, J=7.3 Hz), 2.18-2.06 (m, 2H), 1.96-1.80 (m, 2H), 1.60-1.46 (m, 2H), 1.28 (s, 3H, C3-CH₃), 1.40-1.04 (m, 14H)

[0629] Step 8) Synthesis of (3RS,4RS)-7-hydroxy-3-methyl-4[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-3-(4-pyridyl)chroman

[0630] To a solution of (3RS,4RS)-7-methoxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-3-(4-pyridyl)chroman (15.2 mg, 0.0265 mmol) in methylene chloride (1 ml) was added at −78° C. BBr₃ (1.0 mol/l, 0.080 ml), which was then slowly warmed, and stirred for 2 hours under ice-cooling. After the reaction was completed. saturated aqueous NaHCO₃, solution was added under ice-cooling, the resulting mixture was then extracted with chloroform and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:1) to give (3RS,4RS)-7-hydroxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylthio)nonyl]-3-(4-pyridyl)chroman (6.3 mg, yield 43%).

[0631]¹H-NMR (270 MHz, CDCl₃) δ: 8.59 (d, 2H, J=5.9 Hz, pyridyl), 7.16 (d, 2H, J=5.9Iz, pyridyl), 6.91 (d, 1H, J=8.3 Hz, Ar—H), 6.42 (dd, 1H, J=2.3, 8.3 Hz, Ar—H), 6.39 (d, 1H, J=2.3 Hz, C8-H), 4.53 (d, 1H, J=10.2 Hz, C2-H), 4.26 (d, 1H, J=10.2 Hz, C3-H), 2.74-2.66 (m, 1H, C4-H), 2.58 (t, 2H, J=6.9 Hz), 2.48 (t, 2H, J=7.3 Hz), 2.18-2.02 (m, 2H), 1.96-1.80 (m, 2H), 1.60-1.46 (m, 2H), 1.28 (s, 3H, C3CH₃), 1.40-1.04 (m, 14H)

[0632] Step 9) Synthesis of (3RS,4RS)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-3-(4-pyridyl)chroman

[0633] To a solution of (3RS,4RS)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-3-(4-pyridyl)chroman (6.1 mg, 0.011 mmol) in tetrahydro- furan (0.5 ml) was added under ice-cooling a solution of Oxone^(R) (monopersulfate compound; DuPont product) (3.4 mg, 0.0055 mmol) in water (0.5 ml), which was then stirred for 5 hours. After the reaction was completed, the reaction solution was extracted with ethyl acetate and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography(ethyl acetate) to give (3RS,4RS)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-3-(4-pyridyl)chroman (5.1 mg, yield 81%).

[0634] EI-MS: 575(M+)

[0635]¹H-NMR (270 MHz, CDCl₃) δ: 8.58 (d, 2H, J=5.9 Hz, pyridyl), 7.1 6 (d, 2H, J=5.9 Hz, pyridyl), 6.90 (d, 1H, J=8.2 Hz, Ar—H), 6.43 (dd, 11H, J=2.3, 8.2 Hz, Ar—H), 6.39 (d, 1H, J=2.3 Hz, C8-H), 4.54 (d, 1H, J=10.6 Hz, C2-H), 4.26 (d, 1H, J=10.6 Hz, C2-H), 2.94-2.54 (m, 5H), 2.36-2.10 (m, 4H), 1.80-1.54 (m, 2H), 1.28 (s, 3H, C3-CH₃), 1.44-1.04 (m, 14H)

EXAMPLE 13

[0636] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]thiochroman

[0637] Step 1) Synthesis of 4,4,5,5,5-pentafluoropentylsulfonyl chloride ${CF}_{3}{{CF}_{2}\left( {CH}_{2} \right)}_{3}{{OTs}\underset{Acetone}{\overset{LiBr}{}}{CF}_{3}}{{CF}_{2}\left( {CH}_{2} \right)}_{3}{{Br}\underset{H_{2}O}{\overset{{Na}_{2}{SO}_{3}}{}}\underset{\underset{({3{\quad \quad}{step}{\quad \quad}34\%})}{DMF}}{\overset{{SOCl}_{2}}{}}{CF}_{3}}{{CF}_{2}\left( {CH}_{2} \right)}_{3}{SO}_{2}{Cl}$

[0638] To a solution of 1,1,1,2,2-pentafluoro-5-p-toluenesulfonyloxypentane (11.0 g, 3.0 mmol) in acetone (10 nm) was added LiBr (523 mg, 6.02 mmol), which was then heated under reflux for 4 hours. After the reaction solution was filtered, the solvent was removed under reduced pressure. The residue thus obtained was dissolved in water (10 ml), Na₂SO₃ (759 mg, 6.02 mmol) was added thereto, and the resulting mixture was heated under reflux for 17 hours. After the reaction was completed, to the residue which was obtained by removing the solvent under reduced pressure was added EtOH. This mixture was filtered while hot, and the filtrate was concentrated under reduced pressure. The residue was dissolved in benzene (5 ml), DMF (0.5 ml) and thionyl chloride (0.383 ml, 5.25 mmol) were added thereto, and the mixture was heated under reflux overnight. After the reaction was completed, saturated aqueous NaHCO₃ solution was added. The resulting mixture was then extracted with methylene chloride and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=10:1) to give 4,4,5,5,5-pentafluoropentylsulfonyl chloride (267 mg, yield 34%).

[0639]¹H-NMR (300 MHz, CDCl₃) δ: 3.77 (t, 2H, J=6.6Hz, CH ₂SO₂Cl), 2.48-2.24 (m, 4H)

[0640] Step 2) Synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]thiochroman

[0641] To a solution of a mesylate (152 mg, 0.292 mmol, separately synthesized) in DMF (1 ml) was added under nitrogen NaN₃ (25.5 mg, 0.392 mmol), which was then stirred overnight at room temperature. After the reaction was completed, water was added under ice-cooling. The resulting mixture was extracted with ethyl acetate, and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and then the residue which was obtained by removing the solvent under reduced pressure was dissolved in MeOH (1 ml). Pd—C (40 mg) was added to this solution, and the resulting mixture was stirred under hydrogen overnight at room temperature. After the reaction solution was filtered, the residue obtained by removing the solvent under reduced pressure was dissolved in methylene chloride (2 ml). 4,4,5,5,5-penta-fluoropentylsulfonylchloride (155 mg, 0.595 mmol) and triethylamine (0.1 ml) were added thereto under ice-cooling, which was then stirred for 10 minutes. After the reaction was completed, saturated aqueous NaHCO₃ solution was added. The resulting mixture was then extracted with methylene chloride and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=8:1) to give 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]thiochroman (126 mg, yield 65%).

[0642]¹H-NMR (270 MHz, CDCl₃) δ: 7.29 (d, 2H, J=8.8 Hz, Ar—H), 6.93 (d, 2H, J=8.8 Hz, Ar—H), 6.90 (d, 1H, J=6.9 Hz, Ar—H), 6.73 (d, 1H, J=2.7 Hz, C8-H), 6.58 (dd, 1H, J=2.7, 6.9 Hz, Ar—H), 4.20-4.10 (m, 1H, NH), 3.83, 3.78 (respectively s, respectively 3H, OCH ₃×2), 3.64 (d, 1H, J=11.8 Hz, C2-H), 3.12-3.04 (m, 4H, CHNHSO₂ CH ₂), 3.00 (d, 1H, J=11.8 Hz, C2-H), 2.76-2.70 (m, 1H, C4-H), 2.36-2.06 (m, 4H, CH ₂ CH ₂CF₂CF₃), 1.58-1.44 (m, 2H, CH ₂CH₂NH), 1.17 (s, 1H, C3-CH₃), 1.30-1.00 (m, 14H)

[0643] Step 3) Synthesis of (3RS,4RS)-7-hydyoxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]thiochroman

[0644] To a solution of 7-methoxy-3-(4methoxyphenyl)-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]thiochroman (124 mg, 0-186 mmol) in methylene chloride (1 ml) was added at −78° C. BBr₃ (1.0 mol/l, 1.12 ml), which was then slowly warmed over 3 hours. After the reaction was completed, saturated aqueous NaHCO₃ solution was added at 0° C. The resulting mixture was then extracted with methylene chloride and washed with saturated saline solution. The organic layer was dried over magnesium sulfate, and the solvent was removed under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:2) to give (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]thiochroman (85.0 mg, yield 72%) and trans form thereof (12.0 mg, yield 10%).

[0645]¹H-NMR (270 MHz, CDCl₃) δ: 7.24 (d, 2H, J=8.5 Hz, Ar—H), 6.88 (d, 1H, J=8.3 Hz, Ar—H), 6.84 (d, 2H, J=8.5 Hz, Ar—H), 6.67 (d, 1H, J=2.7 Hz, C8-H), 6.51 (dd, 1H, J=2.7, 8.3 Hz, Ar—H), 5.28 (s, 1H, OH), 4.86 (s, 1H, OH), 4.32-4.26 (m, 1H, NH), 3.63 (d, 1H, J=11.5 Hz, C2-H), 3.16-3.06 (m, 4H, CH ₂NHSO₂ CH ₂), 2.96 (d, 1H, J=11.5 Hz, C2-H), 2.72-2.66 (m, 1H, C4-H), 2.36-2.10 (m, 4H, CH ₂ CH ₂CF₂CF₃), 1.58-1.44 (m, 2H, CH ₂CH₂NH), 1.17 (s, 1H, C3-CH₃), 1.30-1.00 (m, 14H)

EXAMPLE 14

[0646] Synthesis of (3RS,4RS)-3-(4-fluorophenyl)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5 pentafluoropentylsulfinyl)nonyl]thiochroman

[0647] Step 1) Synthesis of 3-(4-fluorophenyl)-7-methoxy-3-methylthiochroman-4 one

[0648] 3-(4-fluorophenyl)-7-methoxy-3-methylthiochroman-4-one was prepared from ethyl 4-fluorophenylacetate according to the same procedure described in International Patent Appln. No. PCT/KR97/00265.

[0649]¹H-NMR (270 MHz, CDCl₃) δ: 8.17 (1H, d, J=9 Hz, C5-H), 7.19 (2H, m, Ar—H), 6.98 (2H, m, Ar—H), 6.71 (1H, dd, J=9 and 2 Hz, C&H), 6.58 (1H, d, J=2 Hz, C8-H), 3.78 (3H, s, OCH₃), 3.44 (2H, d, J=5 Hz, C2-H), 1.59 (3H, s, C3-CH₃)

[0650] Step 2) Synthesis of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-3-(4-fluorophenyl)-4-hydroxy-7-methoxy-3-methylthiochroman

[0651] An alkyne compound (3.81 g, 15 mmol) separately prepared was dissolved in dry tetrahydrofuran (30 ml) and cooled down to −20° C. under argon. To this solution was added dropwise n-butyllithium (1.66 mol/l solution in hexane, 8.4 ml, 14 mmol), and the resulting mixture was stirred at −20° C. to —10° C. for 1 hour. Then, 3-(4-fluorophenyl)-7-methoxy-3-methylthiochroman-4-one(0.50 g, 5 mmol) dissolved in tetrahydrofuran (20 ml) was added dropwise thereto, and the mixture was stirred at −10° C. to 0° C. for 3 hours. After the reaction was completed, the mixture was poured to ice-water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the crude product. This crude product was subjected to silica gel column chromatography (n-hexane:ethyl acetate=20:1) to give 4-[9-t-butyldimethylsilyl oxy)-1-nonynyl]-3-(4-fluorophenyl)-4-hydroxy-7-methoxy-3-methylthiochroman (1.78 g, yield 64%).

[0652]¹H-NMR (270 MHz, CDCl₃) δ: 7.84 (1H, d, J=8 Hz, C5-H), 7.66 (2H, m, Ar—H), 7.01 (2H, m, Ar—H), 6.66-6.61 (2H, m, C6-H and C8-H), 4.23 (1H, d, J=13 Hz, C2-H), 3.78 (3H, s, OCH₃), 3.60 (2H, t, J=6 Hz, CH₂OTBS), 2.73 (1H, d, J=13 Hz, C2-H), 2.17 (3H, t, J=7 Hz, CH ₂C≡C and OH), 1.58 (3H, s, C3-CH ₃), 1.50-1.28 (10H, m, alkyl-H), 0.90 (9H, s. t-butyl-H), 0.05 (6H, s. Si(CH ₃)₂)

[0653] Step 3) Synthesis of 4-(9-hydroxynonyl)-3-(4-fluorophenyl)-7-methoxy-3-methylthiochroman

[0654] To a solution of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-3-(4-fluorophenyl)-4-hydroxy-7-methoxy-3-methylthiochroman (0.55 g, 0.99 mmol) in 1,2-dichloroethane (30 ml) were added zinc iodide(II) (0.35 g) and sodium cyanoborohydride (0.30 g), which was then stirred at 0° C. for 4 hours. After the reaction was completed, water was poured thereto, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give a crude product. This crude product was subjected to silica gel column chromatography (n-hexane:ethyl acetate=10:1) to give 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-3-(4-fluorophenyl)-7-methoxy-3-methylthiochroman (374 mg, yield 70%). This product thus obtained (374 mg) was dissolved in a solvent mixture of ethanol (30 ml) and tetrahydrofuran (10 ml), 20% palladium hydroxide carbon (0.16 g) washed with the reaction solvent was added, and the mixture was stirred under hydrogen at room temperature for 20 hours. The reaction solution was filtered through a cellite to remove the palladium carbon, and the filtrate was concentrated under reduced pressure to give the crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate-5:1) to give 4-(9-hydroxynonyl)-3-(4-fluorophenyl)-7-methoxy-3-methylthiochroman (a mixture of (3RS,4RS) and (3RS,4SR), (3RS,4RS)/(3RS,4SR)=about 6/1)(220 mg, yield 74%).

[0655]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.35 (2H, m, Ar—H), 7.06 (2H, m, Ar—H), 6.93 (1H, d, J=9 Hz, C5=H), 6.73 (1H, d, J=2 Hz, C8-H), 6.59 (1H, dd, J=9 and 2 Hz, C6H), 3-78 (3H, s, OCCH ₃), 3.66-3.59 (4H, m, C2-H and —CH ₂OH), 2.98 (1H, d, J=12 Hz, C2-H), 2.73 (1H, brs, C4-H), 1.19 (3H, s, C₃-CH ₃), 1.54-1.05 (16H, m. alkyl-H)

[0656] Step 4) Synthesis of 3-(4-fluorophenyl)-4-(9-methanesulfonyloxynonyl)-7-methoxy-3-methylthiochroman

[0657] 4-(9-Hydroxynonyl)-3-(4-fluorophenyl)-7-methoxy-3-methylthiochroman (0.41 g, 0.95 mmol) was dissolved in dichloromethane (50 ml), methanesulfonyl chloride (0.44 g) and triethylamine (0.41 g) were added thereto, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, water was poured thereto, and the mixture was extracted with chloroform (50 ml). The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=3:1) to give 3-(4-fluorophenyl)-4-(9-methanesulfonyloxynonyl)-7-methoxy-3-methylthiochroman (a mixture of (3RS,4RS) and (3RS, 4SR), (3RS,4RS)/(3RS,4SR)=about 6/1)(480 mg, yield 99%).

[0658]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.35 (2H, m, Ar—H), 7.06 (2H, m, Ar—H), 6.93 (1H, d, J=9 Hz, C5=H), 6.73 (1H, d, J=3 Hz, C8-H), 6.59 (1H, dd, J=9 and 3 Hz, C6-H), 4.19 (2H, t, J=7 Hz, —CH ₂OMs), 3.78 (3H, s, OCH ₃), 3.68-3.63 (1H, m, C2-H), 2.99 (4H, m, —SO₂CH ₃ and C2-H), 2.72 (1H, brs, C4-H), 1.19 (3H, s, C3-CH₃), 1.72-1.07 (16H, mn, alkyl-H)

[0659] Step 5) Synthesis of 3-(4-fluorophenyl)-7-methoxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[0660] A thioacetate (1.37 g, 5.8 mmol, separately prepared) was dissolved in methanol (10 ml), sodium methoxide (5.3 ml, 5.3 mmol, 1 mol/l in MeOH) was added thereto, and the mixture was stirred at room temperature for 1 hour. Then,

[0661] 3-(4-fluorophenyl)-4-(9-methanesulfonyl oxynonyl)-7-methoxy-3-methylthiochroman (0.48 g, 0.95 mmol) dissolved in tetrahydrofuran (10 ml) was added dropwise thereto, which was stirred at room temperature for 18 hours. After the reaction was completed, the reaction solution was neutralized by 50% aqueous acetate solution, water was poured thereto, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=30:1) to give 3-(4-fluorophenyl)-7-methoxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]methylthiochroman (a mixture of (3RS,4RS) and (3RS,4SR), (3RS,4RS)/(3RS,4SR)=about 6/1)(678 mg, stoichiometric yield):

[0662]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.34 (2H, m, Ar—H), 7.05 (2H, m, Ar—H), 6.93 (1H, d, J=8 Hz, C5=H), 6.73 (1H, d, J=2 Hz, C8-H), 6.59 (1H, dd, J=8 and 2 Hz, C6-H), 3.78 (3H, s, OCH:.), 3.64 (1H, d, J=12 Hz, C2-H), 2.98 (1H, d, J=12 Hz, C2-H), 2.72 (1H, brs, C4-H), 2.57 (2H, t, J=7 Hz, CH ₂—S—), 2.47 (2H, t, 1=7 Hz, CH ₂—S—), 2.30-1.84 (4H, m, —CH ₂CH₂CF₂CF₃), 1.55 (2H, m, —CH ₂CH₂S—CH₂)₃ CF₂CF₃), 1.19 (3H, s, C3-CH ₃), 1.39-1.05 (14H, m, alkyl-H)

[0663] Step 6) Synthesis of (3RS,4RS)-3-(4-fluorophenyl)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[0664] 3-(4-Fluorophenyl)-7-methoxy-3-methyl-4-[9-4,4 5,5,5-pentafluoropenty thio)nonyl]thiochroman (678 mg, 1.1 mmol) was dissolved in dry dichloro methane (40 ml), which was then cooled down to −78° C. under argon. To this solution was added dropwise BBr₃ (1.0 mol/l solution in dichloromethane, 35 ml, 35 mmol), and the reaction mixture was warmed to room temperature over 12 hours. After the reaction was completed, the mixture was poured into ice-water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, concentrated under reduced pressure to give a crude product. The crude product thus obtained was subjected to column chromatography (n-hexane:ethyl acetate=10:1, Lobar column) to purify the cis form, and thus (3RS,4RS)-3-(4-fluorophenyl)-7-hydroxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman (107 mg, yield 19%) was given.

[0665]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.34 (2H, m, Ar—H), 7.06 (2H, m, Ar—H), 6.89 (1H, d, J=8 Hz, C5-H), 6.68 (1H, d, J=3 Hz, C8-H), 6.51 (1H, dd, J=8 and 3 Hz, C6-H), 3.64 (1H, d, J=12 Hz, C2-H), 2.98 (1H, d, J=12 Hz, C2-H), 2-72 (1H, d, J=8 Hz, C4-H), 2.58 (2H, t, J=7 Hz, CHrS—), 2.48 (2H, t, J=7 Hz, CH _(2—)S—), 2.20-2.07 (2H, m, —CH ₂CF₂CF₃), 1.93-1.85 (2H, m, —CH ₂CH₂CF₂CF₃), 1.56-1.47 (2H, m, —CH ₂CH₂—S—(CH₂)₃CF₂CF₃), 1.19 (3H, s, C₃-CH ₃), 1.39-1.00 (14H, m, alklyl-H)

[0666] Step 7) Synthesis of (3RS,4RS)-344-fluorophenyl)-7-hydroxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman

[0667] To a solution of (3RS,4RS)-3-(4-fluorophenyl)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman (107 mg, 0.18 mmol) in tetrahydrofuran (8 ml) was added Oxone^(R) (monopersulfate compound; DuPont product)(60 mg, 0.1 0 mmol), which was then stirred at 0° C. for 5 minutes. Water (0.5 ml) was added thereto, and the resulting mixture was stirred at 0° C. for 1 hour. The reaction solution was poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. The crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=2:1) to give (3RS,4RS)-3-(4-fluorophenyl)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman (73 mg, yield 66%).

[0668]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.34 (2H, m, Ar—H), 7.05 (2H, m, Ar—H), 6.87 (1H, d, J=8 Hz, C5=H), 6.70-6.67 (2H, m, C8-H and OH), 6.58-6.52 (2H, m, C6-H and OH), 3.64 (1H, d, J=12 Hz, C2-H), 2.97 (1H, d, J=12 Hz, C2-H), 2.82-2.54 (5H, m, CH ₂—S—CH ₂, and C4-H), 2.29-2.13 (4H, m, —CH—CH ₂CF₂CF₃), 1.68 (2H, m, —CH ₂CH₂—SO—(CH₂)₃CF₂CF₃), 1.19 (3H, s, C3-CH₃), 1.39-1.05 (14H, m, alkyl-H)

EXAMPLE 15

[0669] Synthesis of (3RS,4RS)-3-(3fluorophenyl)-7-hydroxy-3methyl-4-[9-4,4,5,5,5-pentanuoropentylsulfinyl)nonyl]thiochroman

[0670] Step 1) Synthesis of 3-(3-fluorophenyl)-7-methoxy-3-methylthiochroman-4-one

[0671] 3-(3-Fluorophenyl)-7-methoxy-3-methylthiochroman-4-one was prepared from ethyl 3-fluorophenylacetate according to the same procedure described in International Patent Appln. No. PCT/KR97/00265.

[0672]¹H-NMR (270 MHz, CDCl₃) δ: 8.18 (1H, d, J=9 Hz, CS—H), 7.30-7.22 (1H, m, Ar—H), 7.00-6.91 (3H, m, Ar—H), 6.72 (1H, dd, J=9 and 2 Hz, C6-H), 6.59 (1H, d, J=2 Hz, C8-H), 3.80 (3H, s, OCH₃), 3.45 (2H, d, l=4 Hz, C2-H), 1.61 (3H, s, C3-CH₃)

[0673] Step 2) Synthesis of (3RS,4RS)-3-(3-fluorophenyl)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman

[0674] (3RS,4RS)-3-(3-Fluorophenyl)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentylsulfinyl)nonyl]thiochroman was prepared from 3-(3-fluorophenyl)-7-methoxy-3-methylthiochroman-4-one according to the same procedure as Steps 2 to 7 of Example 14

[0675]¹H-NMR (270 MHz CDCl₃, (3RS,4RS)) δ: 7 37-6.53 (8H, m, Ar—H and OH), 3.63 (1H, d, J=12 Hz, C2-H). 2.96 (1H, d, J=12 Hz, C2-H), 2.78-2.54 (5H, m, CH ₂—S—CH ₂, and C4-H), 2.40-2.18 (4H, m, —CH ₂CH ₂CF₂CF₃), 1.68 (2H, m, —CH ₂CH_(2—)SO—CH₂)₃CF₂CF₃), 1.19 (3H, s, C3-CH₃), 1.50-0.88 (14H, m, alkyl-H)

EXAMPLE 16

[0676] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[N-5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentylamino]propyl}chroman

[0677] Step 1) Synthesis of 4,4,5,5,5-pentafluoropentyl Thioacetate

[0678] To a solution of 4,4,5,5,5-pentafluoropentanol (23.2 g, 130 mmol) in dry dichloromethane (100 ml) were added dropwise at 0° C. triethylamine (27 g, 267 mmol) and methanesulfonylchloride (30 g, 262 mmol), which was then warmed to room temperature over 12 hours. After the reaction was completed, the mixture was poured into ice-water, and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product (33.9g). This crude product thus obtained was then dissolved in acetone (500 ml), potassium thioacetate(18 g, 158 mmol) was added thereto at room temperature, and the resulting mixture was stirred for 12 hours. The precipitate was filtered, and the filtrate was concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=20:1) to give 4,4,5,5,5-pentafluoropentyl thioacetate (15.8 g, yield 51%).

[0679]¹H-NMR (270 MHz, CDCl₃) δ: 2.94 (2H, t, J=7 Hz, CH ₂SAc), 2.34 (3H, s, COCH ₃), 2.20-1.80 (4H, m, alkyl-H)

[0680] Step 2) Synthesis of 5,5-imethoxy-1-(4,4,5,5,5-pentafluoropentylthio)pentane

[0681] To a suspension of LAH (0.4 g, 11 mmol) in tetrahydrofuran (20 ml) was added dropwise at 0° C. methyl 5,5-dimethoxyvalerate (3.5 g, 20 mmol) dissolved in tetrahydrofuran (30 ml), which was then stirred for 2 hours. After the reaction was completed, the mixture was poured into ice-water (50 ml) and then extracted with ether. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate-2:1) to give 5,5-dimethoxypentanol (1.02 g, yield 34%). Methanesulfonylchloride (3.2 g, 28 mmol) and triethylamine (3.0 g, 30 mmol) dissolved in dichloromethane (50 ml) were added thereto, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product (2.36 g). While, 4,4,5,5,5-pentafluoropentyl thioacetate (5.7 g, 24 mmol) prepared in Step 1 was dissolved in methanol (10 ml), sodium methoxide (23 mg, 23 mmol, 11.0 mol/l) was added thereto, and the resulting mixture was stirred at room temperature for 1 hour. To this solution was added dropwise the crude product prepared above (0.90 g) dissolved in tetrahydrofuran (10 ml), which was then stirred at room temperature for 5 hours. After the reaction was completed, the reaction mixture was poured into water and extracted with ether. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=20:1) to give 5,5- dimethoxy-1-(4,4,5,5,5-pentafluoropentylthio)pentane(460 mg).

[0682]¹H-NMR (270 MHz CDCl₃) δ: 4.35 (1H, t, J=6 Hz, CH(OCH₃)₂), 3.31 (6H, s, CH(OCH ₃)₂), 2.61-2.48 (4H, m, CH ₂—S—CH ₂), 2.30-2.05 (2H, m, —CH ₂CF₂CF₃), 1.93-1.82 (2H, CH ₂CH₂CF₂CF₃), 1.70-1.40 (6H, m, CH ₂CH ₂CH ₂CH(OCH₃)₂)

[0683] Step 3) Synthesis of 5,5-dimethoxy-1-(4,4,5,5,5-pentafluoropentylsulfinyl)pentane

[0684] To a solution of 5,5-dimethoxy-1-(4,4,5,5,5-pentafluoropentylthio)pentane (460 mg, 1.4 mmol) in methanol (10 mg) were added sodium periodate (420 mg, 2.0 mmol) dissolved in water (8 ml) and methanol (5 ml), and the resulting mixture was stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=2:1) to give 5,5-dimethoxy-1-(4,4,5,5,5-pentafluoropentylsulfinyl)pentane (365 mg, yield 76%).

[0685]¹H-NMR (270 MHz, CDCl₃) δ: 4.35 (1H, t, J=5 Hz, CH(OCH₃)₂), 3.31 (6H, s, CH(OCH ₃)₂), 2.80-2.60 (4H, m, CH ₂—SO—CH ₂), 2.30-2.10 (4H, m, —CH ₂CH ₂CF₂CF₃), 1.85-1.45 (6H, m, CH ₂CH ₂CH₂CH(OCH₃)₂)

[0686] Step 4) Synthesis of 5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentanal

[0687] 5,5-Dimethoxy-1-(4,4,5,5,5-pentafluoropentylsulfinyl)pentane (355 mg, 0.10 mmol) was dissolved in chloroform (2 ml), 50% TFA aqueous solution (2 ml) was added thereto at room temperature, and the resulting mixture was then stirred for 2 hours. After the reaction was completed, the reaction solution was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=2:1-1:1-ethyl acetate) to give 5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentanal (28 mg, yield 93%).

[0688]¹H-NMR (270 MHz, CDCl₃) δ: 9.79 (1H, s, CHO), 2.98-2.54 (6H, m, CH ₂—SO—CH ₂ and CH ₂CHO), 2.38-2.17 (4H, m, —CH ₂CH ₂CF₂CF₃), 1.82 (4H, m, CH ₂CH ₂CH₂CHO)

[0689] Step 5) Synthesis of 4-[3-(t-butyldimethylsilyloxy)-1-propynyl]-4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0690] An alkyne compound (1.5 g, 8.8 mmol, separately prepared) was dissolved in dry tetrahydrofuran (20 mg), which was then cooled down to −20° C. under argon. To this solution was added dropwise n-butyllithium (1.66 mol/l solution in hexane, 4.8 ml., 8.0 mmol), and the mixture was stirred at −20° C. to −10° C. for 1 hour. Then, a solution of the chromanone derivative(7)(1.0 g, 2.8 mmol) dissolved in dry tetrahydrofuran (20 ml) was added dropwise, and the mixture was stirred at −10C to 0° C. for 1 hour. After the reaction was completed, the reaction mixture was poured into ice-water and extracted with ether. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=5:1) to give 4-[3-(t- butyidimethylsilyloxy)-1-propynyl]-4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl chroman (1.26 g, yield 85%).

[0691]¹H-NMR (270 MHz, CDCl₃) δ: 7.65 (1H, d, J=9 Hz, C5-H), 7.50 (2H, d, J=9 Hz, Ar—H), 7.05 (2H, d, J=9 Hz, Ar—H), 6.66 (1H, dd, J=9 and 2 Hz, C6-H), 6.57 (1H, d, J=2 Hz, C8-H), 5.18 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.89 (1H, d, J=11 Hz, C2-H), 4.40 (2H, s, —CH ₂OTBS), 7.23-4.05 (1H, m, C2-H), 3.48 (3H, s, —OCH₃), 3.47 (3H, s, —OCH₃), 1.52 (3H, s, C3-CH₃), 0.92 (9H, s, t-butyl-H), 0.10 (6H, s, Si(CH ₃)₂)

[0692] Step 6) Synthesis of 4-[3-(t-butyldimethylsilyloxy)-1-propynyl-3-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0693] To a solution of 4-[3-(t-butyldimethylsilyloxy)-1-propynyl}-4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (1.26 g, 2.4 mmol) in 1,2-dichloroethane (80 ml) were added zinc iodide (II) (1.1 g) and sodium cyanoborohydride (1.1 g), which was then stirred at room temperature for 1 hour.

[0694] After the reaction was completed, the reaction mixture was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=5:1) to give 4-[3-(t-butyidimethylsilyloxy)-1-propynyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (a mixture of (3RS,4RS) and (3RS,4SR), (3RS,4RS)/(3RS,4SR)=about 6/1)(0.72 g, yield 59%).

[0695]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.35-6.51 (7H, m, Ar—H), 5.14 (2H, s, —OCH ₂O), 5.13 (2H, s, —OCH ₂O), 4.49 (1H, d, J=11 Hz, C2-H), 4.23-3.90 (4H, m, C2-H, —CH₂OTBS and C4-H), 3.47 (6H; s, (OCH₃)×2), 1.38 (3H, s, C3-CH₃), 0.83 (9H, s, t-butyl-H), 0.03 (6H, s, Si(CH₃)₂)

[0696] Step 7) Synthesis of −4-(3-hydroxypropyl)-7-methoxymethoxy-344-methoxymethoxyphenyl)-3-methylchroman

[0697] 4-[3-(t-Butyldimethylsilyloxy)-1-propynyl]-7-methoxymethoxy-3{(4-methoxymethoxyphenyl)-3-methylchroman (560 mg, 1.1 mmol) was dissolved in methanol (60 ml) and tetrahydrofuran (10 ml), 10% palladium on carbon (0.23g) was added thereto, and the resulting mixture was stirred at room temperature under hydrogen for 20 hours. The reaction solution was filtered through cellite and concentrated under reduced pressure to give a crude product. This crude product thus obtained was crudely purified using silica gel column chromatography (n-hexane:ethyl acetate=10:1) to give 4-[3-t-butyldimethylsilyloxy)propyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (0.44 g, yield 82%). This crude compound thus obtained (0.44g) was dissolved in methanol (20 ml), PPTS (pyridinium p-toluenesulfonate) (0.40g) was added thereto, and the mixture was stirred at room temperature for 3 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure to give a crude product. This crude product was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=2:1) to give 4-(3-hydroxypropyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchro man (a mixture of (3RS,4RS) and (3RS,4SR), (3RS,4RS)/(3RS, 4SR)=about 6/1)(0.28 g, yield 82%).

[0698]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.16-6.94 (5H, m, Ar—H), 6.58-6.51 (2H, m, Ar—H), 5.18 (2H, s, —OCH ₂O), 5.14 (2H, s, —OCH ₂O), 4.54 (1H, d, J=11 Hz, C2-H), 4.27 (1H, d, J=11 Hz, C2-H), 3.49-3.41 (8H, m, (OCH₃)×2 and CH ₂OH), 2.68 (1H, brs, C4-H), 1-26 (3H,. s, C3-CH₃), 1.56-1.06 (4H, m, alkyl-H)

[0699] Step 8) Synthesis of (3RS,4RS)-4-(3-azidopropyl)-7-methoxymethoxy-3-4-methoxymethoxyphenyl)-3-methylchroman

[0700] 4-(3-Hydroxypropyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (280 mg, 0.70 mmol) was dissolved in dichloromethane (50 ml), methanesulfonylchloride (0.32 g) and triethylamine (0.30 g) were added thereto, and the mixture was stirred at room temperature for 1 hour After the reaction was completed, the reaction mixture was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=3:1) to give 4-(3-methanesulfonyloxypropyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (a mixture of (3RS,4RS) and (3RS,4SR), (3RS,4RS)/(3RS,4SR)=about 6/1) (350 mg, stoichiometric yield). Then, to a solution of the product (0.59 g, 1.2 mmol) in DMF (15 ml) was added sodium azide (0.14g), and the mixture was stirred at 60° C. for 2 hours. After the reaction was completed, the reaction mixture was poured into water and extracted with ether. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC (n-hexane/ethyl acetate=10/1 for twice, 5/1 for twice) to produce (3RS,4RS)-4-(3-azidopropyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-m ethylchroman (220 mg, yield 42%).

[0701]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.14 (2H, d, J=9 Hz, Ar—H), 7.04 (2H, d, J=9 Hz, Ar—H), 6.95-6.91 (1H, m, Ar—H), 6.596.57 (2H, m, Ar—H), 5.18 (2H, s, OCH ₂O), 5.15 (2H, s, OCH ₂O), 4.52 (1H, d, J=11 Hz, C2-H), 4.29 (1H, d, J=11 Hz, C2-H), 3.49 (6H, s, (OCH₃)×2), 3.03 (2H, t, J=7 Hz, CH ₂N₃), 2.67 (1H, brs, C4-H), 1.19 (3H, s, C3-CH ₃), 1.57-1.10 (4H, m, alkyl-H)

[0702] Step 9) Synthesis of (3RS,4RS)-4-(3-aminopropyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0703] (3RS,4RS)-4-(3-Azidopropyl}7-methoxymethoxy-3-(4-methoxymethoxy phenyl)-3-methylchroman (170 mg, 4.0 mmol) was dissolved in methanol (20 ml) and tetrahydrofuran (5 ml), 10% palladium on carbon (50 mg) was added to this solution, which was then stirred at room temperature under hydrogen for 12 hours. The reaction solution was filtered through cellite and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (chloroform:methanol:ammonia water=10:1:0.1) to give (3RS,4RS)-4-(3-aminopropyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-m ethylchroman (116 mg, yield 73%).

[0704]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.13 (2H, d, J=9 Hz, Ar—H), 7.02 (2H, d, J=9 Hz, Ar—H), 6.96-6.93 (1H, m, Ar—H), 6.57 (2H, brs, Ar—H), 5.17 (2H, s, OCH ₂O), 5.14 (2H, s, OCH ₂O), 4.53 (1H, d, J=10 Hz, C2-H), 4.27 (1H, d, J=10 Hz, C2-H), 3.49 (6H, s, (OCH₃)×2), 2.66 (1H, brs, C4-H), 2.60-2.35 (2H, m, CH ₂NH₂), 1.25 (3H, s, C3-CH ₃), 1.60-1.00 (4H, m, alkyl-H)

[0705] Step 10) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-(3-N-5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentylamino]propyl} chroman

[0706] To a solution of (3RS,4RS)-4-(3-aminopropyl)-7-methoxymethoxy-3-4-methoxymethoxyphenyl)-3-methylchroman (80 mg, 0.20 mmol) and 5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentanal (80 mg, 0.19 mmol) in methanol (5 ml) was added a solution of sodium cyanoborohydride (12 mg, 0.19 mmol) in methanol (5 ml), which was then stirred at 0 for 2 hours. The reaction solution was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC on silica gel using chloroform/methanol/ammonia water (7/1/0.1) as a mobile phase to give (3RS,4RS)-7-methoxymethoxy-3-4-methoxymethoxyphenyl)-3-methyl-4-{3-[N-5-(4,4,5,5,5-pentafluoropentylsulfinyl)pe ntylamino]propyl}chroman (38 mg, yield 28%).

[0707]¹H-NMR (270 MHz, CDCl₃, (3RS,4RS)) δ: 7.14-6.95 (5H, m, Ar—H), 6.56-6.54 (2H, m, Ar—H), 5.17 (2H, s, —OCH ₂OCH₃), 5.12 (2H, s, —OCH ₂OCH₃), 4:51 (1H, d, J=11 Hz, C2-H), 4.25 (1H, d, J=11 Hz, C2-H), 3.49 (3H, s, —OCH₃), 3.47 (3H, s, —OCH₃), 2-73-2.45 (9H, m, CH ₂—SO—CH, CH ₂NHCH ₂ and C4-H), 2.41-2.08 (4H, m, —CH ₂CH ₂CF₂CF₃), 1.25 (3H, s, C3-CH₃), 1.79-1.10 (10H, m, alkyl-H)

[0708] Step 11) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(3-[N-5-(4,4,5,5,5-pentafluoropentyl sulfinyl)pentylamino]propyl}chroman

[0709] (3RS,4RS)-7-Methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-{3-[N-5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentylamminopropyl}chroman (38 mg, 0.056 mmol) was dissolved in hydrochloric acid/methanol (3 ml), which was then stirred at room temperature for 2 days. This reaction solution was basified using ammonia water, and concentrated under reduced pressure to give a crude product This crude product thus obtained was subjected to preparative TLC on aminosilica gel using chloroform/methanol (5/1) as a mobile phase to give (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-N-5S4,4,5,5,5-pentafluor opentyl sulfinyl)pentylamino]propyl) chroman (27 mg, yield 82%).

[0710]¹H-NMR (270 MHz, CD₃OD, (3RS,4RS)), δ: 7.05 (2H, d, J=9Ht, Ar—H), 6.85-6.71 (3H, m, Ar—H), 6.23-6.19 (2H, m, Ar—H), 4.46 (1H, d, J=10 Hz, C2-H), 4.16 (1H, d, J=10 Hz, C2-H), 2.86-2.60 (5H, m, CH ₂—SO—CH ₂ and C4-H), 2.40-2.27 (6H, m, —CH ₂CF₂CF₃ and CH ₂—NH—CH ₂), 2.05-1.99 (2H, m, —CH ₂CH₂CF₂CF₃), 1.12 (3H, s, C3-CH₃), 1.66-1.09 (10H, m, alkyl-H)

EXAMPLE 17

[0711] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(N-methyl-N-4,4,5,5,5-pentafluoropentyl)aminononyl]chroman

[0712] Step 1) Synthesis of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0713] An alkyne compound (2.0 g, 7.8 mmol, separately prepared) was dissolved in dry tetrahydrofuran (15 ml), which was then cooled down to −20° C. under argon. n-Butyllithium (1.66 mol/l solution in hexane, 4.2 ml, 7.0 mmol) was added dropwise to this solution, and the mixture was stirred at −20° C. to −10° C. for 1 hour. Then, the chromanone derivative (0.75 g, 2.1 mmol) dissolved in dry tetrahydrofuran (20 ml) was added dropwise thereto, which was stirred at −10° C. to 0° C. for 1 hour. After the reaction was completed, the reaction mixture was poured into ice-water and extracted with ether. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=5:1) to give 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl-4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (1.16 g, yield 90%).

[0714]¹H-NMR (270 MHz, CDCl₃) δ: 7.66 (1H, d, 1=9 Hz, C5-H), 7.48 (2H, d, J=9 Hz, Ar—H), 7,05 (2H, d, J=9 Hz, Ar—H), 6.67 (1H, dd, J=9 and 2 Hz, C6-H), 6.56 (1H, d, J=2 Hz, C8-H), 5.19 (2H, s, —OCH ₂OCH₃), 5.16 (2EI, s, —OCH ₂OCH₃), 4.91 (1H, d, J=11 Hz, C2-H), 4.60 (1H, d, J=11 Hz, C2-H), 3.60 (2H, t, J=7 Hz, —CH ₂OTBS), 3.50 (3H, s, —OCH₃), 3.47 (3H, s, —OCH₃), 2.27 (2H, t, J=7 Hz, —CH ₂C≡C), 1.51 (3H, s, C3-CH₃), 1.60-1.34 (IOH, m, alkyl-H), 0.89 (9H, s, t-butyl-H), 0.05 (6H, s, Si(CH ₃)₂)

[0715] Step 2) Synthesis of 4-[9-(t-butyldimethylsilyloxy)-nonyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0716] To a solution of 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (116 g, 1.9 mmol) in 1,2-dichloroethane (50 ml) were added zinc iodide(II) (0.7g) and sodium cyanoborohydride (0.6 g), which was then stirred at room temperature for 4 hours. After the reaction was completed, the reaction mixture was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=5:1) to give 4-[9-(t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (a mixture of (3RS,4RS) and (3RS,4SR), (3RS,4RS)/ (3RS,4SR)=about 6/1)(590 mg, yield 52%). Then, this compound thus obtained was dissolved in methanol (50 ml) and tetrahydrofuran (10 ml), 10% palladium on carbon (0.23%) was added thereto, and the resulting mixture was stirred at room temperature under hydrogen for 20 hours. The reaction solution was filtered through cellite and concentrated under reduced pressure to give 4-(9-t-butyldimethylsilyloxy)-nonyl)-7-methoxymethoxy-3-(4-methoxymethoxy phenyl)-3-methylchroman (crude product, 640 mg, stoichiometric yield, a mixture of (3RS,4RS) and (3RS,4SR), (3RS,4RS)/(3RS,4SR)=about 6/1).

[0717]¹H-NMR (270 MHz, CDCl₃) δ: 7.22-6.55 (7H, m, Ar—H), 5.18 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.52 (1H, d, J=10 Hz, C2-H), 4.25 (1H, d, J=10 Hz, C2-H), 3.59-3.46 (8H, m, —(OCH₃)×2, and CH ₂OTBS), 2.65 (1H, brs, C4-H), 1.47-1.07 (16H, m, alkyl-H), 1.25 (3H, s, C3-CH₃), 0.89 (9H, s, t-butyl-H), 0.05 (6H, s, Si(CH ₃)₂)

[0718] Step 3) Synthesis of (3RS,4RS)A-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0719] 4-[9-(t-Butyldimethylsilyloxy)-nonyl]-7-methoxymethoxy-3-(4-methoxy- methoxyphenyl)-3-methylchroman (0.62 g, 11.0 mmol) was dissolved in methanol (30 ml), PPTS (0.70 g) was added thereto, and the mixture was stirred at room temperature for 4 hours. After the reaction was completed, the reaction mixture was concentrated under reduced pressure. The residue was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=2:1) to give 4-(9-hydroxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (a mixture of (3RS,4RS) and (3RS,4SR), (3RS,4RS)/(3RS,4SR)=about 6/1, 370 mg, yield 77%). This compound thus obtained was dissolved in dichloromethane (20ml), methanesulfonylchloride (0.40 g) and triethylamine (0.38 g) were added thereto, and the mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC using n-hexane/ethyl acetate(5/1 for 6 times) to produce (3RS,4RS)-4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (241 mg, yield 56%).

[0720]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (2H, d, J=9 Hz, Ar—H), 7.03 (2H, d, J=9 Hz, Ar—H), 6.96-6.93 (1H, m, Ar—H), 6.58-6.55 (2H,- m, Ar—H), 5.18 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.52 (1H, d, J=10 Hz, C2-H), 4.23-4.17 (3H, m, C2-H and CH ₂OMs), 3.50 (6H, m, —(OCH₃)×2), 2.99 (3H, s, —OSO₂CH ₃), 2.65 (1H, brs, C4-H), 1.71 (2H, m, —CH ₂CH₂OMs), 1.25 (3H, s, C3-CH₃), 1.34-1.11 (14H, m, alkyl-H)

[0721] Step 4) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[9-(methylamino)-nonyl]chroman

[0722] To (3RS,4PS)-4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-4-methoxymethoxyphenyl)-3-methylchroman (241 mg, 0.43 mmol) was added a solution of 40% monomethylamine in methanol (40 ml), which was then stirred at room temperature for 24 hours. After the reaction was completed, the mixture was concentrated under reduced pressure- The residue was poured into 10% aqueous potassium carbonate solution, and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give (3RS,4RS)-7-methoxymethoxy-3-(4-methoxy-methoxyphenyl)-3-methyl-4-[9-(methylamino)-nonyl]chroman (191 mg, yield 90%).

[0723]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (2H, d, J=9 Hz, Ar—H), 7.02 (2H, d, J=9 Hz, Ar—H), 6.96-6.93 (1H, m, Ar—H), 6.57-6.55 (2H, m, Ar—H), 5.18 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.52 (1H, d, J=1 Hz, C2-H), 4.25 (1H, d, J=11 Hz, C2-H), 3.49 (6H, 's, —(OCH₃)×2), 2.64 (1H, brs, C4-H), 2.53 (2H, t, J=7 Hz, —CH ₂NHCH₃), 2.42 (3H, s, —NHCH ₃), 1.23 (3H, s, C3-CH₃), 1.46-1.11 (16H, m, alkyl-H)

[0724] Step 5) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[9-(N-methyl-N-4,4,5,5,5-pentafluoropentyl)-aminononyl]chroman

[0725] (3RS,4RS)-7-Methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[9-(methylamino)nonyl]chroman (73 mg, 0.14 mmol), 4,4,5,5,5-pentafluoropentyl-1 (p-toluenesulfonyloxy)pentane(180 mg, 0.54 mmol, separately prepared) and potassium carbonate(75 mg, 0.54 mmol) were dissolved in toluene, which was then stirred at 120° C. for 4 days. The reaction solution was concentrated under reduced pressure, water was poured into the residue, and the mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC on silica gel using chloroform/methanol (20/1) as a mobile phase to give (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[9-(N-methyl-N-4,4,5,5,5-pentafluoropentyl)aminononyl]chroman (80 mg, yield 88%).

[0726]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (21 d, J=9H7, Ar—H), 7.02 (2H, d, J=9 Hz, Ar—H), 6.976.93 (1H m, Ar—H), 6.59 (2H, brs, Ar—H), 5.18 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.53 (1H, d, J=10 Hz, C2-H), 4.26 (1H, d, J=10 Hz, C2-H), 3.50 (6H, s, —(OCH₃)×2), 2.65 (1H, brs, C4-H), 2.40-2.27 (4H, m, —CH ₂NMeCH ₂—), 2.19 (3H, s, —NCH ₃), 2.14-1.97 (2H, m, —CH ₂CF₂CF₃), 1.25 (3H, s, C3-CH₃), 1.76-1.11 (18H, m, alkyl-H)

[0727] Step 6) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(N-methyl-N-4,4,5,5,5-pentafluoropentyl)-aminononyl]chroman

[0728] 5% Hydrochloric acid/methanol (20 ml) was added to (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[9-(N-methyl-N-4,4,5,5,5-pentafluoropentyl)-aminononyl]chroman (85 mg, 0.13 mmol), which was then stirred at room temperature for 12 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC on silica gel using chloroform/methanol (10/1) as a mobile phase to give (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl[9-(N-methyl-N-4,4,5,5,5-pentafluoropentyl)-aminononyl chroman (66 mg, yield 90%).

[0729]¹H-NMR (270Mfz, CD₃OD, (3RS,4RS)) δ; 7.08 (2H, d, J=9 Hz, Ar—H), 6.85 (1H, d, J=8 Hz, C5-H), 6.77 (2H, d, J=9 Hz, Ar—H), 6.30 (1H, dd, J=8 and 2 Hz, C6-H), 6.24 (1H, d, J=2 Hz, C8-H), 4.49 (1H, d, J=11Hz, C2-H), 4.20 (1H, d, J=11 Hz, C2-H), 2.62 (1H, brs, C4-H), 2.50-2.35 (4H, m, —CH ₂NMeCH ₂) 2.25 (3H, s, —NCH ₃), 2.17-2.11 (2H, m, —CH ₂CF₂CF₃), 1.82-1.73 (2H, m, —CH ₂CH₂CF₂CF₃), 1.45-1.09 (16H, m, alkyl-H), 1.20 (3H, s, C3-CH₃)

EXAMPLE 18

[0730] Synthesis of N-methyl-N-(4,4,5,5,5pentafluor pentyl)-9-[(3RS,4RS)-7-hydroxy-(3-(4-hydroxyphenyl)-3-methylchroman-4yl]nonylamine N-oxide

[0731] To a solution of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(N-methyl-N-4,4,5,5,5-pentafluoropentyl)-aminonoyl]chroman (66 mg, 0.12 mmol) in chloroform was added at 0° C. mCPBA (30 mg, 0.12 mmol, 70%), which was then stirred for 3 hours. After the reaction was completed, the reaction solution was basified by adding ammonia water and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC on silica gel using chloroform/methanol (10/1) as a mobile phase to give N-methyl-N-(4,4,5,5,5-pentafluoropentyl)-9-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]nonylamine N-oxide(53 mg, yield 78%).

[0732]¹H-NMR (270 MHz, CD₃OD, (3RSi-4RS)) δ: 7.10-7.07 (2H, m, Ar—H), 6.85 (1H, d, J=8 Hz, C5-H), 6.78 (2H, d, J=9 Hz, Ar—H), 6.30 (11H, dd, J=9 and 2 Hz, C6-H), 6.24 (1H, d, J=2 Hz, C8-H), 4.49 (1H, d, J=10 Hz, C2-H), 4.20 (1H, d, J=10 Hz, C2-H), 3.29-3.16 (4H, m, —CH ₂N(O)MeCH ₂), 3.06 (3H, s, —N(O)CH ₃), 2.62 (1H, brs, C4-H), 2.32-2.10 (4H, m, —CH ₂CH ₂CF₂CF₃), 1.77-1.70 (2H, m, —CH ₂CH₂N(O)Me(CH₂)₃ CF₂CF₃), 1.27-1.00 (14H, m, alkyl-H), 1.20 (3H, s, C3-CH₃)

EXAMPLE 19

[0733] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3methyl-4-{3-4-[2-(4,4,5,5,5-pentafluoropentylsulfinyl)ethoxy]phenoxy}propyl}thiochroman

[0734] Step 1) Synthesis of 4-(2-t-butyldimethylsilyloxy)ethoxy phenol

[0735] 2-(4-Hydroxyphenoxy)-ethanol (1) (500 mg, 3.2 mmol) was dissolved in DMF (15 ml), which was then cooled down to 0° C. Imidazole (221 mg, 3.2 mmol) and TBSCl (489 mg, 3.2 mmol) were added thereto, and the mixture was stirred for 1 hour- Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magensium sulfate, concentrated under reduced pressure, and subjected to silica gel column chromatography to give 4-(2-t-butyldimethylsilyloxy)ethoxyphenol (2) (778 mg, yield 89%) as a colorless oily substance.

[0736]¹H NMR (270 MHz, CDCl₃) δ: 6.85-6.70 (4H, m), 4.7-4.6 (1H, brs), 4.0-3.9 (4H, m), 0.91 (9H, s), 0.10 (6H, s)

[0737] Step 2) Synthesis of 3-[4-(2-t-butyldimethylsilyloxyethoxy)phenoxy]-1-propyne

[0738] 4-(2-t-Butyldimethylsilyloxy)ethoxy phenol (2) (268 mg, 1.0 mmol) prepared in Step 1) was dissolved in acetone (5 ml), potassium carbonate (166 mg, 1.2 mmol) and propargyl bromide (163 mg, 1.1 mmol) were added thereto, and the mixture was heated under reflux for 20 hours. The reaction solution was cooled, and the precipitate was separated by filtration. The filtrate was diluted with ether and washed with 10% aqueous sodium hydroxide solution. The ether layer was acidfied with diluted hydrochloric acid and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, concentrated, and subjected to silica gel column chromatography to give 3-[4-(2-t-butyldimethylsilyloxyethoxy)phenoxy]-1-propyne (3) (237 mg, yield 78%) as a yellow oily substance.

[0739]¹H NMR (270 MHz, CDCl₃) δ: 6.95-6.80 (4H, m), 4.64 (2H, d, J=2.3 Hz), 4.05-3.90 (4H, m), 2:50 (1H, t, J=2.3 Hz), 0.91 (9H, s), 0.10 (6H, s)

[0740] Step 3) Synthesis of 4-[{3-[4-(2-t-butyldimethylsilyloxyethoxy)phenoxy]-1-propynyl}-4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman

[0741] The alkyne compound (3) prepared in Step 2 (1.61 g, 5.3 mmol). was dissolved in dry tetrahydrofuran (15 ml), which was then cooled down to −78° C. n-Butyllithium(1.59 mol/l, 2.97 mg, 4.7 mmol) was added dropwise thereto, and the mixture was warmed to −10C and stirred for 1 hour. To this reaction solution was added dropwise the separately synthesized ketone compound (4) (655 mg, 1.8 mmol) dissolved in dry tetrahydrofuran (15 ml), which was then stirred for 3 hours. Water was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, concentrated, and subjected to silica gel column chromatography to give 4-{3-[4-(2-t-butyldimethyl-silyloxyethoxy)phenoxy]-1-propynyl}-4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman (5) (938 mg, yield 79%) as a brown oily -substance.

[0742]¹H NMR (270 MHz, CDCl₃) δ: 7.71 (2H, d, 1=8-9 Hz), 7.49 (2H, d, J=8-9 Hz), 6.95 (2H, d, J=8.9 Hz), 6.90-6.80 (5H, m), 6.70 (2H, dd, J=8-6 Hz, 1.6 Hz), 5.17 (3H, s), 5.14 (3H, s), 2.33 (2H, s), 4.21 (1H, J=12.5 Hz), 4.05-3.90 (4H, m), 3.49 (3H, s), 3.46 (3H, s), 2.65 (2H, d, J=12.5 Hz), 2.23 (1H, s), 1.53 (3H, s), 0.91 (9H, s), 0.10 (6H, s)

[0743] Step 4) Synthesis of 4-{3-[4-(2-t-butyldimethylsilyloxyethoxy)phenoxy]-1propynyl}-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman

[0744] 4-{3-[4-(2-t-Butyldimethylsilyloxyethoxy)phenoxy]-1-propynyl}-4-hydroxy-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman (5) prepared in Step 3 (916 mg, 1.4 mmol) was dissolved in 1,2-dichloroethane (13.5 ml), zinc iodide (644 mg, 2 mmol) and sodium cyanoborohydride (634 mg, 10 mmol) were added, and the resulting mixture was stirred at room temperature for 1 day and stirred at 40° C. for further 3 hours. Water was added thereto, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, concentrated, and subjected to silica gel column chromatography to give 4-{3-[4-(2-t-butyldimethylsilyloxyethoxy) phenoxy]-1-propynyl}-7-methoxymethoxy-3-[4-methoxymethoxy)phenyl]-3-methyl thiochroman (6) (408 mg, yield 46%) as a yellow oily substance.

[0745]¹H NMR (270 MHz, CDCl₃) δ: 7.22 (2H, d, J=8-6 Hz), 7.16 (2H, d, J=8.6 Hz), 6.92 (2H, d, J=8.9 Hz), 6.82-6.68 (5H, m), 5.15 (2H, s), 5.13 (2H, s), 4.49 (2H, d, J=1.65), 4.02-3.9 (4H, m), 3.82 (1H, s), 3.83 (1H, s), 3.59 (1H, d, J=12.5 Hz), 3.47 (3H, s), 3.46 (3H, s), 2.92 (1H, s), 1.41 (3H, s), 0.92 (9H, s), 0.10 (6H, s)

[0746] Step 5) Synthesis of 4-{3-[4-(2-hydroxyethoxy)phenoxy]propyl}-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman

[0747] 4-{3-[4-(2-t-Butyldimethylsilyloxyethoxy)phenoxy]-1-propynyl}-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman (6) prepared in Step 4 (408 mg) was dissolved in a solvent mixture of ethanol (6 ml) and tetrahydrofuran (2 ml), 20% palladium hydroxide/carbon (130 mg) washed with ethanol was added, and the resulting mixture was stirred under hydrogen for 17 hours. The reaction solution was filtered through cellite, concentrated, and subjected to silica gel column chromatography to give 4-(3-[4-2-hydroxyethoxy)phenoxy]propyl}-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman (7) (241 mg, yield 71%) as a yellow oily substance.

[0748]¹H NMR (270 MHz, CDCl₃) δ: 7.28 (2H, d, J=10 Hz), 7.02-6.64 (9H, m), 5.18 (2H, s), 5.15 (2H, s), 4.1-3.96 (2H, m), 3.96-3.9 (2H, m), 3.7-3.6 (2H, m), 3.5 (3H, s), 3-49 (3H, s), 3.42 (1H, d, J=3.6 Hz), 3.0 (1H, d, J=12 Hz), 2.82 (1H, d, J=9.6 Hz), 1.65-1-5 (2H, m), 1.4-1.19-(5H, m)

[0749] Step 6) Synthesis of 4-{3-[4-(2-methanesulfonyloxyethoxy)phenoxy]propyl}-7-methoxymethoxy-3-[4-(methoxymethoxy)pbenyl]-3-methylthiochroman

[0750] 4-{3-[4-(2-Hydroxyethoxy)phenoxy]propyl}-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl}-3-methylthiochroman (7) prepared in Step 5 (45.6 mg, 0.082 mmol) was dissolved in CH₂Cl₂ (0.4 ml), which was then cooled down to 0° C. Triethylamine (23 μl, 0.17 mmol) and methanesulfonylchloride (16 μl, 0.21 mmol) were added thereto, and the mixture was stirred for 30 minutes. Saturated aqueous ammonium chloride solution was added, and the resulting mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, concentrated, and subjected to silica gel column chromatography to give 4-{3-[4-(2-methanesulfonyloxyethoxy)phenoxy]propyl}-7-methoxymethoxy-3-[4-(me thoxymethoxy)phenyl]-3-methylthiochroman (8) (49.2 mg, yield 95%) as a colorless oily substance.

[0751]¹H NMR (270 MHz, CDCl₃) δ: 7.8 (2H, d, J=11 Hz), 7.0-6.6 (9H, m), 5.18 (3H, s), 5.14 (3H, s), 4.6-4.5 (2H, m), 4.2-4.](2H, m), 3.7-3.6 (2H, m), 3.50 (3H, s), 3.49 (3H, s), 3.42 (1H, d, J=3.3 Hz), 3.08 (3H, s), 3.08 (1H, d, J=2.6 Hz), 2.83 (1H, d, J=7.6 Hz), 1.65-1.5 (2H, m), 1.3-1.19 (5H, m)

[0752] Step 7) Synthesis of (3RS,4RS) and (3RS,4SR)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-{3-{4-[2-(4,4,5,5,5-pentafluoropentylthio) ethoxy]phenoxy}propyl}thiocbroman

[0753] Pentafluoropentyl-thioacetate separately prepared (504 mg, 2.1 mmol) was dissolved in absolute methanol (1 ml), 1N sodium methoxide (2 ml) was added, and the resulting mixture was stirred for 1 hour. To this reaction solution was added dropwise 4-{3-[4-2-methanesulfonyloxyethoxy)phenoxy]propyl}-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methylthiochroman (8) prepared in Step 6 (270 mg, 0.43 mmol) dissolved in dry tetrahydrofuran (1 ml), which was then stirred for 20 hours. Saturated aqueous ammonium chloride solution was added, and the resulting mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, concentrated, and subjected to silica gel column chromatography and thin layer chromatography to give (3RS,4RS)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-{3-{4-[2-(4,4,5,5,5-pentafluoropentylthio)ethoxy]phenoxy}propyl}thiochroman (9) (167 mg, yield 54%) as a yellow oily substance and (3RS,4SR)-7-methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl-4-{3-{4-[2-(4,4,5,5,5-pentafluorop entylthio)ethoxy]phenoxy}propyl}thiochroman (10) (42 mg, yield 13%) as a yellow oily substance.

[0754]¹H NMR (270 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.28 (2H, d, J=8.8 Hz), 6.99 (3H, dd, J=8.9 Hz, 8.6 Hz), 6.89 (1H, d, J=2.3 Hz), 6.76 (2H, d, 1=8.9 Hz), 6.72 (1H, d, J=2.3 Hz), 6.65 (2H, d, J=9.2 Hz), 5.18 (21}, s), 5.14 (2H, s), 4.07 (2H, t, J=6.6 Hz), 3.7-3.6 (3H, m), 3.66 (3H, s), 3.62 (3H, s), 3.0 (1H, d, J=11.6 Hz), 2.9-2.8 (3H, m), 2.7 (21H, t, J=7.1 Hz), 2.3-2.1 (2H, m), 2.0-1.9 (2H, m), 1.7-1.5 (2H, m), 1.4-1.2 (2, m), 1.19 (3H, s)

[0755]¹H NMR (270 MHz, CDCl₃, 3RS,4SR-compound) δ: 7.3 (2H, d, J=8.9 Hz), 6.85-6.78 (7H, m), 6.7 (1H, d, J=2.0 Hz), 6.53 (2H, dd, J=8.3 Hz, 8.6 Hz), 5.08 (2H, s), 5.04 (2H, s), 4.09 (2H, t, J=6.6 Hz), 3.92-3.8 (2H, m), 3.43 (3H, s), 3.42 (3H, s), 3.27 (1H, d, J=13 Hz), 3.23 (1H, d, J=13 Hz), 3.0 (1H, d), 2.88 (2H, t, J=6.9 Hz), 2.71 (2H, t, J=6.9 Hz), 2.3-2.1 (2H, m), 2.0-1.9 (2H, m), 1.8-1.5 (4H, m), 1.39 (3H, s)

[0756] Step 8) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-{4-[2-(4,4,5,5,5-pentafluoropentylthio)ethoxy]phenoxy}propyl}thiochroman

[0757] (3RS,4RS)-7-Methoxymethoxy-3-[4-(methoxymethoxy)phenyl]-3-methyl 4-{3-{4-[2-(4,4,5,5,5-pentafluoropentylthio)ethoxy]phenoxy}propyl}thiochroman (9) prepared in Step 7 (144 mg, 0.2 mmol) was dissolved in hydrochloric acid/ methanol (1 ml) and tetrahydrofuran (0.1 ml), which was then stirred at room temperature for 4 days. Saturated aqueous sodium hydrogen carbonate solution was added to the reaction solution, and the resulting mixture was extracted with ethyl acetate and chloroform. The organic layer was dried over anhydrous magnesium sulfate, concentrated, and subjected to silica gel column chromatography to give (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-{4-[2-(4,4,5,5,5-pentafluoropentylthio)ethoxy]phenoxy)propyl}thiochroman (11) (110 mg, yield 87%) as a yellow oily substance.

[0758]¹H NMR (270 MHz, CDCl₃) δ: 7.22 (2H, d, J=9.6 Hz), 6.91 (1H, d, J=7.9 Hz), 6.50 (1H, dd, J=8.3 Hz, 2.6 Hz), 5.0 (2H, brs), 4.08 (2H, t, 1=6.6 Hz), 3.8-3.6 (3H, m), 2.98 (1H, d, J=11.5 Hz), 2.87 (2H, t, J=6.6 Hz), 2.78 (1H, d, J=9.2 Hz), 2.70 (2H, t, 1=6.9 Hz), 2.3-2.1 (2H, m), 2.0-2.9 (21, m), 1.7-1.5 (21, m), 1.4-1.2 (2H, m), 1.18 (3H, s)

[0759] Step 9) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-(4-[2-(4,4,5,5,5-pentafluoropentylsulfinyl)ethoxy]phenoxy}propyl}thiochroman

[0760] (3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-{4-[2-(4,4,5,5,5-pentafluoropentylthio)ethoxy]phenoxy}propyl}thiochroman (11) prepared in Step 8 (110 mg, 0.17 mmol) was dissolved in tetrahydrofuran (5 ml), which was then cooled down to 0° C. Oxone^(R) (monopersulfate compound; DuPont product)(63 mg, 0.1 mmol) and water (3drops) were added thereto, and the resulting mixture was stirred for 1 hour. Water (2drops-3′ was further added, and the mixture was stirred for 1 hour. Water was added to the reaction solution and the resulting mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, concentrated, and subjected to silica gel column chromatography to give (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-{4-[2-(4,4,5,5,5-pentafluo ropentylsulfinyl)ethoxy]phenoxy}propyl}thiochroman (12) (64.5 mg, yield 57%) as a colorless foamy substance.

[0761]¹H NMR (270 MHz, CDCl₃) δ: 7.10 (2H, d, J=8.6 Hz), 7.8-7.65 (8H, m), 6.58 (1H, d, J=8.9 Hz), 6.43 (1H, m), 6.26 (1H, d, J=20.8 Hz), 4.5-4.3 (2H, m), 3.8-3.7 (2H, m), 3.72 (1H, d, J=4.6 Hz), 3.3-2.9 (5H, m), 2.67 (1H, d, J=8.8 Hz), 2.4-2.16 (4H, m), 1.62-1.4 (2H, m), 1.35-1.2 (2H, m), 1.12 (3H, s)

[0762] FAB-MS 659 (M+1)

EXAMPLE 20

[0763] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman

[0764] Step 1) Synthesis of 9-(t-butyldimethylsilyloxy)-4-oxa-1-nonyne

[0765] To a solution of alcohol compound (2.96 g, 13.6 mmol, separately prepared), in dry tetrahydrofuran (100 mg) was added sodium hydride(597 mg, 60% in oil, 14.9 mmol) at room temperature. After stirring for 30 minutes, propargyl bromide(4.04 g, 80% in toluene, 27.2 mmol) was added, and resulting the mixture was warmed to 50° C. and stirred for 6 hours. After the reaction was completed, ice-water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=6.1) to give the title compound (3.23 g, yield 93%).

[0766]¹H-NMR (270 MHz, CDCl₃) δ: 4.13 (d, 2H, J=2.31 Hz), 3.61 (t, 2H, J=6.3 Hz), 3.51 (t, 2H. J=6.6 Hz), 2.41 (t, 1H, J=2.3 Hz), 1.67-1.51 (m, 4H), 1.49-1.36 (m, 2H), 0.89 (s, 9H), 0.04 (s, 6H)

[0767] Step 2) Synthesis of 4-[9-(t-butyldimethylsilyloxy)-4-oxa-1-nonynyl]4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0768] An alkyne compound separately prepared (1.02 g, 3.98 mmol) was dissolved in dry tetrahydrofuran (10 ml), which was then cooled down to −70° C. under hydrogen. n-Butyllithium (1.61M, 2.4mt, 3.81 mmol) was added dropwise to this solution, and the mixture was warmed to 40° C. and stirred for 10 minutes. Then, the cromanone derivative (630 mg, 2.0 mmol) dissolved in dry tetrahydrofuran (10 ml) was added dropwise thereto, and the resulting mixture was warmed to room temperature over 4 hours. After the reaction was completed, ice-water was -added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound (1.1 g, yield 96%).

[0769]¹H-NMR (270 MHz, CDCl₃) δ: 7.82 (d, 1H, J=8.6 Hz), 7.61 (d, 2H, J=8.9 Hz), 6.88 (d, 2H, 1=8.9 Hz), 6.68-6.62 (m, 2H), 4.24 (d, 1H, J=17.2 Hz), 4.14 (s, 2H), 3.81 (s, 3H), 3.78 (s, 3H), 3.60 (t, 2H, J=6.6 Hz), 3.37 (t, 2H, J=6-6 Hz), 2.71 (d, 1H, J=12.2 Hz), 2.26 (s, 1H), 1.58-1.48 (m, 7H), 141-1.32 (m, 2H), 0.89 (s, 9H), 0.04 (s, 6H)

[0770] Step 3) Synthesis of (3RS,4RS) and (3RS,4SR)-4-[9-(t-butyldimethylsilyloxy)-4-oxa-1-nonynyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0771] To a solution of alcohol compound (1.0 g, 1.75 mmol) in 1,2-dichloroethane (30 ml) were added sequentially sodium cyanoborohydride (880 mg, 14 mmol) and zinc iodide (1.1 g, 3.5 mmol) at room temperature. The mixture was stirred at room temperature for 30 minutes at the same condition. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound[575 mg, yield 59%; (3RS,4RS):(3RS,4SR)=4:1].

[0772]¹H-NMR (270 MHz, CDCl₃; 3RS,4RS)*8: 7.3 1 (d, 2H, J=8.9 Hz), 7.23 (d, 1H, J=8.3 Hz), 6.83 (d, 2H, J=8.9 Hz), 6.69 (d, 1H, J=2.3 Hz), 6.62 (dd, 1H, J=8.3 Hz and 2.3 Hz), 3.99 (d, 2H, J=2.0 Hz), 3.89 (s, 1H), 3.78 (s, 3H), 3.77 (s, 3H), 3.68 (d, 1H, J=12.2 Hz), 3.58 (t, 2H, J=6.5 Hz), 3.16 (t, 2H, J=6.3 Hz), 3.01 (d, 1H, J=12.2 Hz), 1.50-1,30 (m, 9H), 0.89 (s, 9H), 0.05 (s, 6H)

[0773] Step 4) Synthesis of (3RS,4RS) and (3RS,4SR)-4-19 (t-butyldimethylsilyloxy)₄-oxanonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0774] The alkyne compound above(575 mg, 1.04 mmol) was dissolved in ethyl acetate (10 ml), platinum oxide (273 mg, 1.04 mmol) was added, and the resulting mixture was stirred at room temperature under hydrogen for 20 hours. The reaction solution was concentrated and filtered through silica gel to give the title compound[550 mg, yield 95%; (3RS,4RS):(3RS,4SR)=4:1] as a crude product.

[0775]¹H-NMR (270 MHz, CDCl₃; 3RS,4RS) δ: 7.29 (d, 2H, J=8.9 Hz), 6.95 (d, 1H, J=8.2 Hz), 6.89 (d, 2H, J=8.9 Hz), 6.72 (d, 1H, J=2.6 Hz), 6.57 (dd, 1H, J=8.2 Hz and 2.6 Hz), 3.82 (s, 3H), 3.77 (s, 3H), 3.63 (d, 1H, J=11.6 Hz), 3.57 (t, 2H, J=6.6 Hz), 3.21 (t, 2H, J=6.6 Hz), 3.14 (t, 2H, J=6.6 Hz), 2.99 (d, 1H, J=11.6 Hz), 2.77-2.76 (m, 1H), 1.52-1.21 (m, 8H), 1.18 (s, 3H), 0.88 (s, 9H), 0.03 (s, 6H)

[0776] Step 5) Synthesis of (3RS,4RS) and (3RS,4SR)-4-{-9-hydroxy-4-oxanonyl)-7-methoxy-3-(4methoxyphenyl)-3-methylthiochroman

[0777] The compound protected by TBS (550 mg, 0.99 mmol) was dissolved in tetrahydrofuran (10 ml), and tetra-n-butylammonium fluoride (TBAF, 20 ml, 1.0M solution in tetrahydrofuran) was added thereto at 0° C. The mixture was stirred at room temperature for 1 hour, and stirred at 50° C. for further 2 hours. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:1) to give the title compound [380 mg, yield 87%; (3RS,4RS):(3RS,4SR)=4:1].

[0778]¹H-NMR (270 MHz, CDCl₃; 3RS,4RS) δ: 7.29 (d, 2H, J=8.9 Hz), 6.94 (d, 1H, J=8.3 Hz), 6.90 (d, 2H, J=8.9 Hz), 6.73 (d, 1H, J=2.3 Hz), 6.57 (dd, 1H, J=8.3 Hz and 2.3 Hz), 3.82 (s, 3H), 3.78 (s, 3H), 3.64 (d, 1H, J=11.9 Hz), 3.60 (t, 2H, J=6.3 Hz), 3.22 (t, 2H, J=6.6 Hz), 3.16 (t, 2H, J=6.6 Hz), 3.00 (d, 1H, J=11.9 Hz), 2.78-2.75 (m, 1H), 1.56-1.26 (m, 11H), 1.18 (s, 3H)

[0779] Step 6) Synthesis of (3RS,4RS) and (3RS,4SR)-4-(9-methanesulfonyloxy-4-oxanonyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0780] An alcohol compound (380 mg, 0.86 mmol) was dissolved in dichloromethane (10 ml), and triethylamine (174 mg, 1.72 mmol) and methanesulfonylchloride (100 ml, 128 mmol) were sequentially added thereto at 0° C. The mixture was stirred at the same temperature for 10 minutes. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:1) to give the title compound[420 mg, yield 94%; (3RS,4RS):(3RS,4SR)=4:1].

[0781]¹H-NMR (270 MHz, CDCl₃; 3RS,4RS) δ: 7.29 (d, 2H, J=8.9 Hz), 6.95 (d, 1H, J=8.6 Hz), 6.90 (d, 2H, J=8.9 Hz), 6.73 (d, 1H, J=2.7 Hz), 6.57 (dd; 1H, J=8.6 Hz and 2.7 Hz), 4.19 (t, MH, J=6.6 Hz), 3.82 (s, 3H), 3.78 (s, 3H), 3.64 (d, 1H, J=11.9 Hz), 3.22 (t, 2H, J=6.7 Hz), 3.14 (t, 2H, J=6.3 Hz), 3.00 (d, 1H, J=11.9 Hz), 2.99 (s, 3H), 2.79-2.75 (m, 1H), 1.83-1.71 (m, 2H), 1.65-1.31 (m, 8H), 1.18 (s, 3H)

[0782] Step 7) Synthesis of (3RS,4RS) and (3RS,4SR)-7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-[4-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[0783] To a solution of thioacetate separately prepared (328 mg, 1.39 mmol) in methanol (5 ml) was added sodium methoxide (1.3ml, 11.0M solution in methanol, 1.32 mmol) at room temperature. The mixture was stirred for 15 minutes, and a solution of mesylate(340 mg, 0.65 mmol) in tetrahydrofuran (5 ml) was added thereto. This mixture was stirred at room temperature for 2 days. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound[405 mg, Stoichiometric yield, (3RS,4RS):(3RS,4SR)=4:1]. 17)

[0784]¹H-NMR (270 MHz, CDCl₃; 3RS,4RS) δ: 7.29 (d, 2H, J=8.9 Hz), 6.95 (d, 1H, J=8.6 Hz), 6.90 (d, 2H, J=8.9 Hz), 6.72 (d, 1H, J=2.3 Hz), 6.57 (dd, 1H, J=8.6 Hz and 2.3 Hz), 3.82 (s, 3H), 3.78 (s, 3H), 3.63 (d, 1H, J=11.6 Hz), 3.22 (t, 2H, J=6.6 Hz), 3.16 (t, 2H, J=6.6 Hz), 3.00 (d, 1H, J=11.6 Hz), 2.75 (t, 1H, J=6.9 Hz), 2.57 (t, 2H, J=7:0 Hz), 2.47 (t, 2H, J=6.9 Hz), 2.19-2.01 (m, 2H), 1.92-1.81 (m, 2H), 1.60-1.31 (m, 10H), 1.18 (s, 3H)

[0785] Step 8) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[0786] Thioether (253 mg, 0.41 mmol) was added to DIBAL-H solution (8.2 ml, 1.0M solution in toluene, 8.16 mmol), which was then heated under reflux for 10 hours. After the reaction was completed, water was added, and then diluted hydrochloric acid was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to high pressure silica gel column chromatography (n-hexane:ethyl acetate=2:1) to give the tide compound (175 mg, yield 72%).

[0787]¹H-NMR (270 MHz, CDCl₃) o: 7.24 (d, 2H, J=8.6 Hz), 6.89 (d, 1H, J=8.2 Hz), 6.82 (d, 2H, J=8.6 Hz), 6.66 (d, 1H, J=2.3 Hz), 6.48 (dd, 1H, J=7.9 and 2.3 Hz), 4.87 (brs, 1H), 4.68 (brs, 1H), 3.62 (d, 1H, J=11.5 Hz), 3.21 (t, 2H, J=6.3 Hz), 3.17 (t, 2H, J=6.6 Hz), 2.97 (d, 1H, J=11.5 Hz), 2.74 (d, 1H, J=11.2 Hz), 2.59 (t, 2H, J=6.9 Hz), 2.49 (t, 2H, J=7.3 Hz), 2.20-2.07 (m, 2H), 1.93-1.82 (m, 2H), 1.60-1.26 (m, 10H), 1.18 (s, 3H)

[0788] Step 9) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman

[0789] To a solution of thioether (163 mg, 0.28 mmol) in tetrahydrofuran (2 mg) was added Oxone^(R) (monopersulfate compound; DuPont product)(85 mg, 0.14 mmol) at 0° C. Water (50 μl) was added thereto at the same temperature, which was then stirred for 2 hours. After the reaction was completed, the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:1) to give the title compound (99 mg, yield 59%).

[0790]¹H-NMR (270 MHz, CDCl₃) δ: 7.58 (br, 1H), 7.22 (d, 2H, J=8.6 Hz), 6.86 (d, 1H, J=8.3 Hz), 6.84 (d, 2H, J=8.6 Hz), 6.68 (d, 1H, J=2.3 Hz), 6.49 (dd, 1H, J=8.3 and 2.3 Hz), 5.46 (br, 1H), 3-67 (dd, 1H, J=12.6 and 12.2 Hz), 3.32-2.63 (m, 10H), 2.32-2.17 (m, 4H), 1.81-1.70 (m, 2H), 1.35-1.18 (m, 11H)

EXAMPLE 21

[0791] Synthesis of (3RS,4RS)-7-hydr xy-3-(4-hydr xyphenyl)-3-methyl-4-[9-(4,4,5,5,5pentafluorop entylaminosulfonyl)nonyl]chroman

[0792] Step 1) Synthesis of 4-(9-acetylthiononyl)-7-methoxymethoxy-3-(4-methoxy- methoxyphenyl)-3-methylchroman

[0793] Alcohol compound separately prepared (115 mg, 0.236 mmol) was dissolved in methylene chloride (1 ml) and ice-cooled. Then, triethylamine (0.036 ml, 0.26 mmol) and MsCl (0.020 ml, 0.26 mmol) were added dropwise thereto, which was then stirred for 20 minutes. After the reaction was completed, the mixture was ice-cooled, and then saturated saline solution was added thereto. The resulting mixture was extracted with methylene chloride and washed with saturated saline solution. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue thus obtained was subjected to silica gel column chromatography (n-hexane:etbyl acetate=2: 1) to give 4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (126 mg, yield 95%). Thus obtained 4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-4methoxymethoxyphenyl)₃-methylchroman (126 mg, 0.222 mmol) was dissolved in DMF (1 ml), KSAc (27.9 mg, 0.244 mmol) was added dropwise thereto, and the resulting mixture was stirred at 40° C. for 2 hours- After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate and washed with saturated saline solution. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=2:1) to give 4-(9-acetylthiononyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)₃-methylchroman (114 mg, yield 94%).

[0794]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (d, 2H, J=8.9 Hz, Ar—H), 7.02 (d, 2H, J=8.9 Hz, Ar—H), 7.00-6.92 (m, 1H, Ar—H), 6.60-6.54 (m, 2H, Ar—H), 5.18, 5.15 (respectively s, respectively 2H, OCH ₂O), 4.52 (d, 1H, J=10.6 Hz, C2-H), 4.26 (d, 1H, J=10.6 Hz, C2-H), 3.50, 3.49 (respectively s, respectively 3H, OCH₃), 2.84 (t 2H, J=7.3 Hz, CH ₂SAc), 2.31 (s, 3H, C(O)CH ₃) 2.68-2.60 (m, 1H, C4-H), 1.25 (s, 1H, C3-CH₃), 1.30-1.00 (m, 16H)

[0795] Step 2) Synthesis of 4,4,5,5,5-pentafluoropentylcarbamic Acid t-butylester ${{TsO}\left( {CH}_{2} \right)}_{3}{CF}_{2}{{CF}_{3}\underset{{MeOH},{H_{2}O}}{\overset{{NaN}_{3}}{}}{N_{3}\left( {CH}_{2} \right)}_{3}}{CF}_{2}{{CF}_{3}\underset{\underset{({2\quad {step}{\quad \quad}50\%})}{MeOH}}{\overset{H_{2},{{({Boc})}_{2}O}}{}}{{BocNH}\left( {CH}_{2} \right)}_{3}}{CF}_{2}{CF}_{3}$

[0796] 1,1,1,2,2-Pentafluoro-5-p-toluenesulfonyloxypentane (4.00 mg, 12.0 mmol) was dissolved in methanol (40 ml), NaN₃ (936 mg, 14.4 mmol) dissolved in water (10 ml) was added thereto, and the mixture was stirred overnight at 60° C. After the reaction was completed, the reaction mixture was extracted with chloroform and washed with saturated saline solution. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue was dissolved in methanol (40 ml), (Boc)₂O (2.62 g, 12.0 mmol) and Pd—C (800 mg) were added thereto, and then the mixture was stirred overnight under hydrogen. After the reaction was completed, the mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give 4,4,5,5,5-pentafluoro-pentylcarbamic acid t-butylester(1.12 g, yield 50%).

[0797]¹H-NMR (300 MHz, CDCl₃) δ: 4.55 (brs, 1H, NH), 4.12 (q, 2H, J=7.2 Hz, CH ₂NH), 2.18-1.96 (m, 2H, CF₂ CH ₂), 1.84-1.72 (m, 2H), 1.45 (s, 9H, t-Bu)

[0798] Step 3) Synthesis of 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylaminosulfonyl)nonyl]chroman

[0799] 4-(9-Acetylthiononyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (40.0 mg, 0.0735 mmol) was dissolved in methanol (1 ml) under nitrogen, 2N—NaOH (0.5 ml) was added dropwise thereto, and the mixture was stirred at room temperature for 30 minutes. After the reaction was completed, the reaction mixture was cooled, and 2N—HCl aqueous solution was poured thereinto. This solution was extracted with chloroform and washed with saturated saline solution. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue thus obtained was added to a solvent mixture of methylene chloride (1 ml) and water (0.5 ml), N-chlorosuccinimide (39.3 mg, 0.294 mmol) was added, and the resulting mixture was stirred for 15 minutes. After the reaction was completed, saturated aqueous NAHCO₃ solution was added thereto. The mixture was extracted with methylene chloride and washed with saturated saline solution. The organic layer was dried over magnesium sulfate and concentrated- under reduced pressure to give a mixture containing 4-(9-chlorosulfonylnonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl chroman. 4,4,5,5,5-Pentafluoropentylcarbamic acid t-butylester (61.8 mg, 0.221 mmol) was dissolved in methylene chloride (1 ml), TFA (1 ml) was added dropwise thereto, and the mixture was stirred at room temperature for 15 minutes. After the reaction was completed, the solvent was removed under reduced pressure. The residue thus obtained was dissolved in methylene chloride (1 ml) and cooled. To this solution was added a mixture containing triethylamine (0.051 ml, 0.37 mmol) and 4-(9-chlorosulfonylnonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman dissolved in methylene chloride (1 ml), which was then stirred for 1 hour. After the reaction was completed, the organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:1) to give 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylaminosulfonyl)nonyl]chroman (8.0 mg, yield 16%).

[0800]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (d, 2H, J=8.6 Hz, Ar—H), 7.02 (d, 2H, J=8.6 Hz, Ar—H), 7.00-6.92 (m, 1H, Ar—H), 6.60-6.54 (m, 2H, Ar—H), 5.18, 5.15 (respectively s, respectively 2H, OCH ₂O), 4.52 (d, 1H, 3=10.6 Hz, C2-H), 4.26 (d, 1H, J=10.6 Hz, C2-H), 3.49 (s, 6H, OCH₃×2), 3.44-3.30 (m, 2H), 3.28-3.14 (m, 2H), 2.68-2.60 (m, 1H, C4-H), 2.22-1.96 (m,2H), 1.90-1.52 (m, 4H), 1.24 (s, 1H, C3-CH₃), 1.30-1.00 (m, 14H)

[0801] Step 4) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylaminosulfonyl)nonyl]chroman

[0802] 7-Methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylaminosulfonyl)nonyl]chroman (8.0 mg, 0.0113 mmol) was dissolved in a solvent mixture of THF (0.2 ml) and isopropanol (0.2 ml), 5N—HCl aqueous solution (0.6 ml) was added dropwise thereto, and the mixture was stirred at room temperature for 0.3 days. After the reaction was completed, the mixture was cooled, and then saturated aqueous NaHCO₃ solution was added thereto. The resulting mixture was extracted with chloroform and washed with saturated saline solution. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure. The residue thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:1)- to give (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-4,4,5,5,5-penta-fluoropentylaminosulfonyl)nonyl]chroman (0.78 mg, yield 11%).

[0803]¹H-NMR (270 MHz, CDCl₃) δ: 7.08 (d, 2H, J=8.3 Hz, Ar—H), 6.90-6.80 (m, 1H, Ar—H), 6.83 (d, 2H, J=8.3 Hz, Ar—H), 6.40-6.34 (m, 2H, Ar—H), 5.23, 4.72 (respectively s, respectively 1H, OH), 4.51 (d, 1H, J=10.2 Hz, C2-H), 4.24 (d, 1H, J=10.2 Hz, C2-H), 3.30-3.18 (m, 2H, NHCH ₂), 3.00 (t, 2H, J=7.6 Hz, CH ₂SO₂), 2.64-2.56 (m, 1H, C4-H), 2.24-2.00 (m, 2H), 1.94-1.62 (m, 4H), 1.25 (s, 1H, C3-CH₃), 1-40-1.00 (m,14H)

EXAMPLE 22

[0804] Synthesis of (3′RS,4′RS)-10-17-hydroxy-3-(4-hydroxyphenyl)-3methyltbiochroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid

[0805] Step 1) Synthesis of 6-bromo-1-(t-butyldimethylsilyloxy)hexane

[0806] 6-Bromo-1-hexanol (20 g, 110.42 mmol) was dissolved in dry tetrahydrofuran (700 ml) and cooled to 0° C. under argon atmosphere, to which were added imidazole(15g. 220.84 mmol) and t-butyldimethylsilyl chloride (33 g, 220.84 mmol) and the resulting solution was stirred overnight. After the reaction was completed, the mixture was poured in ice-water and extracted with ethyl acetate. The organic solvent was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. This crude product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1:40. After removal of the solvent, 30g of the title compound was obtained as colorless oil. (yield : 92.4%)

[0807]¹H-NMR (300 MHz, CDCl₃) δ: 3.61 (t, 2H, 3=6.4 Hz), 3.41 (t, 2H, J=7.2 Hz), 1.87 (m, 2H), 1.56-1.30 (m, 6H), 0.89 (s, 9H), 0.05 (s, 6H)

[0808] Step 2) Synthesis of 8-(t-butyldimethylsilyloxy)-1-octyne

[0809] 6-Bromo-1-(t-butyldimethylsilyloxy)hexane (20 g, 110.42 mmol) was dissolved in dry dimethyl sulfoxide (500 ml) and tetrahydrofuran (50 ml) and cooled to 0° C. under argon atmosphere, to which was added lithium acetylide ethylene diamine complex (28.0 g, 304.74 mmol) and the resulting solution was stirred for 1 day at 4° C. After the reaction was completed, the mixture was poured in ice-water and extracted with ethyl ether. The organic solvent was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. This crude product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1:40. After removal of the solvent, 18 g of the title compound was obtained as colorless oil. (yield: 73.8%)

[0810]¹H-NMR (300 MHz, CDCl₃) δ: 3.59 (t, 2H, J=6.4 Hz), 2.15 (m, 2H), 1.90 (t, 1H, J=2.4 Hz), 1.55-1.30 (m, 8H), 0.88 (s, 9H), 0.05 (s, 6H)

[0811] Step 3) Synthesis of 4-[8-(t-Butyldimethylsilyloxy)-1-octynyl]-4-hydroxy-7-methoxy-3-(4-methoxyphenyl}3-methylthiochroman

[0812] 8-(t-Butyldimethylsilyloxy)-1-octyne(12 g, 49.9 mmol) was dissolved in dry tetrahydrofuran (150 ml) under argon atmosphere and then cooled to −78C. 2.5M n-Butyllithium (18 ml, 44.9 mmol) was added dropwise thereto, and the mixture was warmed to −10° C. and stirred for 1 hour and then cooled to −78° C. 7-Methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one (860 mg,2.9 mmol) was added portionwise and then warmed to room temperature and stirred for 1.5 hour. The mixture was quenched by water. The reaction solvent was evaporated off, then the residue was dissolved in ethyl acetate, which was washed with water. The organic solvent was dried over anhydrous magnesium sulfate and removed by evaporation under vacuum. This product was purified by column chromatography on silica gel, eluting with 10% ethyl acetate in n-hexane. After removal of the solvent, 14 g of the title compound was obtained as colorless oil. (yield : 99.3%)

[0813]¹H NMR (300 MHz, CDCl₃) δ: 7.83 (d, 1H, J=8.7 Hz), 7.57 (d, 2H, J=8.7 Hz), 6.85 (d, 2H, J=9.0 Hz), 6.65 (m, 2H), 4.23 (d, 1H, J=12.4 Hz), 3.79 (s, 3H), 3.76 (s, 3H), 3.57 (t, 2H, J=6.4 Hz), 2.69 (d, 1H, J=12.4 Hz), 2.15 (m, 2H), 1.50 (m, 8H), 0.87 (s, 9H), 0.02 (s, 6H)

[0814] Step 4) Synthesis of (3RS,4RS)-4-[8-(t-Butyldimethylsilyloxy)-1-octyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0815] 4-[8-(t-Butyldimethylsilyloxy)-1-octynyl]-4-hydroxy-7-methoxy-3-(4-methox yphenyl)-3-methylthiochroman (14 g, mmol) was dissolved in 1,2-dichloroethane (300 ml) and cooled to 0° C. Zinc iodide (II) (24.2 g, 75.69 mmol) and sodium cyanoborohydride (9.51 g, 151.38 mmol) was sequentially added and slowly warmed to room temperature and stirred for 2 hours. After the reaction was completed, the reaction solvent was removed under reduced pressure. The residue was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and removed by evaporation under vacuum. This product was purified by column chromatography on silica gel, eluting with 10% ethyl acetate in n-hexane. After removal of the solvent, crude 11 g of the title compound was obtained as pale yellow oil. (yield: 79.5%) Then, this compound thus obtained (11 g) was dissolved in tetrahydrofuran (300 ml). 0.2N NaHCO₃(300 ml) and 10% palladium on carbon (3 g) was added and stirred for 2 day under hydrogen (atmospheric pressure). The reaction mixture was filtered through cellite and concentrated under reduced pressure. The residue was dissolved in ethyl acetate, which was washed with water and brine. The organic solvent was dried over anhydrous magnesium sulfate and removed by evaporation under vacuum. This product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1:40. After removal of the solvent, 5.6 g of the title compound was obtained as colorless oil. (yield: 50.5%).

[0816]¹H NMR (300 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.27 (d, 2H, J=9.0 Hz), 6.90 (m, 3H), 6.70 (d, 1H, J=2.6 Hz), 6.56 (dd, 1H, J=2.6, 8.7 Hz), 3.79 (s, 3H), 3.76 (s, 3H), 3.62 (d, K1, J=11.7 Hz), 3.53 (t, 2H, J=6.4 Hz), 2.96 (d, 1H, J=12.7 Hz), 2.70 (bd, 1H), 1.40 (m, 2H), 1.15 (s, 3H), 1.20-0.90 (m, 12H), 0.86 (s, 9H), 0.01 (s, 6H)

[0817] Step 5) Synthesis of (3RS,4RS)-4-(8-hydroxyoctyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0818] (3RS,4RS)-4-[8-(t-Butyldimethylsilyloxy)-1-octyl]-7-methoxy-3-4methoxy phenyl)-3-methylthiochroman (4.5 g, 8.29 mmol) was dissolved in tetrahydrofuran (100 ml), and cooled to 0°. To this solution was added tetrabutylammonium fluoride (16.6 ml, 16.58 mmol), and the reaction mixture was stirred at room temperature for 2 hours. The solvent was removed by evaporation under reduced pressure and the residue was dissolved in ethyl acetate, which was washed with water. The organic layer was separated, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The product was purified by column chromatography on silica gel, eluting with 300/c ethyl acetate in n-hexane to afford 3.3g of the title compound as a pale yellow oil. (yield: 93.0%)

[0819]¹H-NMR (300 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.27 (d, 2H, J=8.7 Hz), 6.90 (m, 3H), 6.70 (d, 1H, J=2.6 Hz), 6.56 (dd, 1H, J=2.6, 8.7 Hz), 3.80 (s, 3H), 3.76 (s, 3H), 3.67 (d, 1H, J=13.2 Hz), 3.53 (t, 2H, J=6.4 Hz), 2.96 (d, 1H, J=11.7 Hz), 2.71 (bd, 1H), 1.16 (s, 3H), 1.30-1.07 (m, 14H)

[0820] Step 6) Synthesis of (3RS,4RS)-4-(8-methanesulfonyloxyoctyl)-7-methoxy-3-(4-methoxy-phenyl)-3-methylthiochroman

[0821] (3RS,4RS)-4-(8-hydroxyoctyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthi o-chroman (3.25 g, 7.58 mmol) was dissolved in dichloromethane (100m), to which were added triethylamine (1.59nit, 11.37 mmol) and methanesulfonyl chloride (0.88 ml, 11 37 mmol). The reaction mixture was stirred at room temperature for 1 hour. After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with methylene chloride. The organic layer was washed with 1M HCl solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated. The product was purified by column chromatography on silica gel, eluting with 30% ethyl acetate in n-hexane to afford 3.75g of the title compound as a pale yellow oil. (yield 97.7%)

[0822]¹H-NMR (300 MHz, CDCl₃) δ: 7.27 (d, 2H, I=9.0 Hz), 6.90 (m, 3H), 6.70 (d, 1H, J=2.6 Hz), 6.56 (dd, 1H, J=2.6, 8.3 Hz), 4.15 (t, 2H, J=6.4 Hz), 3.80 (s, 3H), 3.76 (s, 3H), 3.62 (d, 1H, 3=11.7 Hz), 2.97 (d, 1H, J=11.7 Hz), 2.96 (s, 3H), 2.71 (bd, 1H), 1.60 (m, 2H), 1.15 (s, 3H), 1.20-0.96 (m, 12H)

[0823] Step 7) Synthesis of (3RS,4RS)-4 (8-iodooctyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[0824] (3RS,4RS)—(8-methanesulfonyloxyoctyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (3.75 g, 7.40 mmol) was dissolved in acetone (70 ml). To the reaction solution was added sodium iodide(3.33 g, 22.20 mmol). The reaction mixture was heated at reflux temperature, with stirring, for 4 hours and then allowed to cool to ambient temperature, then concentrated under reduced pressure in order to remove acetone. The residue was dissolved in ethyl acetate and filtrated. The organic layer was washed with 1% Na₂S₂O₃ solution, water and brine dried over anhydrous magnesium sulfate, and removed by evaporation under vacuum. This product was purified by column chromatography on silica gel, eluting with 10% ethyl acetate in n-hexane to afford 3.73g of the title compound as a colorless oil. (yield : 93.6%)

[0825]¹H-NMR (300 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.27 (d, 2H, J=8.7 Hz), 6.90 (m, 3H), 6.72 (d, 1H, J=2.6 Hz), 6.56 (dd, 1H, J=2.6, 8.7 Hz), 3.81 (s, 3H), 3.76 (s, 3H), 3.63 (d, 11, J=11.7 Hz), 3.12 (t, 211, J=6.8 Hz), 2.96 (d, 1H, J=11.7 Hz), 2.70 (bd, 1H), 1.70 (m, 2H), 1-16 (s, 3H), 1.28-11.00 (m, 14H)

[0826] Step 8) Synthesis of (Methylsulfonyl)oxy(4,4,5,5,5-pentafluoropentyl)

[0827] 4,4,5,5,5-Pentafluoropentanol (25 g, 0.132 mol) was dissolved in dichloromethane (50 mg) and cooled to 0° C., to which were added triethylamine (46 me, 0.330 mol) and methanesulfonyl chloride (20.4md, 0.264 mol). The reaction mixture was stirred at, room temperature for 3 hour. After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with dichlorornethane. The organic layer was washed with 1M HCl solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated. The product was purified by column chromatography on silica gel, eluting with 50% ethyl acetate in n-hexane to afford 34 g of the title compound as a pale yellow oil. (yield quantitative)

[0828]¹H-NMR (300 MHz, CDCl₃) δ: 4.30 (t, 2H), 3.05 (s, 3H), 2.30-2.05 (m, 4H)

[0829] Step 9) Synthesis of 1,1,1,2,2-Pentafluoro-5-iodopentane

[0830] (Methyl sulfonyl)oxy(4,4,5,5,5-pentafluoropentyl)(20 g, 0.781 mol) was dissolved in acetone (200 ml). To the reaction solution was added sodium iodide (35.1 g, 2:154 mol). The reaction mixture was stirred at reflux overnight and then allowed to cool to ambient temperature, then filtrated and concentrated under reduced pressure. The residue was dissolved in ethyl ether and filtered- The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, and removed by evaporation under reduced pressure to afford 21.1g of the title compound as a colorless oil. (yield 93.4%)

[0831]¹H-NMR (300 MHz, CDCl₃) δ: 3.22 (t, 2H, J=6.8 Hz), 2.28-2.10 (m, 4H)

[0832] Step 10) Synthesis of diethyl 2-(4,4,5,5,5-pentafluoropentyl)propane-1,3-dioate

[0833] To a solution of sodium hydride (60%) (3.90 g, 96.07 mol) in tetrahydrofuran (160 ml) was added dropwise a solution of diethyl malonate (16.6 ml, 110.85 mol) under ice-cooling, which was then stirred for 30 minutes. Then, 1,1,1,2,2-Pentafluoro-5-iodopentane (21 g, 73.9 mol) was added dropwise thereto, and reaction mixture was warmed to room temperature, with stirring, for overnight. After the reaction was completed, the reaction was quenched with water, extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, and removed by evaporation under reduced pressure. This product was purified by column chromatography on silica gel, eluting with dichloromethane:n-hexane=1:3 to afford 18.3g of the title compound as a colorless oil. (yield : 78.4%)

[0834]¹H-NMR (300 MHz, CDCl₃) δ: 4.22 (q, 4H, J=7.1 Hz), 3.35 (t, 1H, J=6.0 Hz), 2.15-1.93 (m, 4H), 1.67 (m, 2H), 1.28 (t, 6H, J=7.1 Hz)

[0835] Step 11) Synthesis of (3′RS,4′RS) diethyl 2-{8-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]octyl}-2-(4,4,5,5,5-pentafluoropentyl)propane-1,3-dioate

[0836] To a solution of sodium hydride (60%) (312 mg, 7.799 mmol) in tetrahydrofuran (14 ml) was added dropwise a solution of 2-4,4,5,5,5-pentafluoropentyl)propane-1,3-dioate (2.38 g, 7.428 mmol) in tetrahydrofuran (8 ml) under ice-cooling, which was then stirred for 1 hour. Then, a solution of (3RS,4RS)-4-(8-iodooctyl)-7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman (2.0 g, 3.714 mmol) in tetrahydrofuran (8 ml) was added dropwise thereto, and reaction mixture was warmed to room temperature, with stirring , for 2 days. After the reaction was completed, the reaction was quenched with water, extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous' magnesium sulfate, and removed by evaporation under vacuum. This product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1:4→1:1 to afford 2.60 g of the title compound as a colorless oil. (yield: 95.9%)

[0837]¹H-NMR (300 MHz, CDCl₃) δ: 7.26 (d, 2H, J=8.7 Hz), 6.89 (m, 3H), 6.70 (d, 1H, J=2.6 Hz), 6.56 (dd, 1H, J=2.6, 8-3 Hz), 4.15 (q, 4H, J=7.1 Hz), 3.80 (s, 3H), 3.76 (s, 3H), 3.62 (d, 1H, J=11.7 Hz), 2.96 (d, 1H, J=11.7 Hz), 2.70 (bd, 1H), 2.00 (m, 2H), 1.87 (m, 4H), 1.48 (m, 2H), 1.15 (s, 3H), 1.20-0.96 (m, 12H)

[0838] Step 12) Synthesis of (3′RS,4′RS)-{8-[7-methoxy-3-(4-methoxyphenyl)₃-methylthio-chroman-4-yl]octyl}(4,4,5,5,5-pentafluoropentyl)methane-1,1-dicarboxylic acid

[0839] To a solution of (3RS,4RS)-4-(8-iodooctanyl)-7-methoxy-3-4-methoxyphenyl)-3-methylthiochroman (2.6 g, 3.557 mmol) in ethyl alcohol (40 ml) was added a solution of potassium hydroxide (7.8 g, 142.30 mmol) in water (20 ml). The resulting mixture was heated under reflux for overnight. The residue, left after removal of ethyl alcohol, was dissolved in water and the mixture was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, and removed by evaporation under vacuum to afford 2.30 g of the title compound as a white foam. (yield: quantitative)

[0840]¹H-NMR (300 MHz, CDCl₃) δ: 7.28 (d, 2H, J=8.7 Hz), 6.90 (m, 3H), 6.71 (d, 1H, J=2.6 Hz), 6.57 (dd, 1H, J=2.6, 8.3 Hz), 3.82 (s, 3H), 3.77 (s, 3H), 3.62 (d, 1H, J=11.7 Hz), 2.97 (d, 1H, J=11.7 Hz), 2.70 (bd, 1H), 2.07 (m, 4H), 1.87 (m, 2H), 1.56 (m, 2H), 1.15 (s, 3H), 1.13-1.0O(m, 14H)

[0841] Step 13) Synthesis of (3′RS,4′RS)-10-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]-2-4,4,5,5,5-pentafluoropentyl)decanoic acid

[0842] To a solution of (3′RS,4′RS)-{8-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]octyl}(4,4,5,5,5-pentafluoropentyl)methane-1,1-dicarboxylic acid (2.0 g, 3.093 mol) in dimethyl sulfoxide (20 ml) was heated under 130-140° C. for 4 hours. The reaction mixture was dissolved in ethyl- acetate(300 ml) and washed with water (20 ml×4) and brine (20 ml×2), dried over anhydrous magnesium sulfate. This product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1:9→1:5→1:1 to afford 1.60 g of the title compound as a white foam (yield: 82.1%)

[0843]¹H-NMR (300 MHz, CDCl₃) δ: 7.27 (d, 2H, J=8.7 Hz), 6.90 (m, 3H), 6.70 (d, 1H, J=2.6 Hz), 6.56 (dd, 1H, J=2.6, 8.3 Hz), 3.80 (s, 3H), 3.76 (s, 3H), 3.62 (d, 1H, J=11.7 Hz), 2.96 (d, 1H, J=11.7 Hz), 2.70 (bd, 1H), 2.34 (m, 1H), 2.06 (m, 2H), 1.70-1.40 (m, 6H), 1.15 (s, 3H), 1.20-1.00 (m, 14H)

[0844] Step 14) Synthesis of (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid

[0845] The solution of (3′RS,4′RS)-10-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid (1.3 g, 2.061 mmol) in dry dichloromethane (30 ml) was cooled to −78° C. under argon atmosphere. To this solution was added dropwise boron tribromide (1.0 mol/9 solution in dichloromethane, 12.4 ml, 12.366 mmol) for 10 min and the resulting solution was stirred for 1 hours. and then warmed to −5C, and stirred for 1 hour. After the reaction was completed, the mixture *was poured in ice-water and extracted with dichloromethane. The organic solvent was dried over anhydrous magnesium sulfate and concentrated under vacuum. This crude product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1:5→1:3→2:3. After removal of the solvent, 1.1 g of the title compound was obtained as white foam. (yield: 88.7%, HPLC=94%)

[0846]¹H-NMR (300 MHz, CDCl₃) δ: 7.1 6 (d, 2H, J=8.7 Hz), 6.75 (m, 3H), 6.60 (d, 1H, J=2-4 Hz), 6.56 (dd, 1H, J=8.2, 2.4 Hz), 3.55 (d, 1H, J=11.5 Hz), 2.88 (d, 1H, J=11.5 Hz), 2.62 (bd, 1H), 2.33 (m, 1H), 1.94 (m, 2H), 1.70 1.40 (m, 6H), 1.10 (s, 3H), 1.10-1.00 (m, 14H)

[0847] Mass(ESI): 625[M+Na], 603[M+1]

EXAMPLE 23

[0848] Synthesis of (3′RS,4′RS)-{8-[7-hydroxy-3-(4-hyroxyphenyl)-3-methylthiochroman-4-yl]octyl}(4,4,5,5,5-pentafluoropentyl)methane-1,1-dicarboxylic Acid

[0849] Step 1) Synthesis of (3′RS,4′RS)-{8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]octyl}(4,4,5,5,5-pentafluoropentyl)methane-1,1-dicarboxylic Acid

[0850] The solution of (3RS,4RS)-{8-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]octyl}(4,4,5,5,5-pentafluoropentyl)methane-1,1-dicarboxylic. acid (170 mg, 0.252 mmol) in dry dichloromethane (30 ml) was cooled to 0° C. under argon atmosphere. To this solution was added dropwise boron tribromide (11.0 mol/l solution in dichloromethane, 0.52 mg, 0.59 mmol) and stirred for 1 hour. After the reaction was completed, the mixture was poured in ice-water and extracted with dichloromethane. The organic solvent was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. This crude product was purified by column chromatography on silica gel, eluting, with 15% methanol in dichloromethane After removal of the solvent, 120 mg of the title compound was obtained as white foam. (yield 73.0%)

[0851]¹H-NMR (300 MHz, CDCl₃) δ: 7.27 (d, 2H, J=9.0 Hz), 6.88 (d, 1H, 3=8.3 Hz), 6.81 (d, 1H, J=8.7 Hz), 6.60 (d, 1H, J=2.6 Hz), 6.48 (dd, 1H, 3=8.3, 2.6 Hz), 3.64 (d, 1H, J=11.7 Hz), 2.99 (d, 1H, J=11.7 Hz), 2.77 (bd, 1H), 2.10 (m, 1H), 1.85 (m, 2H), 1.75 (bs, 2H), 1.53 (m, 2H), 1.16 (s, 3H), 1.10-100 (m, 14H)

[0852] Mass(ESI): 647[M+1]

EXAMPLE 24

[0853] Synthesis of methyl (3′RS,4′RS) 10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(4,4,5,5,pentafluoropentyl)decanoate

[0854] Step 1) Synthesis of methyl (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydooxyphenyl)-3-methylthiochroman-4-yl]-2-4,4,5,5,5-pentafluoropentyl)decanoate

[0855] The solution of (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3 methylthiochroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid (100 mg, 0.166 mmol) in dry diethyl ether (2 ml) was cooled to 0° C. under argon atmosphere. To this solution was added dropwise diazo methane (ca. 1.0 mol/l solution in diethyl ether, 2 ml) and the resulting solution was stirred for 10 minutes and then quenched by acetic acid. The residue, left after removal of acetic acid and diethyl ether, was extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. This crude product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1 :3. After removal of the solvent, 80 mg of the title compound was obtained as white foam. (yield : 78.4%)

[0856]¹H-NMR (300 MHz, CDCl₃) δ: 7.21 (d, 2H, J=8.7 Hz), 6.83 (m, 3H), 6.66 (d, 1H, J=2.3 Hz), 6.56 (dd, 1H, J=7.2, 2.3 Hz), 5.86 (d, 1H, J=7.9 Hz), 5.28 (d, 1H, J=7.5 Hz), 3.70 (s, 3H), 3.61 (d, 1H, J=11.7 Hz), 2.93 (d, 1H, J=11.7 Hz), 2.67 (bd, 1H), 2.37 (m, 1H), 2.00 (m, 2H), 1.69-1.30 (m, 6H), 1.16 (s, 3H), 1.13-1.00 (m, 14H)

[0857] Mass(ESI): 617[M+1]

EXAMPLE 25

[0858] Synthesis of (3′RS,4′RS)-2-{8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methyl thiochroman-4-yl]octyl)-2-(4,4,5,5-pentafluoropentyl)propane-1,3-diol

[0859] Step 1) Synthesis of (3′RS,4′RS) dimethyl 2-{8-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl 3octyl}-2-(4,4,5,5,5-pentafluoropentyl)propane-1,3-dioate

[0860] To a solution of (3′RS,4′RS)-{8-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]octyl) (4,4,5,5,5-pentafluoropentyl)methane-1,1-dicarboxylic acid (150 mg, 0.222 mmol) in dimethylformamide (5 ml) was added powdered potassium carbonate (320 mg, 2.220 mmol) and iodomethane (0.14 ml, 2.220 mmol) and stirred for overnight at room temperature. The reaction mixture was dissolved in ethyl acetate(300 ml) and washed with water (20 ml×4) and brine (20 ml×2), dried over anhydrous magnesium sulfate. This product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1:5 to afford 145 mg of the title compound as a white foam. (yield: 93.0%)

[0861]¹H-NMR (300 MHz, CDCl₃) δ: 7.27 (d, 2H, J=9.0 Hz), 6.90 (m, 3H), 6.70 (d, 1H, J=2.6 Hz), 6.56 (dd, 1H, J=2.6, 8.3 Hz), 3.80 (s, 3H), 3.76 (s, 3H), 3.69 (s, 6H), 3.62 (d, 1H, J=11.7 Hz), 2.96 (d, 1H, J=11.7 Hz), 2.66 (bd, 1H), 2.00 (m, 2H), 1.87 (m, 2H), 1.73 (m, 2H), 1.48 (m, 2H), 1.16 (s, 3H), 1.21-1.06 (m, 14H)

[0862] Step 2) Synthesis of (3′RS,4′RS)-2-{8-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]octyl}-2-(4,4,5,5,5-pentafluoropentyl)propane-1,3-diol

[0863] To a solution of (3′RS,4′RS) dimethyl 2-{8-[7-methoxy-3-4-methoxyphenyl)-3-methylthiochroman-4-yl]octyl}-2-4,4,5,5,5-pentafluoropentyl)pro pane-1,3-dioate (135 mg, 0.192 mmol) in tetrahydrofuran (5 ml) was added powdered lithium aluminum hydride (14.6 mg, 0.384 mmol) and stirred for 1 hour at room temperature and then quenched by ethyl acetate. The residue, left after removal of tetrahydrofuran, was extracted with ethyl acetate. The organic layer was washed with water and, brine, dried over anhydrous magnesium sulfate. and concentrated under reduced pressure. This crude product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1:1. After removal of the solvent, 100 mg of the title compound was obtained as white foam. (yield : 80.6%)

[0864]¹H-NMR (300 MHz, CDCl₃) δ: 7.26 (d, 2H, J=8.7 Hz), 6.89 (m, 3H), 6.70 (d, 1H, J=2.6 Hz), 6.56 (dd, 1H, J=8.7, 2.6 Hz), 3.80 (s, 3H), 3.76 (s, 3H), 3.61 (d, 1H, J=11.7 Hz), 3.55 (m, 4H), 2.96 (d, 1H, J=11.7 Hz), 2.70 (bd, 1H), 2.00 (m, 6H), 1.38 (m, 2H), 1.15 (s, 3H), 1.21-1.06 (m, 14H)

[0865] Step 3) Synthesis of (3′RS,4′RS)-2-{8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]octyl)-2-(4,4,5,5,5-pentafluoropentyl)propane-1,3-diol

[0866] The solution of (3′RS,4RS)-2-{8-[7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman-4-yl]-octyl}-2-(4,4,5,5,5-pentafluoropentyl)propane-1,3-diol (100 mg, 0.155 mmol) in dry dichloromethane (5 ml) was cooled to 0° C. under argon atmosphere. To this solution was added dropwise boron tribromide (11.0 mol/l solution in dichloromethane, 0.93 ml, 0.928 mmol) and the resulting solution was warmed to 4° C. and stirred for overnight. After the reaction was completed, the mixture was poured in ice-water and extracted with dichloromethane The organic solvent was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. This crude product was purified by preparative TLC on silica gel, eluting with ethyl acetate:n-hexane=1:1. After removal of the solvent, 75 mg of the title compound was obtained as white foam. (yield: 78.1%)

[0867]¹H-NMR (300 MHz, CDCl₃) δ: 7.21 (d, 2H, J=9.0 Hz), 6.82 (m, 3H), 6.65 (d, 1H. J=2.6 Hz), 6.48 (dd, 1H, J=8.7, 2.6 Hz), 5.88 (bs, 1H), 4.88 (bs, 1H), 3.62 (d, 1H, J=11.7 Hz), 3.60 (m, 4H), 2.93 (d, 1H, J=11.7 Hz), 2.67 (bd, 1H), 2.35 (bs, 2H), 2.00 (m, 2H), 1.30 (m, 6H), 1.15 (s, 3H), 1.21-1.06 (m, 14H)

[0868] Mass(ESI): 641[M+Na], 619[M+1]

EXAMPLE 26

[0869] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3methyl-4-(9-(2-aza-2-carbonyl-1-(4,4,5,5,5-pentafluoropentylamino)ethenyl)aminononyl)thiochroma n

[0870] Step 1) Synthesis of 1-cyano-3-(4,4,5,5,5-pentafluoropentyl)-2-methylisothiourea

[0871] A solution of 4,4,5,5,5-pentafluoropentylamine (0.1 18M, 30 ml, 3-55 mmole) and of dimethyl N-cyanodithioiminocarbonate(700 mg, 4-26 mmole) in ethanol (30 ml) was heated under reflux for 18 hours. Concentration under reduced pressure, followed by crystallization from ethyl acetate and petroleum ether afforded 1-cyano-3-(4,4,5,5,5-pentafluoropentyl)-2-methylisothiourea(677 mg, 69%).

[0872]¹H-NMR (300 MHz, CDCl₃) δ: 3.5 (m, 2H), 2.5 (s, 3H), 2-0 (m, 4H)

[0873] Step 2) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-(2-aza-2-carbonyl -1-(4,4,5,5,5-pentafluoropentylamino)ethenyl)aminononyl)thioch roman

[0874] Silver nitrate(155 mg, 0.915 mmole) was added to a solution of 1-cyano-3-(4,4,5,5,5-pentafluoropentyl)-2-methylisothiourea (277 mg, 1.006 mmole) and (3RS,4RS)-7-methoxymethoxy-3-methyl-3-(4-methoxymethoxyphenyl)-4-(9-aminono nyl)thiochroman (459 mg, 0.915 mmole) in 10 ml of a mixture of tniethylamine/DMF(1/1). The reaction was stirred for 40 minutes at room temperature followed by filtration over celite. The filtrate was concentrated in vacuo and the residue was diluted with water and the resulting solution was extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was dissolved in 6N hydrochloric acid (2 ml) and methanol (6 ml), which was then stirred at 90° C. for 2 hours. This reaction solution was concentrated under reduced pressure which was subjected to flash chromatography on silica gel (dichloromethane:methanol=9:1) to give the title compound (94 mg) as white solid.

[0875]¹H-NMR (300 MHz, CD₃OD) δ: 7.14 (d, 2H, J=8.7 Hz, Ar—H), 6.75 (d, 1H., J=8.2 Hz, Ar—H), 6.68 (d, 2H, J=8.7 Hz), 6.47 (d, 1H, J=2.4 Hz), 6.35 (dd, 1H, J=8.2 Hz, J=2.4 Hz), 3.51 (d, 1H, J=11.6 Hz, C2-H), 3.2 (t, 2H, J=6.8 Hz), 3.07 (t, 2H, J=6.9 Hz), 2.85 (d, 1H, J=11.6 Hz, C2-H), 2.6 (m, 1H), 2.1 (m, 2H), 1.7 (m, 2H), 1.5 (m, 2H), 1.02 (s, 3H, C3-CH₃), 0.8-1.l(m, 14H)

[0876] Mass(ESI) 659 (M+1)

EXAMPLE 27

[0877] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydr xyphenyl)-3-methyl-4-9-((1-((4,4,5,5,5pentafuoropentyl)amino)-2-nitroethenyl)amino)nonyl)thiochroman

[0878] Step 1) Synthesis of (3RS,4RS)-4-(azidononyl)-7-methoxymethyloxy-3-[4-(methoxymethyloxy)phenyl]-3-methylthiochroman

[0879] (3RS,4 RS)-4-(9-Methanesulfonyloxynonyl)-7-methoxymethyloxy-3-[⁴-methoxymethyloxy)phenyl]-3-methylthiochroman (982 mg, 1.69 mmol) was dissolved in anhydrous N,N-dimethylformamide (25 ml). Sodium azide (441 mg, 6.76 mmol) and 18-crown-6 (45 mg, 0.169 mmol) was added. The mixture was stirred at 65° C. (for 19h under nitrogen atmosphere. The mixure was filtered after cooling to room temperature. The filtrate was evaporated in vacuo. The residue was diluted with water and then extracted with ethyl acetate. The extracted organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:ethyl acetate=8:1) to produce 873 mg (yield:98%) of the title compound as a pale yellow oil.

[0880]¹H-NMR (300 MHz, CDCl₃) δ 7.27 (d, 2H, J=9 Hz), 7.01 (d, 2H, J=9 Hz), 6.91 (d, 1H, J=9 Hz), 6.86 (d, 1H, J=2 Hz), 6.67 (dd, 1H, J=9 Hz, J=2 Hz), 5.17 (s, 2H), 5.12 (s, 2H), 3.61 (d, 1H, J=12 Hz), 3.48 (s, 3H), 3.47 (s, 3H), 3.20 (t. 2H, J=7 Hz), 2.98 (d, 1H, J=12 Hz), 2.72 (br, 1H), 1.50 (m. 2H), 1.27 (m, 4H), 1.15 (s, 3H), 0.90-1.12 (m, 10H)

[0881] Step 2) Synthesis of (3RS,4RS)-4-(azidononyl)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman

[0882] (3RS,4RS)-4-(Azidononyl)-7-methoxymethyloxy-3-[4-methoxymethyloxy) phenyl]-3-methylthiochroman (595 mg, 1.13 mmol) was dissolved in methanol (12 ml) and 6N HCl (0.2 ml). The mixture was stirred at 65° C. for 3h under nitrogen atmosphere. When the reaction was completed, the mixture was evaporated. The residue was subjected to column chromatography (n-hexane:ethyl acetate=4:1) to give 480 mg (yield: 97%) of the title compound as a colorless oil.

[0883]¹H-NMR (300 MHz, CDCl₃) δ 7.22 (d, 2H, J=9 Hz), 6.86 (d, 1H, J=8 Hz), 6.81 (d, 2H, J=9 Hz), 6.65 (d, 1H, J=3 Hz), 6.48. (dd, 1H, J=8 Hz, J=3 Hz), 4.92 (s, 1H), 4.74 (s, 1H), 3.61 (d, 1H, J=12 Hz), 3.22 (t, 2H, J=2 Hz), 2.94 (d, 1H, J=12 Hz), 2.69 (br, 1H), 151 (m, 2H), 1.24 (m, 4H), 1.15 (s, 3H), 0.90-1.13 (m, 10H)

[0884] Step 3) Synthesis of (3RS,4RS)-4-(aminononyl)-7-hydroxy-3-(4-hydroxy phenyl)-3-methylthiochroman

[0885] Methanol (70 ml) and-10% Pd/C (137 mg) were added to (3RS,4RS) 4-(azidononyl)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman (410 mg, 0.93 mmol) and the mixture was stirred for 2 h under hydrogen (normal pressure). When the reaction was completed, the mixture was filtered through celite pad, the filtrate was evaporated in vacuo to give 380 mg (yield: 98%) of the title compound as a pale yellow oil.

[0886]¹H-NMR (300 MHz, CDCl₃) δ 7.36 (d, 2H, J=10 Hz). 6.97 (d, 1H, J=8 Hz), 6.90 (d, 2H, J=9 Hz), 6.68 (d, 1H, J=2 Hz), 6.56 (dd, 1H, J=3 Hz, J=2 Hz), 3.73 (d, 1H, J=12 Hz), 3.07 (d, 1H, J=12 Hz), 2.86 (br, 1H), 2.72 (t, 2H, J=7 Hz), 1.53 (m, 2H), 1.33 (m, 4H), 1.24 (s, 3H) 0.9-1.21 (m, 10H)

[0887] Mass (ESI) 414 (M+1)

[0888] Step 4) Synthesis of (4,4,4,5,5,5-pentafluoropentyl)benzylamine

[0889] 4,4,5,5,5-Pentafluoropentyloxytoluenesulfonate (1 g, 3 mmol) was dissolved in acetonitrile (10 mI). Benzylamine (646 mg, 6 mmol) and potassium carbonate (829 mg, 6 mmol) were added. The mixture was refluxed for 10h under nitrogen atmosphere. When the reaction was completed, the mixture was cooled to room temperature. Water was added to reaction solution which was then extracted with ethyl acetate. The extracted organic layer was dried over anhydrous magnesium sulfate and then concentrated. The- residue was subjected to column chromatography (dichloromethane:ethyl acetate=19:1) to give 590 mg (yield: 74%) of the title compound as a pale yellow liquid.

[0890]¹H-NMR (300M&, CDCl₃) δ 7.36 (m, 5H), 3.83 (s, 2H), 2.74 (t, 2H, J=7 Hz), 2.16 (m, 2H), 1.71 (m, 2H), 1.00 (s, 1H)

[0891] Step 5) Synthesis of (1-methylthio-2-nitrovinyl)(4,4,5,5,5-pentafluoropentyl)amine

[0892] Ethanol (40 ml) and 20% Pd(OH)₂/C (400 mg) were added to (4,4,4,5,5,5-pentafluoropentyl)benzylamine (2.04 g, 7.64 mmol) and then stirred at room temperature for 10 h under hydrogen (normal pressure). The reaction mixture was filtered through celite pad. The filtrate (15.55 g, calculated 2.82 mmol) was added to dichloroethane (5 ml) and 1,1-bismethylthio-2-nitroethylene (112 mg, 0.68 mmol). The resulting mixture was stirred at room temperature for 10 minutes under nitrogen atmosphere. The mixture was heated at reflux for 16 h. When the reaction was completed, the mixture was cooled to room temperature. Water was added to reaction solution which was then extracted with dichlororpethane. The extracted organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was subjected to column chromatography (100% dichloromethane) to give 532 mg (yield: 64%) of the title compound as a white solid.

[0893]¹H-NMR (300 MHz, CDCl₃) a 6.53 (s, 11H)-3.51 (m, 2H), 2.42 (s, 3H), 2.07 (m, 2H), 1.22 (s, 2H)

[0894] Step 6) Synthesis of (3RS,4RS)-7-hydroxy-3-methyl-3-(4-hydroxyphenyl)-4-(9-(2-aza-2-carbamoyl-1-4,4,5,5,5-pentafluoropentylamino)ethenyl)aminononyl)th iochroman

[0895] (3RS,4RS)-4-(aminononyl)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-thiochroman (380 mg, 0.92 mmol) was added to acetonitrile (50 ml) and (1-methylthio-2-nitrovinyl)(4,4,5,5,5-pentafluoropentyl)amine (1.66 g, 5.61 mmol). The mixture was refluxed for 25h under nitrogen atmosphere and then cooled to room temperature. The mixture was evaporated in vacuo. The residue was subjected to column chromatography (dichloromethane:methanol=97:3) to give 63 mg (yield: 10%) of the title compound as a yellow oil.

[0896]¹H-NMR (300 MHz, acetone-d-6) δ 7.29 (d, 2H, J=9 Hz), 6.91 (d, 1H, J=8 Hz), 6.83 (d, 2H, J=9 Hz), 6.63 (d, 1H, J=2 Hz), 6.50 (dd, 1H, J=8 Hz, J=2 Hz), 5.59 (s, 1H), 3.62 (d, 11, J=12 Hz), 3.41 (m, 2H), 3.29 (m, 2H), 3.00 (d 1H, J=12 Hz), 2.86 (br, 1H). 2.30 (m, 2H), 1.94 (m, 2H), 1.60 (m, 2H), 1.28 (m, 2H), 0-85-1.25 (m, 13H) Mass(ESI) 660 (M+I)

EXAMPLE 28

[0897] Synthesis of (3RS,4RS),-7-hydroxy-3-(4-hydroxyphenyl)-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfonylamino)octyl]chroman

[0898] Step 1) Synthesis of (3RS,4RS)-4-(8-methanesulfonyloxyoctyl}7-methoxymethoxy-3-(4-methoxy-methoxyphenyl)-3-methylchroman

[0899] The title compound was prepared (yield 95.6%) from (3 RS,4RS)-4-(8-hydroxyoctyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)₃-methylchroman according to the same procedure as Step 5 of Example 7.

[0900]¹H-NMR (300 MHz, CDCl₃) δ: 7.10 (d, J=8.96 Hz, 2H), 7.01 (d, J=9.04 Hz, 2H), 6.92 (d, J=8.67 Hz, 1H), 6.56-6.53 (m, 2H), 5.15 (d, J=9.79 Hz, 4H), 4.50 (d, J=10.55 Hz, 1H), 4.24 (d, J=10.55 Hz, 1H), 4-16 (t, J=6.78 Hz, 2H), 3.47 (s, 6H), 2.63 (brd, J=8.29 Hz, 1H), 1-69-0.98 (m, 17H).

[0901] Step 2) Synthesis of (3RS,4RS)-4-(8-azidooctyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0902] The title compound was prepared (yield 73.2%) from (3RS,4RS)-4-(8-methanesulfonyloxy-octyl)-7-methoxymethoxy-3-(4-methoxy -methoxyphenyl)-3-methylchroman according to the same procedure as Step 6 of Example 7.

[0903]¹H-NMR (300 MHz, CDCl₃) δ: 7.12 (d, J=9.04 Hz, 2H), 7.01 (d, J=8.67 Hz, 2H), 6.93 (d, J=9.04 Hz, 1H), 6.57-6.53 (m, 2H), 5.14 (d, J=9.80 Hz, 4H), 4.51 (d, J=10.55 Hz, 1H), 4.24 (dd, 1=10.55 Hz, 1.88 Hz, 1H), 3.48 (d, J=1.50 Hz, 6H), 3.19 (t, J=7.16 Hz, 2H), 2.63 (brd, J=9.04 Hz, 1H), 1.55-0.98 (m, 17H).

[0904] Step 3) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropentylsulfonylamino)octyl]chroman

[0905] The title compound was prepared (yield 74.6%) from (3RS,4RS)-4-(8-azidooctyl )-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman according to the same procedure as Step 2 of Example 13.

[0906]¹H-NMR (300 MHz, CDCl₃) δ: 7.12 (d, J=8.67 Hz, 211), 7.01 (d, J=9.04 Hz, 2H), 6.94-6.91 (m, 1H), 6.57-6.53 (m, 2H), 5.15 (d, J=10.93 Hz, 4H), 4.51 (d, J=10.55 Hz, 1H). 4.264.15 (m, 2H), 3.48 (d, 1=2.26 Hz, 6H), 3.15-3.00 (m, 4H), 2.64-2.61 (brd, 1H), 12.30-2.05 (m, 4H), 1.51-0.90 (m, 17H).

[0907] Step 4) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-pentafluoropenTyl sulfonylamino)octylchroman

[0908] The title compound was prepared (yield 63.3%) from (3RS,4RS)-7-methoxymethoxy-344-methoxymethoxyphenyl)-3-methyl-4-[8-4,4,5,5,5-pentafluoro -pentylsulfonylamino)octyl]chroman according to the same procedure as Step 6 of Example 17.

[0909]¹H-NMR (300 MHz, CDCl₃) δ: 7.07 (d, J=8.66 Hz, 2H), 6.88 (d, J=7.53 Hz, 1H), 6.83 (d, J=8.66 Hz, 2H), 6.37-6.34 (m, 2H), 5.31 (s, 1H), 4.63 (s, 1H), 4.99 (d, J=10.17 Hz, 1H), 4.24-4.18 (m, 2H), 3.11-3.02 (m, 4H), 2.59-2.55 (m, 1H), 2.30-2.10 (m, 4H), 1.51-0.95 (m, 17H)

[0910] Mass(ESI): 608 (M+1)

EXAMPLE 29

[0911] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-(hydroxyphenyl)-3-methyl-4-[4-(4-piperidylbutyloxy)phenyl]chroman

[0912] Step 1) Synthesis of (3RS,4RS)-4-[4-(4-chlorobutyloxy)phenyl]-(7-(methoxy-methoxy)-3-(4-(methoxymethoxy)phenyl)-3-methylchroman

[0913] To (3RS,4RS)-4-[4-4-hydroxyphenyl]-(7-(methoxymethoxy)-3-{4-(methoxymethoxy)phenyl)-3-methylchroman (413 mg, 0.9 mmol) and K₂CO₃ (261 mg, 1.9 mmol) in acetone (10 mL) was added 1-bromo-4-chlorobutane (436 mg, 3.6 mmol). The mixture was stirred at reflux for 5h and then cooled to rt and poured into water. The aqueous layer was extracted with ethyl acetate. The extract was dried over MgSO₄ and filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=8:1) to give 393 mg (yield. 78%) of a colorless oil

[0914]¹H-NMR (300 MHZ, CDCl₃) δ: 7.17 (dd, J=8.67 Hz, 1H), 6.79 (d,, 2H), 6-70 (dd, J=8.7 Hz, 2H), 6.09 (s, 1H). 6-59 (s, 1 μl), 6.45 (m, 2H), 6.15 (d, 1H) 5.98 (s, 1H), 5.04 (d, 4H), 4.53 (dd, J=10.5 Hz. 1H), 3.96 (dd, J=10.3, 1H), 3.84 (s, 1H), 3.79 (t, 2H), 3.55 (t, 2H), 3.45 (d, 6H), 1.95-1.82 (m, 4H), 1.43 (s, 3H)

[0915] Step 2) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-(methoxymethoxy) phenyl)-3-methyl-4-[4-(4-piperidylbutyloxy)phenyl]chroman

[0916] To (3RS,4RS)-4-[4-4-chlorobutyl oxy)phenyl]-(7-(methoxymethoxy)-3-(4-(methoxymethoxy)phenyl)-3-methylchroman (393 mg, 0.75 mmol) was added piperidine (738 mg, 7.5 mmol) and the mixture was refluxed for 12h. After cooling, the mixture was extracted with ethyl acetate, dried over MgSO₄, and filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel columnchromatography (CH₂Cl₂:methanol=20:1) to give 325 mg (yield. 75%) of a colorless oil.

[0917]¹H-NMR (300 MHZ, MeOH-d) δ: 7.10 (dd, J=8.69 Hz, 1H), 6.78 (d, 2H), 6.71 (dd, J=8.7 Hz, 2H), 6.63 (s, 1H), 6.60 (s, 1H), 6.5 (m, 2H), 6.15 (d, 1H) 5.96 (s, 1H), 5.09 (d, 4H), 4.61 (dd, J=10.5 Hz, 1H), 3.97 (dd. J=10.6 Hz, 1H), 3.82 (s, 1H), 3.48 (t, 2H), 3.43 (t, 2H), 2.78 (t, 6H), 1.7 (m, 6H), 1.5 (m, 2H), 1.3 (s, 3H)

[0918] Step 3) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-(4-piperidylbutyloxy)phenyl]chroman

[0919] A mixture of (3RS,4RS)-7-methoxymnethoxy-3-(4-(.Methoxymethoxy) phenyl)-3-methyl-4-[4-(4-piperidylbutyloxy)phenyl]chroman (325 mg, 0.56 mmol) p-toluenesulfonic acid (1.42 g, 5.6 mmol) and methanol was stirred at reflux for 12h. After cooling, the mixture was extracted with ethyl acetate, dried over MgSO₄, and filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel column chromatography (CH₂Cl₂:methanol=10:1) to give 160 mg (yield. 58%) of a white foamy solid.

[0920]¹H-NMR (300 MHZ, MeOH-d) a : 7.2 (dd, J=8.5 Hz, 2H), 6.7 (d, 1H), 6.48 (dd, J=8.7 Hz, 2H), 6.43 (m, 4H), 6.30 (s, 1H), 6.13 (d, 1H), 5.39 (s, 1H) 4.44 (dd, 3=10.2 Hz, 1H), 3.87 (dd, J=t-0.5 Hz, 1H), 3.83 (s, 1H), 3.7 (t, 2H), 2.94 (m, 2H), 2.81 (m, 2H), 1.67 (m, 8H), 1.46 (2H), 1.3 (s, 3H).

EXAMPLE 30

[0921] Synthesis of (3RS,4RS)-7-hydroxy-3-methyl-3-(4-hydroxyphenyl)-4-(4-(3 (2-(4,4,5,5,5-pentafuoropentylsulfinyl)ethoxy)(R)-2-hydroxypropyloxy) phenyl)chroman

[0922] Step 1) Synthesis of 1-((2-oxiranyl)methoxy)-2-(4,4,5,5,5--pentafluoropentylthio)ethane

[0923] A mixture of 50% acqueous NaOH(1.85 ml), S-epichlorohydrin (1.142 g, 12.34 mmole) and t-butylammonium hydrogen sulfate(24 mg) was vigorously stirred at 0° C., for half an hour and allowed to reach room temperature. To this mixture was added 2-(4,4,5,5,5-pentafluoropentylthio)ethan-1-ol (735 mg, 3.08 mmole) at room temperature. The reaction mixture was stirred for 18 hours and quenched with water. The aqueous phase was extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=7:1) to give the title compound (568mcy, yield 63%) as a colorless oil.

[0924]¹H-NMR (300 MHz, CDCl₃) δ: 3.73 (dd, 1H, J=11.3 Hz, J=2.5 Hz), 3.63 (m 2H), 3.32 (dd, 1H, 1=11.3 Hz, J=5.5 Hz), 3.2 (m, 1H), 2.73 (m, 1H), 2.66 (t, 2H, J=6.3 Hz), 2.6 (t, 2k, J=7.1 Hz), 2.55 (dd, 1H, J=4.9 Hz, J=2.6 Hz), 2.16 (in, 1H), 1.88 (m 2H)

[0925] Mass(ESI): 295(M+1), 327 (M+Na)

[0926] Step 2) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxy-methoxyphenyl)-3-methyl-4-(4-(3-2-(4,4,5,5,5-pentafluoropentylthio)ethoxy)-(R)-2-hydroxypropyl oxy)phenyl)chroman

[0927] A mixture of (3RS,4RS)-7-methoxymethoxy-3-methyl-3-(4-methoxy methoxyphenyl)-4-(4-hydroxyphenyl)chroman (31 1 mg, 0.71 mmole), 1-((2-oxiranyl)methoxy)-2-4,4,5,5,5-pentafluoropentylthio)ethane(568 mg, 1.93 mmole), acetonitrile (9 ml), water (3 ml) and pyridine (5 drops) was refluxed for 10 hours. After cooling, the reaction mixture was diluted with water and the aqueous phase was extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=3:1) to give the title compound (448 mg, yield 86%) as a colorless oil.

[0928]¹H-NMR (300 MHz, CDCl₃) δ: 6.84 (d,, 2H, 3=9 Hz ), 6.78 (d, 2H. J=8.6 Hz ), 6.73 (d, 1H, J=8.6 Hz), 6.65 (d, 1H, 3=3.78 Hz), 6.5 (m 5H), 5.14 (s, 2H). 5.08 (s. 2H), 4.55 (d, 1H, J=10.7 Hz, C2-H), 4.0 (m 2H), 3.9 (m, 3H), 3.6 (m, 4H), 3.48 (s, 3H), 3.43 (s, 3H), 2-69 (t, 2H, J=6.8 Hz), 2.61 (t, 2H, 3=6.9 Hz), 2.5 (m, 1H), 2.15 (m 2H), 1.85 (m, 2H), 1.46 (s, 3H)

[0929] Mass(ESI): 731 (M+1)

[0930] Step 3) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(4-(3-(2-(4,4,5,5,5-pentafluoropentyl thio)ethoxy)-(R)-2-hydroxypropyloxy)phenyl)chro man

[0931] To a solution of 7-methoxymethoxy-3-(4-methoxymethoxy phenyl)-3-methyl -4-(4-(3-(2-(4,4,5,5,5-pentafluoropentylthio)ethoxy)-(R)-2-hydroxyp ropyloxy)phenyl)chroman (440 mg, 0 613 mmol) in methanol (9 ml) was added 6N HCl (3 nm) at room temperature, which was stirred for 40 minutes at 70° C. Water was added .thereto, and the resulting solution was extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=3:2) to give the title compound (269 mg, yield 68%) as a white solid.

[0932]¹H-NMR (300 MHz, CD₃OD) δ: 6.7 (d,, 2H, J=6.9 Hz ), 6.46 (m 7H), 6.27 (d,, 1H, J=2.4 Hz ), 6.18 (dd, 1H, J=2.4 Hz, 8.2 Hz), 4.44 (d, 1H, J=10.6 Hz, C2-H), 3.75 (m, 5H), 3.51 (t, 2H, J=6.5 Hz), 3.4 (m, 2H), 2.57 (t, 2H, J=6.5 Hz), 2.51 (t, 2H, J=7.0 Hz), 2.1 (m, 2H), 1.7 (m 2H), 1.31 (s, 3H)

[0933] Mass(ESI): 643 (M+1)

[0934] Step 4) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4.4-(3-(2-(4,4,5,5,5-pentafluoropentylsulfinyl)ethoxy)-R)-2-hydroxypropyloxy)phenyl) chroman

[0935] 7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(4-(3-(2-(4,4,5,5,5-pentafluoro-pentylthio)ethoxy)-(R)-2-hydroxypropyloxy)phenyl)chroman (118 mg, 0.18 mmol) was dissolved in MeOH(5 mg). Water (1 ml) and sodium periodate (59 mg, 0.28 mmol) were added thereto, and then the mixture was stirred at room temperature for 18 hours. The reaction solution was filtered, and the filtrate was concentrated. The residue was extracted with ethyl acetate, dried over anhydrous magnesium sulfate, and subjected to flash column chromatography (dichloromethane:methanol=19:1) to give the title compound (84 mg, yield 70%) as a yellow foamy solid.

[0936]¹H-NMR (300 MHz, CD₃OD) δ: 6.82 (d, 2H, J=8.6 Hz ), 6.6 (m, 7H, Ar—H), 6.39 (d, 1H, J=2.3 Hz), 6.3 (dd, 1H, J=2.3 Hz, 8.3 Hz), 4.57 (d, 1H, J=10.6 Hz, C2-H), 3.8 (m 7H), 3.5 (m, 2H), 3.05 (m, 1H), 2.8 (m, 3H), 2.3 (m, 2H), 2.1 (m, 2H), 1.51 (s, 3H)

[0937] Mass(ESI): 659 (M+1)

EXAMPLE 31

[0938] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3methyl-4-(14-(4,4,5, 5,5-pentafluoropentylsulfinyl)butyloxy]butyl}chroman

[0939] To a solution of (3RS,4RS)-4-(4-hydroxybutyl)-7-methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman (245 mg, 0.588 mmol) in dry THF (4 ml) were added 95%(w/w) sodium hydride(18 mg, 0-706 mmol) and 1-bromo-4-chlorobutane (0.67 ml, 5.88 mmol) at 0° C., and the mixture was stirred overnight under reflux. After the reaction was completed, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude intermediate(240 mg). To this crude intermediate and 4,4,5,5,5- pentafluoropentyl thioacetate(335 mg, 1.419 mmol) in methanol (4 ml)/water (2 ml) co-solvent were added sodium iodide (78 mg, 0520 mmol) and sodium hydroxide (85 mg, 2.125 mmol), and the mixture was stirred for 18 hours under heating (50-60° C.). After the reaction was completed, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed under reduced pressure to obtain a crude intermediate. This crude intermediate was subjected to silica gel chromatography (n-hexane:ethyl acetate=4:1) to obtain pure intermediate (293 mg). To this intermediate in methanol (6 ml) was added c-HCl (0.6 ml), and the mixture was stirred for 3 hours under heating (50-55° C.). After the reaction was completed, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed under reduced pressure to obtain a crude intermediate (250 mg). To this intermediate in methanol (3 ml), water (1 ml), 1,4-dioxane (1 ml) co-solvent was added sodium periodate (105 mg, 0.490 mmol), and the mixture was stirred for 6 hours at room temperature. After the reaction was completed, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, and filtered. The organic solvent was removed under reduced pressure to obtain a crude intermediate. This crude intermediate was subjected to silica gel chromatography (n-hexane:ethyl acetate=1:1) to give the title product (184 mg) as solid (56%).

[0940]¹H-NOR (300 MHz, CDCl₃) δ: 7.14 (d, 2H), 6.88 (d, OH), 6.83 (d, 2H), 6.49-6.33 (m, 2H), 4.49 (dd, 1H), 4.21 (dd, 1H), 3.26-3.09 (m, 4H), 2.87-2.72 (m, 3H), 2.68-2.54 (m, 2H), 2.33-2.08 (m, 4H), 1.83-1.02 (m, 10H), 1.26 (s, 3H)

[0941] Mass(ESI) 593 (M+1)

EXAMPLE 32

[0942] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-methyl-4-15-1N-methyl-N-[3-(4,4,5,5,5-pentafluoropentyl)sulfinylpropyl]aminopentyl}chroman and (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-methyl-4-{5-{N-methyl-N-oxo-N-[3-(4,4,5,5,5-pentafluoropentyl)suilfinylpropyl]aminopentyl}chroman

[0943] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl({5-{N-methyl-N-[3-(4,4,5,5,5-pentafluoropentylthio)propyl]aminopentyl}chroman (112 mg, 0.19 mmol) was dissolved in methanol (6 mL) and water (1.2 mL). Sodium periodate (50 mg, 0.23 mmol) was added thereto, and then the mixture was stirred for 13 hours at ambient temperature. Water was added and the reaction mixture was extracted with ethyl acetate. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The mixture was subjected to column chromatography (dichloromethane:methanol=10:1) to give the title compounds of 76.6 mg (66.6%) and 26.2 mg (22.8%) as an oil, respectively.

[0944] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{5-{N-methyl-N-[3-(4,4,5,5,5-pentafluoropentyl)sulfiny]propyl}aminopentyl}chroman

[0945]¹H-NMR (300 MHz, CD₃OD); δ 6.99 (d, J=8.67 Hz, 2H), 6.77 (d, J=8.23 Hz, 1H), 6.68 (d, J=8.68 Hz, 2H), 6.22 (dd, J=2.49 and 8.22 Hz, 1H), 6.15 (d, J=2.41 Hz, 1H), 4.40 (d, 10.50 Hz, 1H), 4.11 (dd, J=1.59 and 10.51 Hz, 1H), 2.71-2.79 (m, 4H), .2.54 (m, 1H), 2.40 (t, 2H), 2.17-2.22 (m, 4H), 2.12 (s, 3H), 2.01 (m, 2H), 1.83 (m, 2H), 1.00-1.21 (m, 11H)

[0946] Mass(ESI): M+1=606

[0947] (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{5-{N-methyl-N-oxo-N-[3-4,4,5,5,5-pentafluoropentyl)sulfiny]propyl}aminopentyl}chroman

[0948]¹H-NMR (300 MHz, CD₃OD); δ 7.01 (m, 2H), 6.81 (m, 1H), 6.66 (m, 2H), 6.13-6.25 (m, 2H), 4.42 (m, 1H), 2.63-3.08 (mi, 9H), 2.52 (m, 1H), 1.89-2.32 (m, 6H), 1.36-1.53 (m, 2H), 0.92-1.32 (m, I1H)

[0949] Mass(ESI): M+1=622

EXAMPLE 33

[0950] Synthesis of (3′RS,4′RS)-2-(4-(7-hydroxy)-3-(4-hydroxyphenyl)-3methylchroman-4-yl)butyl-6-(4-(4,4,5,5,5pentafluoropentyl)sulfinyl)hexanoic acid

[0951] Step 1) Synthesis of 4-[4-(t-butyldimethylsilyloxy)-1-butynyl]-4-hydroxy-7-methoxymethoxy-3-(4-(methoxymethoxy)phenyl)-3-methylchroman

[0952] 4-(t-Butyldimethylsilyloxy)-1-butyne (0.17 g, 6.4 mmol) was dissolved in dry tetrahydrofuran (20 ml) under argon atmosphere, which -was then cooled down to −78° C. n-Butyllithium(2.29 ml, 5.72 mmol, 2.5M solution in tetrahydrofuran) was slowly added dropwise thereto, and the mixture was stirred at −78° C. for 30 minutes. To this mixture was added dropwise 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-one(1.14 g, 3.18 mmol) dissolved in dry tetrahydrofuran (10ml) at −78° C., and the resulting reaction mixture was stirred at room temperature for 3 hours, and the reaction mixture was cooled to 0° C. The reaction was quenched with water, and the reaction solution was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous -magnesium sulfate, and concentrated. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=5:1) to give the title compound (1.6 g, yield 93%) as a colorless oil.

[0953]¹H-NMR (3000 MHz, CDCl₃) δ: 7.63 (d, 1H), 7.48 (d, 2H), 7.02 (d, 2H), 6.63 (dd, 1H), 6.53 (d, 1H), 5.15 (d, 4H). 4.9 (d, 1H), 4.15 (d, 1H), 3.75 (t, 2H), 3.5 (d, 6H), 2-49 (t, 2H), 2.1 (s, 1H), 1.5 (s, 3H), 0.9 (s, 9H), 0.08 (s, 6H)

[0954] Step 2) Synthesis of (3RS,4RS)-4-[4-(t-butyldimethylsilyloxy)-1-butyl]-7-methoxymethoxy-3-(4-(methoxymethoxy)phenyl)-3-methylchroman

[0955] 4-[4-(t-butyl dimethylsilyloxy)-1-butynyl]4-hydroxy-7-methoxymethoxy-3-(4-(methoxymethoxy)phenyl)-3-methylchroman (1.6 g, 2.95 mmol) was dissolved in ethyl acetate (30 ml), and then 10% Pd/C (0.6g) was added thereto. The reaction suspension was stirred under hydrogen for 1 hour, filtered, and concentrated. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=20:1) to give the title compound (680 mg, yield 44%) as a colorless oil.

[0956]¹H-NMR (300 MHz, CDCl₃) δ: 7.25 (d, 2H), 7.05 (d, 2H), 6.98 (d, 1H), 6.6 (m, 2H), 5.2 (d, 4H), 4.55 (d, 1H), 4.3 (d, 1H), 3.53 (d, 6H), 3.45 (t, 2H), 2.7 (d, 1H), 1.4-1.08 (m, 9H), 0.9 (s, 9H), 0.07 (s, 6H)

[0957] Step 3) Synthesis of (3RS,4RS)-4-{-4-hydroxybutyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0958] (3RS,4RS)-4-[4-(t-butyl dimethylsilyloxy)-1-butyl 3-7-methoxymethoxy-3-(4-(methoxymethoxy)phenyl)-3-methylchroman (680 mg, 1.28 mmol) was dissolved in tetrahydrofuran (10 ml), and cooled to 0° C. To this solution was added tetrabutylammonium fluoride (2.6 ml, 2.56 mmol), and the reaction mixture was stirred at room temperature for 6 hours The solvent was removed by evaporation under vacuum, and the residue was dissolved in ethyl acetate, which was washed with water. The organic layer was separated, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The product was purified by column chromatography on silica gel, eluting with 30% ethyl acetate in n-hexane to afford 487 mg of the title compound as a colorless oil. (yield: 92.4%)

[0959]¹H-NMR (300 MHz, CDCl₃) δ: 7.1 (d, 2H), 7.0 (d, 2H), 6.92 (d, 1H), 6.55 (m, 2H), 5.15 (d, 4H), 4.5 (d, 1H), 4.25 (d, 1H), 3.48 (d, 6H), 3.45 (d, 2H), 2.65 (d, 1H), 1.4-1.0 (m, 9H)

[0960] Step 4) synthesis of (3RS,4RS)-4-(4-methansulfonyloxybutyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[0961] Hydroxy compound (487 mg, 1.17 mmol) was dissolved in dichloromethane (10 ml) and cooled to 0° C., to which were added triethylamine (0.41 ml, 2.9 mmol) and methanesulfonyl chloride (0.23 ml, 2.9 mmol). The reaction mixture was stirred at room temperature for 1.5 hour. After the reaction was completed, water was added to the reaction. solution, and the resulting mixture was extracted with methylene chloride. The organic layer was washed with 1M HCl solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated. The product was purified by column chromatography on silica gel, eluting with 50% ethyl acetate in n-hexane to afford 578 mg of the title compound as a colorless oil. (yield: quant.)

[0962]¹H-NMR (300 MHz CDCl₃) δ 7.1 (d, 2H), 7.03 (d, 2H), 6.93 (d, 1H), 6.58 (m, 2H), 5.28 (d, 4H), 4.5 (d, 1H), 4.38 (d, 1H), 4.02 (t, 2H), 3.5 (d, 6H), 2.9 (s, 3H), 2.65 (d, 1H), 1.4-1.1 (m, 9H)

[0963] Step 5) Synthesis of (3RS,4RS)-4-4-iodobutyl)-7-methoxymethoxy-3-(4 ( methoxymethoxy)phenyl)-3-methylchroman

[0964] Mesylated compound (578 mg, 1.17 mmol) was dissolved in acetone (15 mI). To the reaction solution was added sodium iodide (0.87 g, 5.8 mmol). The reaction mixture was heated at reflux temperature, with stirring, for 3 hours and then allowed to cool to ambient temperature, then concentrated under reduced pressure in order to remove all of the acetone. the residue was dissolved in ethyl acetate and filtrated. The organic solvent was removed by evporation under vacuum. This product was purified by column chromatography on silica gel, eluting with 10% ethyl acetate in n-hexane to afford 539 mg of the title compound as a colorless oil. (yield 87.5%)

[0965]¹H-NMR (300 MHz CDCl₃) δ: 7.12 (d, 2H), 7.0 (d, 2H), 6.9 (d, 1H), 6.53 (m, 2H), 5.15 (d, 4H), 4.5 (d, 1H), 4.28 (d, 1H), 3.5 (d, 6H), 3.0 (t, 2H), 2.65 (d, 1H), 1.4-1.1 (m, 9H)

[0966] Step 6) Synthesis of 4-(phenylmethoxy)butane-1-ol

[0967] To a solution of diol compound (4.51 g, 50 mmol) in dry THF(50 ml) was added 60% NaH (1.6 g, 43 mmol) at 0° C. After stirring for 2 hours, benzyl bromide (5.7 g, 33 mmol) was added dropwise and stirred for 15 hours. After the reaction was completed, ice-water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=10:1) to give the title compound (936 mg, yield 16%).

[0968]¹H-NMR (300 MHz, CDCl₃) δ: 7.35 (m, 5H), 4.5 (s, 2H), 3.6 (t, 2H), 3.5 (t, 2H), 2.05 (bs, 1H), 1.7 (m, 4H)

[0969] Step 7) Synthesis of (methyl sulfonyl)oxy(4-(phenylmethoxy)butane

[0970] 4-(Phenylmethoxy)butane-1-ol (936 mg, 5.2 mmol) was dissolved in dichloromethane (10 ml), to which were added triethylamine (1.8 ml, 13 mmol) and methanesulfonyl chloride (0.8 ml, 10.4 mmol). The reaction mixture was stirred at room temperature for 1 hour. After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with methylene chloride. The organic layer was washed with 1M HCl solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated. The product was purified by column chromatography on silica gel, eluting with 30% ethyl acetate in n-hexane to afford 1.34g of the title compound as a colorless oil. (yield: quant)

[0971] Step 8) Synthesis of 4-iodo-1-(phenylmethoxy)butane

[0972] Mesylated compound (1.34 g, 5.2 mmol) was dissolved in acetone (30 ml). To the reaction solution was added sodium iodide(2.33 g, 15.5 mmol). The reaction mixture was stirred at reflux, for 14 hours and then allowed to cool to ambient temperature, then concentrated under reduced pressure. The residue was dissolved in ethyl acetate and filtrated. The organic solvent was removed by evporation under vacuum. This product was purified by column chromatography on silica gel, eluting with 5% ethyl acetate in n-hexane to afford 1.28 g of the title compound as a colorless oil. (yield 85%)

[0973]¹H-NMR (300 MHz, CDCl₃) δ: 7.32 (m, 5H), 4.5 (s, 2H). 3.48 (t, 2H), 3.2 (t, 2H), 1.9 (m, 2H), 1.7 (m, 2H)

[0974] Step 9) Synthesis of diethyl 2-(4-(phenylmethoxy)butyl)propane-1,3-dioate

[0975] To a solution of diethyl malonate (0.4 g, 2.5 mmol) in dry THF(5 ml) was added 60% NaH(95 mg, 2.4 mmol) at room temperature. After stirring for 10 minutes, iodide compound (0.6 g, 2.07 mmol) was added and stirred at 50° C. for 2.5 hours. After the reaction was completed, the reaction mixture was cooled to room temperature. ice-water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=10:1) to give the title compound (621 mg, yield 93%).

[0976]¹H-NMR (300 MHz, CDCl₃) δ: 7.32 (m, 5H), 4.5 (s, 2H), 4.2 (q, 4H), 3.97 (t, 2H), 3.8 (t, 1H), 1.9 (m, 2H), 1.6 (m, 2H), 1.4 (m, 2H), 1.25 (t, 6H)

[0977] Step 10) Synthesis of (3RS,4RS)diethyl 2-4-hydroxybutyl)-2-{4-[7-methoxymethoxy-3-(4-(methoxymethoxy)phenyl)-3-methylchroman-4-yl]butyl}-2-(4-phenoxybutyl)propan-1,3-dioate

[0978] To a solution of diol compound (322 mg, 0.99 mmol) in dry TEF(15 ml) was added 60% NaH(200 mg, 1.65 mmol) at room temperature. After stirring for 10 minutes, iodide compound (175 mg, 0.33 mmol) was added and the mixture was stirred for 20 hours at room temperature. After the reaction was completed, ice-water was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=5:1) to give the title compound (230 mg, yield 97%).

[0979]¹H-NMR (300MHz, CDCl₃) δ: 7.3 (d, 5H), 7.1 (d, 2H), 7.0 (d, 2H), 6.9 (d, 1H), 6.53 (m, 2H), 5.1 (d, 4H), 4.5 (d, 1H), 4.43 (s, 2H), 4.2 (d, 1H), 4.1 (m, 4H), 3.47 (s, 6H), 3.4 (t, 2H), 2.6 (d, 1H), 1.8 (m, 2H), 1.7 (m, 2H), 1.55 (m, 2H) 1.3-1.15 (m, 17H)

[0980] Step 11) Synthesis of (3RS,4RS)diethyl 2-(4-hydroxybutyl)-2-(4-(7-(methoxymethoxy)-3-(4-(methoxymethoxy)phenyl)-3-methylchroman-4-yl)butyl)prop ane-1,3-dioate

[0981] (3RS,4RS)-diethyl 2-4-hydroxybutyl)-2-{4-[7-methoxymethoxy-3-(4-(methoxymethoxy)phenyl)-3-methylchroman-4-yl]butyl}-2-(4-phenoxybutyl) propan-1,3-dioate(442 mg, 0.613 mmol) was dissolved in abs. EtOH (15 mg), and then 10% Pd/C (0.25g) was added thereto. The reaction suspension was stirred under hydrogen for 2 hours, filtered, and concentrated. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=3:1) to give the title compound (344 mg, yield 89.0%) as a colorless oil.

[0982]¹H-NMR (300 MHz, CDCl₃) δ: 7.12 (d, 2H), 7.02 (d, 2H), 6.92 (d, 1H), 6.55 (m, 2H), 5.25 (d, 4H), 4:5 (d, 1H), 4.25 (d, 1H), 4.1 (m, 4H), 3.6 (t, 2H), 3.48 (s, 6H), 2.6 (d, 1H), 1.8 (m, 2H), 1.7 (m, 2H), 1.5 (m, 2H), 1.3-1.0 (m, 17H)

[0983] Step 12) Synthesis of diethyl (3RS,4RS)-2-(4-(7-(methoxymethoxy)-3-4-(methoxymethoxy)phenyl)-3-methylchroman-4-yl)butyl)-2-(4-(methylsulfonyloxy butyl)propane-1,3-dioate

[0984] Hydroxy compound (344 mg, 0.545 mmol) was dissolved in dichloromethane (15 ml), to which were added triethylamine (0.19 ml, 1.36 mmol) and methanesulfonyl chloride (0.084 ml, 1.1 mmol). The reaction mixture was stirred at room temperature for 1 hour. After the reaction was completed, water was added to the reaction solution, and the resulting mixture was extracted with methylene chloride. The organic layer was washed with 1M HCl solution, water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated. The product was purified by column chromatography on silica gel, eluting with 30% ethyl acetate in n-hexane to afford 374 mg of the title compound as a colorless oil. (yield: 97.0%)

[0985]¹H-NMR (300 MHz CDCl₃) δ: 7.15 (d, 2H), 7.0 (d, 2H), 6.92 (d, 1H), 6.58 (m, 2H), 5.18 (d, 4H). 4.52 (d, 1H), 4.25 (d, 1H), 4.2-4.15 (m, 6H), 3.48 (s, 6H), 2.98 (s, 3H), 2.62 (d, 1H), 1.85-1.48 (m, 6H), 1.3-1.0 (m, 17H)

[0986] Step 13) Synthesis of diethyl (3RS,4RS)-2-4-7-(methoxymethoxy)-3-4-(methoxymethoxy)phenyl)-3-methylchroman-4-yl)butyl)-2-4-4,4,5,5,5-pentafluoro pentylthio)butyl) propanc-1,3-dioate

[0987] 1-(4,4,5,5,5-Pentafluoropentylthio)ethan-1-one (369 mg, 1.56 mmol) was dissolved in MeOH (1.3 ml). 2N-NaOH (0.8 ml) was added thereto, and the mixture was stirred at room temperature for 30 minutes. Mesylated compound (360 mg, 0.52 mmol) dissolved in MeOH (10.3 ml) was added thereto, which was then stirred at 60° C. for 1 hour. The reaction solution was cooled down to room temperature, water was added, and the resulting mixture was extracted with ethyl acetate. The organic extract was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was subjected to flash column chromatography (n-hexane:ethyl acetate=5:1) to give the title compound (390 mg, yield 93%) as a colorless oil.

[0988]¹H-NMR (300 MHz, CDCl₃) δ: 7.15 (d, 2H), 7.0 (d, 2H), 6.9 (d, 1H), 6.55 (m, 2H), 5.15 (d, 4H), 4.5 (d, 1H), 4.25 (d, 1H), 4.1 (m, 4H), 3.5 (s, 6H), 2.65 (d, 1H), 2.55 (t, 2H), 2.45 (t, 2H), 2.2 (m, 2H), 1.9 1.6 (m, 6H), 1.5 (m, 2H), 1.3-10 (m, 17H)

[0989] Step 14) Synthesis of (3′RS,4′RS)-4-(7-(methoxymethoxy)-3-(4-(methoxymethoxy)phenyl)-3-methylchroman-4-yl)butyl)(4-(4,4,5,5,5-pentafluoropent ylthio)butyl)methan-1,1-dicarboxylic acid

[0990] A soluton of dioate(386 mg, 0.48 mmol) and 85% KOH(1.26 g, 19.2 mmol) in ethanol (10 ml) and H₂O(5 ml) was held at reflux for 14 hours. After cooling, aqueous 1N HCl solution was added to adjust to pH 4-5. The reaction mixture was extracted with EA and concentrated under reduced pressure to give a crude title compound (345 mg, 96%) as a white foam.

[0991]¹H-NMR (300 MHz, CDCl₃) δ: 7.15 (d, 2H), 7.0 (d, 2H), 6.9 (d, 1H), 6.5 (m, 2H), 5.2 (m, 4H), 4.5 (d, 1H), 4.3 (d, 1H), 3.5 (m, 6H), 2.65 (d, 1H), 2.52 (m, 2H), 2.48 (m, 2H), 2.2 (m, 21, 1.85 (m, 4H), 1.7 (m, 2H), 1.5 (m, 2H), 1.3-1.0 (m, 11H)

[0992] Step 15) Synthesis of (3′RS,4′RS)-6-7-hydroxy)-3-hydroxyphenyl)-3-methylchroman-4-yl)-2-(4-(4,4,5,5,5-pentafluoropentylthio)butyl)hexanoic acid

[0993] (3′RS,4′RS)-4-(7-(methoxymethoxy)-3-(4-methoxymethoxy)phenyl)-3-methylchroman-4-yl)butyl)(4-4,4,5,5,5-pentafluoropentylthio)butyl)methan-1,1-dicar boxylic acid (345 mg, 0.46 mmol) was dissolved in hydrochloric acid/methanol (10 ml), which was then stirred at 50° C. for 2 hours. The reaction solution was cooled down to room temperature, water was added, and the resulting mixture was extracted with ethyl acetate. - The organic extract was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (310 mg, yield: quant) as a white foam

[0994]¹H-NMR (300 MHz, CDCl₃+CD₃OD) δ: 7.15 (d, 2H), 6.9 (d, 1H), 6.8 (d, 2H), 6.45 (m, 2H), 4.5 (d, 1H), 4.2 (d, 1H), 2.7-2.4 (m, 5H), 2.2 (m, 2H), 1.95-1-65 (m, 6H), 1-15 (m, 2H). 1.3-1.0 (m, 11H)

[0995] Step 16) Synthesis of 6-(7methoxymethoxy)-3-(4-methoxymethoxy)phenyl)₃-methylchroman-4-yl)-2-(4-(4,4,5,5,5-pentafluoropentylthio)butyl)hexanoic Acid

[0996] A solution of diacid (295 mg, 0.445 mmol) in toluene(50 ml) was held at reflux for 80 hours. After cooling, the organic solvent was removed under reduced pressure. The residue was subjected to column chromatography(EA:Hex=1:1) to give the target compound (271 mg, 95%) as a white foam.

[0997]¹H-NMR (300 MHz, CD₃OD) δ: 7.0 (d, 2H), 6.75 (d, 1H), 6.68 (d, 2H), 6.2 (m, 2H), 4.4 (d, 1H), 4.1 (d, 1H), 2.55 (m, 3H), 2.45 (m, 2H), 2.2 (m, 3H), 1.75 (m, 2H), 1.6-0.9 (m, 17H)

[0998] Mass(ESI): 619 (M+1)

[0999] Step 17) Synthesis of (3RS,4′RS)-2-4-(7-hydroxy)-3-(4-hydroxyphenyl)-3-methylchroman-4-yl)butyl-6-(4-(4,4,5,5,5-pentafluoropentyl)sulfinyl)hexanoic acid

[1000] (3′RS,4′RS)-6-(7-(methoxymethoxy)-3-(4-methoxymethoxy)phenyl)-3-methylchroman-4-yl)-2-(4-(4,4.5,5,5-pentafluoropentylthio)butyl)hexanoic acid (163 mg, 0.26 mmol) was dissolved in MeOH (1 ml) and 1,4-dioxane(1 ml). Water (0.25 ml) and sodium periodate (67 mg, 0.3 mmol) were added thereto, and then the mixture was stirred under the atmosphere of normal temperature for 4 hours. The reaction solution was filtered, and the filtrate was concentrated. The residue was extracted with ethyl acetate, dried over anhydrous magnesium sulfate, and subjected to flash column chromatography (methanol:ethyl acetate=1:40) to give the title compound (130 mg, yield 78%) as a white foamy solid.

[1001]¹H-NMR (300 MHz, CD₃OD) δ: 7.0 (d, 2H), 6.75 (d, 1H), 6.6 (d, 2H), 6.2 (m, 2H), 4.4 (d, 1H), 4.1 (d, 1H), 2.75 (m, 4H), 2.5 (d, 1H), 2.3 (m, 2H), 2.0 (m, 3H), 1.65 (m, 2H), 1.5-0.9 (m, 12H)

[1002] Mass (ESI): 635(M+1)

EXAMPLE 34

[1003] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(N-cyano-N-pentylcarbonyl)aminononyl]thiochroman

[1004] Step 1) synthesis of (3RS,4RS)-4-[9-(N-cyano)aminononyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[1005] To a solution of (3RS,4RS)-4-[9-iodononyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (381 mg, 0.69 mmol) in anhydrous dimethylformamide (2 ml) were added potassium carbonate (238 mg, 1.72 mmol) and cyanoamide (116 mg, 2.76 mmol), which was then stirred for 4h at 50° C. Water was added thereto, and the resulting solution was extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=3:1) to give the title compound (238 mg, yield 74%) as a colourless oil.

[1006]¹H-NMR (300 MHz, CD₃OD) δ: 7.28 (m, 2H), 6.92-6.87 (m, 3H), 6.71 (m, 1H), 6.56 (m, 1H), 3.78 (s, 3H), 3.72 (s, 3H), 3.62 (m, 1H), 3.47 (m, 1H), 3.05-2.96 (m, 3H), 2.69 (bs, 1H), 1.52 (m, 2H), 1.28-0.92 (m, 17H)

[1007] Step 2) Synthesis of (3RS,4RS)-7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(N-cyano-N-pentylcarbonyl)aminononyl]thiochroman

[1008] To a solution of (3RS,4RS)-4-[9-(N-cyano)aminononyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (238 mg, 0.51 mmol) in anhydrous acetonitrile (2m)) were added diusopropylethylamine (0.186 ml, 1.07 mmol) and hexanoylchloride (0.086 ml, 0.61 mmol), which was then stirred for 10 min at 0oC. When the reaction was completed, water was added to the reaction mixture and extracted with ethyl acetate. Then, the organic layer was washed with water and 1N—HCl solution. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=7:1) to give the title compound (288 mg, yield 99%) as a colourless oil.

[1009]¹H-NMR (300 MHz, CDCl₃) δ: 7.27 (m. 2H), 6.93-6.88 (m, 3H), 6.72 (n, 1H), 6.55 (m, 1H), 3.78 (s, 3H), 3-71 (s, 3H), 3.62 (dd, 1H), 3.49 (t, 3H), 2.98 (dd, 1H), 2.70 (bs, 1H), 2.59 (t, 2H), 1.70-1.52 (m, 4H), 1.34-0.88 (m, 24H)

[1010] Mass (ESI): 587 (M⁻+Na)

[1011] Step 3) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(N-cyano-N-pentylcarbonyl)aminononyl]thiochroman

[1012] The title compound was prepared from (3RS,4RS)-7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(N-cyano-N-pentylcarbonyl)aminononyl]th iochroman according to the- same procedure as step 3 of Example 8.

[1013]¹H-NMR (300 MHz, CD₃OD) δ: 7.16 (m, 2H), 6.76 (m, 1H), 6.68 (m, 2H), 6.47 (m, 1H), 6.35 (m, 1H), 3.54-3.42 (m, 3H), 2.88 (m, 1H), 2.63 (m, 1H), 2.50 (t, 2H), 1.61-1.42 (m, 4H), 1.34-0.79 (m, 24H)

[1014] Mass (ESI) 537 (M⁺+1)

EXAMPLE 35

[1015] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-(hydroxyphenyl)-3-methyl-4-15-oxa-9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]chroman

[1016] Step 1) Synthesis of (3RS,4RS)-4-(9-bromo-5-oxanonyl)-7-methoxymethoxy-3-4-(methoxymethoxy)phenyl)-3-methylchroman

[1017] To a solution of alcohol compound (400 mg, 0.96 mmol) in dry tetrahydrofuran (5 mL) was added sodium hydride (27 mg, 1.1 mmol) at 0° C. After stirring for 30 minutes, 1,4-dibromobutane (2.07 g, 9.6 mmol) was added, and the resulting mixture was refluxed for 2 days. After the reaction was completed, water was added and the aqueous layer was extracted with ethyl acetate. The extract was dried over MgSO₄ and filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=8:1) to give 276 mg (yield. 52%) of a colorless oil.

[1018]¹H-NMR (300 MHz, CDCl₃) o-8 : 7.04 (dd, J=8.6 Hz, 2H), 6.95 (m, 3H), 6.6 (d, 2H), 5.16 (d, 4H), 4.53 (dd, J₁=10.2 Hz, 1H), 4.26 (dd, J=10.5 Hz, 1H), 3.50 (d, 6H), 3.43 (t, 2H), 3.37 (t, 2H), 3.25 (t 2H), 2.63 (dd, 1H), 1.69 (m, 13H).

[1019] Step 2) Synthesis of (3RS,4RS)-4-(9-azido-5-oxanonyl)-7-methoxymethoxy-3-(4-(methoxymethoxy)phenyl}3-methylchroman

[1020] To (3RS,4RS)-4-(9-bromo-5-oxanonyl)-7-methoxymethoxy-3-(4-methoxy-methoxy)phenyl)-3-methylchroman (276 mg, 0.5 mmol) in. DMSO was added sodium azide (65.1 mg, 1 mmol). The mixture was stirred at 80° C. for 3h. After cooling,. the mixture was extracted with ethyl acetate, dried over MgSO₄, and filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=10:1) to give 269 mg (yield. 100%) of a colorless oil.

[1021]¹H-NMR (300 MHz, CDCl₃) δ: 7.18 (dd, J=8.6 Hz, 2H). 6.9 (m, 3H), 6.5 (d, 2H), 5.13 (d, 4H), 4.53 (dd, J=10.3 Hz, 1H), 4.23 (dd, J=10.5 Hz, 1H), 3.60 (d, 6H), 3.43-3.2 (m, 4H), 2.7 (dd, 1H), 1.8 (m, 2H), 1.5-0.9 (m, 13H).

[1022] Step 3) Synthesis of (3RS,4RS)-4-(9-amino-5-oxanonyl)-7-methoxymethoxy-3-(4-(.methoxymethoxy)phenyl)-3-methylchroman

[1023] The (3RS,4RS)-4-(9-azido-5-oxanonyl)-7-methoxymethoxy-3-(44methoxy methoxy)phenyl)-3-methylchroman (250 mg, 0.19 mmol) was dissolved in methanol-tetrahydofura (1.8/0.2 mL). Palladium charchol (75 mg, 0.05 mmol) was added, and resulting mixture was stirred at rt under hydrogen for 2h. The mixture solution was concentrated and filtered through silica gel to give 170 mg of crude product as a colorless oil.

[1024]¹H-NMR (300 MHz, CDCl₃) δ: 7.08 (dd, J=8.63 Hz, 2H), 6.9 (m, 3H), 6.57 (d, 2H), 5.16 (d, 4H), 4.53 (dd, J=10.2 Hz, 1H), 4.26 (dd, J=10.5 Hz, 1H), 3.55 (d, 6H), 3-4-3.18 (m, 42H), 2.7 (m, 3H, C4,), 1.890.9 (m, 13H).

[1025] Step 4) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-(methoxymethoxy) phenyl)-3-methyl-4-[5-oxa-9-4,4,5,5,5-pentafluoropentylsulfonylwnino)nonyl]chrom an

[1026] To (3RS,4RS)-4-9-amino-5-oxanonyl)-7-methoxymethoxy-3-(4-(methoxy-methoxy)phenyl)-3-methylchroman (109 mg, 0.2 mmol) in methylenchloride (3 mL) were added triethylamine (93.5 μL, 0.6 mmol) and 4,4,5,5,5-penta-fluoropentylsulfonylchloride (145.6 mg, 0.5 mmol). The mixture was stirred at rt for h. After cooling, the mixture was extracted with methylenchloride, dried over MgSO₄, and filtered. The filtrate was evaporated under reduced pressure, and the concentrate thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give 125 mg (yield. 72%) of a colorless oil.

[1027]¹H-NMR (300 MHz, CDCl₃): 7.15 (dd, J=8.6 Hz, 2H), 6.7 (m, 3H), 6.61 (d, 2H), 5.17 (d, 4H), 4.52 (dd, J=10.2 Hz, 1H), 4.28 (dd, J=10.5 Hz, 1H), 3.48 (d, 6H), 3.39-3.28 (m, 5H), 3.1 (t, 2H), 2.65 (dd, 1H), 2.41-2.02 (m, 4H), 1.78-0.9 (m, 15H).

[1028] Step 5) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-(hydroxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]chroman

[1029] To (3RS,4RS)-7-methoxymethoxy-3-(4-(methoxymethoxy)phenyl)-3-methyl 4-f-5-oxa-9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]chroman (125 mg, 0.17 mmol) was treated with dry hydrochloric acid/methanol (2 mL), which was then stirred at rt for 2h. Saturated aqueous sodium hydrogen carbonate was added to reaction solution and extracted with ethyl acetate, dried (MgSO₄), and filtered- The filtrate was evaporated under reduced pressure, and the concentrate. thus obtained was subjected to silica gel column chromatography (n-hexine:ethyl acetate=2:1) to give 76.2 mg (yield. 72%) of a colorless oil.

[1030]¹H-NMR (300 MHz, CDCl₃) δ: 7.08 (dd, J=8.6 Hz, 2H), 6.80 (m, 3H), 6.32 (d, 2H), 6.0 (dd, J=8.2 Hz, . 1H), 5.08 (t, 1H), 4.52 (dd, J=10.2 Hz, 1H), 4.25 (dd, J=10.6 Hz 1H), 3.30 (m, 4H), 3.09 (m, 4H), 2.63 (dd, J=8.9 Hz 1H), 2.38-1.92 (m, 4H). 1.52-0.61 (m, 15H).

EXAMPLE 36

[1031] Synthesis of (3′RS, 4′RS-6,6,7,7,7-pentafuoro-2-2-4-4-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl)butyl)phenyloxy)ethyl)heptanoic acid

[1032] Step 1) Synthesis of 3-methyl-7-methyloxymethyloxy)-3-(4-(methyloxymethyl oxy)phenyl)-4-(4-4-(t-butyldiriiethylsilyloxy)phenyl)but-1-ynyl)chroman-4-ol

[1033] 1-(4-but-3-ynylphenyloxy)- 1,1,2,2-tetramethyl-1-silapropane(2.2 g, 8.4 mmol) was dissolved in dry tetrahydrofuran (15 ml) under argon atmosphere and then cooled to −78° C. 1.6M n-Butyllithium(Smt, 8.0 mmol) was added dropwise thereto, and the mixture was warmed to −10° C. and stirred for 1 hour and then cooled to −78° C. 7-Methyloxymethyloxy-3-(4-methyloxymethyloxyphenyl)₃-methy-1 chroman-4-one (1.151 g, 4.2 mmol) was added portionwise and then warmed to room temperature and stirred for 1.5 hour. The reaction mixture was quenched by water. The reaction solvent was evaporated off, then the residue was dissolved in ethyl acetate, which was washed with water. The organic solvent was dried over anhydrous magnesium sulfate and removed by evaporation under vacuum This product was purified by column chromatography on silica gel, eluting with 10% ethyl acetate in n-hexane. After removal of the solvent, 1.87g of the title compound was obtained as colorless oil. (yield: 72%)

[1034]¹H NMR (300 MHz, CDCl₃) δ: 7.53 (d, 1H, J=8.66 Hz), 7.36 (d, 2H, J=9.0 Hz), 6.99 (m, 4H), 6.71 (d, 2H, J=8.29 Hz), 6.61 (dd, 1H, J=2.26, 8.67 Hz), 6.5 (d, 1H, J=2.26 Hz), 5.14 (s, 2H), 5.11 (s, 2H), 4.83 (d, 1H, J=10.55 Hz), 3.99 (1H, J=10.55 Hz), 3.45 (s. 3H), 3.43 (s, 3H), 2.75 (m, 2H), 2.50 (m, 2H), 1.39 (s, 3H), 093 (s, 9H), 0.13 (s. 6H)

[1035] Step 2) Synthesis of (3RS,4RS)-4-(methyloxym ethyloxy)- -(3-methyl-7-methyloxy-methyloxy)-4-(4-(t-butyldimethylsilyloxy)phenyl)butyl)chroman-3-yl)benzene

[1036] 3-methyl-7-(methyloxymethyloxy)-3-(4-(methyloxymethyloxy)phenyl)-4-(4-(4-(t-butyldimethylsilyloxy)phenyl)but-1-ynyl)chroman-4-ol (1.056 g, 1.7 mmol): 79.5%) was dissolved in ethylacetate (10 ml) and 10% palladium on carbon (352 mg) was added and stirred for 30 minutes under hydrogen (atmospheric pressure). The reaction mixture was filtered through cellite and concentrated under reduced pressure. . The residue was purified by column chromatography on silica gel, eluting with ethyl acetate: n-hexane=1:19. After removal of the solvent, 772 mg of the title compound was obtained as colorless oil.

[1037]¹H NMR (300 MHz, CDCl₃. 3RS,4RS-compound) δ: 7.1 (d, 2H, J=8.7 Hz), 7.0 (d, 2H, J=9.0 Hz), 6.87 (m, 3H), 6.67 (d, 2H, J=8.3 Hz), 6.54 (m, 2H), 5.16 (s, 2H), 5.13 (s, 2H), 4.5 (d, 1H, J=10.55 Hz), 4.23 (d, 1H, J=10.55 Hz), 3.47 (s, 6H), 2.59 (m, 1H), 2.33 (t, 2H, J=7.5 Hz), 1.22 (s, 3H), 1.0-1.4 (m, 6H), 0.95 (s, 9H), 0.15 (s, 6H)

[1038] Step 3) Synthesis of (3RS,4RS)-44-(3-methyl-7-(methyloxymethyloxy)-3-4-(methyloxymethyloxy)phenyl)chroman-4-yl)butyl)benzen-1-ol

[1039] (3RS,4RS)-4-(methyloxymethyloxy)-1-(3-methyl-7-(methyloxymethyloxy) 4-(4-(t-butyldi methylsilyloxy)phenyl)butyl)chroman-3-yl)benzene (730 mg, 1.2 mmol) was dissolved in tetrahydrofuran (7 ml), and cooled to 0°. To this solution was added tetrabutylammonium fluoride (2.4 ml, 2.4 mmol), and the reaction mixture was stirred at room temperature for 2 hours. The solvent was removed by evaporation under reduced pressure and the residue was dissolved in ethyl acetate, which was washed with water. The organic layer was separated, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The product was purified, by column chromatography on silica gel, eluting with 30% ethyl acetate in n-hexane to afford 572 mg of the title compound as a pale yellow oil. (yield: 96.0%)

[1040]¹H-NMR (300 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.07 (d, 2H, J=9.0 Hz), 6.97 (d, 2H, J=8.67 Hz), 6.8 (m, 3H), 6.64 (d, 2H, J=8.66 Hz), 6.5 (m, 2H), 5.14 (s, 2H), 5.12 (s, 2H), 4.49 (d, 1H, J=10.55 Hz), 4.21 (d. 1H, J=10.55 Hz), 3.46 (s, 6H), 2.6 (m, 1H), 2.3 (m, 2H), 1.19 (s, 3H), 1.0-1.4 (m, 6H)

[1041] Step 4) Synthesis of Diethyl 2-(2-bromoethyl)-2-(4,4,5,5,5-pentafluoropentyl) propane-1,3-dioate

[1042] Diethyl 2-(4,4,5,5,5-pentafluoropentyl)propane-1,3-dioate (51 0 mg, 1.592 mmol) was dissolved in anhydrous dimethoxyethane (5 ml). Sodium hydride (60%. 88 mg, 2.2 mmol) was added to the solution and then stirred at room temperature for 1 h under nitrogen atmosphere. Dibromoethane (0.82 ml, 9.55 mmol) was added to the mixture and then stirred at 70°(: for 5h under nitrogen atmosphere. When the reaction was completed, the mixture was cooled to room temperature. Water was added to reaction solution which was then extracted with ethyl acetate. The extracted organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was subjected to column chromatography (n-hexane:dichloromethane=3:1) to obtain 489 mg (yield: 72° C.) of the title compound as a colorless oil.

[1043]¹H-NMR (300 MHz, CDCl₂) δ: 4.2 (q, 4H, J=7.1H4z), 3.32 (m, 2H), 2.45 (m. 2H), 2.0 (m, 4H), 1.5 (m, 2H), 1.24 (t, 6H, J=7.1 Hz)

[1044] Step 5) Synthesis of (3′RS,4′RS)-(4,4,5,5,5-pentafluoropentyl)(2-(4-(4-(3-methyl-7-(methyl oxymethyl oxy)-3-(4-(methyloxymethyl oxy)phenyl)chroman-4-yl) butyl)phenyloxy)ethyl)methane-1,1-dicarboxylic Acid

[1045] (3RS,4RS)-4-(4-(3-methyl-7-(methyloxymethyloxy)-3-(4-(methyloxymethyl-oxy)phenyl)chroman-4-yl)butyl)benzen-1-ol (335 mg, 0.68 mmol) was dissolved in anhydrous DMF (3 ml). Sodium hydride (60%, 35 mg, 0.884 mmol) was added to the solution and then stirred at room temperature for 1 h under nitrogen atmosphere. Diethyl 2-(2-bromoethyl)-2-4,4,5,5,5-pentafluoropentyl)propane-1,3-dioate (726 mg, 1.7 mmol) was added to the mixture and then stirred at 70° C. for 3h under nitrogen atmosphere. When the reaction was completed, the mixture was cooled to room temperature. Water was added to reaction solution which was then extracted with ethyl acetate. The extracted organic layer was dried over anhydrous magnesium sulfate and then concentrated. The residue was dissolved in ethyl alcohol (20 ml) and a solution of potassium hydroxide (1.85 g, 28 mmol) in water (10 ml) was added thereto. The resulting mixture was heated under reflux for overnight. The residue, left after removal of ethyl alcohol, was dissolved in water and adjusted to pH 3 with diluted HCl and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous magnesium sulfate, and removed by evaporation under vacuum to afford 549 mg of the title compound as a white foam.

[1046]¹H-NMR (300 MHz, CDCl₃, 3RS,4RS-compound) δ: 7.05 (d, 2H, J=8.9 Hz), 6.98 (d, 2H. J=8.9 Hz), 6.81 (d, 2H, J=8.7 Hz), 6.65 (d, 1H, J=8.3 Hz), 6.64 (d, 2H, J=8.7 Hz). 6.5 (d, 1H, J=2.4Iz), 6.44 (dd, 1H, J=8.3 Hz, 2.4 Hz), 5.2 (m, 4H), 4.45 (d, 1H, J=10.5 Hz), 4.21 (d, 1H. J=10.5 Hz), 4.0 (m, 2H), 3.5 (s, 3H), 3.49 (s, 33H), 2.5 (m, 3H), 2.3 (m, 2H), 2.05 (m, 4H), 1.6 (m, 21), 1.17 (s, 3H), 1.0-1.4 (m, 6H)

[1047] MS(ESI): 783 (M+1), 805(M+Na)

[1048] Step 6) Synthesis of (3′RS,4′RS)-(4,4,5,5,5-pentafluoropentyl)(2-(4-(4-(7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl)butyl)phenyloxy)ethyl) methane-1,1-dicarboxylic Acid

[1049] (3′RS,4′RS)(4,4,5,5,5-pentafluoropentyl)(2-(4-(4-(3-methyl-7-(methyloxy methyloxy)-3-(4-(methyloxymethyloxy)phenyl)chroman-4-yl)butyl)phenyloxy)ethyl) methane-1,1-dicarboxylic acid (549 mg, 0.679 mmol) was dissolved in hydrochloric acid/methanol (20 mg), which was then stirred at 50° C. for 2 hours. The reaction solution was cooled down to room temperature, water was added, and the resulting mixture was extracted with ethyl acetate. The organic extract was dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give the title compound (463 mg, yield: 98%) as a white foam

[1050]¹H-NMR (300 MHz, CD₃OD) δ: 7.05 (d, 2H, J=8.6 Hz), 6.87 (d, 2H, J=8.6 Hz), 6.7 (m, 5H), 6.3 (m, 2H), 4.46 (d, 1H, J=10.5 Hz), 4.16 (d, 1H, J=10.5 Hz), 4.0 (m, 2H), 2.57 (m, 1H), 2.3 (m, 4H), 2.0 (m, 4H), 1.2 (s, 3H), 0.9-1.6 (m, 8H)

[1051] MS(ESI): 695(M+1), 717 (M+Na)

[1052] Step 7) Synthesis of (3′RS,4′RS)-6,6,7,7,7-pentafluoro-2-(2-(4-(4-(7-hydroxy-3-(4-hydroxyphenyl)-3-methylcbroman-4-yl)butyl)phenyl oxy)ethyl)heptanoic acid

[1053] To a solution of (3′RS,4′RS)-(4,4,5,5,5-peniafluoropentyl)(2-(4-(4-(7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl)butyl)phenyloxy)ethyl)me thane-1,1-dicarboxylic acid (389 mg, 0.559 mmol) in dimethyl sulfoxide (3 ml) was heated to 130 140° C. for 3 hours. The reaction mixture was dissolved in ethyl acetate and washed with water and brine, dried over anhydrous magnesium sulfate. This product was purified by column chromatography on silica gel, eluting with ethyl acetate:n-hexane=1:2→2:1 to afford 268 mg of the title compound as a white foam. (yield 74%)

[1054]¹H-NMR (300 MHz CD₃OD) δ: 7.1 (d, 2H, J=8.7 Hz), 6.9 (d, 2H, J=8.7 Hz), 6.75 (m, 5H), 6.3 (m, 2H), 4.5 (d, 1H, J=10.5 Hz), 4.2 (d, 1H, J=10.5 Hz), 4.0 (t, 2H, J=6.1 Hz), 2.63 (m, 2H), 2.35 (t, 2H, J=7.2 Hz), 2.1 (m, 4H), 1.67 (m, 4H), 1.2 (s, 3H), 0.9-1.3 (m, 6H)

[1055] MS(ESI): 651 (M+1), 673 (M+Na)

EXAMPLE 37

[1056] Synthesis of (3RS,4RS)-4-allyl-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[1057] Step 1) Synthesis of 4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman

[1058] To a solution of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman 4-one (6.29 g, 20 mmol) in THF (20 ml) and EtOH (10 ml) was added NaBH₄ (1.51 g, 40 mmol), which was stirred overnight at room temperature. The reaction solution was added saturated aqueous NH₄Cl solution, extracted with CHCl₃, and washed with brine. The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure. The residue was purified by recrystallization with CHClt-hexane to give 5.33g (84%) of 4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman.

[1059]¹H-NMR (270 MHz, CDCl₃) δ: 7.42 (d, 2H, J=8.8 Hz, Ar—H), 7.20 (d, 1H, J=8.2 Hz, Ar—H), 6.94 (d, 2H, J=8.8 Hz, Ar—H), 6.73 (d, 1H, J=2.8 Hz, Ar—H), 6.65 (dd, 1H, J=1.8, 8.5 Hz, Ar—H), 4.62 (brs, 1H, C4-H), 3.94 (d, 1H, J=12.1 Hz), 3.82 (s, 3H, OMe), 3.79 (s, 3H, OMe), 2.87 (d, 1H, .=12.1 Hz), 1.58 (d, 1H, J=3.0 Hz), 1.31 (s, 3H, C3-Me).

[1060] Step 2) Synthesis of (3RS,4RS)+allyl-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[1061] To a solution of 4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (11.4 g, 36.3 mmol) in 1,2-dichloroethane (360 ml) was added zinc iodide (13.9 g, 43.5 mmol) and allyltrimethylsilane (11.5 ml, 72.5 mmol). which was stiirred for 1 day at room temperature. The reaction solutior. was added saturated aqueous NHCl solution, extracted with CHCl₃, and washed with brine. The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure. The residue was purified by chromatography on silica-gel with 1% AcOEt in hexane to give 9.1⁹g (74%) of (3RS,4RS)-4-allyl-7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman.

[1062]¹H-NMR (300 MHz CDCl₃) δ: 7.30 (d, 2H, J=9.1 Hz, Ar—H), 6.92 (d, 1H, J=8.9 Hz, Ar—H), 6.90 (d, 2H, J=8.5 Hz, Ar—H), 6.73 (d, 1H, J=2.8 Hz, Ar—H), 6.56 (dd, 1H, J=2.8, 8.5 Hz, Ar—H), 5.4-5.7 (m, 1H, allyl), 4.82 (d, 1H, J=9.9 Hz. allyl), 4.65 (d, 1H, J=7.0 Hz, allyl), 3.83 (s, 3H, OMe), 3.78 (s, 3H, OMe), 3.64 (d, 1H, J=11.8 Hz, C2-H), 2.87 (dd, 1H, J=1.7, 11.8 Hz, C2-H), 2.8-2.9 (m, 1H, C4-H), 1.8-2.0 (m, 2H), 1.23 (s, 3H, C3-Me).

EXAMPLE 38

[1063] Synthesis of (3RS,4RS)-7-hydroxy-3-(4hydroxyphenyl)-3-methyl-4-{9-[2-(2,2,2-trifluoroethoxy)ethylsulfinyl]nonyl}thiochroman

[1064] Step 1) Synthesis of t-butyl-2,2,2-trifluoroethoxyacetate

[1065] To a suspension of NaH (240 mg, 60-72%) in tetrahydrofuran (5 ml) was added 2,2,2-trifluoroethanol (500 mg, 5 mmol) at 0° C. After the mixture was stirred for 45 minutes at room temperature, t-butyl bromoacetate(0.9 ml, 6 mmol) was added and stirred at room temperature for 15 hours. The mixture was poured into ice-water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated to give crude t-Butyl 2,2,2-trifluoroethoxyacetate (1.08 g, quant.).

[1066]¹H-NMR (270 MHz, CDCl₃) δ: 3.97 (2H, dd, J=9 and 18 Hz, —OCH ₂CF₃), 4.11 (2H, s, —CH ₂CO₂tBu), 1.48 (9H, s, tBu)

[1067] Step 2) Synthesis of 2-(2,2,2-trifluoroethoxy)ethyl p-toluenesulfonate

[1068] To a suspension of LAH (750 mg, 19.7 mmol) in ether (40 ml) was added crude t-butyl-2,2,2-trifluoroethoxyacetate (2.0 g, 9.3 mmol) in ether (10 ml) at 0° C. The mixture was stirred for 45 minutes at 0° C. Then, the mixture was poured into ice-water and extracted with ether. The organic layer was dried over anhydrous magnesium sulfate and concentrated to give crude 2-(2,2,2-trifluoroethoxy)ethanol (1.09 g, 81%). To a solution of crude 2-(2,2,2-trifluoroethoxy)ethanol (150 mg, 11.0 mmol) in dichloromethane (3 ml) was added triethylamine (110 mg, 1.1 mmol) and p-toluenesulfonylchloride (200 mg, 1.1 mmol). The mixture was stirred at room temperature for 2 days. The mixture was poured into water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate. After concentration, silica gel column chromatography (n-hexane/ethyl acetate=5/1) gave 2-(2,2,2-trifluoroethoxy)ethyl p-toluenesulfonate(188 mg, 63%)

[1069]¹H-NMR (270 MHz, CDCl₃) δ: 7.80 (2H, d, J=8 Hz, Ar—H), 7.35 (2H, d, J=8 Hz, Ar—H), 4.18 (2H, t, J=4 Hz, —CH ₂OTs), 3.85-3.76 (4H, m, CF_(x) CH ₂OCH ₂—), 2.45 (3H, s, Ar—CH₃)

[1070] Step 3) Synthesis of 2-(2,2,2-Trifluoroethoxy)ethyl Thioacetate

[1071] 2-(2,2,2-trifluoroethoxy)ethyl p-toluenesulfonate (14.0 g, 47 mmol) and potassium thioacetate (1.00 g, 88 mmol) were dissolved in acetone (100 ml) and the mixture was stirred at room temperature for 2 days. The mixture was poured into water and extracted with- ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate. After concentration, silica gel column chromatography (n-hexane/ethyl acetate=10/1) gave 2-(2,2,2-Trifluoroethoxy)ethyl thioacetate (8.3 g, 87%)

[1072]¹H-NMR (270 MHz, CDCl₃) δ: 3.84 (2H, dd, J=9 and 17 Hz, CF₃ CH ₂O—), 3.73 (2H, t, J=6 Hz, CF₃CH₂OCH ₂—), 3.10 (2H, t, J=6 Hz, —CH ₂SAc), 2.35 (3H, s, —COCH ₃)

[1073] Step 4) Synthesis of (3RS,4RS)-7-Methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-{9-[2-(2,2,2-trifluoroethoxy)ethylthio]nonyl}thiochroman

[1074] To a solution of 2-(2,2,2-Trifluoroethoxy)ethyl thioacetate (210 mg, 1.0 mmol) in methanol (3 ml) was added 1N sodium methoxide methanol solution (1.0 ml, 1.0 mmol) at room temperature . The mixture was stirred for 1 hour at room temperature. Then, 4-(9-mesyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl}3-methylthiochroman (130 mg, 0.224 mmol) dissolved in tetrahydrofuran (3 ml) was added and stirred at room temperature for 1 day. After the reaction was completed, the mixture was concentrated, poured into ice-water and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate. After concentration, silica gel column chromatography (n-hexane/ethyl acetate=20/1) gave (3RS,4RS)-7-Methoxy methoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-{9-[2-(2,2,2-trifluoroethoxy)ethyl thio]nonyl}thiochroman (228 g, 95%)

[1075]¹H-NMR (270 MHz, CDCl₃) δ: 7.29 (2H, d, J=9 Hz, Ar—H), 7.03 (2H, d, J=9 Hz, Ar—H), 6.92 (1H, d, J=0.9 Hz, Ar—H), 6.88 (1H, d, J=2 Hz, Ar—H), 6.69 (1H, dd, J=8 and 2 Hz, Ar—H), 5.19 (2H, s, —OCH ₂OCH₃), 5.14 (2H, s, —OCH ₂OCH₃), 3.90-3.74 (4H, m, —CH ₂OCH ₂CF₃), 3.63 (1H, d, J=11Hz, C2-H), 3.50 (3H, s, —OCH₃), 3.49 (3H, s, —OCH₃), 2.98 (1H, d, J=11 Hz, C2-H), 2.73-2.68 (3H, m, C4-H and —SCH ₂—), 2.52 (2H, t, J=7 Hz, —SCH ₂—), 1.56-1.07 (16H, m, alkyl-H), 1.17 (3H, s, C3-CH ₃)

[1076] Step 5) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2,2,2-trifluoroethoxy)ethylthio]nonyl}thiochroman

[1077] (3RS,4RS)-7-Methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl 4-{9-[2-(2,2,2-trifluoroethoxy)ethylthio]nonyl}thiochroman (136 mg, 0.211 mmol) was dissolved in 10% HCl/MeOH (20 ml) and the mixture was stirred at room temperature for 1 day. After the reaction was completed, the mixture was concentrated, and silica gel column chromatography (n-hexane/ethyl acetate=5/1) gave (3RS,4RS)-7-Hydroxy-3-(4-hydroxyphenyl)-3-methyl-4 {9-[2-2,2,2-trifluoro-ethoxy)ethylthio]nonyl thiochroman (100 mg, 85%)

[1078]¹H-NMR (270 MHz, CDCl₃) δ: 7.24 (2H, d, Ar—H), 6.89-6.82 (3H, m, Ar—H), .6.67 (1H, d, J=2 Hz, Ar—H), 6.50 (1H, dd, j=8 and 2 Hz, Ar—H), 3.91-3.76 (4H, m, —CH ₂OCH ₂CF—). 3.63 (1H, d, J=12 Hz, C2-H), 2.96 (1H, d, J=12 Hz, C2-H), 2.75-2.70 (3H, m, C4-H and —S CH ₂—), 2.54 (2H, t, J=7 Hz, —SCH ₂—), 1.58-1.06 (16H, m, alkyl-H), 1.17 (3H, s, C3-CH ₃)

[1079] Step 6) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2,2,2-trifluoroethoxy)ethylsulfinyl]nonyl}thiochroman

[1080] To a solution of (3RS,4RS)-7-hydroxy-344-hydroxyphenyl)-3-methyl-4-{9[2-(2,2,2-trifluoroethoxy)ethylthio]nonyl}thiochroman(100 mg, 0.180 mmol) in tetrahydrofuran (10 ml) was added Oxone^(R) (monopersulfate compound; DuPont product) (56 mg, 0.090 mmol) at 0° C. Then, water (0.1 ml) was added to this mixture and stirred for 1 hour at 0° C. The mixture was dried over anhydrous magnesium sulfate, concentrated and. silica gel column chromatography (n-hexane/ethyl acetate=1/3) gave (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2,2,2-trifluoroethoxy)e thylsulfinyl]nonyl}thiochroman (74 mg, 72%)

[1081]¹H-NMR (270 MHz, CD₃OD) δ: 7.17 (2H, d, J=9 Hz, Ar—H), 6.79 (1H, d, J=8 Hz, Ar—H), 6.70 (2H, d, J=9 Hz, Ar—H), 6.48 (1H, d, J=2 Hz, Ar—H), 6.37 (1H, dd, J=8 and 2 Hz, Ar—H), 3.97-3.87 (4H, m, —CH ₂OCH ₂CF₃), 3.55 (1H, d, J=12 Hz, C2-H), 3.13-2.66 (6H, m, C2-H, C4-H and —CH ₂SOCH ₂), 1.65 (2H, t, J=8 Hz, alkyl-H), 1.40-1.02 (14H, m, alkyl-H), 1.05 (3H, s, C3-CH ₃)

EXAMPLE 39

[1082] Synthesis of (3′RS,4′RS)-8-[7-hydroxy-3-(4-hydroxyphenyl)₃methylthio chroman-4-yl]octanoic Acid

[1083] Step 1) Synthesis of 6-(t-butyldimethylsilyloxy)-1-hexyne

[1084] To a solution of 5-hexyn-1-ol(4.81 g, 49.0 mmol) in N,N-dimethylformamide (100 ml) were added imidazole (4.0 g, 59-Ommol) and t-butyldimethylsilylchloride (8.12 g, 54.0 mmol) at 0° C., which was then stirred at the same temperature for 3 hour After the reaction was completed, water was added to the reaction solution, and the mixture was extracted with. ethyl acetate. The extract was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was subjected to column chromatography (n-hexane:ethyl acetate-10:1) to give the title compound (10.0 g, yield 99%) as a colorless oil.

[1085]¹H-NMR (270 MHz, CDCl₃) δ: 3-63 (t, J=6.6 Hz, 2H, —CH₂OTBS), 2.25-2.16 (m, 2H, propargyl-CH₂), 1.94 (t, J=2.6 Hz, 1H, acetylene-H), 1.62-1.43 (m, 4H, —CH₂CH₂—), 0.89 (s, 9H, -t-butyl-H), 0.05 (s, 6H, —SiMe2).

[1086] Step 2) Synthesis of 4-[6 (t-butyldimethylsilyloxy)-1-hexynyl]-4-hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[1087] To a solution of 6-(t-butyldimethylsilyloxy)-1-hexyne(10.8 g, 50.9 mmol) in dry tetrahydrofiuran (100 ml) was added dropwise n-butyl lithium (30.1 ml, 48.9 mmol, 1.63M in tetrahydrofuran) at −78° C., which was then stirred at −20° C. for 1 hour. To the reaction mixture , was then added 7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-one(8.0 g, 25.5 mmol) dissolved in tetrahydrofuran at −78 C for 30 min, and the resulting mixture was stirred at −10° C. (for 24 hours. After the reaction was completed, saturated ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was subjected to column chromatography (n-hexane:ethyl acetate=4:1) to-give the title compound (12.5 g, yield 93%).

[1088]¹H-NMR (270 MHz, CDCl₃) δ: 7.85 (d, J=8.6 Hz, 1H, C5-H), 7.69 (d, J=8.9 Hz, 2H, Ar—H), 6.87 (d, J=8.9 Hz, 2H, Ar—H), 6.89-6.62 (m, 2H, C6-H and C8-H), 4.25 (d, J=12.5 Hz, 1H, C2-H), 3.81 (s, 3H, —OCH₃), 3.80 (s, 3H, —OCH₃), 3.60-3.55 (m, 2H, —CH₂OBS), 2.70 (d, J=12.5 Hz, 1H, C2-H), 2.24-2.28 (m, 2H, propargyl-CH2), 2.17 (s, 1H, —OH), 1.59 (s, 3H, C3-CH₃), 1.58-1.45 (m, 4H, —CH₂CH₂—), 0.89 (s, 9H, -tbutyl-H), 0.05 (s, 6H, —SiMe2).

[1089] Step 3) Synthesis of 4-(6-hydroxyhexyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman

[1090] To a solution of 4-[6-(t-butyldimethylsilyloxy)-1-hexynyl])hydroxy-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (12.5 g, 23.8 mmol) in dichloromethane (200 ml) were added zinc iodide (15.2 g, 47.5 mmol) and sodium cyanoborohydride (12.0 g, 190.4 mmol), which was then stirred at room temperature for 12 hours. After the reaction was completed, water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was used to next reaction without further purification.

[1091] The crude alkyne compound (12g) was dissolved in ethyl acetate(100 ml), platinum oxide (3.0g) was added, and the resulting mixture was stirred at room temperature under hydrogen for 20 hours. The reaction solution was concentrated and filtered through silica gel to give the crude compound.

[1092] The crude compound protected by TBS (12 g) was dissolved in tetrahydrofuran (100 ml), and tetra-nbutylammonium fluoride (TBAF, 30 ml, 11.0M solution in tetrahydrofuran) was added thereto at 0° C. The mixture was stirred at room temperature for, 1 hour, and stirred at 50° C., for further 2 hours. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=1:1) to give the title compound (3.8 g, yield 37%;(3RS,4RS):(3RS,4SR)-=4:1).

[1093]¹H-NMR (270 MHz, CDCl₃) δ: 7.29 (d, J=8.9 Hz, 2H, Ar—H), 6.92 (d, J=8.2 Hz, 1H, C5-H), 6.90 (d, J=8.9 Hz, 2H, Ar—H), 6.73 (d, J=2.mlz, 1H, C8-H), 6.58 (dd, J=8.2 Hz and 2.7 Hz, 1H, C6-H), 3.82 (s, 3H, —OCH₃), 3.78 (s, 3H, —OCH₃), 3.68 (d, J=12.2 Hz, 1H, C2-H), 3.52 (t, J=6.6 Hz, 2H, —CH₂O—), 2.98 (d, J=12.2 Hz, 1H, C2-H), 2.74-2.71 (m, 1H, C4-H), 1.58-1:23 (m, 5H), 1.18 (s, 3H, C3-CH₃), 1.16-1.03 (m, 6H).

[1094] Step 4) Synthesis of 6-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman 4-yl]hexanal

[1095] To a solution of oxalyl chloride (238 mg, 1.88 mmol) in dichloromethane (5 ml) was added dimethylsulfoxide (316 mg, 3.75 mmol) in dichloromethane (lmli at −70° C., which was then stirred at the same temperature for 10 minutes. Next, to the solution was added 4-(6-hydroxyhexyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (500 mg, 1.25 mmol) in dichloromethane (5 ml) at −70° C., which was then stirred at the same temperature for 30 minutes. Then, to the reaction mixture was added triethylamine (1.0 ml, 7.5 mmol) at the same temperature and stirred for 30 minutes and warmed to room temperature. After the reaction was completed, water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was used to next step without purification(470 mg, yield 94%).

[1096]¹H-NMR (270 MHz, CDCl₃) δ: 9.66 (d, J=1.7 Hz, 1H, —CHO), 7.28 (d, J=8.9 Hz, 2H, Ar—H), 6.92 (d, J=8.6 Hz, 1H, C5-H), 6.90 (d, J=8.9 Hz, 2H, Ar—H), 6.73 (d, J=2.6 Hz, I, C8-H), 6.58 (dd, J=8.6 Hz and 2.6 Hz, 1H, C6-H), 3.82 (s, 3H, —OCH₃), 3.78 (s, 3H, —OCH₃), 3.68 (d, J=11.8 Hz, 1H, C2-H), 2.99 (d, J=11.8 Hz, 1H, C2-H), 2.73-2.71 (m, 1H, C4-H), 2.27 (dt, J=1.7 Hz and 7.2 Hz, 2H, —CH2-CHO), 1.57-1.23 (m, 4H), 1.18 (s, 3H, C3-CH₃), 1.16-1.04 (m, 6H).

[1097] Step 5) Synthesis of methyl 8-[7-methoxy-3*4-methoxyphenyl)-3-methyl-thiochroman-4-yl]-2-octenate

[1098] To a solution of 6-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman 4-yl]hexanal (180 mg, 0.45 mmol) in dichloromethane (1 ml) was added methyl (triphenylphosphoranylidene)acetate (227 mg, 0.68 mmol) at room temperature, which was then stirred at the same temperature for 2 days.

[1099] After the reaction was completed, the organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound (160 mg, yield 75%;(3RS,4RS):(3RS,4SR)=4:1).

[1100]¹H-NMR (270 MHz. CDCl₃) δ: 7.29 (d, J=9.2 Hz, 2H, Ar—H), 6.92 (d, J=8.5 Hz, 1H, C5-H), 6.90 (d, J=9.2 Hz, 2H, Ar—H), 6.85 (d, J=15.8 Hz, 1H, —CH═CHCO₂—), 6.73 (d, J=2.3 Hz, 1H, C8-H), 6.58 (dd, J=8.5 Hz and 2.3 Hz, 1H, C6-H), 5.73 (d, J=16.2 Hz, 1H, —CH═CHCO₂—), 3.82 (s, 3H, —OCH₃), 3.78 (s, 3H, —OCH₃), 3.71 (s, 3H, —CO₂CH₃), 3.69 (d, J=11.6 Hz, 1H, C2-H), 2.98 (d, J=11.6 Hz, 1H, C2-H), 2.73-2.70 (m, 1H, C4-H), 2.05-2.00 (m, 2H, —CH2CH═), 1.37-1.18 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.16-1.02 (m, 6H).

[1101] Step 6) Synthesis of Methyl 8-[7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman-4-yl]octanate

[1102] To a solution of methyl 8-[7-Methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman-4-yl]-2-octenate(160 mg, 0.34 mmol) in methanol (3 ml) and tetrahydrofuran (1 ml) were added sodium borohydride (129 mg, 3.40 mmol) and nickel (n) chloride hexahydrate (16 mg, 0.068 mmol) at 0° C., which was then stirred at the same temperature for 2 hours. After the reaction was completed, water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound (118 mg, yield 73%;(3RS,4RS):(3RS,4SR)=4:1).

[1103]¹H-NMR (270 MHz, CDCl₃) d: 7.29 (d, J=8.9 Hz, 2H, Ar—H), 6.92 (d, J=8.3 Hz, 1H, C5-H). 6.90 (d, J=8.9 Hz, 2H, Ar—H), 6.74 (d, J=1.7 Hz, 1H, C8-H), 6.57 (dd, J=8.3 Hz and 1.7 Hz, 1H, C6-H), 3.82 (s, 3H, —OCH₃), 3.78 (s, 3H, —OCH₃), 3.64 (s, 3H, —CO₂CH₃), 3.63 (d, J=11.5 Hz, 1H, C2-H), 2.98 (d, J=11.5 Hz

[1104] 1H, C2-H), 2.75-2.71 (m, 1H, C4-H), 2.22 (t, J=7.6 Hz, 2H, —CH ₂CO₂—), 1.56-1.45 (m, 2U), 1.35-1.18 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.16-1.02 (m, 8H).

[1105] Step 7) Synthesis of methyl (3′RS,4′RS)-8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]octanoate

[1106] To a solution of methyl 8-[7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman-4-yl]octanoate(120 mg, 0.25 mmol) in dichloromethane (2 ml) was added boron tribromide (1.5 ml, 1.5 mmol, 1.0M solution in dichloromethane) at −78° C., which was then stirred at the same temperature for 1 hour and warmed up to room temperature and stirred for 5 hours. After the reaction was completed, water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product.

[1107] To a solution of this crude product in methanol (2 ml) was added concentrated hydrochloride (0.1 ml) at room temperature, which was then stirred at the same temperature for 24 hours. After the reaction was- completed, water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC(n-hexane:ethyl acetate=4:1) to give the title compound (77 mg, yield 68%).

[1108]¹H-NMR (270 MHz, CDCl₃) δ: 7.24 (d, J=8.6 Hz, 2H, Ar—H), 6.86 (d, J=7-9 Hz, 1H, C5-H), 6-85 (d, J=8.6 Hz, 2H, Ar—H), 6.67 (d, J=2.7 Hz, 1H, C8-H), 6.49 (dd, J=7.9 Hz and 2.7 Hz, 1H, C6-H), 5.45 (brs, 1H, —OH), 4.72 (brs, 1H, —OH), 3-68 (s, 3H, —CO₂CH₃), 3.63 (d, J=11.9 Hz, 1H, C2-H), 2.93 (d, J=11.9 Hz, 1H, C2-H), 2.70-2.61 (m, 1H, C4-H), 2.24 (t, J=7.3 Hz, 2H, —CH ₂CO₂—), 1.56-1.42 (m, 2H), 1.19 (s, 3H, C3-CH₃), 1.16-0.90 (m, 10H).

[1109] Step 8) Synthesis of (3′RS,4′RS)-8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-thiochroman-4-yl]Octanoic Acid

[1110] To a solution of (3′RS,4′RS)-methyl 8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl] octanoate (77 mg, 0.18 mmol) in methanol (0.5 ml) was added sodium hydroxide solution (0.5 ml, 2N solution in water) at room temperature, which was then stirred at the same temperature for 2 hours. After the reaction was completed, 2N hydrochloride solution (0.6 ml) and water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC(n-hexane:ethyl acetate=1:2) to give the tfle compound (70 mg, yield 94%).

[1111]¹H-NMR (270 MHz, CD₃OD) d: 7.24 (d, J=8.6 Hz, 0.2H, Ar—H), 6.85 (d, J=8.2 Hz, 1H, C5-H), 6.78 (d, 1=8.6 Hz, 2H, Ar—H), 6.56 (d, J=2.3 Hz, 1H, C8-H), 6.44 (dd, J=8.2 Hz and 2.3 Hz, 1H, C6-H), 3.61 (d, J=11.5 Hz, 1H, C2-H), 2.95 (d, J=11.5 Hz, 1H, C2-H), 2.78-2.70 (m, 1H, C4H), 2.20 (t, J=7.6 Hz, 2H, —CH ₂CO₂—), 1.48 (quin, J=6.9 Hz, 2H, —CH ₂CH₂CO₂—), 1.27-1.03 (m, 13H).

EXAMPLE 40

[1112] Synthesis of (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthio-chroman-4-yl]hexanoic Acid

[1113] Step 1) Synthesis of (3′RS,4′RS)-6-[7-methoxy-3-(4methoxyphenyl)-3-methylthiochroman-4- yl]Hexanoic Acid

[1114] To a solution of (3′RS,4′RS)-4-(6-hydroxyhexyl)-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman (100 mg, 0.25 mmol) in N,N-dimethylformamide (1 ml) was added pyridinium dichromate (188 mg, 0.50 mmol) at room temperature, which was then stirred at the same temperature for 15 hours. After the reaction was completed, the reaction mixture was filtered, and concentrated under reduced pressure to give a crude product. This crude product (34 mg) thus obtained was used to next step without purification.

[1115] To a solution of trifluoroacetic anhydride(66 mg, 0.32 mmol) in acetone (1 ml) was added dropwise a solution of the crude product (34 mg) and sodium iodide (36 mg, 0.24 mmol) in acetone (1 ml) at −60° C., which was then stirred at the same temperature for 10 minutes. After the reaction was completed, saturated sodium hydrogencarbonate solution was added to the reaction mixture, and then 5% sodium thiosulfate solution was also added. The resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC(n-hexane:ethyl acetate=1:2) to give the title compound (31 mg, yield 30%).

[1116]¹H-NMR (270 MHz CDCl₃). δ: 7.29 (d, J=8.9 Hz, 2H, Ar—H), 6.92 (d, J=8.3 Hz, 1H, C5-H), 6.90 (d, J=8.9 Hz, 2H, Ar—H), 6.74 (d, J=1.7 Hz, 1H, C8-H), 6.57 (dd, J=8.3 Hz and 1.7 Hz, 1H, C6-H), 3.82 (s, 3H, —OCH₃), 3.78 (s, 3H, —OCH₃), 3.64 (s, 3H, —CO₂CH₃), 3.63 (d, J=11.5 Hz, 1H, C2-H), 2.98 (d, J=11.5 Hz. 1H, C2-H), 2.75-2.71 (m, 1H, C4-H), 2.22 (t. J=7.6 Hz, 2H, —CH ₂CO₂—), 1.56-1.45 (m, 2H), 1.35-1.18 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.16-1.02 (m, 9H).

[1117] Step 2) Synthesis of methyl (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)₃-methylthiochroman-4-yl]hexanoate

[1118] The title compound was prepared from (3′RS,4′RS)-6-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]hexanoic acid according to the same procedure as Step 7 of Example 39 (yield 74%).

[1119]¹H-NMR (270 MHz, CDCl₃) δ: 7.23 (d, J=8.6 Hz, 2H, Ar—H), 6.85 (d, J=8.3 Hz, 1H, C5-H), 6.82 (d, J=8.6 Hz, 2H, Ar—H), 6.67 (d, J=2.5 Hz, 1H, C8-H), 6.49 (dd, J=8.3 Hz and 2.5 Hz, 1H, C6-H), 4.79 (brs, 1H, —OH), 4.65 (brs, 1H, —OH), 3-62 (s, 3H, —CO₂CH₃), 3.60 (d, J=11.6 Hz, 1H, C2-H), 2.95 (d, J=11.6 Hz, 1H, C2-H), 2.72-2.65 (m, 1H, C4-H), 2.16 (t, J=7.6 Hz, 2H, —CH ₂CO₂—), 1.40 (quin, J=7.6 Hz, 2H, —CH ₂CH₂CO₂—), 1.17 (s, 3H, C3-CH₃), 1.16-1.02 (m, 6H).

[1120] Step 3) Synthesis of (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthio-chroman-4-yl]Hexanoic Acid

[1121] The title compound was prepared from methyl (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxy-phenyl)-3-methylthiochroman-4-yl]hexanoate according to the same procedure as Step 8 of Example 39 (yield 78%).

[1122]¹H-NMR (270 MHz, CD₃OD) δ: 7.24 (d, -J=8.3 Hz, 2H, Ar—H), 6.87 (d, J=8.3 Hz, 1H, C5-H), 6.78 (d, J=8.3 Hz, 2H, Ar—H), 6.56 (d, J=2.3 Hz, 1H, C8-H), 6.45 (dd, J=8.3 Hz and 2.3 Hz, 1H, C6-H), 3.61 (d, J=11.5 Hz, 1H, C2-H), 2.95 (d, J=11.5 Hz, 1H, C2-H), 2.80-2.72 (m, 1H, C4-H), 2.14 (t, J=7.3 Hz, 2H, —CH ₂CO₂—), 1.42-1.30 (m 2H, —CH ₂CH₂CO₂—), 1.22-1.01 (m, 9H).

EXAMPLE 41

[1123] Synthesis of (3′RS,4′RS)-7-[7-hydrox -3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]hepta noic Acid

[1124] Step 1) Synthesis of (3′RS,4′RS)-7-[7-methoxy-3-(4-methoxyphenyl)-3-methy-1-thiochroman-4-yl]heptane nitrile

[1125] To a solution of (3′RS,4′RS)-46-hydroxyhexyl)-7-methoxy-3-4methoxy phenyl)-3-methylthiochroman (200 mg, 0.50 mmol) in dichloromethane (5 ml) were added triethyamine (152 mg, 1.50 mmol) and methanesulfonyl chloride (86 mg, 0.75 mmol) at 0° C. which was then stirred at the same temperature for 10 minutes. After the reaction was completed, water was added to the reaction mixture. The resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was used to next reaction without purification (235 mg).

[1126] To a solution of the crude product (235 mg, 0.49 mmol) in dimethylsulfoxide (1 ml) was added sodium cyanide (74 mg, 1.85 mmol) at room temperature, which was then stirred at 60° C. for 2 hours. After the reaction was completed, water was added to the reaction mixture. The resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC(n-hexane:ethyl acetate=3:2) to give the title compound (178 mg, yield 89%).

[1127]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=8.6 Hz, 2H, Ar—H), 6.90 (d, J=8.9 Hz, 1H, C5-H), 6.89 (d, J=8.6 Hz, 2H, Ar—H), 6.73 (d, J=2.7 Hz, 1H, C8-H), 6.58 (dd, J=8.9 Hz and 2.7 Hz, 1H, C6-H), 3.83 (s, 3H, —OCH₃), 3.78 (s, 3H, —OCH₃), 3.68 (d, J=11.9 Hz, 1H, C2-H), 2.98 (d, J=11.9 Hz, 1H, C2-H), 2.75-2.71 (m, 1H, C4-H), 2.21 (t, 3=7.3 Hz, 2H, —CH ₂CN), 1.60-1.45 (m, 2H), 1.18 (s, 3H, —CH₃), 1.22-1.02 (m, 8H).

[1128] Step 2) Synthesis of (3′RS,4′RS)-7-[7-methoxy-3-(4-methoxyphenyl)-3-methylthio-chroman-4-yl]Heptanoic Acid

[1129] To a solution of (3′RS,4′RS)-7-[7-methoxy-3-(4-methoxyphenyl)-3-methyl thiochroman-4-yl]heptanenitrile(1 11 mg, 0.27 mmol) in ethanol (2 ml) and water (2 ml) was added sodium hydroxide (300 mg, 5.4 mmol) at room temperature, which was then stirred at 80° C. for 15 hours. After the reaction was completed, 2N hydrochloride solution and water was added to the reaction mixture, and the resulting mixture was extracted with ethyl acetate- The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product This crude product thus obtained was subjected to preparative TLC(n-hexane:ethyl acetate=1:2) to give the title compound (110 mg, yield 95%).

[1130]¹H-NMR (270 MHz, CDCl₃) δ: 7.29 (d, J=8.6 Hz, 2H, Ar—H), 6.92 (d, J=8.2 Hz, 1H, C5-H), 6.89 (d, J=8.6 Hz, 2H, Ar—H), 6.73 (d, J=1.7 Hz, 1H, C8-H), 6.58 (dd, J=8-2 Hz and 1.7 Hz, 1H, C6-H), 3.82 (s, 3H, —OCH₃), 3.78 (s, 3H, —OCH₃), 3-68 (d, J=11.5 Hz, 1H, C2-H), 2-98 (d, 1=11.5 Hz, 1H, C2-H), 2.75-2.71 (m, 1H, C4-H), 2.23 (t, J=7.2 Hz, 2H, —CH ₂CO₂—), 1.56-1.02 (m, 11H), 1.17 (s, 3H, —CH₃).

[1131] Step 3) Synthesis of methyl (3′RS,4′RS)-methyl-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]Heptanoic Acid

[1132] The title compound was prepared from (3′RS,4′RS)-7-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-ylheptanoic acid according to the same procedure as Step 7 of Example 39 (yield 90%).

[1133]¹H-NMR (270 MHz, CDCl₃) δ: 7.23 (d, J=8.3 Hz, 2H, Ar—H), 6.87 (d, J=7.9 Hz, 1H, C5-H), 6.83 (d, J=8.3 Hz, 2Hz, Ar—H), 6.67 (d, J=2.3 Hz, 1H, C8-H), 6.49 (dd, J=7.9 Hz and 2.3 Hz, 1H, C6-H), 5.03 (brs, 11, —OH), 4.72 (brs, 1H, —OH), 3.65 (s, 3H, —CO₂CH₃), 3.63 (d, J=11.6 Hz, 11, C2-H), 2.95 (d, J=11.6 Hz, 1H, C2-H), 2.72-2.65 (m, 1H, C4-H), 2.18 (t, J=7.9 Hz, 2H, —CH₂CO₂—), 1.55-1.40 (m, 2H), 1.18 (s, 3H, —CH₃), 1.17-1.02 (m, 8H).

[1134] Step 4) Synthesis of (3′RS,4′RS)-7-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]Heptanoic Acid

[1135] The title compound was prepared from methyl (3′RS,4′RS}7-[7-hydroxy-3-4-hydroxyphenyl)-3-methylthiochroman-4-yl]heptanoate according to the same procedure as Step 8 of Example 39 (yield 84%).

[1136]¹H-NMR (270 MHz, CD₃OD) δ: 7.24 (d, J=8.9 Hz, 2H, Ar—H), -6.85 (d, J=8.2 Hz, 1H, C8-H), 6.78 (d, J=8.9 Hz, 2H, Ar—H), 6.56 (d, J=2.3 Hz, 1H, C5-H), 6.44 (dd, J=82 Hz and 2-3 Hz, 1H, C6-H), 3.62 (d, J=11.5 Hz, 1H, C2-H), 2.95 (d, J=11.5 Hz, 1H, C2-H), 2.80-2.72 (m, 1H, C4-H), 2.17 (t, J=7.3 Hz, 2H, —CH₂CO₂—), 1.48-1.40 (m 2H, CH₂CH₂CO₂), 1.22-1.01 (m, 11H).

EXAMPLE 42

[1137] Synthesis of (3RS,4RS)-4-[4,7-dioxa-9-(4,4,5,,5pentafluoropentylsuirinyl)nonyl]-7-hydromy-3-(4hydroxyphenyl)-methylthiochroman

[1138] Step 1) Synthesis of 5-(t-butyldimethylsilyloxy)-3-oxa-1-pentanol

[1139] To a solution of di(ethyleneglycol) (2.0 g, 18.8 mmol) in dry tetrahydrofuran (80 ml) was added sodium hydride (754 mg, 60% in oil, 18.8 mmol) at 0° C., which then stirred at room temperature for 1 hour. Then, to the reaction mixture was added t-butyldimethylsilylchloride (2.84 g, 18.8 mmol) at 0° C., and the resulting mixture was stirred at the room temperature for 2 hours. After the reaction was completed, water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound (2.16 g, yield 52%).

[1140]¹H-NMR (270 MHz, CDCl₃) δ: 3.78 (t, J=5.0 Hz, 0.2H, —CH₂), 3.72 (t, J=5.6 Hz, 2H, —CH₂), 3.62 (t, J=4.3 Hz, 2H, —CH₂), 3.60 (t, J=5.0 Hz, 2H, CH₂), 2.42 (t, 5.6 Hz, 1H, —OH), 0.91 (s, 9H, -tBu), 0.08 (s, 6H, -SiMe-2).

[1141] Step 2) Synthesis of 9-(t-butyldimethylsilyloxy)-4,7-dioxa-1-nonyne

[1142] To a solution of 5-(t-butyldimethylsilyloxy)-3-oxa-1-pentanol (2.]6 g, 9.8 mmol) in dry tetrahydrofuran (20 ml) was added sodium hydride(432 mg, 60% in oil, 10.8 mmol) at room temperature. The mixture was stirred for 30 minutes, and propalgyl bromide(2.9 g, 19.6 mmol) was added thereto. The mixture was stirred at room temperature for 12 hours. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=8:1) to give the title compound (950 mg, yield 38%).

[1143]¹H-NMR (270 MHz, CDCl₃) δ: 4.21 (d, J=2.3 Hz, 2H, C2-CH₂), 3.78 (t, J=5.3 Hz, 2H, —CH₂), 3.69 (s, 4H, —CH2×2),. 3.57 (t, J=5.6 Hz, 2H, —CH₂), 2.42 (t, 2.3 Hz, 1H, C1-CH), 0.90 (s, 9H, -tbutyl-H), 0.07 (s, 6H, —SiMe₂).

[1144] Step 3) Synthesis of 4-[9-(t-butyldimethylsilyloxy)-4,7-dioxa-1-nonynyl]-4-hydroxy-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman

[1145] To a solution of 9-t-butyldimethylsilyloxy)-4,7-dioxa-1-nonyne (1.03 g, 4.01 mmol) in dry tetrahydrofuran (10 ml) was added dropwise -n-butyl lithium (2.3 ml, 3.74 mmol, 1.63 molell in tetrahydrofuran) at −78° C., which was then stirred at −20° C. for 1 hour. Then, to this reaction mixture was added 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman-4-one (1.0 g, 2.67 mmol) dissolved in tetrahydrofuran (10 ml) at the same temperature for 30 min, and the resulting mixture was stirred at −10° C. (for 24 hours. After the reaction was completed, saturated ammonium chloride solution was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was subjected to column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound (1.1-5 g, yield 68%) as a colorless oil.

[1146]¹H-NMR (2.70 MHz, CDCl₃) δ: 7.82 (d, J=8.9 Hz, 1H, C5-H), 7.61 (d, J=8.9 Hz, 2H, Ar—H), 7.01 (d, J=8.9 Hz, 2H, Ar—H), 6.84 (d, J=2.3 Hz, 1H, C8-H), 6.75 (dd, J=8.9 Hz and 2.3 Hz, 1H, C6-H), 5.18 (s, 2H, —OCH ₂OCH₃), 5.15 (s, 2H, —OCH ₂OCH₃), 4.23 (d, J=12.1 Hz, 1H, C2-H), 4.22 (s, 2H, —CH ₂O—), 3.77 (t, J=5.5 Hz, 2H, —CH₂O—), 3.65-3.45 (m, 6H), 3.49 (s, 3H, —OCH₂OCH ₃), 3.47 (s, 3H, —OCH₂OCH ₃), 2.70 (d, J=12.1 Hz, 1H, C2-H), 2.31 (s, 1H, —OH),-1.58 (s, 3H, C3-CH₃), 0.89 (s, 9H, -tbutyl-H), 0.06 (s, 6H, —SiMe₂).

[1147] Step 4) Synthesis of 4-(4,7-dioxa-9-hydroxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyli-3-methylthiochroman

[1148] The title compound was prepared from 4-[9-(t-butyldimethylsilyloxy)-4,7-dioxa-1-nonynyl]4-hydroxy-7-methoxymethoxy-3-4methoxymethoxyphenyl)-3-methylthiochroman according to the same procedure as Step 3 of Example 39 (yield 33%).

[1149]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.95 (d, 1=8.5 Hz, 1H, C5-H), 6.88 (d, J=2.3 Hz, 1H, C8-H), 6.68 (dd, J=8.5 Hz and 2.3 Hz, 1H, C6-H), 5.19 (s, 2H, —OCH ₂OCH₃), 5.14 (s, 2H, —OCH₂OCH ₃). 3.69-3.38 (m, 9H), 3.50 (s, 3H, —OCH₂OCH₃), 3.49 (s, 3H, —OCH₂OCH ₂), 3.30-3.19 (m, 2H), 2.98 (d, J=11.6 Hz, 1H, C2-H), 2.81-2.75 (m, 1H, C4-H), 2.28 (brs, 1H, —OH), 1.53-1.20 (m, 4H), 1.17 (s, 3H, C3-CH₃).

[1150] Step 5) Synthesis of 4-[4,7-dioxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman

[1151] 4-(4,7-dioxa-9-hydroxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxy-phenyl)-3-methylthiochroman (290 mg, 0.57 mmol) was dissolved in dichloro- methane(2 ml), and triethylamine (173 mg, 1.71 mmol) and methanesulfonylchloride (67 μl, 0.86 mmol) were sequentially added thereto at 0° C. The mixture was stirred at the same temperature for 10 minutes. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product This crude product thus obtained was used to next reaction without purification.

[1152] To a solution of thioesteracetate separately prepared(404 mg, 1.71 mmol) in methanol (2 ml) was added sodium methoxide (1.6 ml, 1.0M solution in methanol, 1.6 mmol) at room temperature. The mixture was stirred for 30 minutes, and a solution of crude mesylate in tetrahydrofuran (2 ml) was added thereto. The mixture was stirred at room temperature for 1 day. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=3:1) to give the title compound (250 mg, yield 64%, (3RS,4RS):(3RS,4SR)=4:1).

[1153]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=8-3 Hz, 2H, Ar—H), 7.02 (d, J=8.3 Hz, 2H, Ar—H), 6.94 (d, J=8.2 Hz, 1H, C5-H), 6.87 (d, J=2.3 Hz, 1H, C8-H), 6.68 (dd, J=8.2 Hz and 2.3 Hz-1H, C6H), 5.19 (s, 2H, —OCH ₂OCH₃), 5.14 (s, 2H, —OCH ₂OCH₃), 3.68-3.38 (m, 9H), 3.50 (s, 3H, —OCH₂OCH ₃), 3.49 (s, 3H, —OCH₂OCH ₃), 3.23-3.17 (m, 2H), 2.99 (d, 1=11.5 Hz, 1H, C2-H), 2.81-2.75 (m, 1H, C4-H), 2.75-2.59 (m, 4H, —CH2SCH₂—), 2.17-2.05 (m, 4H, —CH₂CH₂CF₂CF₃), 1.53-1.20 (m, 4H), 1.17 (s, 3H, C3-CH₃).

[1154] Step 6) Synthesis of (3RS,4RS)-4-[4,7-dioxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman

[1155] To a solution of 4-[4,7-dioxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman (234 mg, 0.34 mmol) in tetrahydrofuran (1 ml) was added 6N hydrochloride solution (1 ml) at room temperature, which was then stirred for 26 hours. After the reaction was completed, saturated sodium hydrogencarbonate solution was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC(n-hexane:ethyl acetate=3:2) to give the title compound (45 mg, yield 22%).

[1156]¹H-NMR (270 MHz, CDCl₃) δ: 7.23 (d, J=8.6 Hz, 2H, Ar—H), 6.88 (d, J=8.3 Hz, 1H, C5-H), 6.82 (d, 3=8.6 Hz, 2H, Ar—H), 6.66 (d, J=2.4 Hz, 1H, C8-H), 6.47 (dd, J=8.3 Hz and 2.4 Hz, 1H, C6-H), 4.94 (brs, 1H, —OH), 4.82 (brs, 1H, —OH), 3.65-3.52 (m, 3H), 3.52-3.43 (m, 2H), 3.42-3.35 (m, 2H), 3.25-3.15 (m, 2H), 2.96 (d, J=11.5 Hz, 1H, C2-H), 2.78-2.70 (m, 1H, C4-H), 2.67 (t, J=6.6 Hz, 2H, —SCH₂—), 2.62 (t, J=7.2 Hz, 2H, —SCH₂—), 2.22-2.10 (m, 2H, —CH₂CH ₂CF₂CF₃), 1.90-1.72 (m, 2H, —CH ₂CH₂CF₂CF₃), 1.50-1.33 (m, 4H), 1.17 (s, 3H, C3-CH₃).

[1157] Step 7) Synthesis of (3RS,4RS)-4-[4,7-dioxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman

[1158] To a solution of thioether (43 mg, 0.072 mmol) in tetrahydrofuran (1 ml) was added Oxone^(R) (monopersulfate compound; DuPont product)(22 mg, 0.036 mmol) at 0° C. Water (0.1 ml) was added thereto at the same temperature, which was then stirred for 2 hours. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to preparative TLC (n-hexane:ethyl acetate=1:10) to give the title compound (23 mg, yield 52%).

[1159]¹H-NMR (270 MHz, CDCl₃) δ: 7.55 and 7.26 (s, total 1H, —OH), 7.22 (d, J=8.6 Hz, 2H, Ar—H), 6.86 (d, J=8.4 Hz, 1H, C5-H), 6.85 (d, J=8.6 Hz, 2H, Ar—H), 6.67 (d, J=2.3 Hz, 1H, C8-H), 6.49 (dd, J=8.4 Hz and 2.3 Hz, 1H, C6-H), 5.49 and 5.36 (s, total 1H, —OH), 3.84-3.51 (m, 4H), 3.48-3.05 (m, 6H), 3.00-2.60 (m, 5H), 2.35-2.10 (m, 4H, —CH ₂CH ₂CF₂CF₃), 1.42-1.22 (m, 4H), 1.21 and 1.19 (s, total 3H, C3-CH₃).

[1160] EI-MASS m/e=610 (M+).

EXAMPLE 43

[1161] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[6-oxa-9-(4,4,5,5,5-pentafluoropentyls ulfinyl)nonyl]thiochroman

[1162] Step 1) Synthesis of 1-bromo-3-(t-butyldimethylsilyloxy)propane

[1163] The title compound was prepared from 3-bromo-1-propanol according to the same procedure as Step 1 of Example 39 (yield 67%).

[1164]¹H-NMR (270 MHz, CDCl₃) δ: 3.77-3.49 (m, 4H, BrCH2CH₂CH₂OTBS), 2.08-1.91 (m, 2H, BrCH₂CH ₂CH₂OTBS), 0.90 (s, 9H, t-butyl-H), 0.07 (s, 6H, —SiMe₂).

[1165] Step 2) Synthesis of 9-(t-butyldimethylsilyloxy)-6-oxa-1-nonyne

[1166] To a solution of 4-pentyn-1-ol (2.1 g, 26.1 mmol) in dry N,N-dimetylformamide (100 ml) was added sodium hydride (1.04 g, 60% in oil, 26.1 mmol) at room temperature. The mixture was stirred for 40 minutes, and 1-bromo-3-(t-butyldimethylsilyloxy) propane(4.4 g, 17.⁴ mmol) was added thereto. The mixture was stirred at room temperature for 2 hours. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=20:1) to give the title compound (920 mg, yield 21%).

[1167]¹H-NMR (270 MHz, CDCl₃) δ: 3.69 (t, 1=6.3 Hz, ZH, —CH₂OTBS), 3.50 (t, J=6.3 Hz, 4H, —CH ₂OCH ₂—), 2.28 (dt, J=2.6 Hz and 7.0 Hz, 2H, propargyl-CH₂), 1.94 (t, J=2.6 Hz, 1H, acetylene-CH), 1.83-1.70 (m, 4H, —CH₂×2), 0.89 (s, 9H, -tbutyl-H), 0.05 (s, 6H, —SiMe₂).

[1168] Step 3) Synthesis of 4-(9-hydroxy-6-oxanonyl)-7-methoxymethoxy-3-4-methoxym ethoxyphenyl)-3-methylthiochroman

[1169] The title compound was prepared from 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman-4-one according to the same procedure as Steps 2 to 3 of Example 39.

[1170]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=8.9 Hz, 21H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.92 (d, J=8.2 Hz, 1H, C5-H), 6.88 (d, J=2.6 Hz, 1H, C8-H), 6.69 (dd, 3=8.2 Hz and 2.6 Hz, 1H, C6-H), 5.19 (s, 2H, —OCH ₂OCH₃), 5-15 (s, 2H, —OCH ₂OCH₃), 3.74-3.70 (m, 2H, —CH ₂OH), 3.62 (d, J=11.6 Hz, 1H, C2-H), 3.55 (t, J=6.3 Hz, 2H, —OCH₂—), 3.51 (s, 3H, —OCH₂OCH₃), 3.49 (s, 3H, —OCH₂OCH), 3.28 (t, J=6.3 Hz, 2H, —OCH₂), 2.98 (d, J=11.6 Hz, 1H, C2-H), 2.74-2.70 (m, 1H, C4-H), 2.41 (brs, 1H, —OH), 1.84-1.74 (m, 2H), 1.42-1.25 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.17-1.00 (m, 6H).

[1171] Step 4) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[6-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[1172] The title compound was prepared. from 4-(9-hydroxy-6-oxanonyl}-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman according to the same procedure as Step 5 of Example 42 (yield 74%)

[1173]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=8.6 Hz, 2H, Ar—H), 7.02 (d, J=86 Hz 2H, Ar—H), 6.92 (d, J=8g-3 Hz, 1H, C5-H), 6.88 (d, J=2.7 Hz, 1K C8-H), 6.68 (dd, J=8.3 Hz and 2.7 Hz. 1H, C6-H), 5.19 (s, 2H, —OCH₂OCH₃), 5.14 (s, 2H, —OCH ₂OCH₃), 3.63 (d, J=11.6 Hz, 1H, C2-H), 3.51 (s, 3.14, —OCH ₂OCH₃), 3.49 (s, 3H, —OCH₂OCH ₃), 3.41 (t, J=6.2 Hz, 2H, —OCH₂—), 3.26 (t, J=6.6 Hz, 2H, —OCH₂—), 2.98 (d, J=11.6 Hz, 1H, C2-H), 2.78-2.70 (m, 1H, C4-H), 2.57 (t, J=6.9 Hz, 2H, —CH₂SCH ₂—), 2.55 (t, J=6.9 Hz, 2H, —CH ₂SCH₂—), 2.25-2.05 (m, 2H, —CH ₂CF₂CF₃), 1.92-1.74 (m, 4H, —CH ₂CH₂CF₂CF₃ and —CH ₂—), 1.38-1.32 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.17-1.01 (m, 6H).

[1174] Step 5) Synthesis of k-3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[6-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[1175] The title compound was prepared from (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[6-oxa-9-4,4,5,5,5-pentafluoropentylthio)-nonyl]thiochroman according to the same procedure as Step 6 of Example 42 (yield 97%).

[1176]¹H-NMR (270 MHz, CDCl₃) δ: 7.24 (d, J=8.9 Hz, 2H, Ar—H), 6.86 (d, J=8.3 Hz, 1H, C5-H), 6.82 (d, J=8.9 Hz, 2H, Ar—H), 6.67 (d, J=2.3 Hz, 1H, C8-H), 6.49 (dd, J=8.3 Hz and 2.3 Hz, 1H, C6-H), 4.89 (brs, 1H, —OH), 4.74 (brs, 1H, —OH), 3.61 (d, J=11.5 Hz, 1H, C2-H), 3.41 (t, J=6.3 Hz, 2H, —OCH₂—), 3.26 (t, J=6.3 Hz, 2H, —OCH₂—), 2.95 (d, J=11.5 Hz, 1H, C2-H), 2.74-2.68 (m, 1H, C4-H), 2.58 (t, J=6.6 Hz, 2H, —SCH₂—), 2.55 (t, J=7.2 Hz, 2H, —SCH2-), 2.23-2.08 (m, 2H, —CH ₂CF₂CF₃), 1.93-1.74 (m, 4H, —CH ₂CH₂CF₂CF₃ and —CH₂—), 1.36-1.30 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.17-1.01 (m, 6H).

[1177] Step 6) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[6-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman

[1178] The title compound was prepared from (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[6-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thio-chroman according to the same procedure as Step 7 of Example 42 (yield 64%).

[1179]¹H-NMR (270 MHz, CDCl₃) δ: 7.61 and 7.31 (s, 1H, —OH), 7.22 (d, J=8.6 Hz, 2H, Ar—H), 6.87 (d, J=8.3 Hz, 1H, C5-H), 6.86 (d, J=8.6 Hz, 2H, Ar—H), 6.67 (d, J=2.4 Hz, R₁, C8-H), 6-49 (dd, J=8.3 Hz and 2.4 Hz, 1H, C6-H),. 5.31 and 5.10 (s, total 1H, —OH), 3.63 (dd, J=11.2 Hz and 2.6 Hz, 11, C2-H), 3.45-3.35 (m, 2H), 3.32-3.19 (m, 2H), 3.00-2.63 (m, 6H), 2.38-2.12 (m, 4H, —CH2CH2CF₂CF₃), 2.03-1.92 (m, 2H), 1.39-1.20 (m, 2H), 1.20 (s, 3H, C3-CH₃), 1.18-1.02 (m, 6H).

EXAMPLE 44

[1180] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3methyl-4-[7-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman

[1181] Step 1) Synthesis of ethyl 3-oxa-8-nonynoate

[1182] To a solution of 5-hexyn-1-ol (2.0 g, 20.4 mmol) in N,N-dimethylformamide (40 ml) was added sodium hydride(815 g, 60% in oil, 20.41 mmol) at 0° C. The mixture was stirred for 1 hour, and ethyl bromoacetate(3.4 ml, 30.5 mmol) was added thereto. The mixture was stirred at the same time for 1 hour. After the reaction was completed, water was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=4:1) to give the title compound (1.38 g, yield 37%).

[1183]¹H-NMR (270 MHz, CDCl₃) δ: 4.28-4.13 (m, 2H, —CO₂CH₂CH₃), 4.07 (d, J=2.0 Hz, 1H, —OCH₂CO₂—), 3.56 (t, J=6.3 Hz, 2H, —CH₂O—), 2.24 (dt, J=2.7 Hz and 7.0 Hz, 2H, propargyl-CH₂), 1.97-1.94 (m, 1H, acetylene-H), 1.84-1.55 (m, 2H, —CH₂CH₂—), 1.33-1.23 (m, 3H, —CO₂CH₂CH₃).

[1184] Step 2) Synthesis of 9-(t-butyldimethylsilyloxy)-7-oxa-1-nonyne

[1185] To a solution of ethyl 3-oxa-8-nonynoate (1.38 g, 7.5 mmol) in dry tetrahydrofuran (20 ml) was added lithium aluminium hydride(285 mg, 7.5 mmol) at 0° C., which was stirred at the same temperature for 30 minutes. After the reaction was completed, ethyl acetate was added thereto. The resulting mixture was extracted with ethyl acetate. The organic layer was washed with saturated saline solution, dried over anhydrous sodium sulfate, and filtered. The organic solvent was removed under reduced pressure to give a crude product. This crude product thus obtained was used to next reaction without purification (1.12 g).

[1186] To a solution of crude alcohol(1.12 g, 7.9 mmol) in N,N-dimethylformamide (10 ml) were added imidazole (591 mg, 8.7 mmol) and t-butyldimethylsilyl chloride (1.3 g, 8.7 mmol) at 0° C., which was then stirred at the same temperature for 30 minutes. After the reaction was completed, water was added to the reaction solution, and the mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was subjected to column chromatography (n-hexane:ethyl acetate=10:1) to give the title compound (900 mg, yield 47%) as a colorless oil.

[1187]¹H-NMR (270 MHz, CDCl₃) δ: 3.75 (t, J=5.3 Hz, 2H, —CH₂OTBS), 3.49 (t, J=6.9H, 4H, —CH₂OCH₂—), 2.22 (dt, J=2.6 Hz and 6.6 Hz, 2H, propargyl-CH2), 1.94 (t, J=2.6 Hz, 1H, acetylene-H), 1.72-1.55 (m, 4H, —CH₂CH), 0.90 (s, 9H, t-butyl-H, 0.07 (s, 6H, —SiMe₂).

[1188] Step 3) Synthesis of (3RS,4RS)-4-(9-hydroxy-7-oxanonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphen yl)-3-methylthiochroman

[1189] The title compound was prepared from 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman-4-one according to the same procedure as Steps 2 to 3 of Example 39.

[1190]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.92 (d, J=8.3 Hz, 1H, C5-H), 6.88 (d, J=2.7 Hz, 1H, C8-H), 6.69 (dd, J=8.3 Hz and 2.7 Hz, 1H, C6-H), 5.19 (s, 2H, —OCH₂OCH ₃), 5.14 (s, 2H, —OCH ₂OCH₃), 3.72-3.67 (m, 2H, —CH ₂OH), 3.63 (d, J=11.5 Hz, 1H, C2-H), 3.51 (s, 3H, —OCH₂OCH ₃), 3.49 (s, 3H, —OCH₂OCH ₃), 3.48 (t, J=5.7 Hz, 2H, —OCH ₂CH₂OH), 3.36 (t, J=6.6 Hz, 2H, —CH ₂OCH₂CH₂OH), 2.98 (d, J=11.5 Hz, 1H, C2-H), 2.74-2.70 (m, 1H, C4-H), 1.95 (t, J=5.9 Hz, 1H, —OH), 1.54-1.17 (m, 4H), 1.17 (s, 3H, C3-CH₃), 1.16-1.01 (m, 6H).

[1191] Step 4) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[7-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[1192] The title compound was prepared from (3RS,4RS)-4-(9-hydroxy-7-oxanonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphen yl)-3-methylthiochroman according to the same procedure as Step 5 of Example 42 (yield 70%).

[1193]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=8.6 Hz, 21, Ar—H), 7.02 (d, 3=8.1 Hz, 2H, Ar—H), 6.92 (d, J=8.6 Hz, 1H, C5-H), 6.88 (d, -=2.6 Hz, 1H, C8-H), 6.68 (dd, J=8.6 Hz and 2.6 Hz, 1H, C6-H), 5.19 (s, 2H, —OCH ₂OCH₃), 5.14 (s, 2H, —OCH ₂OCH₃), 3.62 (d, J=11.5 Hz, 1H, C2-H), 3.54 (t, J=6.6 Hz, 2H, —OCH ₂CH₂S—), 3.50 (s, 3H, —OCH₂OCH ₃), 3.49 (s, 3H, —OCH₂OCH ₃), 3.33 (t, J=6.6 Hz, 2H, —CH ₂OCH₂CH₂S—), 2.98 (d, J=11.5 Hz, 1H, C2-H), 2.75-2.70 (m, 1H, C4-H), 2.66 (t, J=6.9 Hz, 2H, . —CH₂SCH ₂—), 2.63 (t, J=6.9 Hz, 2H, —CH ₂SCH₂—), 2.25-2.05 (m, 2H, —CH ₂CF₂CF₃), 1.93-1.82 (m, 2H, —CH ₂CH₂CF₂CF₃), 1.45-1.36 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.17-1.01 (m, 8H).

[1194] Step 5) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[7-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[1195] The title compound was prepared from (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[7-oxa-9-(4,4,5,5,5-pentafluoropentylthio)-nonyl]thiochroman according to the same procedure as Step 6 of Example 42 (yield 92%).

[1196]¹H-NMR (270 MHz, CDCl₃) δ: 7.24 (d, J=8.9 Hz, 2H, Ar—H), 6.86 (d, J=8.6 Hz, 1H, C5-H), 6.82 (d, J=8.9 Hz, 2H, Ar—H), 6.67 (d, J=2.3 Hz, 1H, C8-H), 6.49 (dd, J=8.6 Hz and 2.3 Hz, 1H, C6-H), 4.92 (brs, 1H, —OH), 4.71 (brs, 2H, —OH), 3.62 (d, J=11.5 Hz, 1H, C2-H), 3.54 (t, J=6.6 Hz, 2H, —OCH ₂CH₂S—), 3.32 (t, J=6.6 Hz, 2H, —CH ₂OCH₂CH₂S—), 2.95 (d, J=11.5 Hz, 1H, C2-H), 2.70-2.65 (m, 1H, C4-H), 2.67 (t, J=6.6 Hz, 2H, —CH ₂SCH₂—), 2.64 (t, J=6.9 Hz, 2H, —CH ₂SCH₂—), 2.19-2.05 (m, 2H, —CH ₂CF₂CF₃), 1.94-1.86 (m, 2H, —CHCH₂CF₂CF₃), 1.43-1.36 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.17-1.01 (m, 8H).

[1197] Step 6) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[7-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman

[1198] The title compound was prepared from (3RS,4RS)-7-hydroxy-3-4-hydroxy-phenyl)-3-methylb-[7-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thio-chroman according to the same procedure as Step 7 of Example 42 (yield 62%).

[1199]¹H-NMR (270Mz CDCl₃) δ: 7.67 and 7.26 (s, total 1H, —OH), 7.23 (d, J=8.6 Hz, 2H, Ar—H), 6.86 (d, 3=8.3 Hz, 1H, C5-H), 6.85 (d, J=8.6 Hz, 2H, Ar—H), 6.52 (d, J=3.0 Hz, 1H, C8-H), 6.48 (dd, J=8.3 Hz and 3.0 Hz, 1H, C6-H), 5.27 and 4.92 (s, total 1H, —OH), 3.82-3.76 (m, 2H), 70-3.60 (m, 1H), 3.38-3.21 (m, 2H), 3.20-3.09 (m, 1H), 3.00-2.80 (m, 5H), 2.70-2.60 (m, 1H), 2.38-2.18 (m, 4H, —CH ₂CH ₂CF₂CF₃), 2.03-1.92 (m, 2H), 1.38-126 (m, 2H), 1.21 (s, 3H, C3-CH₃), 1.20-0.80 (m, 6H).

EXAMPLE 45

[1200] Synthesis of (3RS,4P—S-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman

[1201] Step 1) Synthesis of 4-(t-butyldimethylsilyloxy)-1-butanol

[1202] The title compound was prepared from 1,4-butanediol according to the same procedure as Step 1 of Example 42 (yield 64%).

[1203]¹H-NMR (270 MHz, CDCl₃) δ: 3.67 (t, J=6.6 Hz, 2H, —CH₂OH), 3.65 (t, J=6.6 Hz, 2H, —CH₂OTBS), 2.51 (brs, 1H, —OH), 1.69-159 (m, 4H -CH₂CH₂—), 0.91 (s, 9H, t-butyl-H), 0.07 (s, 6H, —SiMe₂—H).

[1204] Step 2) Synthesis of 4-(t-butyldimethylsilyloxy)butyl p-toluenesulfonate

[1205] To a solution of 4-t-butyldimethylsilyloxy)-1-butanol (2.8 g, 13.7 mmol) in dichloromethane (30 ml) were added triethyamine (3.83 ml, 27.4 mmol) and p-toluenesulfonyl chloride (2.88 g, 15.1 mmol) at 0° C., which was then stirred at the same temperature for 2 hours. After the reaction was completed, water was added to the reaction mixture. The resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=5:1) to give the title compound (4.0 g, yield 81%).

[1206]¹H-NMR (270 MHz, CDCl₃) δ: 7.79 (d, J=8.2 Hz, 2H, Ar—H), 7.34 (d, J=8.2 Hz, 2H, Ar—H), 4.06 (t, J=6.6 Hz, 2H, —CH₂OTs), 3.55 (t, J=6.2 Hz, 2H, —CH₂OTBS), 2.45 (s, 3H, —CH₃), 1.77-1.67 (m, 2H, —CH₂—), 1.56-1.47 (m, 2H, —CH₂—), 0.85 (s, 9H, t-butyl-H), 0.01 (s, 6H, —SiMe₂—H).

[1207] Step 3) Synthesis of 9-(t-butyldimethylsilyloxy)-5-oxa-1-nonyne

[1208] To a solution of 4-butyn-1-ol (587 mg, 8.38 mmol) in N,N-dimethyl-formamide (20 ml) were added sodium hydride (335 mg, 60% in oil, 8.38 mmol) and 15-crown-5 (369 mg, 1.12 mmol) at 0° C., which was then stirred at the same temperature for 1 hour. Then, to the reaction mixture was added 4-(t-butyldimethylsilyloxy)butyl p-toluenesulfonate (2.0 g, 5.58 mmol) in N,N-dimethylformamide (5 ml) at 0° C. which was then stiffed at the same temperature for 1 hour. After the reaction was completed, water was added to the reaction mixture. The resulting mixture was extracted with ethyl acetate. The extract was dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give - a crude product. This crude product thus obtained was subjected to silica gel column chromatography (n-hexane:ethyl acetate=5:1) to give the title compound (1.36 g, yield 96%).

[1209]¹H-NMR (270 MHz, CDCl₃) δ: 3.63 (t, J=6.2 Hz, 2H, —OCH₂—), 3.65 (t, J=7.0 Hz, 2H, —OCH₂—), 3.48 (t, J=6.3 Hz, 2H, —OCH₂—), 2.46 (dt, J=2.6 Hz and 7.0 Hz, 1H, propargyl-CH₂), 1.97 (t, J=2.6 Hz, 1H, acetylene-CH), 1.66-1.51 (m, 4H, —CH₂CH₂—), 0.89 (s, 9H, t-butyl-H), 0.04 (s, 6H, —SiMe₂—H).

[1210] Step 4) Synthesis of (3RS,4RS)-4-(9-hydroxy-5-oxanonyl)-7-methoxy methoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman

[1211] The title compound was prepared from 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylthiochroman-4-one according to the same procedure as Steps 2 to 3 of Example 39.

[1212]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=8.9 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.93 (d, J=8.2 Hz, 1H, C5-H), 6.88 (d, J=2.3 Hz, 1H, C8-H), 6.69 (dd, J=8.2 Hz and 2.3 Hz, 1H, C6-H), 5.19 (s, 2H, —OCH ₂OCH₃), 5.14 (s, 2H, —OCH ₂OCH₃), 3.63 (d, J=11.8 Hz, 1H, C2-H), 3.62-3.60 (m, 2H, —CH ₂OH), 3.50 (s, 3H, —OCH₂OCH ₃), 3.49 (s, 3H, —OCH₂OCH ₃), 3.33 (t, J=5.6 Hz, 2H, —OCH₂—), 3.22 (t, J=5.6 Hz, 2H, —OCH₂—), 2.98 (d, J=11.8 Hz, 1H, C2-H), 2.74-2.70 (m, 1H, C4-H), 2.41 (brs, 1H, —OH), 1.64-1.52 (m, 4H), 1-50-1.20 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.16-1.02 (m, 4H).

[1213] Step 5) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[1214] The title compound was prepared from (3RS,4RS)-4-(9-hydroxy-5oxanonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphen yl)-3-methylthiochroman according to the same procedure as Step 5 of Example 42 (yield 83%).

[1215]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=8.6 Hz, 2H, Ar—H), 7.02 (d, J=8.9 Hz, 2H, Ar—H), 6.93 (d, J=8.2 Hz, 1H, C5-H), 6.88 (d, J=2.3 Hz, 1H, C8-H), 6.69 (dd, J=822 Hz and 2.3 Hz, 1H, C6-H), 5.19 (s, 2H, —OCH₂OCH ₃), 5.14 (s, 2H, —OCH ₂OCH₃), 3 63 (d, J=11.2 Hz, 1H, C2-H), 3.50 (s, 3H, —OCH₂OCH ₃), 3.49 (s, 3H, —OCH₂OCH ₃), 3.38-3.26 (m, 2H, —OCH₂—), 3.25-3.14 (m, 2H, —OCH₂—), 2.98 (d, J=11.2 Hz, 1H, C2-H), 2.76-2.71 (m, 1H, C4-H), 2.58 (t, J=6.9 Hz, 2H, —CH₂SCH ₂—), 2.52-2.45 (m, 2H, —CH ₂SCH₂—), 2.20-2.05 (m, 2H, —CH ₂CF₂CF₃), 1.93-1 82 (m, 2H, —CH ₂CH₂CF₂CF₃), 1.61-1.40 (m, 4H), 1.40-1.25 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.17-1.03 (m, 4H).

[1216] Step 6) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman

[1217] The title compound was prepared from (3RS,4RS)-7-methoxymethoxy-34-methoxymethoxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-thiochroman according to the sarne procedure as Step 6 of Example 42 (yield 78%).

[1218]¹H-NMR (270 MHz, CDCl₃) δ: 7.24 (d, J=8.9 Hz, 2H, Ar—H), 6-87 (d, J=8.3 Hz, 1H, C5-H), 6.82 (d, J=8.9 Hz, 2H, Ar—H), 6.67 (d, J=2.6 Hz, 1H, C8-H), 6.49 (dd, 3=8.3 Hz and 2.6 Hz, 1H, C6-H), 4.93 (brs, 1H, —OH), 4.80 (brs, 2H. —OH), 3.62 (d, J=11.6 Hz, 1H, C2-H), 3.30-3.23 (m, 2H, —OCH₂—), 3.19 (t, J=6.3 Hz, 2H, —OCH₂—), 2.95 (d, J=11.6 Hz, 1H, C2-H), 2.74-2.68 (m, 1H, C4-H), 2.59 (t, J=7.0 Hz, 2H, —CH₂SCH ₂—), 2.55-2.46 (m, 2H, —CH ₂SCH₂—), 2.23-2.05 (m, 2H, —CH ₂CF₂CF₃), 1.94-1.86 (m, 2H, —CH ₂CH₂CF₂CF₃), 1.5&1.50 (m, 2H), 1.42-1.30 (m, 2H), 1.17 (s, 3H, C3-CH₃), 1.17-1.01 (m, 6H).

[1219] Step 7) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman

[1220] The title compound was prepared from (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylthio)nonyl-1thio-chroman according to the same procedure as Step 7 of Example 42 (yield 64%).

[1221]¹H-NMR (270 MHz, CDCl₃) δ: 7.22 (d, J=8.9 Hz, 2H, Ar—H), 7.03 and 6.64 (s, total 1H, —OH), 6.87 (d, J=8.2 Hz, 1H, C5-H), 6.86 (d, J=8.9 Hz, 2H, Ar—H), 6.67 (d, J=2.6 Hz, 1H, C8-H), 6.52 (dt, J=8.2 Hz and 2.6 Hz, 1H, C6-H), 6.04 and 5.71 (s, total 1H, —OH), 3.68-3.62 (m, 1H), 3.25-3.09 (m, 4H), 3.00-2.58 (m, 7H), 2.38-2.18 (m, 4H, —CH ₂CH ₂CF₂CF₃), 1.82-1.60 (m, 4H), 1.38-1.05 (m, 6H), 1.21 and 1.20 (s, total 3H, C3-CH₃).

EXAMPLE 46

[1222] Synthesis of (3′RS,4′RS)-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthio-chroman-4-yl]nonanoic Acid

[1223] Step 1) Synthesis of (3′RS,4′RS)-6-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]-3-nonenoic Acid

[1224] To a solution of Ph₃P(CH₂)₂CO₂H Cl salt (1.162 g, 3.14 mmol) in DMSO (1 ml) was added freshly prepared 2 M NaCH₂SOCH₃ in DMSO solution (0.5 ml) and the mixture was stirred for 0.5 h at room temperature. The DMSO solution (1.5 ml) of 6-[7-methoxy-3-(4-methoxyphenyl)-3-methyl-thiochroman-4-yl]hexanal (250 mg, 0.63 mmol) was added to the above solution at room temperature and the resulting mixture was stirred at 60° C. for 16 h. The reaction was quenched with 6N HCl, which was extracted with ethyl acetate. The organic layer obtained was washed with water and saturated saline solution and then, dried over MgSO₄. The solvent was evaporated off and the residue was subjected to flash chromatography on silica gel (hexane:ethyl acetate=2:1) to give the title compound (283 mg, yield 100%).

[1225]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=9 Hz, 2H, Ar—H), 6.94 (d, J=8 Hz, 1H, Ar—H), 6.90 (d, J=9 Hz, 2H, Ar—H), 6.75 (d, J=2 Hz, 1H, Ar—H), 6.58 (dd. J=8, 2 Hz, 1H, Ar—H), 5.80-5.40 (m, 2H, olefin-H), 3.82 (s, 3H, OCH₃), 3.77 (s, 3H, OCH₃), 3.62 (d, J=11 Hz, 1H, C2-H), 2.97 (d, 1=11 Hz, 1H, C2-H). 2.75 (brs, 1H, C4-H), 2.10 (m. 2H, CH₂CO₂H), 1.20-0.90 (m, 13H, alkyl-H and CH₂CH═CH).

[1226] Step 2) Synthesis of 6-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]-nonanoic Acid

[1227] To a solution of &[7-hydroxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]-3-nonenoic acid (254 mg, 0-56 mmol) in ethyl acetate (5 ml) was added platinum (IV) oxide hydrate (130 mg, 0.56 mmol) and the mixture was stirred for 16 h at room temperature under hydrogen atmosphere. The catalyst was filtered off and washed with methanol. The filtrate was concentrated and the residue was subjected to flash chromatography on silica gel (ethyl acetate) to give the title compound (222 mg, yield 87%).

[1228]¹H-NMR (270 MHz, CDCl₃) δ: 7.30 (d, -J=9 Hz, 2H, Ar—H), 6.94 (d, J=8 Hz, 1H, Ar—H), 6.90 (d, 3=9 Hz, 2H, Ar—H), 6.72 (d, J=2 Hz, 1H, Ar—H), 6.57 (dd, J=. 8, 2 Hz, 1H, Ar—H), 3.82 (s, 3H, OCH₃), 3.78 (s, 3H, OCH₃), 3.62 (d, J=11 Hz, 1H, C2-H), 2.97 (d, J=11 Hz, 1H, C2-H), 2.75 (brs, 1H, C4-H), 2.29 (t, J=7 Hz, 2H, CH₂CO₂H), 1.65-1.45 (q, J=7 Hz, CH₂CH₂CO₂H), 1.30-0.90 (m, 15H, alkyl-H).

[1229] Step 3) Synthesis of Methyl (3′RS,4′RS) and (3SR,4RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]nonanoate

[1230] To a solution of 6-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]nonanoic acid (222 mg, 0 49 mmol) in methylene chloride (6 ml) was added BBr₃ (1.0 M, 3.0 ml, 3 mmol) at −78° C., which was then slowly warmed over 3 h. After the reaction was completed, saturated aqueous NaHCO₃ was added at 0° C. The resulting mixture was then extracted with methylene chloride and the organic layer obtained was washed with saturated saline solution. The organic layer was dried over MgSO₄ and the solvent was evaporated off. The residue (210 mg) was used for the next step without further purification. The residue was dissolved with methanol (5 ml) and one drop of concentrated H₂SO₄ was added to the solution at room temperature. The reaction mixture was stirred for 3 h and then, saturated aqueous NaHCO₃ was added. The mixture was extracted with ethyl acetate and the organic layer obtained was washed with saturated saline solution and dried over MgSO₄ and then, the solvent was. evaporated off. The residue was subjected to preparative thin layer chromatography on silica gel (n-hexane:ethyl acetate=4:1) to give the less polar (3RS,4RS) and the more polar (3SR, 4RS) title compounds (140 mg, yield 53% for (3RS,4RS), 19 mg, yield 7% for (3SR, 4RS)).

[1231]¹H-NMR (270 MHz, CDCl₃) δ: 7.29 (d, J=9 Hz, 2H, Ar—H), 6.91 (d, J=8 Hz, 1H, Ar—H), 6.98 (d, J=9 Hz, 2H, Ar—H), 6.72 (d, J=2 Hz, 1H, Ar—H), 6.54 (dd, J=8, 2 Hz, 1H, Ar), 6.05 (brs, 1H, ArOH), 5.28 (brs, 1H, ArOH), 3.74 (s, 3H, CO₂CH₃), 3.67 (d, J=11 Hz, 1H, C2-H), 2.97 (d, J=11 Hz, 1H, C2-H), 2.75 (brs, 1H, C4-H), 2.32 (t, J=7 Hz, 2H, CH ₂CO₂CH₃), 1.65-1.45 (q, J=7 Hz, CH ₂CH₂CO₂CH₃), 1.30-0.90 (m, 15H, alkyl-H). : 7.25 (d, J=9 Hz, 2H, Ar—H), 6.70 (d, J=8 Hz, 1H, Ar—H), 6.43 (d, J=9 Hz, 2H, Ar—H), 6.48 (d, J=2 Hz, 1H, Ar—H), 6.33 (dd, J=8, 2 Hz, 1H, Ar—H), 5.20 (brs, 2H, ArOH), 3.67 (s, 3H, CO₂CH₃), 3.21 (AB q, J=11 Hz, 2H, C2-H), 2.85 (brd, 1H, C4-H), 2.32 (t, J=7 Hz, 2H, CH ₂CO₂CH₃), 1.65-1.45 (q, 3=7 Hz, CH ₂CH₂CO₂CH₃), 1.30-0.90 (m, 15H, alkyl-H).

[1232] Step 4) Synthesis of (3′RS,4RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-ylgnonanoic Acid

[1233] To a solution of methyl (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl)nonanoate (70 mg, 0.16 mmol) in methanol (1 ml) was added 2N NaOH (0.5 ml) at -room temperature and the reaction mixture was stirred for 3 h. After 6N HCl was added, the mixture was extracted with diethyl ether. The organic layer obtained was washed with saturated saline solution, which was dried over MgSO₄ and the solvent was evaporated off. The residue was subjected to preparative thin layer chromatography on silica gel (ethyl acetate) to give the title compound (60 mg, yield 88%).

[1234]¹H-NMR (270Mlz, CD₃OD) δ: 7.23 (d, J=9 Hz. 2H, Ar—H), 6.86 (d, J=8 Hz, 1H, Ar—H), 6.78 (d, J=9 Hz, 2H, Ar—H), 6.57 (d, J=2 Hz, 1H, Ar—H), 6.45 (dd, J=8, 2 Hz, 1H, Ar—H), 3.60 (d, J=11 Hz, 1H, C2-H), 2.94 (d, J=11 Hz, 1H, C2-H), 2.75 (brs, 1H, C4-H), 2.22 (t, J=7 Hz, 2H, CH ₂CO₂H), 1.60-1.40 (q, J=7 Hz, CH ₂CH₂CO₂H), 1.30-0.90 (m, 15H, alkyl-H).

EXAMPLE 47

[1235] Synthesis of (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-methyl thiochroman-4-yl]decanoic Acid

[1236] Step 1) Synthesis of 6-[7-methoxy-3-(4-methoxyphenyl)-3-methylthio-chroman-4-yl]4-decenoic Acid

[1237] To a solution of Ph₃P(CH₂)3CO₂HCl salt (1.87 g, 4.87 mmol) in DMSO (3 ml) was added freshly prepared 2 M NaCH₂SOCH₃ in DMSO solution (4.87 ml) and the mixture was stirred for 0.5 h at room temperature. The DMSO solution (4.0 ml) of 6-[7-methoxy-3-(4-methoxyphenyl)-3-methylthio-chroman-4-yl]hexanal (388 mg, 0.97 mmol) was added to the above solution at room temperature and the resulting mixture was stirred at 60° C. for 16 h. The reaction was quenched with 6N—HCl, which was extracted with ethyl acetate. The organic layer obtained was washed with water and saturated saline solution and then, dried over MgSO₄. The solvent was evaporated off and the residue was subjected to flash chromatography on silica gel (hexane:ethyl acetate=2:1) to give the title compound (445 mg, yield 98%).

[1238]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (d, J=9 Hz, 2H, Ar—H), 6.94 (d, J=8 Hz, 1H, Ar—H), 6.90- (d, 3=9 Hz, 2H, Ar—H), 6.72 (d, J=2 Hz, 1H, Ar—H), 6.57 (dd, J=8, 2 Hz, 1H, Ar—H), 6.40-6.20 (m, 2H, olefin-H), 3.82 (s, 3H, OCH₃), 3.77 (s, 3H, OCH₃), 3.62 (d, J=11 Hz, 1H, C2-H), 2.97 (d, J=11 Hz, 1H, C2-H), 2.75 (brs, 1H, C4-H), 2.45-2.20 (m, 4H, CH₂CH₂CO₂H), 1.90-1.80 (m, 2H, CH₂CH—CH), 1.20-0.90 (m, 11H, alkyl-H).

[1239] Step 2) Synthesis of 6-[7-methoxy-3-(4-methoxyphenyl)-3-methylthio-chroman-4-yl]decanoic Acid

[1240] The title compound was prepared from 6-[7-methoxydroxy-3-4-methoxyphenyl)-3-methylthiochroman-4-yl]-decenoic acid (445 mg, 0.95 mmol) according to the same procedure for the synthesis of 6-(7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]nonanoic acid (400 mg, yield 90%).

[1241]¹H-NMR (270, CDCl₃) δ: 7.30 (d, J=9 Hz, 2H, Ar—H), 6.94 (d, J=8 Hz, 1H, Ar—H), 6.90 (d, J=9 Hz, 2H, Ar—H), 6.72 (d, J=2 Hz, 1H, Ar—H), 6.57 (dd, J=8, 2 Hz, 1H, Ar—H), 3.82 (s, 3H, OCH₃), 3.78 (s, 3H, OCH₃), 3.62 (d, J=11 Hz, 1H, C2-H), 2.97 (d, J=11 Hz, 1H, C2-H), 2.75 (brs, 1H, C4-H), 2.29 (t, J=7 Hz, 2H, CH ₂CO₂H), 1.65-1.45 (q, J=7 Hz, CH ₂CH₂CO₂H), 1.30-0.90 (m, 17H, alkyl-H).

[1242] Step 3) Synthesis of methyl (3′RS,4′RS)-6-[7-hydroky-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]decanoate

[1243] The title compound was prepared from 6-[7-methoxy-3-4-methoxyphenyl)-3-methylthiochroman-4-yl]decanoic acid (400 mg, 0.85 mmol) according to the same procedure for the synthesis of methyl (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]nonanoate (219 mg, yield 56%).

[1244]¹H-NMR (270 MHz, CDCl₃) δ: 7.22 (d, J=9 Hz, 2H, Ar—H), 6.87 (d, J=8 Hz, 1-H, Ar—H), 6.83 (d, J=9 Hz, 2H, Ar—H), 6.67 (d. J=2 Hz, 1H, Ar—H), 6.50 (dd, J=8, 2 Hz, 1H, Ar—H), 5.88 (brs, 1H, ArOH), 5.20 (brs, 1H, ArOH), 3.70 (s, 3H, CO—CH₃), 3.63 (d, J=11 Hz, 1H, C2-H), 2.95 (d, J=11 Hz, 1H, C2-H), 2.68 (brs, 1H, C4-H), 2.31 (t, J=7 Hz, 2H, CH₂CO₂CH₃), 1.65-1.45 (q, J=7 Hz, CH₂CH₂CO₂CH₃), 1.30-0.90 (m, 17H, alkyl-H).

[1245] Step 4) Synthesis of (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]decanoic Acid

[1246] The title compound was prepared from methyl (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]decanoate (35 mg, 0.076 mmol) according to the same procedure for the synthesis of (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]nonanoic acid.

[1247]¹H-NMR (270 MHz, CD₃OD) δ: 7.24 (d, J=9 Hz, 2H, Ar—H), 6.86 (d, J=8 Hz, 1H, Ar—H), 6.78 (d, J=9 Hz, 2H, Ar—H), 6.57 (d, J=2 Hz, 1H, Ar—H), 6.45 (dd, J=8, 2 Hz, 1H, Ar—H), 3.61 (d, J=11 Hz, 1H, C2-H), 2.94 (d, J=11 Hz, 1H, C2-H), 2.75 (brs, 1H, C4-H), 2.25 (t, J=7 Hz, 2H, CH ₂CO₂H), 1.60-1.40 (q, J=7 Hz, CH ₂CH₂CO₂H), 130-0.90 (m, 17H, alkyl-H).

EXAMPLE 48

[1248] Synthesis of (E)-3-[7-hydroxy-3-(4-hydoxyphenyl)-2H-chromen-4-yl]phenyl Acrylic Acid

[1249] Step 1) Synthesis of 4-[3-(1,3-dioxolan-2-yl)-phenyl]-7-methoxy-3-(4-methoxyphenyl)thiochroman-4-ol

[1250] To a solution of 2-(3-bromophenyl)-1,3-dioxolane (3.04 g, 13.28 mmol) in dry tetrahydrofuran (35 ml) was added n-butyl lithium (8.37 ml, 13.316 mmol, 1.59 mol/A tetrahydrofuran solution) dropwise as −78° C. over 10 minutes and stirred for 50 minutes at the same temperature. Then to the reaction mixture was added 7-methoxy-3-(4-methoxyphenyl)thiochroman-4-one (2 g, 6.658 mmol) dissolved in tetrahydrofliran at the same temperature over 10 minutes. The reaction mixture was stirred for 6 h at −78° C. and followed at −10C for 2 h. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=8:1 to 7:3) to give 1.50 g (yield: 50%.) of the title compound as a colorless oil. In this reaction, 0.77 g (38%) of the unreacted starting- compound was recovered.

[1251]¹H-NMR (270 MHz, CDCl₃) δ: 7.30-7.06 (m, 5H, Ar—H), 6.85 (m, 2H, Ar—H), 6.72 (d, J=2.3 Hz, 1H, C8-H), 6.65 (d, J=8.6 Hz, 2H, C5-H), 6.50 (dd, J=8.6 and 2.7 Hz, 1H, C6-H), 5.71 (s, 1H, dioxolan C2-H), 3.98 (m. 4H, 2×OCH2), 3.78 (s, 3H, OCH3), 3.74 (m, 1H, C3-H), 3.71 (s, 3H, OCH3), 3.30 (dd, J=10.8 and 2.3 Hz, 1H, C2-H), 2.87 (dd, J=12.5 and 2.7 Hz, 1H. C2-H), 2.17 (s, 1H, OH)

[1252] Step 2) Synthesis of 3-[7-methoxy-3-(4-methoxyphenyl)-2H-chromen-4-yl]benzaldehyde

[1253] The solution of 4-[3-(1,3-dioxolan-2-yl)-phenyl]-7-methoxy-3-(4-methoxyphenyl)-thiochroman-4-ol (1.4 g, 3.107 mmol) in SN hydrochloric acid solution (65 ml) was heated at 100° C. for 4.5 h. When the reaction was completed, water was added to the reaction mixture and extracted with ethyl acetate. The extract was washed with saturated sodium hydrogen carbonate solution and sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was flash chromatographied on silica gel (n-hexane:ethyl acetate=8:2) to give 0.963 g (yield: 80%) of the title compound as a colorless oil.

[1254]¹H-NMR (270 MHz, CDCl₃) δ: 9.88 (s, 1H, CHO), 7.71 (d, J=7.5 Hz, 1H, Ar—H), 7.51 (s, 1H, Ar—H), 7.53 (m, 2H, Ar—H), 6.93 (m, 3H, Ar—H), 6.64 (m, 3H, Ar—H), 6.53 (dd, J=8.5 and 2.7 Hz, 1H, thiochroman C6-H), 3.80 (s, 3H, OCH₃), 3.79 (m, 2H, thiochroman C2-H), 3.71 (s, 3H, OCH₃)

[1255] Step 3) Synthesis of (E)-3-[7-methoxy-3-(4-methoxyphenyl)-2H-chromen-4-yl]-phenylacrylic Acid

[1256] The mixture of 3-[7-methoxy-3-(4-methoxyphenyl)-2H-cbromen-4-yl]benzaldehyde (0.963 g, 2.479 mmol) and malonic acid (0.774 g, 7.44 mmol) in piperidine (0.24 ml) and pyridine (2.4 ml) was stirred at 65° C. for 2h. When the reaction was completed, water and ethyl acetate were added to the reaction mixture, which was acidified with 1N hydrochloric acid solution. Then the mixture was extracted with ethyl acetate, washed with water and saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The organic solution was filtrated and evaporated to give 1.00 g (yield:93%) of the title compound as a white solid.

[1257]¹H-NMR (270 MHz, CDCl₃) δ: 7.60 (d, J=15.8 Hz, 1H, C3-H), 7.31 (d, J=7.3 Hz, 1H, Ar—H), 7.14 (m, 3H, Ar—H), 7.01 (d, J=7.6 Hz, 1H, Ar—H), 6.90 (m, 2H, Ar—H), 6.62 (m, 3H, Ar—H)), 6.48 (dd, J=8.5 and 2.3 Hz, 1H, thiochroman C6-H), 6.23 (d, J=15.8 Hz, 1H, C2-H), 3.75 (s, 3H, OCH₃), 3.68 (m, 2H, thiochroman C2-H), 3.67 (s, 3H, OCH₃)

[1258] Step 4) Synthesis of (E)-3-[7-hydroxy-3-(4-hydoxyphenyl)-2H-chromen-4-yl]-phenylacrylic Acid

[1259] To a solution of (E)-3-[7-methoxy-3-(4-methoxyphenyl)-2H-chromen-4-yl]phenylacrylic acid. (505 mg, 1.173 mmol) in methylene chloride (30 ml) was added borontribromide (11.0M in methylene chloride, 7.03 ml) at −78° C. and stirred at 0° C. for 3.5 h. After the reaction was completed, the reaction was quenched with sodium thiosulfate solution and water, which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was flash chromatographied on silica gel (n-hexane:ethyl acetate=10:4) to give 60 mg of the title compound (unstable on air) as a pink oil.

[1260]¹H-NMR (270 MHz, CDCl₃) δ: 7.63 (d, J=15.8 Hz, 1H, C3-H), 7.35 (d, J=6.9 Hz, 1H. Ar—H), 7.23 (m, 3H, Ar—H), 7.07 (d, J=7.9 Hz, 1H, Ar—H), 6.89 (m, 2H, Ar—H), 6.65 (dd, J=8.6 and 2.6 Hz, 1H, Ar—H), 6.58 (d, J=8.6 Hz, 2H, Ar—H), 6.46 (dd, J=8.6 and 2.6 Hz, 1H, thiochroman C6-H), 6.28 (d, J=15.8 Hz, 1H, C2-H), 3.74 (m, 2H, thiochroman C2-H)

EXAMPLE 49

[1261] Synthesis of (3′RS,4′RS)-(E)-3-[-7-hydroxy-3-(4-hydoxyphenyl)thiochroman-4-yl]Phenylacrylic Acid

[1262] Step 1) Synthesis of 4-[3-(t-butyidimethylsilyloxymethyl)phenyl]-7-methoxy-3-4-methoxyphenyl)thiochroman-4-ol

[1263] To a solution of (3-bromobenzyloxy)-t-butyldimethylsilane (2.207 g, 7.326 mmol) in dry tetrahydrofuran (20 ml) was added n-butyl lithium (4.18 ml, 6.66 mmol, 1.59M tetrahydrofuran solution) at −78° C. over 25 minutes and stirred for 50 minutes. Then to the reaction mixture was added 7-methoxy-3-(4-methoxyphenyl)thiochroman-4-one (1 g, 3.33 mmol) dissolved in tetrahydrofuran at the same temperature over 10 minutes. The reaction mixture was stirred for 20 minutes at −78° C., followed at −15° C. for 12 h and at 0° C. for 8 h. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=8:2) to give 0.49 g (yield: 28%) of the title compound as a colorless oil. In this reaction 0.55 g (55%) of the unreacted starting compound was recovered.

[1264]¹H-NMR (270 MHz, CDCl₃) δ: 7.1 0 (m, 5H, Ar—H), 6.88 (dd, J=8.9 Hz, 2H. Ar—H), 6.72 (d, J=2.6 Hz, 1H, CS—H), 6.65 (d, J=8.6 Hz, 2H, Ar—H), 6.51 (dd, J=8.9 and 2.6 Hz, 1H, C6-H), 4.63 (s, 2H, OCH₂TBS), 3.78 (s, 3H, OCH₃), 3.72 (s, 3H, OCH₃), 3.70 (m, 1H, C3-H), 3.55 (dd, J=11.6 and 2.3 Hz, 1H, C2-H), 2.89 (dd, J=11.2 and 2.3 Hz, 1H, C2-H), 2.12 (s, 1H,OH), 0.88 (s, 9H, t-butyl H), 0.02 (s, 6H, 2×CH₃)

[1265] Step 2) Synthesis of 4-[-3-(t-butyldimethylsilyloxymethyl)phenyl]-7-methoxy-3-4-methoxyphenyl)thiochroman

[1266] To a solution of 4-[3-(t-butyldimethylsilyloxymethyl)phenyl]-7-methoxy-3-(4-methoxyphenyl)thiochroman-4--ol (619 mg, 1.184 mmol) in 1,2-dichloroethane (70 ml) were added zinc iodide (567 mg, 1.776 mmol) and sodium cyanoborohydride (558 mg, 8.88 mmol) and stirred at 68° C. for 2.5 d. When the reaction was completed, water was added to the reaction mixture and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was flash chromatographed on silica gel (n-hexane:ethyl acetate=8:2) to give 365 mg (yield:61%, 3RS,4RS/3RS,4SR=6:1) of the title compound as a white solid. In this reaction, 260 mg (42%) of the unreacted starting compound was recovered.

[1267]¹H-NMR (270 MHz, CDCl₃) δ: 7.02 (m, 3H, Ar—H), 6.85 (d, J=8.6 Hz, 1H, Ar—H), 6.71 (m, 4H, Ar—H), 6.54 (m, 2H, Ar—H), 6.45 (d, J=7.3 Hz, 1H, Ar—H), 4.56 (s, 2H, O—CH₂TBS), 4.18 (d, J=3.3 Hz, 1H, C4-H), 3.78 (s, 3H, OCH₃), 3.77 (s, 3H, OCH₃), 3.55 (ddd, J=12.6, 3.3 and 2.6 Hz, 1H, C3-H), 3.40 (dd, J=12.6 and 12.3 Hz, 1H, C2-H), 2.78 (dd, J=12.3 Hz, and not resolved, 1H, C2-H), 0.88 (s, 9H, t-butyl H), 0.02 (s, 6H, 2×CH₃)

[1268] Step 3) Synthesis of 3-[7-methoxy-3-(4-methoxyphenyl)thiochroman-4-yl]benzyl-alcohol

[1269] 4-[3-(t-butyldimethylsilyloxymethyl)phenyl]-7-methoxy-3-(4-methoxy-phenyl)thiochroman (480 mg, 0.947 mmol) was dissolved in tetrahydrofuran (40 ml), and added 3N hydrochloric acid solution (2.7 ml) thereto. The reaction mixture was stirred at room temperature for 4 h. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was washed with sodium hydrogen carbonate solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was flash chromatographied on silica gel (n-hexane:ethyl acetate=1:1) to obtain 358 mg (yield: 96%)- of the title compound as a white solid.

[1270]¹H-NMR (270 MHz, CDCl₃) δ: 7.14 (m, 2K Ar—H), 7.07-6.49 (m, 9H, Ar—H), 4.47 (s, 2H, OCH₂TBS), 4.20 (d, J=3.3 Hz, 1H, thiochroman C4-H), 3.79 (s, 3H, OCH₃), 3.78 (s, 3H, OCH₃), 3.58 (ddd, J=12.6, 3.3 and 2.6 Hz, 1H, thiochroman. C3-H), 3.38 (dd, J=12.6 and 12.2 Hz, 1H, thiochroman C2-H), 2.79 (dd, J=12.2 Hz, and not resolved, 1H, thiochroman C2-H)

[1271] Step 4) Synthesis of 3-[7-methoxy-3-(4-methoxyphenyl)thiochroman-4-yl]benzaldehyde

[1272] The mixture of 3-[7-methoxy-3-(4-methoxyphenyl)thiochroman-4-yl]benzyl alcohol (358 mg, 0.912 mmol) and manganese (IV) oxide (634 mg, 7.296 mmol) in methylene chloride (80 ml) was stirred at 40° C. for 3 h. When the reaction was completed, methylene chloride was added to the reaction mixture, which was then filtrated over silica gel and washed with several times with methylene chloride. The organic layer was concentrated under reduced pressure to give 360 mg (quant.) of the title compound as a white crystal.

[1273]¹H-NMR (270 MHz, CDCl₃) δ: 9.79 (s, 1H, CHO), 7.67 (d, J=13.6 Hz, 1H, Ar—H), 7.05-6.63 (m, 9H, Ar—H), 6.56 (dd, J=8.6 and 2.7 Hz, 1H, thiochroman C6-H), 4.29 (d, J=4.0 Hz, 1H, thiochroman C4-H), 3.80 (s, 3H, OCH₃), 3.77 (s, 3H, OCH₃), 3.63 (ddd, J=12.8, 3.3 and 3.0 Hz, 1H, thiochroman C3-H), 3.30 (dd, J=12.9 and 12.5 Hz, 1H, thiochroman C2-H), 2.83 (dd, J=12.5 Hz, and not resolved, 1H, thiochroman C2-H)

[1274] Step 5) Synthesis of (E)-3-[7-methoxy-3-(4-methoxyphenyl)thiochroman-4-yl]Phenylacrylic Acid

[1275] The title compound was prepared from 3-[7-methoxy-3-(4-methoxyphenyl)-thiochroman-4-yl]benzaldehyde and malonic acid according to the same method for the synthesis of (E)-3-[7-methoxy-3-4-methoxyphenyl)-2H-chromen-4-yl]phenylacrylic acid.

[1276]¹H-NMR (270 Mhz CDCl₃) δ: 7.59 (d, J=16.2 Hz, 1H, C3-H), 7.31-6.33 (m, 1H, Ar—H), 6.13 (d, J=16.2 Hz, C2-H), 4.21 (d, J=3.3 Hz, 1H, thiochroman C4-H), 3.80 (s, 3H, OCH₃), 3.79 (s, 3H, OCH₃), 3.62 (ddd, J=13.2, 3.6 and 3.0 Hz, 1H, thiochroman C3-H), 3.30 (dd, J=13.2 and 12.2 Hz, H, thiochroman C2-H), 2.82 (dd, J=12.2 Hz, and not resolved, 1H, thiochroman C2-H)

[1277] Step 6) Synthesis of (3′RS,4′RS)-(E)-3-[-7-hydroxy-3-(4-hydoxyphenyl)-thiochroman-4-yl]Phenylacrylic Acid

[1278] To a solution of (E)-3-[7-methoxy-3-(4-methoxyphenyl)thiochroman-4-yl]phenylacrylic acid (478 mg, 1.106 mmol) in methylene chloride (60 ml) was added borontribromide (6.64 ml, 11.0 mol/A in methylene chloride) at −78° C. and stirred at 0° C. for 3 h. After the reaction was completed, the reaction was quenched with sodium thiosulfate solution and water, which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the crude product (430 mg). Then the crude product was dissolved in methanol (40 ml) and added conc. sulfuric acid 8 drops. After the reaction mixture was stirred at 40° C. for 6 h, the solvent was evaporated. The residue was subjected to flash chromatography on silica gel (n-hexane:ethyl acetate=7:3) to give 390 mg of the 3RS,4RS/3RS,4SR mixture (10:1.5). The purification using the preparative TLC (n-hexane:ethyl acetate:methanol=9:1:0.5) afforded the 3RS,4RS isomer in 115 mg. Then to the solution of the 3RS,4RS ester (115 mg, 0.274 mmol) in methanol (3 ml) was added 2N sodium hydroxide solution (ImI) and stirred for 1 hour. After the hydrolysis was completed, the reaction mixture was acidified with 1N hydrochloric acid solution, extracted with ethyl acetate and washed with water and sodium chloride solution. The organic layer was dried over magnesium sulfate, concentrated under reduced pressure and purified with preparative TLC (n-hexane:ethyl acetate=2:1) to give 65.4 mg (59% from ester) of the title compound as a white solid.

[1279]¹H-NMR (270 MHz, CD₃OD) δ: 7.36 (d, J=15.9 Hz, 1H, C3-H), 7.23 (d, 17.3 Hz, 1H, Ar—H), 7.04 (dd, J=7.9 and 7.2 Hz, 1H, Ar—H), 6.68 (d, J=8.5 hz, 1H, Ar—H), 6.56 (m, 7H, Ar—H), 6.34 (dd, I=8.2 and 2.3 Hz, 1H, thiochroman C6-H), 6.06 (d, J=15.9 Hz, C2-H), 4.13 (d, J=3.3 Hz, 1H, thiochroman C4-H), 3.42 (ddd, J=13.2, 3.6 and 3.3 Hz, 1H, thiochroman C3-H), 3.20 (dd, J=not resolved, 1H, thiochroman C2-H), 2.82 (dd, J=not resolved, 1H, thiochroman C2-H)

EXAMPLE 50

[1280] Synthesis of (3RS,4RS)-4-[9-(4-cyanobutylsulfinyl)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman

[1281] Step 1) Synthesis of (3RS,4RS)-4-[9-(4-cyanobutylthio)nonyl]-7-methoxy-3-(4-methoxyphenyl>3-methylthiochroman

[1282] To a solution of 4-cyanobutyl thioacetate (613 mg, 3.90 mmol) in methanol (10 ml) and was added 1M sodium methoxide (3.06 ml) and stirred at room temperature for 1 h. Then (3RS,4RS)-4-(9-methansulfonyl oxynonyl)-7-methoxy-3-(4-methoxyphenyl)-3-Methylthiochroman (290 mg, 0.557 mmol) dissolved in dry tetrahydrofuran (5 ml) was added dropwise thereto at room temperature and stirred overnight. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution and dried over anhydrous magnesium sulfate. The residue was concentrated under reduced pressure and flash chromatographed on silica gel (n-hexane:ethyl. acetate=8:2) to give 495 mg (165%, contains the 4-cyanobutan-1-thiol) of the title compound as a colorless oil.

[1283]¹H-NMR (270 MHz, CDCl₃) δ: 7.24 (d, J=8.6 Hz, 2H, Ar—H), 6.86 (m, 3H, Ar—H), 6.67 (d, J=2.3 Hz, 1H, C8-H), 6.52 (dd,]=8.2 and 2.3 Hz, 1H, C&H), 3.76 (s, 3H, OCH₃), 3.72 (s. 3H, OCH₃), 3.62 (d, J=12.2 Hz, 1H, C2-H), 2.93 (d, J=12.2 Hz, 1H, C2-H), 2.72 (brt, 1H, C4-H), 2.53-2.30 (m, 6H, 2×SCH₂ and CH₂CN), 1.74-1.65 (m, 6H, alkyl-H), 1.46-1.02 (m, 17H, C3-CH₃ and alkyl-H)

[1284] Step 2) Synthesis of (3RS,4RS)-4-[9-4-cyanobutyjthio)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman

[1285] The title compound was prepared from 4-[9-(4-cyanobutylthio)nonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman according to the same method for the synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman described in International Patent Appln. No. PCT/KR97/00265.

[1286]¹H-NMR (270 MHz, CDCl₃) δ: 7.24 (d, J=8.6 Hz, 2H, Ar—H), 6.85 (in, 3H, Ar—H), 6.66 (d, J=2.3 Hz, 1H, C8-H), 6.50 (dd, J=8.3 and 2.3 Hz, 1H, C6-H), 5.20 (s, 1H, OH), 4.96 (s, 1H, OH), 3.62 (d, J=11.5 Hz, 1H, C2-H), 2.95 (d, J=11.5 Hz, 1H, C2-H), 2.69 (brt, 1H, C4-H), 2.57-2.36 (m, 6H, 2×SCH₂ and CH₂CN), 1.78-1.65 (in, 6H, alkyl-H), 1.52-1.05 (m, 17H, C3-CH₃ and alkyl-H)

[1287] Step 3) Synthesis of (3RS,4RS)-4-[9-(4-cyanobutylsulfinyl)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman

[1288] The title compound was prepared from 4-[9-(4-yanobutylthio)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman according to the same method for the synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl) 3-methyl -4-[9-(4,4,5,5,5-pentafluoropentyl sulfinyl)nonyl]thiochroman described in International Patent Appln. No. PCT/KR97/00265.

[1289]¹H-NMR (270MHz, CD₃OD) δ: 7.17 (m, 2H, Ar—H), 6.74 (m, 3H, Ar—H), 6.48 (brd, 1H, C8-H), 6.35 (brdd, 1H, C&H), 3.53 (d, J=11.2 Hz, 1H, C2-H), 2.88 (d, J=11.2 Hz, 1H, C2-H), 2.75 (m, 5H, C4-H and 2×S(O)CH₂), 2.45 (t, J=6.6 Hz, 2H, CH₂CN), 1.75-1.61 (m, 4H, alkyl-H), 1.31-1.05 (m, 19H, C3-CH, and alkyl-H)

EXAMPLE 51

[1290] Synthesis of (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoro pentylsulfinyl)nonyl]chroman-3-yl}Benzoic Acid

[1291] Step 1) Synthesis of 3-(4-hydroxyphenyl)-7-methoxymethyloxy-3-methylchroman-4-one

[1292] To a solution of 7-hydroxyl-3-(4-hydroxyphenyl}3-methylchroman-4-one (4.65 g, 17.20 mmol) in dry dimethylformamide (120 ml) was added sodium hydride (454 mg, 18.92 mmol) at room tempetarure and stirred for 30 minutes. To the reaction mixture was then added methoxymethyl chloride (1.523 g, 18.92 mmol) at the same temperature and stirred for 2 h. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=8:2 to 7:3) to give 3.55 g (yield: 66%) of the title compound as a white solid.

[1293]¹H-NMR (270 MHz, CDCl₃) δ: 7.87 (d, J=8.9 Hz, 1H, C5-H), 7.24 (d, J=8.9 Hz, 2H, Ar—H), 6.74 (d, J=8.5 Hz, 2H, Ar—H), 6.65 (dd, J=8.2 and 2.3 Hz, 1H, C6-H), 6.53 (d, J=2.3 Hz, 1H, C8-H), 5.84 (s, 1H, OH), 5.16 (s, 2H, OCH ₂OCH₃), 4.78 (d, J=11.8 Hz, C2-H), 4.30 (d, J=11.8 Hz, C2-H), 3.45 (s, 3H, OCH₂OCH₃), 1.44 (s, 3H, C3-CH₃)

[1294] Step 2) Synthesis of 3-(4-benzyloxyphenyl)-7-methoxymethyloxy-3-methyl-chromana-one

[1295] To a mixture of 3-(4-hydroxyphenyl)-7-methoxymethyloxy-3-methylchroman-4-one (3.55 g, 11.293 mmol) and potassium carbonate (9.35 g, 67.76 mmol) in acetone (130 ml) was added benzyl bromide (5.795 g, 33.879 mmol) at room temperature and stirred overnight. When the reaction was completed, water was added to the reaction solution which was then extracted. with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (n-hexane:ethyl acetate=9:1 to 7:3) to give 4.59g (yield: quant.) of the title compound as a colorless oil.

[1296]¹H-NMR (270 MHz CDCl₃) δ: 7.87 (d, J=8.9 Hz. 1H, C5-H), 7.37 (m, 7H, Ar—H), 6.92 (d, J=8.2 Hz, 2H, Ar—H), 6.65 (dd, J=8.2 and 2.3 Hz, 1H, C6-H), 6.53 (d, J=2.3 Hz, 1H, C8-H), 5.16 (s, 2H, OCH₂OCH₃), 5.01 (s, 2H, CH₂-Ph), 4.81 (d, J=11.9 Hz, C2-H), 4.32 (d, J=11.9 Hz, C2-H), 3.45 (s, 3H, OCH₂OCH₃), 1.44 (s, 3H, C3-CH₃)

[1297] Step 3) Synthesis of 3-(4-benzyloxyphenyl-4-[9-(t-butyldimethylsilyloxy)-nonynyl]-7-methoxymethyloxy-3-methylchroman

[1298] The title compound was prepared from 3-(4-benzyloxyphenyl)-7-methoxymethyloxy-3-methylchroman-4-one according to the same method for the synthesis of 4-[9-(t-Butyldimethylsilyloxy)-1-nonynyl]-7-methoxymethyloxy-3-4-methoxymethyloxy-phenyl)-3-methylchroman described in International Patent Appln. No. PCT/KR97/J0,265.

[1299]¹H-NMR (270 MHz, CDCl₃) δ: 7.36-7.19 (m, 8H, Ar—H), 6.85 (d, J=8.5 Hz, 2H, Ar—H), 6.57 (dd, J=8.3 and 2.3 Hz, 1H, C6-H), 6.48 (d, J=2.0 Hz, 1H, C8-H), 5.09 (s, 2H, OCH₂OCH₃), 4.98 (s, 2H, CH₂-Ph), 4.46 (d, J=10.6 Hz, 1H, C2-H), 4.13 (d, J=10.6 Hz,1H, C2-H), 3.78 (brs, 1H, C4-H), 3.55 (t, J=6.6 Hz, 2H, CH₂OTBS), 3.43 (s, 3H, OCH₂OCH₃), 1.97 (m, 2H, propargyl-CH2), 1.53-1.15 (m, 13H, C3-CH₃ and alkyl-H), 0.85 (s, 9H, t-butyl-H), 0.00 (s, 6H, 2×CH₃) step 4) Synthesis of 4-[9-t-butyldimethylsilyloxy)nonyl]-3-(4-hydoxyphenyl)-7-methoxymethyl oxy-3-methylchroman

[1300] The title compound was prepared from 3-(4-benzyloxy]phenyl)-4-[9-t-butyldimethylsi lyloxy)- -nonynyl]-7-methoxymethyloxy-3-methylchroman according to the same method for the synthesis of 4-[9-(t-butyl- dimethylsilyloxy)-1-nonyl]-7-methoxymethyloxy-3*4-methoxymethyloxyphenyl)-3-methylchroman described in International Patent Appln. No. PCT/KR97/00265.

[1301]¹H-NMR (270 MHz, CDtI₃) δ: 7.07 (d, 1=8.6 Hz, 2H,- Ar—H), 6.95 (d, 8.9 Hz, 1H, Ar—H), 6.81 (m, 2H, Ar—H), 6.55 (m, 2H, Ar—H), 5.14 (s, 2H, OCH₂OCH₃), 4.50 (d, J=10.3 Hz, C2-H), 4.24 (d, J=10.6 Hz, C2-H), 3.68 (dd, J=6.6 and 6.3 Hz, 2H, CH₂OH). 3.49 (s, 3H, OCH₂ CH₃), 2.59 (brt, 1H, C4-H), 1.53-1.04 (m, 19H, C3-CH₃ and alkyl-H), 0.89 (s, 9H, t-butyl-H), 0.05 (s, 6H, 2×CH₃)

[1302] Step 5) Synthesis of 4-[9-(t-butyldimethylsilyloxy)nonyl]-7-methoxymethyloxy-3-methyl-3-(4-trifluoromethanesulfonyloxyphenyl)chroman

[1303] To a solution of 4-[9-(t-butyidimethylsilyloxy)nonyl]-3-(4-hydoxyphenyl)-7-methoxymethyloxy-3-(4-hydoxyphenyl)-3-methylchroman (3.38 g, 6.07 mmol) in dry tetrahydrofuran (30 ml) was added sodium hydride (233 mg, 9.712 mmol) at 0° C. and stirred at room temperature for 30 min. After the reaction mixture was cooled to 0° C., N-phenyltrifluoromethansulfonimide (3.469 g, 9.712 mmol) was added potionwise thereto- and: stirred at 50° C. for 30 min. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=8:2) to give 4.50g (yield:>100%, contains small amount of by-products) of the title compound as a pale yellow oil.

[1304]¹H-NMR— (270 MHZ, CDCl₃) δ: 7.24 (m, 4H, Ar—H), 6.92 (m, 1H, Ar—H), 6.55 (m, 2H, Ar—H), 5.11 (s, 2H, OCH ₂OCH₃), 4.49 (d, J=10.3 Hz, 1H, C2-H), 4.22 (d, J=10.6 Hz, 1H, C2-H), 3.54 (dd, J=6.9 and 6.3 Hz, 2H, CH ₂OTBS), 3.53 (s, 3H, OCH₂OCH ₃), 2.68 (brt, 1H, C4-H), 1.39-1.03 (m, 19H, C3-CH₃ and alkyl-H), 0.85 (s, 9H, t-butyl-H), 0.00 (s, 6H, 2×CH₃)

[1305] Step 6) Synthesis of (3′RS,4′RS)-4-{4-[9-(t-butyldimethylsilyloxy)nonyl]-7-methoxymethyloxy-3-methylchroman-3-yl}Benzoic Acid Methyl Ester

[1306] A mixture of 4-[9-(t-butyldimethylsilyloxy)nonyl]7-methoxymethyloxy-3-methyl-3-(4-trifluoromethanesulfonyloxyphenyl)-3-methylchroman (2.80 g, 4.064 mmol), triethylamine (1.13 ml, 8.128 mmol), palladium acetate (320 mg, 1.425 mmol), 1,1-bis(diphenylphosphinoferrocene (850 mg, 1.533 mmol) and methanol (2.7 ml) in dimethyl formamide (8 ml) was purged with carbon monoxide for 5 minutes and stirred under a carbon monoxide ballon at 70° C. for 2.5h. Ethyl acetate and water were added and the ethyl acetate layer was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=95:5) to give 1.61 g (yield: 66%, 3RS,4RS-isomer) of the title compound as a colorless oil.

[1307]¹H-NMR (270 MHz, CDCl₃) δ: 8.03 (d, J=8.3 Hz, 2H, Ar—H), 7.28 (d, J=8.5 Hz, 2H, Ar—H), 6.95 (m, 1H, Ar—H), 6.57 (m, 2H, Ar—H), 5.15 (s, 2H, OCH ₂OCH₃), 4.57 (d, J=10.2 Hz, 1H, C2-H), 4.31 (d, J=10.2 Hz, 1H, C2-H), 3.92 (s, 3H, COOCH₃), 3.56 (t, J=6.6 Hz, 2H, CH ₂OTBS), 3.49 (s, 3H, OCH₂OCH ₃), -2.72 (brt, 1H, C4-H), 1.56-1.07 (m, 19H, C3-CH₃ and alkyl-H), 0.88 (s, 9H, t-butyl-H), 0.03 (s, 6H, 2×CH₃)

[1308] Step 7) Synthesis of (3′RS,4′RS)-4-[4-(9-hydroxynonyl)-7-methoxymethyloxy-3-methylchroman-3-yl]Benzoic Acid Methyl Ester

[1309] The title compound was prepared from (3RS,4RS)-{4-[9-(t-butyl-dimethylsilyloxy)nonyl]-7-methoxymethyloxy-3-methyl-chroman-3-yl}benzoic acid methyl ester according to the same method for the synthesis of 4-(9-hydroxynonyl)-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methyl-chroman described in International Patent Appln. No. PCT/KR97/00265.

[1310]¹H-NMR (270Mz CDCl₃) δ: 8.03 (d, J=8.3 Hz, 2H, Ar—H), 7.29 (d, J=8.6 Hz, 2H, Ar—H), 6.96 (m, 1H, Ar—H), 6.57 (m, 2H, Ar—H), 5.15 (s, 2H, OCH ₂OCH₃), 4.57 (d, J=10.2 Hz, 1H, C2-H), 4.31 (d, J=10.2 Hz, 1H, C2-H), 3.92 (s, 3H, COOCH₃), 3.60 (t, J=6.6 Hz, 2H, CH ₂OH), 3.49 (s, 3H, OCH₂OCH ₃), 2.71 (brt, 1H, C4-H), 1.50-1.06 (m, 19H, C3-CH₃ and alkyl-H)

[1311] Step 8) Synthesis of (3′RS,4′RS)-4-[4-(9-methanesulfonyloxynonyl)-7-methoxy- methyloxy-3-methylchroman-3-yl]Benzoic Acid Methyl Ester

[1312] The title compound was prepared from (3′RS,4RS)-4-[4-(9-hydroxynonyl)-7-methoxymethyloxy-3-methyl-chroman-3-yl]benzoic acid methyl ester according to the same method for the synthesis of. 4-(9-methanesulfonyloxynonyl)-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methyl-chroman described in International Patent Appln. No. PCT/KR97/00265.

[1313]¹H-NMR (270 MHz, CDCl₃) δ: 8.03 (d, J=8.3 Hz, 2H, Ar—H), 7.29 (d, J=8:3 Hz, 2H, Ar—H), 6.95 (m, 1H, Ar—H), 6.57 (m, 2H, Ar—H), 5.15 (s, 2H, OCH ₂OCH₃), 4-57 (d, J=102 Hz, 1H, C2-H), 4.31 (d, J=10.2 Hz, 1H, C2-H), 4.19 (t, J=6.6 Hz, 2H, CH ₂OH), 3.92 (s, 3H, COOCH₃), 3.49 (s, 3H, OCH₂OCH ₃), 2.98 (s, 3H, OSO₂CH₃), 2.98 (brt, 1H, C4-H), 1.72-1.08 (m, 19H, C3-CH₃ and alkyl-H)

[1314] Step 9) Synthesis of (3′RS,4′RS)-4-{7-Methoxymethyloxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylthio)nonyl]chroman-3-yl}Benzoic Acid Methyl Ester

[1315] 4,4,5,5,5-Pentafluoropentyl thioacetate (872 mg, 3.892 mmol) was dissolved in absolute methanol (20 ml) and 1M sodium methoxide (3.9 ml) was added thereto. The reaction solution was stirred for 1 h at room temperature and (3RS,4RS)-4-[4-(9-methanesulfonyloxynonyl)-7-methoxymethyloxy-3-methylchroma n-3-yl]benzoic acid methyl ester (1.46 g, 2.594 mmol) dissolved in dry tetrahydrofuran (15 ml) was added dropwise thereto at room temperature. The reaction mixture was stirred overnight. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=9:1) to. give 1.539 g (yield: 66%) of the title compound as a pale yellow oil.

[1316]¹H-NMR (270 MHz, CDCl₃) δ: 8.03 (d, J=8.3 Hz, 2H, Ar—H), 7.29 (d, J=8.3 Hz, 2H, Ar—H), 6.95 (m, 1H, Ar—H), 6.57 (m, 2H, Ar—H), 5.15 (s, 2H, OCHhd 2OCH₃), 4.56 (d, 10.3 Hz, 1H, C2-H), 4.32 (d, J=10.3 Hz, 1H, C2-H), 3.92 (s, 3H, COOCH₃), 3.49 (s, 3H, OCH₂OCH ₃), 2.76 (brt, 1H, C4-H), 2.57 (dd, J=7.3 and 6.6 Hz, 2H, SCH₂), 2.47 (dd, J=7.3 and 6.6 Hz, 2H, SCH₂), 2.19-1.08 (m, 4H, alkyl-H), 1.60-1.07 (m, 19H, C3-CH₃ and alkyl-H)

[1317] Step 10) Synthesis of (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]chroman-3-yl}Benzoic Acid Methyl Ester

[1318] To a solution of (3′RS,4′RS)-4-{7-methoxymethyloxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]chroman-3-yl}benzoic acid methyl ester (1.539 g, 2.329 mmol) in isopropanol (200 ml) and tetrahydrofuran (40 ml) was added 5N hydrochloric acid solution (75 ml) at room temperature and stirred for 1 d. After adding water, the solution was extracted with ethyl acetate. The organic layer was then washed with water and saturated sodium chloride, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=9:1 to 1:1) to give 1.36g (yield: 95%) of the title compound as a colorless oil.

[1319]¹H-NMR (270 MHz, CDCl₃) δ: 8.03 (d, J=8.3 Hz, 2H, Ar—H), 7.29 (d, J=8.3 Hz, 2H, Ar—H), 6.91 (m, 1H, Ar—H), 6.39 (m, 2H, Ar—H), 5.07 (s, 1H, OH), 4.56 (d, J=10.2 Hz, 1H, C2-H), 4.29 (d, J=10.2 Hz, 1H, C2-H), 3.92 (s, 3H, COOCH₃), 2.76 (brt, 1H, C4-H), 2.57 (dd, J=6.6 and 6.3 Hz, 2H, SCH₂), 2.47 (dd, J=6.6 and 6.3 Hz, 2H, SCH₂), 2.20-1.89 (m, 4H, alkyl-H), 1.60-1.07 (m, 19H, C3-CH₃ and alkyl-H)

[1320] Step 11) Synthesis of (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]chroman-3-yl}Benzoic Acid

[1321] The mixture of (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-4,4,5,5,5-pentafluoro-pentylthio)nonyl]chroman-3-yl)benzoic acid methyl ester (360 mg, 0.583 mmol) and 2N sodium hydroxide (2.25 ml) in methanol (9 ml) and tetrahydrofuran (0.9 ml) was stirred at room temperature for 1 d. When the reaction was completed, water and diethyl ether were added to the reaction solution which was then extracted with diethyl ether. The water layer was acidified with SN hydrochloric acid solution, extracted with ethyl acetate, washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The concentrate was purified with preparative TLC (n-hexane:ethyl acetate=1:1) to give 346 mg (ield: 98%) of the title compound as a white solid.

[1322]¹H-NMR (270 MHz, CDCl₃) δ: 8.11 (d, J=8.5 Hz, 2H, Ar—H), 7.34 (d, J=8.6 Hz, 2H, Ar—H), 6.91 (m, 1H, Ar—H), 6.41 (m, 2H, Ar—H), 4.58 (d, J=10.3 Hz, 1H, C2-H), 4.31 (d, J=10.3 Hz, 1H, C2-H), 2.76 (brt, 1H, C4-H), 2.56 (dd, J=7.3 and 6.9 Hz, 2H, SCH₂), 2.47 (dd, J=7.3 and 6.9 Hz, 2H, SCH₂), 2.24-1.86 (m, 4H, alkyl-H), 1.61-1.08 (m, 19H, C3-CH₃ and alkyl-H)

[1323] Step 12) Synthesis of (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]chroman-3-yl)benzoic Acid

[1324] To a mixture of (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)-nonyl]chroman-3-yl}benzoic acid (346 mg, 0.574 mmol) in tetrahydrofuran (20 ml) and Oxone^(R) (monopersulfate compound; DuPont product) (247 mg, 0.401 mmol) was. added water at the room temperature and stirred for 30 minutes. After adding water, the reaction solution was extracted with ethyl acetate. The extract was concentrated under reduced pressure and purified with preparative TLC with (n-hexane:ethyl acetate=1:1) to give 239 mg (yield: 67%) of the title compound as a white solid.

[1325]¹H-NMR (270 MHz, CDCl₃) δ: 8.07 (d, J=8.6 Hz, 2H, Ar—H), 7.31 (d, J=8.3 Hz, 2H, Ar—H), 6.89 (d, J=7.9 Hz, 1H, Ar—H),6.62 (brs, 1H, COOH), 6.42 (m, 2H, Ar—H), 4.55 (d, J=10.3 Hz, 1H, C2-H), 4.28 (d, J=10.3 Hz, 1H, C2-H),: 2.92-2.59 (m, 5H, C4-H, and 2×S(O)CH₂), 2.18 (m, 4H, alk-yl-H), 1.72 (m, 2H, alkyl-H), 1.30-0.98 (m, 17H, C3-CH₃ and alkyl-H)

EXAMPLE 52

[1326] Synthesis f (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-4,4,5,5-pentafuoro pentylsulfinyl)nonyl]chroman-3yl}benzyl alcohol

[1327] Step 1) Synthesis of (3′RS,4′RS)-4-(7-hydroxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylthio)nonyl]chroman-3-yl}Benzyl Alcohol

[1328] To a solution of (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]chroman-3-yl}benzoic acid methyl ester (58 mg, 0.094 mmol) in dry tetrahydrofuran (3 ml) was added lithium aluminum hydride (10.7 mg, 0.282 mmol) at room temperature and stirred for 3 h. When the reaction was completed, ammonium chloride solution was added to the reaction solution which was then extracted with ethyl acetate. The extract was washed with water, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=1:1) to give 52 mg (yield: 94%) of the title compound as a colorless oil.

[1329]¹H-NMR (270 MHz, CDCl₃) δ: 7.42 (d, J=8.0 Hz, 2H, Ar—H), 7.30 (d, J=9.2 Hz, 2H, Ar—H), 6.97 (d, 3=7.9 Hz, 1H, Ar—H), 6.43 (m, 2H, Ar—H), 5.25 (s, 1H, OH), 4.76 (s, 2H, Ph—CHhd 2OH), 4.61 (d, J=10.6 Hz, 1H, C2-H), 4.34 (d, J=10.6 Hz, 1H, C2-H), 2.77, (brt, 1H, C4-H), 2.63 (dd, J=7.3 and 6.9 Hz, 2H, SCH₂), 2.53 (dd, J=7.3 and 6.9 Hz, 2H, SCH₂), 2.18 (m, 2H, alkyl-H), 1.93 (m, 2H, alkyl-H), 1.56 (m, 2H, alkyl-H), 1.40-0.91 (m, 17H, C3-CH₃ and alkyl-H)

[1330] Step 2)- Synthesis of (3′RS,4′RS)-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]chroman-3-yl}Benzyl Alcohol

[1331] The title compound was prepared from (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]chroman-3-yl}benzyl alcohol according to the same method for the synthesis of (3′RS,4′RS)-1f-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]chroman-3-yl}benzoic acid

[1332]¹H-NMR (270 MHz, CDCl₃) δ 7.35 (d, J=8.2 Hz, 2H, Ar—H), 7.19 (d, J=8.3 Hz, 2H, Ar—H), 6.95 (m, 1H, Ar—H), 6.86 (d, J=8.9 Hz, 1H, Ar—H), 6.38 (m, 2H, Ar—H), 4.68 (s, 2H, Ph—CH ₂OH), 4.54 (d, J=10.6 Hz, 1H, C2-H), 4.26 (d, J=10.6 Hz, 1H, C2-H), 2.81-2.55 (m, 5H, C4-H, and 2×S(O)CH₂), 2.16 (m, 4H, alkyl-H), 1.70 (m, 2H, alkyl-H), 1.36-1.07 (m, 1711, C3-CH₃ and alkyl-H)

EXAMPLE 53

[1333] Synthesis of (A) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[4-(4,4,5,5,5-pentatfluor opentylsulfinyl)propylphenoxy]-1-propyl}Chroman and (B) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[4-(4,4,5,5,5-pentafluor opentylsulfonyl)propylphenoxy]-1-propyl}Chroman

[1334] Step 1) Synthesis of 4-{3-[4-(3-t-butyldimethylsilyloxypropyl)phenoxy]-1-propynyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman-4-ol

[1335] The title compound was prepared from 7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman-4-one and 3-[4-(3-t-butyldimethylsilyloxypropyl)phenoxy]-1-propyn according to the same method for the synthesis of 4-[9-(t-butyldimethylsilyloxy)1-nonynyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman.

[1336]¹H-NMR (270 MHz, CDCl₃): d 7.55 (d, J=8.6 Hz, 1H, C5-H), 7.31 (d, J=8.9 Hz, 2H, Ar—H), 7.14 (d, J=8.6 Hz, 2H, Ar—H), 6.92 (2×d, J=8.6 and 8.5 Hz, 4H, Ar—H), 6.63 (dd, J=8.6 and 2.3 Hz, 1H, C6-H), 6.57 (d, J=2.3 Hz, 1H, C8-H), 5.16 (s, 2H, OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 4.85 (d, J=10.2 Hz, 1H, C2-H), 4.77 (s, 2H, C3-CH₂), 4.02 (d, J=10.2 Hz, 1H, C2-H), 3-62 (t, J=6.3 Hz, 2H, CH₂—OTBS), 3.49 (s, 3H, OCH₂OCH ₃), 3.47 (s, 3H, OCH₂OCH ₃), 2.64 (dd. J=8.0 and 7.5 Hz, PhCH ₂CH₂CH₂—OTBS), 2.13 (s, 1H, OH), 1.81 (m, 2H, PhCH ₂CH₂CH₂—OTBS), 1.43 (s, 3H1, C3-CH₃), 0.90 (s, 9H, t-butyl-H), 0.04 (s, 6H, 2×CH₃)

[1337] Step 2) Synthesis of 4-{3-[4-(3-t-butyldimethylsilyloxypropyl)phenoxy]-1-propynyl}-7-methoxymethyl oxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman

[1338] The title compound was prepared from 4-{3-[4-(3-t-butyldimethylsilyloxypropyl)phenoxy]-1-propynyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman-4-ol according to the same method for the synthesis of 4-[9-t-butyldimethylsilyloxy)-1-nonynyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman described in International Patent Appln. No. PCT/KR 97/00265.

[1339]¹H-NMR (270 MHz, CDCl₃) δ: 7.28 (m, 3H, Ar—H), 7.04 (d, J=8.2 Hz, 2H, Ar—H), δ 90 (d, i=8.7 Hz, 21H, Ar—H), 6.72 (d, J=8.6 Hz, 2H, Ar—H), 6.60 (dd, J=8 6 and 2.3 Hz, 1H, C6-H), 6.52 (d, J=2.3 Hz, 1H, C8-H), 5.14 (s, 2H, OCH ₂OCH₃), 5.13 (s, 2H, OCH ₂OCH₃), 4.52 (s, 2H, C3-CH₂), 4.44 (d, J=10.2 Hz, 1H, C2-H), 4.14 (d, J=10.2 Hz, 1H, C2-H), 3.88 (s, 1H, C4H), 3.63 (t, J=6.3 Hz, 2H, CHROTBS), 3.47 (s, 6H, 2×OCH₂OCH ₃), 2.61 (dd, J=7.9 and 7.3 Hz, PhCH ₂CH₂—OTBS), 1.80 (m, 2H, PhCH₂ CH ₂CH₂—OTBs), 1.36 (s, 3H, C3-CH₃), 0.91 (s, 9H, t-butyl-H), 0.06 (s, 6H, 2×CH₃)

[1340] Step 3) Synthesis of (3RS,4RS)4-{3-[4-3-t-butyldimethylsilyloxypropyl)phenoxy]-1-propyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman

[1341] The title compound was prepared from 4-{3-[4-3-t-butyldimethylsilyloxypropyl)phenoxy]-1-propynyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman according to the same method for the synthesis of 4-[9-t-butyldimethylsilyloxy)-1-nonyl]-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman described in International Patent Appln. No. PCT/KR97/00265.

[1342]¹H-NMR (270 MHz, CDCl₃) δ: 7.28-6.94 (m, 7H, Ar—H), 6.68 (d, J=8.2 Hz, 2H, Ar—H), 6.55 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 4.55 (d, J=10.4 Hz, 1H, C2-H), 4.28 (d, J=10.2 Hz, 1H, C2-H), 3.71 (dd, J=6.9 and 6.3 Hz, 2H, C3-CH₂), 3.60 (t, J=6.3 Hz, 2H, OCH ₂—OTBS), 3.49 (s, 6H, 2×OCH₂OCH ₃), 2.78 (brt, 1H, C4-H), 2.58 (dd, J=8.5 and 7.3 Hz, PhCH ₂CH₂CH₂—OTBS), 1.76 (m, 2H, C2-CH₂ and PhCH₂ CH ₂CH₂—OTBS), 1.44 (m, 2H, C₁-CH₂), 1.27 (s, 3H, C3-CH₃), 0.91 (s, 9H, t-butyl-H), 0.06 (s, 6H, 2×CH₃)

[1343] Step 4) Synthesis of 4-{3-[4-3-hydroxypropyl)phenoxy]-1-propyl}-7-methoxymethyloxy-3-4methoxymethyloxyphenyl)-3-methylchroman

[1344] The title compound was prepared from (3RS,4RS)-4-{3-[4-(3-t-butyl-dimethylsilyloxypropyl)phenoxy]-1-propyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman according to the same method for the synthesis of 4-[9-hydroxy-1-nonyl]-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman described in International Patent Appln. No. PCT/KR97/00265.

[1345]¹H-NMR (270Mz CDCl₃) δ: 7.04 (m, 5H, Ar—H), 6.74 (d, J=8.6 Hz, 2H, Ar—H), 6.67 (d, J=8.6 Hz, 2H, Ar—H), 6.54 (m, 2H, Ar—H), 5.18 (s, 2H, 2×OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 4-54 (d, J=10.5 Hz, 1H, C2-H), 4.28 (d, J=10.5 Hz, 1H, C2-H), 3.69 (m, 4H, C3-CH₂ and CH₂OH), 3.49 (s, 6H, OCH₂OCH ₃), 2.72 (brt, 1H, C4-H), 2.62 (m, 2H, PhCH ₂CH₂CH₂—OTBS), 1.80 (m, 6H, alkyl-H), 1.26 (s, 3H, C3-CH₃)

[1346] Step 5) Synthesis of (3RS,4RS)-4-{3-[4-(3-methanesulfonyloxypropyl) phenoxy]-1-propyl}-7-methoxymethyloxy-34-methoxymethyloxyphenyl)-3-methylc Hroman

[1347] The title compound was prepared from (3RS,4RS8)-4-{3-[4-(3-hydroxypropyl)phenoxy]-1-propyl}-7-methoxymethyloxy-3-(4-methoxymethyloxy phenyl)-3-methylchroman according to the same method for the synthesis of 4-9-methanesulfonyloxynonyl)-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman described in International Patent Appln. No. PCT/KR97/00265.

[1348]¹H-NMR (270 MHz, CDCl₃) δ: 7.28-6.93 (m, 7H, Ar—H), 6.68 (d, J=8.6 Hz, 2H, Ar—H), 6.55 (m, 2H, Ar—H), 5.17 (s, 2H, OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 4.54 (d, 3=10.5 Hz, 1H, C2-H), 4.28 (d, J=10.5 Hz, 1H, C2-H), 4.19 (m, 2H, CH ₂OSO₂CH₃), 3.70 (dd, J=6.9 and 6.3 Hz, 2H, C3-CH₂), 3.49 (s, 6H, 2×OCH₂OCH ₃), 2.98 (s, 3H, OSO₂CH₃), 2.71 (brt, 1H, C4-H), 2.66 (dd, J=7.6 and 6.9 Hz, PhCH ₂CH₂CH₂O), 1.99 (m, 4H, PhCH₂ CH ₂CH₂O and C2-CH₂), 1.73 (m, 2H, C1-CH₂), 1.26 (s, 3H, C3-CH₃)

[1349] Step 6) Synthesis of (3RS,4RS)-7-methoxymethyloxy-3-(4-methoxymethyl oxyphenyl)-3-methyl-4-{3-[4-4,4,5,5,5-pentafluoropentylthio)propylphenoxy]-1-prop yl}Chroman

[1350] The title compound was prepared from (3RS,4RS)-4-{3-[4-(3-methanesulfonyloxypropyl)phenoxy]-1-propyl}-7-methoxymet hyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman according to the same method for. the synthesis of (3RS,4RS)-7-methoxy-3-(4-methoxy phenyl)-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman described in International Patent Appln. No. PCT/KR97/00265.

[1351]¹H-NMR (270 MHz, CDCl₃) δ: 7.28-6.94 (m, 71H, Ar—H), 6.68 (d, J=8.6 Hz, 2H, Ar—H), 6.54 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 4.54 (d, J=10.6 Hz, 1H, C2-H), 4.28 (d, J=10.6 Hz, 1H, C2-H), 3.72 (d, J=7.3 and 6.6 Hz, 21H, C3-CH₂), 3.49 (s, 6H, 2×OCH₂OCH ₃), 2.72 (brt, 1H, C4-H), 2.55 (m, 6H, PhCH ₂CH₂CH₂S and 2×S—CH₂), 2.18 (m, 2H, alkyl-H), 1.85 (m, 6H, PhCH ₂CH₂CH₂S, C2-CH₂, and alkyl-1H), 1.27 (m, 51H, C3-CH and alkyl-H) step 7) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[4-(4,4,5,5,5-pentafluoropentylthio)propylphenoxy]-1-propyl}Chroman

[1352] The title compound was prepared from (3RS,4RS)-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methyl-4-{3-[4-4,4,5,5,5-pentafluoropentylthio)propylphenoxy]-1-propyl}chroman according to the same method for the synthesis of (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]chroman-3-yl}benzoic acid methyl ester.

[1353]¹H-NMR (270Mk, CDCl₃) δ: 7.05 (m, 4H, Ar—H), 6.93 (d, J=8.9 Hz, 1H, C5-H), 6.80 (d, J=8.5 Hz, 2H, Ar—H), 6.67 (d, J=8.5 Hz, 2H, Ar—H), 6.37 (m, 2H, Ar—H), 4.79 (s, 1H, OH), 4.73 (s, 1H, OH), 4.52 (d, J=10.3 Hz, 1H, C2-H), 4.25 (d, J=10.3 Hz, 1H, C2-H), 3.71 (d, J=6.6 and 6.3 Hz, 2H, C3-CH₂), 2.69 (brt, 1H, C4-H), 2.54 (m, 6H, PhCH ₂CH₂CH₂S and 2×S—CH₂), 2.30 (m, 2H, alkyl-H), 1.90-1.55 (m, 6H, PhCH₂CH₂ CH ₂—OTBS, C2-CH₂, and alkyl-H), 1.39-1.07 (m, 5H, C3-CH₃ and alkyl-H)

[1354] Step 8) Synthesis of (A) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[4-(4,4,5,5,5-pentafluoropentylsulfinyl)propylphenoxy]-1-propyl}Chroman and (B) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[4-414,5,5,5-penta fluoropentylsulfonyl)propylphenoxy]-1-propyl}Chroman

[1355] To a mixture of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[4-(4,4,5,5,5-pentafluoropentylthio)propylphenoxy-3-1-propyl}chroman (256 mg, 0.41 mmol) in tetrahydrofuran (20 ml) and Oxone^(R) (monopersulfate. compound; DuPont product) (251 mg, 0.41 mmol) was added water (1 ml) at room temperature and stirred for 30 minutes. After adding water, the reaction solution was extracted with ethyl acetate. The extract was concentrated under reduced pressure and purified with preparative TLC (n-hexane:ethyl acetate=1:1) to give 167 mg (yield:. 63.6%) of the title compound (A) and 92 mg (yield: 34%) of the title compound (B).

[1356]¹H-NMR (270 MHz, CDCl₃ A) δ: 7.02 (d, J=8.3 Hz, 4H, Ar—H), 6.87 (d, J=8.6 Hz, 1H, C5-H), 6.73 (d, J=8.6 Hz, 2H, Ar—H), 6.64 (d, J=8.4 Hz, 2H, Ar—H), 6.37 (m, 2H, Ar—H), 5.66 (s, 1H, OH), 5.63 (s, 1H, OH), 4.50 (d, J=10.6 Hz, 1H, C2-H), 4.23 (d, J=10.6 Hz, 1H, C2-H), 3.79 (m, C3-CH₂), 2.69 (m, 7H, C4-H, PhCCH ₂CH₂S(O) and -2×S(O)CH₂), 2.09 (m, 4H, alkyl-H), 1.62 (m, 2H, alkyl-H), 1.26 (m, 7H, C3-CH₃ and alkyl-H)

[1357]¹H-NMR (270 MHz, CDCl₃ B) δ: 7.04 (m, 4H, Ar—H), 6.91 (d, J=8.9 Hz, 1H, C5-H), 6.77 (d, J=8.5 Hz, 2H, Ar—H), 6.67 (d, J=8.3 Hz, 2H, Ar—H), 6.36 (m, 2H, Ar—H), 5.12 (s, 1H, OH), 4.94 (s, 1H, OH), 4.52 (d, J=10.5 Hz, 1H, C2-H), 4.25 (d, J=10.5 Hz, 1H, C2-H), 3.31 (m, C3-CH₂), 2.97 (m, 2×SO₂CH₂), 2.70 (m. 3H, C4-H and PhCHhd 2CH₂CH₂SO₂), 2.28-2.08 (m, 4H, alkyl-H), 1.69 (m, 2H, alkyl-H), 1.28-1.16 (7H, C3-CH₃ and alkyl-H)

EXAMPLE 54

[1358] Synthesis of (A) (3RS,4RS)-7-hydroxy-3-(4hydroxyphenyl)-3 methyl-4-{4-[4-(4,4,5,5-pentafluoropentylsulfonylethyloxy)phenyl]-1-butyl}Chro man and (B) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[4-(4,4,5,5,5-pentafluoropentylsulfonylethyloxy)phenyl]-1butyl}chroman

[1359] Step 1) Synthesis of 4-{4-[4-(t-butoxycarbonylmethyloxy)phenyl]-1-butyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman

[1360] To a solution of 4-[4-4-hydroxyphenyl)-1-butyl]-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman (481 mg, 0.976 mmol) in dry tetrahydrofuran (8 ml) was added sodium hydride (22.7 mg, 1.418 mmol) at room temperature and stirred for 20 minutes. Bromoacetic acid tert-butylester (276.7 mg, 1.418 mmol) was added thereto at the same temperature and stirred for 20 minutes. After the reaction was completed, water was added to the reaction solution, and the resulting solution was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to give 589 mg (yield: quant.) of the title compound as a colorless oil. The resulting compound was used in the next reaction without purification.

[1361]¹H-NMR (270 MHz, CDCl₃) δ: 7.24 (d, J=8.3 Hz, 2H, Ar—H), 7.00 (m, 5H, Ar—H), 6.75 (d, J=8.3 Hz, 2H, Ar—H), 6.56 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 4.56 (d, J=10.5 Hz, 1H, C2-H), 4.42 (s, 2H, Ph—OCH₂CO), 4.25 (d, J=10.5 Hz, 1H, C2-H), 3.48 (s, 6H, 2×OCH₂OCH ₃), 2.65 (brt, 1H, C4-H), 2:35 (brt, J=not resolved, 2H, C4-CH₂), 1.48-1.08 (16H, C3-CH₃ alkyl-H and t-butyl-H)

[1362] Step 2) Synthesis of 4-{4-[4-(hydroxyethyloxy)phenyl]-1-butyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman

[1363] To a solution of 4-{4-[4-(t-butoxycarbonylmethyloxy)phenyl]-1-butyl)-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman (744 mg, 1.226 mmol) in dry tetrahydrofuran (10mi) was added lithium aluminum hydride (71.8 mg, 1.89 mmol) at 0° C. and stirred for 4 h at the room temperature. When the reaction was completed, 17% sodium hydroxide solution was added to the reaction solution until the white precipitate appeared, and then added ethyl acetate to the reaction mixture. The resulting mixture was filtered over celite and washed several times with ethyl acetate. The filtrate was concentrated under reduced pressure to give the title compound (658 mg, yield: quant.) as a colorless oil. The resulting compound was used in the next reaction without purification.

[1364]¹H-NMR (270 MHz, CDCl₃) δ: 7.12 (d, J=8.5 Hz, 2H, Ar—H), 6.94 (m, 5H, Ar—H), 6.79 (d, J=8.5 Hz, 2H, Ar—H), 6.52 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 4.52 (d, J=10.2 Hz, 1H, C2-H), 4.24 (d, J=10.5 Hz, 1H, C2-H), 4.05 (m, 2H, Ph—OCH ₂CH₂OH), 3.92 (m, 2H, Ph—OCH₂ CH ₂OH), 3.49 (s, 6H, 2×OCH₂OCH ₃), 2.63 (brt, 1H, C4-H), 2.36 (brt, J=not resolved, 2H, C4-CH₂), 1.58-1.07 (m, 9H, C3-CH— and alkyl-H)

[1365] Step 3) Synthesis of 4-{4-[4-(methanesulfonyloxyethyloxy)phenyl]-1-butyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman

[1366] The title compound was prepared from 4-{4-[4-(hydroxyethyloxy)phenyl]-1-butyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchro man according to the same method for the synthesis of 4-(9-methanesulfonyl oxynonyl)-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman described in International Patent Appln. No. PCT/KR97J00265.

[1367]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (d, J=8.9 Hz, 2H, Ar—H), 6.95 (m, 5H, Ar—H), 6.77 (d, J=8.6 Hz, 2H, Ar—H), 6.52 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 4.53 (m, 3H, C2-H and Ph—OCH₂ CH ₂OSO₂CH₃), 4.22 (m, 3H, C2-H and Ph—OCH ₂CH₂OSO₂CH₃), 3.48 (s, 6H, 2×OCH₂OCH ₃), 3.08 (s, 3H, OSO₂CH₃), 2.69 (brt, 1H, C4-H), 2.36 (brt, J=not resolved, 2H, C4CH₂), 1.51-1.08 (m, 9H, C3-CH₃ and alkyl-H)

[1368] Step 4) Synthesis of 7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methyl-4-{4-[4-4,4,5,5,5-pentafluoropentylthioethyloxy)phenyl]-1-butyl}Chroman

[1369] The title compound was prepared from 4-{4-[4-(methanesulfonytoxyethyloxy)-phenyl]-1-butyl}-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman according to the same method for the synthesis of 7-methoxy-3-(4-methoxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]thiochroman described in International Patent Appln. No. PCT/KR97/00265.

[1370]¹H-NMR (270 MHz, CDCl₃) d. 7.13 (d, J=8.6 Hz, 2H, Ar—H), 6.95 (m, 5H, Ar—H), 6.76 (d, J=8.6 Hz, 2H, Ar—H), 6.53 (m, 2H, Ar—H), 5.18 (s, 2H, OCH ₂OCH₃), 5.15 (s, 2H, OCH ₂OCH₃), 4.52 (d, J=10.6 Hz, 1H, C2-H), 4.25 (d, J=10.6 Hz, 1H, C2-H), 4.11 (dd, J=6.6 and 6.2 Hz, 2H, Ph—OCH ₂CH₂S), 3.49 (s, 6H, 2×OCH₂OCH ₃), 2.98 (dd, J=6.9 and 6.2 Hz, 2H, SCH₂), 2.71 (dd, J=6.9 and 6.0 Hz, 2H, SCH₂), 2.66 (brt, 1H, C4-H), 2.35 (dd, J=6.9 and 6.3 Hz, 2H, C4-CH₂), 2.15 (m, 2H, alkyl-H), 1.95 (m, 2H, alkyl-H), 1-56-1.09 (m, 9H, C3-CH₃ and alkyl-H),

[1371] Step 5) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{[4-[4-(4,4,5,5,5-pentafluoropentylthioethyloxy)phenyl]-1-butyl}Chroman

[1372] The title compound was prepared from 7-methoxymethyloxy-3-(4-methoxymethyl-oxyphenyl)-3-methyl-4-{4-[4-(4,4,5,5,5-pentafluoropentylthioethyloxy)phenyl]-1-butyl)chroman according to the same method for the synthesis of 7-hydoxy-3-(4-hydoxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-thiochroman described in International Patent Appln. No. PCT/KR97/00265.

[1373]¹H-NMR (270 MHz, CDCl₃) δ: 7.05 (d, J=8.6 Hz, 2H, Ar—H), 6.94 (d, J=8.5 Hz, 2H, Ar—H), 6.78 (m, 5H, Ar—H), 6.33 (m, 2H, Ar—H), 4.86 (s; 1H, OH), 4.83 (s, 1H, OH), 4.50 (d, J=10.2 Hz, 1H, C2-H), 4.22 (d, J=10.2 Hz, 1H, C2-H), 4.15 (m, 2H, Ph—OCH ₂CH₂S), 2.89 (t, J=6.6 Hz, 2H, SCH₂), 2.72 (t, J=6.9 Hz, 2H, SCH₂), 2.61 (brt, 1H, C4-H), 2.36 (m, C4-CH₂), 2.14 (m, 2H, alkyl-H), 1.94 (m, 2H, alkyl-H), 1.54-1.07 (m, 9H, C3-CH3 and alkyl-H)

[1374] Step 6) Synthesis Of (A) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[4-4,4,5,5,5-pentafluoropentylsulfinylethyloxy)phenyl]-1-butyl}Chroman and (B) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(4-[4-4,4,5,5,5-pentafluoropentylsulfonylethyloxy)phenyl]-1-butyl}Chroman

[1375] The title compounds were prepared from (3RS,4RS) 7-hydroxy-3-4-hydroxyphenyl)-3-methyl-4-{4-[4-4,4,5,5,5-pentafluoropentylthioethyloxy)phenyl]-1-butyl)chroman according to the same methods for the synthesis of (A) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-1 {3-[4-(4,4,5,5,5-pentafluoro pentyl sulfinyl)propyl-phenoxy]-1-propyl}chroman and (B) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[4-4,4,5,5,5-pentafluoropentylsulfonyl)propylphen oxy]-1-propyl}chroman.

[1376]¹H-NMR (270 MHz, CD₃OD, A) δ: 6.69 (d, J=8.2 Hz, 2H, Ar—H), 6.85 (d, J=8.3 Hz, 2H, Ar—H), 6.69 (m, 5H, Ar—H), 6.14 (m, 2H, Ar—H), 4.42 (d, J=10.5 Hz, 1H, C2-H), 4.28 (m, 2H, Ph—OCH ₂CH₂S), 4.11 (d, J=10.5 Hz, 1H, C2-H), 3.23 (m, 2H, S(O)CH₂), 2.91 (m, 2H, S(O)CH₂), 2.51 (brt, 1H, C4-H), 2.26 (m, 4H, alkyl-H), 2.05 (m, 2H, alkyl-H), 1.23-0.92 (m, 9H, C3-CH₃ and alkyl-H)

[1377]¹H-NMR (270 MHz, CDCl₃, B) δ: 7.03 (d, J=8.6 Hz, 2H, Ar—H), 6.96 (d, J=8.6 Hz, 2H, Ar—H), 6.77 (m, 4H, Ar—H), 6.63 (d, J=8.3 Hz, 1H, C5-H), 6.34 (d, J=2.3 Hz, 1H, C8-H), 6.23 (dd, J=7.7 and 2.3 Hz, 1H, C6-H), 5.36 (s, 1H, OH), 5.21 (s, 1H, OH), 4.49 (d, J=10.6 Hz, 1H, C2-H), 4.41 (dd, J=5.3 and 4.9 Hz, 2H, Ph—OCH ₂CH₂S), 4.21 (d, J=10.6 Hz, 1H, C2-H), 3.45 (dd, J=5.3 and 4.9 Hz, 2H, SO₂CH₂), 3.26 (t, J=7.2 Hz, 2H, SO₂CH₂), 2.59 (brt, 1H, C4-H), 2-43-2.20 (m, 6H, alkyl-H), 1.42-1.09 (m, 9H, C3-CH₃ and alkyl-H)

EXAMPLE 55

[1378] Synthesis of (3′RS,4′RS)-1-[7-hydroxy-4-(4-hydroxyphenyl)-3-methyl chroman-4-yl]-14,14,15,15,15-pentafluoropentadecan-1-en-9-one

[1379] Step 1) Synthesis of 13,13,14,14,14-pentafluorotetradec-1-en-9-one

[1380] To a mixture of magnesium turnings (613.5 mg, 25.25 mmol) in dry diethyl ether (30 ml) was added 8-bromo-1-octene (4-236 ml, 25.25 mmol) and stirred at room temperature for 1 h until magnesium was dissolved. Then to the Grignard solution was added dry benzene (₁₅ ml) and followed 5,5,6,6,6-pentafluorohaxanenitrile (1.89 g, 10.10 mmol) dissolved in dry diethyl ether (15 ml) was added dropwise at room temperature. After the reaction mixture was stirred for 1 h, 1N hydrochloric acid solution (27 ml) was added and stirred for 1 hour additionally. Then to the reaction solution was added water, which was extracted with ethyl acetate. The organic layer was washed with water and saturated sodium chloride solution, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=9:1) to give 1.892g (yield: 62%) of the title compound as a colorless oil.

[1381]¹H-NMR (270 MHz, CDCl₃) δ: 5.83-5.71 (m, 1H, CH₂═CH), 4.96 (d, J=17 Hz, 1H, CH ₂═CH), 4.92 (d, J=11 Hz, 1H, CH ₂═CH), 2.51 (t, J=7 Hz, 2H, COCH ₂), 2.39 (t, J=7 Hz, 2H, COCH₂), 2.03-1.83 (m, 6H, CH₂═CHCH ₂ and CF₂CH₂CH₂), 1.56 (m, 2H, COCH₂CH ₂), 1.29 (m, 6H, CH₂CH₂CH₂).

[1382] Step 2) Synthesis of (3′RS,4′RS}-1-[7-methoxymethyloxy-4-(4-methoxymethyloxyphenyl)-3-methylchroman-4-yl]-14,14,15,15,15-pentafluoropentadec-2-en-10-one

[1383] To a solution of (3RS,4RS)-4-allyl-7-methoxymethyloxy-3-(4-methoxymethyloxyphenyl)-3-methylchroman (300 mg, 0.780 mmol) and 13,13,14,14,14-pentafluorotetradec-1-en-9-one (512 mg, 1.706 mmol) in dry methylene chloride (4 ml) was added benzylidenebis(tricyclohexylphosphine)dichlororuthenium (32 mg, 0.039 mmol) dissolved in dry methylene chloride (2.5 ml) and stirred at 45C for 135 minutes. When the reaction was completed, the reaction solution was concentrated under reduced pressure and the residue was purified with column chromatography (n-hexane:ethyl acetate=9:1) to give 402 mg (yield: 78%) of the title compound as a colorless oil.

[1384]¹H-NMR (270 MHz, CDCl₃) δ: 7.15 (d, J=9 Hz, 2H, Ar—H), 7.03 (d, J=9 Hz, 2H, Ar—H), 6.93 (d, J=8 Hz, 1H, Ar—H), 6.55 (m, 2H, Ar—H), 5.25-5.00 (m, 2H, CH═CH), 5.18 (s, 3H, OCH ₂OCH₃), 5.15 (s, 3H, OCH ₂OCH₃), 4.51 (d, J=11 Hz, 1H, C2-H), 4.25 (d, J=11 Hz, 1H, C2-H), 3.50 (s, 3H, OCH₂OCH ₃), 3.49 (s, 3H, OCH ₂OH₃), 2.72 (brt, 1H, C4-H), 2.51 (t, J=7 Hz, COCH₂), 2.39 (t, J=7 Hz, COCH₂), 2.15-1.68 (m, 6H, CH ₂CH═CH₂ and CF₂CH₂CH₂), 1.60-1.10 (m, 13H, alkyl-H).

[1385] Step 3) Synthesis of (3′RS,4′RS)-1-[7-methoxymethyloxy-4-(4-methoxymethyloxyphenyl)-3-methylchroman-4-yl]-14,14,15,15,15-pentafluoropentadecan-10-one

[1386] To a solution of (3′RS,4′RS)-1-[7-methoxymethyloxy-4-(4-methoxy methyloxyphenyl)-3-methylchroman-4-yl]-14,14,15,15,15-pentafluoropentadec-2-en-10-one (402 mg, 0.612 mmol) in ethyl acetate (20 ml) and tetrahydrofuran (1 ml) was added 10% Pd-C (30 mg) and stirred at room temperature overnignt under hydrogen gas (normal pressure). Ethyl acetate was added to the reaction solution which was then filtered over celite and washed several times with ethyl acetate. The organic solution was concentrated under reduced pressure to give the title compound (405 mg, yield:>100%) as colorless oil. The resulting compound was used in the next reaction without purification

[1387]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (d, J=8 Hz, 2H, Ar—H), 7.02 (d, J=8 Hz, 2H, Ar—H), 6.94 (d, J=9 Hz, 1H, Ar—H), 6.56 (m, 2H, Ar—H), 5.18 (s, 3H, OCH ₂OCH₃), 5.15 (s, 3H, OCH ₂OCH₃), 4.52 (d, J=10 Hz, 1H, C2-H), 4.25 (d, J=10 Hz, 1H, C2-H), 3.50 (s, 3H, OCH₂OCH ₃), 3.49 (s, 3H, OCH₂OCH ₃), 2.64 (m, 1H, C4-H), 2.50 (t, J=7 Hz, COCH₂), 2.37 (t, J=7 Hz, COCH₂), 2.12-1.80 (m, 4H, CF₂CH₂CH₂), 1.60-0.95 (m, 19H, alkyl-H).

[1388] Step 4) Synthesis of (3′RS,4′RS)-1-[7-hydroxy-4-(4-hydroxyphenyl)-3-methylchroman-4-yl]-14,14,15,15,15-pentafluoropentadecan-10-one

[1389] To a solution of (3′RS,4′RS)-1-[7-methoxymethyloxy-4-(4-methoxymethyloxyphenyl)-3-methylchroman-4-yl]-14,14,15,15,15-pentafluoropentadecan-10-one (405 mg, 0.615 mmol) in methanol (14 ml) and tetrahydrofuran (5 ml) was added saturated hydrochloric acid in methanol (14 ml) at room temperature and stirred for 2 h. After adding water, the solution was extracted with ethyl acetate. The organic layer was then washed with water and saturated sodium chloride solution, dried over magnesium sulfate and concentrated under reduced pressure. The residue was flash chromatographed on silica gel (n-hexane:ethyl acetate=7:3) to give 345 mg (yield: 98.8%) of the title compound as a colorless oil.

[1390]¹H-NMR (270 MHz, CDCl₃) δ: 7.07 (d, J=8 Hz, 2H, Ar—H), 6.90 (d, J=8 Hz, 2H, Ar—H), 6.84 (d, J=8 Hz, 1H, Ar—H), 6.38 (m, 2H, Ar—H), 5.80 (s, 1H, Ar—OH), 5.06 (s, 1H, Ar—OH), 4.50 (d, J=11 Hz, 1H, C2-H), 4.23 (d, J=11 Hz, 1H, C2-H), 2.60 (m, 1H, C4-H), 2.55 (t, J=7 Hz, COCH₂), 2.42 (t, J=7 Hz, COCH₂), 2.12-1.80 (m, 4H, CF₂CH₂CH₂), 1.50 (q, J=7 Hz, 2H, alkyl-H), 1.30-0.95 (m, 17H, alkyl-H)

[1391] Step 5) Synthesis of (3′RS,4′RS)-1-[7-hydroxy-4-(4hydroxyphenyl)-3-methylchroman-4-yl]-14,14,15,15,15-pentafluoropentadecan-10-ol

[1392] To a solution of (3′RS,4′RS)-1-[7-hydroxy-4-4-hydroxyphenyl)-3-methylchroman-4-yl]-14,14,15,15,15-pentafluoropentadecan-10-one (1 90 mg, 0.333 mmol) in dry tetrahydrofuran (10 ml) was added lithium aluminum hydride (12.6 mg, 0.333 mmol) at 0° C. and stirred for 1 h at the same temperature. When the reaction was completed, 17% sodium hydroxide solution was added to the reaction solution until the white precipitate as formed, and then added ethyl acetate to the reaction mixture. The resulting solution was filtered over celite and washed several times with ethyl acetate. The organic. solution was concentrated under reduced pressure and purified with preparative TLC to give the title compound (180 mg, 94%) as a white solid.

[1393]¹H-NMR (270 MHz, CDCl₃) δ: 7.08 (d, J=8 Hz, 2H, Ar—H), 6.90 (d, J=8 Hz, 2H, Ar—H), 6.82 (d, J=8 Hz, 1H, Ar—H), 6.39 (m, 2H, Ar—H), 5.80 and 5.68 (each s, total 1H, Ar—OH), 5.10 (s, 1H, Ar—OH), 4.50 (d, J=11 Hz, 1H, C2-H), 4.23 (d, J=11 Hz, 1H, C2-H), 3.68 (m, 1H, CHOH), 2.60 (m, 1H, C4H), 2.18-1.90 (m, 4H, CF₂CH₂CH₂), 1.81-1.00 (m, 23H, alkyl-H)

EXAMPLE 56

[1394] Synthesis of (3RS,4RS)-7-hydroxy-3methyl-4 19-(4,4,5,5 pentafluoropentylsulfinyl)nonyl]-3-(3-pyridyl)chroman

[1395] Step 1) Synthesis of 2-hydroxy-4-methoxy-2-(3-pyridyl)acetophenone

[1396] The title compound was prepared from 3-picoline and methyl 4-methoxysalicylate according to the similar procedure described in Example 12, Step 1.

[1397]¹H-NMR (270 MHz, CDCl₃) δ: 12.5 (s, 1H, ArOH), 8.5-8.6 (m, 2H, pyridyl), 7.74 (d, 1H, J=8.9 Hz, Ar—H), 7.5-7.7 (m, 1H), 7.2-7.4 (m, 1H, pyridyl), 6.3-6.6 (m, 2H, Ar—H), 4.23 (s, 2H, C(O)CH2), 3.84 (s, 3H, OMe).

[1398] Step 2) Synthesis of 7-methoxy-3-(3-pyridyl)chroman-4-one

[1399] The title compound was prepared from 2-hydroxy-4-methoxy-2-(3-pyridyl)acetophenone according to the similar procedure described in Example 12, Step 2.

[1400]¹H-NMR (300 MHz, CDCl₃) δ: 8.5-8.7 (m, 2H, pyridyl), 7.89 (d, 1H, J=8.8 Hz, Ar—H), 7.5-7.7 (m, 1H, pyridyl), 7.2-7.3 (m, 1H, pyridyl), 6.5-6.7 (m, 1H, Ar—H), 6.46 (d, 1H, J=2.5 Hz, Ar—H), 4.5-4.8 (m, 2H, C2-H), 3.96 (dd, 1H, J=5.2, 8.5 Hz), 3.86 (s, 3H, OMe).

[1401] Step 3) Synthesis of 7-methoxy-3-methyl-3-(3-pyridyl)chroman-4-one

[1402] The title compound was prepared from 7-methoxy-3-(3-pyridyl)chroman-4-one according to the similar procedure described in Example 12, Step 3.

[1403]¹H-NMR (300 MHz, CDCl) δ: 8.71 (d, 1H, J=2.5 Hz, pyridyl), 8.49 (dd, 1H, J=1.7, 4.9 Hz, pyridyl), 7.86 (d, 1H, J=8.8 Hz, Ar—H), 7.6-7.8 (m, 1H, pyridyl), 7.24 (dd, 1H, J=0.8, 4.9 Hz, pyridyl), 6.57- (dd, 1H, J=2.5, 8.8 Hz, Ar—H), 6.35 (d, 1H, J=2.5 Hz, Ar—H), 4.85 (d, 1H, J=12.1 Hz, C2-H), 4-37 (d, 1H, J=12.1 Hz, C2-H), 3.79 (s, 3H, OMe), 1.51 (s, 3H, C3-Me).

[1404] Step 4) Synthesis of 4-[9-t-butyldimethylsilyloxy)nonyl]4-hydroxy-7-methoxy-3-methyl-3-(3-pyridyl)chroman

[1405] To a solution of 9-(t-butyldimethylsilyloxy)nonyl iodide (1.05 g, 2.7 mmol) in pentane (10 ml) and diethylether (7 ml) was added at −78° C. t-BuLi (1.64M in pentane, 3.62 ml, 5.94 mmol), which was stirred for 10 minutes and then stirred for 1 h at room temperature. The mixture was cooled to −78° C. again, and a solution of 7-methoxy-3-methyl-3-3-pyridyl)chroman-4one (436 mg, 1.62 mmol) dissolved in THF (5 ml) was added thereto. The resulting solution was stirred at −78° C. for 30 minutes, and then stirred for 1 h at room temperature. The reaction solution was neutralized under. ice-cooling using saturated aqueous NH₄Cl solution, extracted with AcOEt, and washed with brine. The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure. The recidue was purified by chromatography on silica-gel with 70% AcOEt/hexane to give 642 mg (75%) of 4-[9-(t-butyldimethylsilyloxy)nonyl]-4-hydroxy-7-methoxy-3-methyl-3-(3-pyridyl)chroman.

[1406]¹H-NMR (300 MHz, CDCl₃) δ: 8.72 (d, 1H, J=1.9 Hz, pyridyl), 8.0-8.1 (m, 1H, pyridyl), 7.7-7.9-(m, 1H, pyridyl), 7.12 (d, 1H, J=-9.3 Hz, Ar—H), 7.02 (dd, 1H, J=4.7, 8.0 Hz, pyridyl), 6.3-6.5 (m, 2H, Ar—H), 4.58 (d, 1H, J=12.1 Hz, C2-H), 4.36 (d, 1H, J=12.1 Hz, C2-H), 3.76 (s, 3H, OMe), 3.58 (t, 2H, J=6.6 Hz, CH ₂O), 2.34 (brs, 1H, OH), 1.9-2.1 (m, 1H), 1.6-1.8 (m, 1H), 1.44 (s, 3H, C3-Me), 0.9-1.8 (m, 14H), 0.89 (s, 9H SiBu-t), 0.04 (s, 6H, SiMe₂).

[1407] Step 5) Synthesis of (3RS,4RS)-4-[9-(t-butyldimethylsilyloxy)nonyl]-7-methoxy-3-methyl-3-(3-pyridyl)chroman

[1408] The title compound was prepared from 4-[9-(t-butyldimethylsilyloxy)-1-nonyl]4-hydroxy-7-methoxy-3-methyl-3-(3-pyridyl)chroman according to the general procedure described in this patent.

[1409]¹H-NMR (300 MHz, CDCl₃) δ: 8.4-8.6 (m, 2H, pyridyl), 7.5-7.6 (in, 1H, pyridyl), 7.2-7.4 (m, 1H, pyridyl), 6.96 (d, 1H, J=8.2 Hz, Ar—H), 6.48 (dd, 1H, J=2.8, 8.5 Hz, Ar—H), 6.43 (d, 1H, J=2.5 Hz, Ar—H), 4.57 (d, 1H, J=10.4 Hz, C2-H), 4.31 (dd, 1H, J=1.9, 10.4 Hz, C2-H), 3:78 (s, 3H, OMe), 3.57 (t, 2H, J=6.9 Hz, CH ₂O), 2.6-2.8 (m, 1H, C4-H), 1.4-1-6 (m, 2H), 1.32 (s, 3H, C3-Me), 1.0-1.4 (m, 14H), 0.88 (s, 9H, SiBu-t), 0.04 (s, 6H, SiMe-2).

[1410] Step 6) Synthesis of (3RS,4RS)-4-(9-hydroxynonyl)-7-methoxy-3-methyl-3-(3-pyridyl)chroman

[1411] The title compound was prepared from (3RS,4RS)-4-[9-(t-butyl-dimethyl-silyloxy)-nonyl]-7-methoxy-3-methyl-3-(3-pyridyl)chroman according to the general procedure described in this patent.

[1412]¹H-NMR (300 MHz, CDCl₃) δ: 8.4-8.6 (m, 2H, pyridyl), 7.5-7.6 (m, 1H, pyridyl), 7.2-7.4 (in, 1H, pyridyl), 6.96 (d, 1H, l=8.2 Hz, Ar—H), 6.4-6.6 (m, 2H, Ar—H), 4.57 (d, 1H, J=10.2 Hz, C2-H), 4.30 (d, 1H, J=10.2 Hz, C2-H), 3.79 (s, 3H, OMe), 3.62 (t, 2H, J=6.0 Hz, CH₂O), 2.6-2.8 (in, 1H, C4-H), 2.00 (brs, 1H, OH), 1.4-1.6 (in, 2H), 1.32 (s, 3H, C3-Me), 1.0-1.4 (in, 14H).

[1413] Step 7) Synthesis of (3RS,4RS)-7-methoxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylthio)nonyl]-3-(3-pyridyl)chroman

[1414] The title compound was prepared from (3RS,4RS)-4-(9-hydroxynonyl) 7-methoxy-3-methyl-3-(3-pyridyl)chroman according to the general procedure described in this patent.

[1415]¹H-NMR (300 MHz, CDCl₃) δ: 8.4-8.6 (m, 2H, pyridyl), 7.4-7.6 (m, 1H, pyridyl), 7.2-7.4 (m, 1H, pyridyl), 6.97 (d, 1H, J=8.3 Hz, Ar—H), 6.4-6.6 (m, 2H, Ar—H), 4.57 (d, 1H, J=10.2 Hz, C2-H), 4.30 (d, 1H, J=10.2 Hz, C2-H), 3.78 (s, 3H, OMe), 2.6-2.8 (m, 1H, C4-H), 2.58 (t, 2H, J=6.9 Hz), 2.48 (t, 2H, J=6.9 Hz), 2.0-2.3 (m, 2H), 1.8-2.0 (m, 2H), 1.4-1.6 (m, 2H), 1.32 (s, 3H, C3-Me),1.0-1.4 (m, 14H).

[1416] Step 8) Synthesis of (3RS,4RS)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-3-(3-pyridyl)chroman

[1417] The title compound was prepared from (3RS,4RS3-7-methoxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]-3-(3-pyridyl)chroman according to the general procedure described in this patent.

[1418]¹H-NMR (300 MHz, MeOH-d-4) δ: 8.48 (d, 1H, J=2.2 Hz, pyridyl), 8.41 (dd, 1H, 1=1.4, 5.0 Hz, pyridyl), 7.7-7.9 (m, 1H, pyridyl), 7.43 (dd, 1H, J=4.7, 8.0 Hz, pyridyl), 6.89 (d, 1H, J=8.2 Hz, Ar—H), 6.33 (dd, 1H, J=2.5, 8.5 Hz), 6.26 (d, 1H, J=2.5 Hz), 4.54 (d, 1H, 3=10.7 Hz, C2-H), 4.29 (d, 1H, 1=10.7 Hz, C2-H). 2.7-2.9 (m, 5H), 2.2-2.5 (m, 2H), 2.S2.2 (m, 2H), 1.6-1.8 (m, 2H), 1.29 (s, 3H, C3-Me), 1.0-1.5 (m, 14H).

EXAMPLE 57

[1419] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-[9-(4,4,5,5,5 pentafluoropentylsulfinyl)nonyl]Chroman

[1420] Step 1) (3RS,4RS)-4-(9-benzyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)chroman-2-one

[1421] To a suspension of 7-methoxymethoxy-3-methoxymethoxyphenyl cromen-2-one (182 mg, 0.532 mmol) in THF (1.5 ml) between −30 and −20° C. under nitrogen was added dropwise 9-benzyloxynonyl magnesium bromide (0.509M in THF, 3.0 ml, 1.53 mmol). The resulting suspension was stirred between −20 and −10° C. for 2.5 h. An additional 9-benzyloxynonyl magnesium bromide (0.509M in THF, 0.5 ml, 0.25 mmol) was added, and the reaction mixture was stirred between −20 and −10° C. for 2 hr. The reaction was quenched by addition of saturated aqueous NH₄Cl (0.6 ml), and the layers were separated. The organic layer was washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, concentrated, and purified by column chromatography (silica gel, 20% AcOEt/hexane) to afford (3RS,4RS)-4-9-benzyloxynonyl)-7-methoxymethoxy-3-(4-methoxy-methoxyphenyl)chroman-2-one (219 mg, 71%).

[1422]¹H-NMR (270 MHz, CDCl₃) δ: 7.38-7.22 (7H, m, Ar—H), 7.18-6.98 (3H, m, Ar—H), 6.84-6.78 (2H, m, Ar—H), 5.18 (4H, s, —OCH ₂OCH₃×2), 4.49 (2H, s, —OCH ₂Ph), 4.11 (1H, s, C3-H), 3.50 (3H, s, —OCH₃), 3.48 (3H, s, —OCH₃), 3.44 (2H, t, J=7.5 Hz, —CH ₂OBn), 3.98-3.88 (1H, mn, C4-H), 1.65-1.02 (16H, m, alkyl-H)

[1423] Step 2) (3RS,4RS)-2-(1-benzyloxynonyl-3-hydoxy-2-methoxymethoxyphenyl)propyl-5-methoxymethoxy-phenol

[1424] To a solution of (3RS,4RS)-4-9-benzyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-chroman-2-one (206 mg, 0.357 mmol) in THF (4 ml) at 0° C. was added LiAlH4 (14 mg, 0-369 mmol). The resulting suspension was stirred at 0° C. for 1 hr. The reaction was quenched by addition of saturated aqueous Na₂SO₄ (0.5 ml) and the mixture was stirred at 0° C. for 1 hour, which was extracted with ethyl acetate, dried over dry Na₂SO₄, and filtered. The filtrate was concentrated and purified by column chromatography (silica gel, 33% AcOEt/hexane) to afford (3RS,4RS)-2-(1-benzyloxynonyl-3-hydoxy-2-methoxymethoxyphenyl)propyl-5-methoxymethoxyphenol (146 mg, 70%).

[1425]¹H-NMR (270 MHz, CDCl₃) δ: 7.47 (1H, brs, —OH), 7.37-7.27 (5H, m, Ar—H), 6.87 (2H, d, J=8.6 Hz, Ar—H), 6.72 (2H, d, J=8.6 Hz, Ar—H), 6.58 (1H, d, J=2.3 Hz, Ar—H), 6.42 (1H, dd, J=8.6 and 2.3 Hz, Ar—H), 6.32 (1H, d, J=8.6 Hz, Ar—H), 5.15 (2H, s, —OCH ₂OCH₃), 5.14 (2H, s, —OCH ₂OCH₃), 4.50 (2H, s, —CH ₂Ph), 3.70-3.60 (2H, m, —CH₂OH), 3.49 (3H, s, —OCH₃), 3.48 (3H, s, —OCH₃), 3.46 (2H, t, J=6.6 Hz, —CH ₂OBn), 3.20-3.10 (1H, m, —CHCH₂OH), 3.83-3.75 (1H, m, C2-CH), 1.70-1.02 (16H, m, alkyl-H)

[1426] Step 3) (3RS,4RS)-4-9benzyloxynonyl)-7-methoxymethoxy-3-(4-methoxy methoxyphenyl)chroman

[1427] To a mixture of (3RS,4RS)-2-(1-benzyloxynonyl-3-hydoxy-2-methoxy methoxyphenyl)propyl-5-methoxymethoxyphenol (160 mg, 0.276 mmol) and triphenylphosphine (217 mg, 0.827 mmol) in dioxane (3 ml) at room temperature under nitrogen was added diethyl azodicarboxylate (0.13 ml, 0.826 mmol). The resulting solution was stirred at room temperature for 1 hr, and then poured into H₂O. The mixture was extracted with AcOEt. The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, concentrated, and purified by column chromatography (silica gel, 20% AcOEt/hexane) to afford (3RS,4RS)-4-(9-benzyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)c hroman (136 mg, 88%).

[1428]¹H-NMR (270 MHz, CDCl₃) δ: 7.36-7.26 (5H, m, Ar—H), 7.08-7.95 (5H, m, Ar—H), 6.62-6.55 (2H, m, Ar—H), 5.16 (2H, s, —OCH₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.49 (2H, s, —CH ₂Ph), 4.43 (1H, d, J=10 Hz, C2-H), 4.37 (1H, dd, J=10 and 4.3 Hz, C2-H), 3.48 (3H, s, —OCH₃), 3.47 (3H, s, —OCH₃), 3.44 (2H, t, J=6.6 Hz, —CH ₂OBn), 3.40-3.30 (1H, m, C3-H), 2.94-2.82 (1H, m, C4-H), 1.70-1.02 (16H, m, alkyl-H)

[1429] Step 4) (3RS,4RS)-4-(9-hydroxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxy phenyl)chroman

[1430] To a solution of (3RS,4RS)-4-9-benzyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)chroman (262 mg, 0.466 mmol) in AcOEt/EtOH (1:1, 10 ml) was added 10% Pd on carbon (25 mg, 0.023 mmol). The reaction flask was flushed with nitrogen, and hydrogen gas was introduced. The black slurry was stirred at room temperature under 1 atm of H₂ for 2 hr. The reaction mixture was filtered through a small pad of celite, and the filtrate was concentrated. The residue was purified by column chromatography (silica gel, 33%- AcOEt/hexane) to afford (3RS,4RS)-4-(9-hydroxynonyl)-7-methoxy-methoxy-3-(4-methoxymethoxyphenyl) chroman (222 mg, quant.)

[1431]¹H-NMR (270 MHz, CDCl₃) δ: 7-05 (2H, d, l=8.6 Hz, Ar—H), 7.00 (11 d, J=7.3 Hz, Ar—H), 6.99 (2H, d, J=8.6 Hz, Ar—H), 6-58 (1H, dd, J=7-3 and 2.6 Hz, Ar—H), 6.57 (1H, d, J=2.6 Hz, Ar—H), 5.17 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.43 (1H, d, J=9.6 Hz, C2-H), 4.38 (1H, dd, J=9.6 and 4.0 Hz, C2-H), 4.67-4.57 (2H, m, —CH ₂OH), 3.49 (6H, S, —OCH₃×2), 3.40-3.30 (1H, m, C3-H), 2.94-2.82 (1H, m, C4-H), 1.60-1.02 (16H, m, alkyl-H)

[1432] Step 5) (3RS,4RS)-4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)chroman

[1433] To a solution of (3RS,4RS)-4-(9-hydroxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)chroman (222 mg, 0.470 mmol) and triethylamine (0.135 ml, 0.961 mmol) in CH₂Cl₂ (5 ml) at 0° C. under nitrogen was added methanesulfonyl chloride (0.055 ml, 0.71 mmol). The resulting solution was stirred at 0° C. for 45 min, and then poured into H₂O. The mixture was extracted with CH₂Cl₂. The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, and concentrated to afford (3RS,4RS)-4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)chroma n (255 mg, 99%).

[1434]¹H-NMR (270 MHz, CDCl₃) δ: 7.08-6.96 (5H, m, Ar—H), 6.61-6.55 (2H, m, Ar—H), 5.17 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.43 (1H, d, J=10 Hz, C2-H), 4.38 (1H, dd, J=10 and 4.0 Hz, C2-H), 4.20 (2H, t, J=6.6 Hz, —CHOMs), 3.49 (6H, s, —OCH₃×2), 3.40-3.30 (1H, m, C3-H), 2.99 (3H, s, —SO₂ CH ₃), 2.94-2.82 (1H, m, C4-H), 1.80-1.02 (16H, m, alkyl-H)

[1435] Step 6) (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]chroman

[1436] To a solution of 4,4,5,5,5-pentafluoropentyl tihoacetate (186 mg, 0.787 mmol) in MeOH (2 ml) at room temperature under nitrogen was added sodium methoxide (1.0M in MeOH, 0.7 ml, 0.7 mmol). The resulting solution was stirred at room temperature for 30 min, and then (3RS,4RS)-4-(9-methanesulfonyloxynonyl)-7-methoxymethoxy-3-(4-methoxymethox yphenyl)chroman (255 mg, 0.463 mmol) in ThF (2 ml) was added. The reaction mixture was stirred at room temperature for 19 hr, and then poured into H₂O. The mixture was extracted with AcOEt. The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, concentrated, and purified by column chromatography (silica gel, 33% AcOEt/hexane) to afford (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-4[9-4,4,5,5,5-pentafluoropentylthio)nonyl]chroman (203 mg, 68%).

[1437]¹H-NMR (270 MHz, CDCl₃) δ: 7.09-6.96 (5H, m, Ar—H), 6.61-6.53 (2H, m, Ar—H), 5.17 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.44 (1H, d, J=10 Hz, C2-H), 4.38 (11, dd, J=10 and 4.0 Hz, C2-H), 3.49 (6H, s, —OCH₃×2), 3.40-3.30 (1H, m, C3-H), 2.94-2.82 (1H, m, C4-H), 2.58 (2H, t, J=6.9 Hz, —SCH ₃—), 2.49 (2H, t, J=6.9 Hz, —SCH ₂—), 2.30-1.80 (4H, m, alkyl-H), 1.60-1.02 (16H, m, alkyl-H)

[1438] Step 7) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4 [9-4,4,5,5,5-pentafluoro pentylthio)nonyl]chroman

[1439] To a solution of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxy phenyl)-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]chroman (204 mg, 0.314 mmol) in EtOH (2 ml) was added 6N HCl (0.2 ml, 1.2 mmol). The resulting solution was stirred between 40 and 45° C. for 17 hr, and then poured into H₂O. The mixture was extracted with AcOEt. The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, concentrated, and purified by column chromatography (silica gel, 33% AcOEtlhexane) to afford (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-[9-4,4,5,5,5-pentafluoropentylthio)non yl]chroman (140 mg, 80%).

[1440]¹H-NMR (270 MHz, CDCl₃) δ: 7.00 (2H, d, J=8.6 Hz, Ar—H), 6.96 (1H, d, J=8.6 Hz, Ar—H), 6.78 (2H, d, J=8.6 Hz, Ar—H), 6.43-6.32 (2H, m, Ar—H), 4.83 (1H, s, OH), 4.68 (1H, s, OH), 6.436.32 (2H, m, C2-H), 3.37-3.27 (1H, m, C3-H), 2.92-2.81 (1H, m, C4-H), 2.59 (2H, t, J=6.9 Hz, —SCH ₂—), 2.49 (2H, t, J=6.9 Hz, —SCH ₂—), 2.23-2.02 (2H, m, alkyl-H), 1.98-1.80 (2H, m, alkyl-H), 1.61-1.02 (16H, m, alkyl-H)

[1441] Step 8) (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-[9-(4,4,5,5,5-pentafluoro pentylsulfinyl)nonyl]chroman

[1442] To a solution of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-[9-(4,4,5,5,5-pentafluoropentylthio)nonyl]chroman (140 mg, 0.250 mmol) and H₂O (0.05 ml) in THF (1.2 ml) at 0° C. was added Oxone^(R) (monopersulfate compound; DuPont product) (77 mg, 0.125 mmol). The resulting solution-was stirred at 0° C. for 3.5 hr, and then poured into H₂O. The mixture was extracted with AcOEt. The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, concentrated, and purified by column chromatography (silica gel, 60% AcOEt/hexane) to afford (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-[9-4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]chroman (105 mg, 73%).

[1443]¹H-NMR (270 MHz, CDCl₃) δ: 7.65 and 7.54 (total 1H, s, OH), 7.02-6.92 (3H, m, Ar—H), 6.80 (2H, d, J=8.2 Hz, Ar—H), 6.40 (1H, dd, J=8.3 and 2.3 Hz, Ar—H), 6.36 (1H, d, J=2.3 Hz, Ar—H), 5.59 and 5.52 (total 1H, s, OH), 4.43-4.32 (2H, m, C2-H), 3-38-3.24 (1H, m, C3-H), 2.95-2.58 (5H, m), 2.38-2.10 (4H, m), 1.82-1.61 (2H, m), 1.44-0.90 (14H, m)

EXAMPLE 58

[1444] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-(9-oxo-14,14,15,15,15-pentafluoro)pentadecyl-3methylchroman

[1445] Step 1) Synthesis of 3-oxo-2-4,4,5,5,5-pentafluoropentyl)dec-9-enoic acid ethyl-ester

[1446] To a solution of 4,4,5;5,5-pentafluoropentyl p-toluenesulfonate (11.5 g, 34.6 mmol) in THF (60 ml) was added lithium iodide (9.26 g, 69.2 mmol). This resulting mixture was refluxed under nitrogen for 2 hr and then cooled.

[1447] On the other hand, to a solution of 3-oxo-dec-9enoic acid ethyl ester (4.32 g, 20.3 mmol) in THF (15 ml) at 0° C. was added potassium tert-butoxide (2.73 g, 24.3 mmol) This resulting mixture was stirred at room temperature under nitrogen for 30 min. The mixture of 4,4,5,5,5-pentafluoro-iodopentane was added and mixture was refluxed under nitrogen for 2 days, and then poured into H₂O. The mixture was extracted with hexane. The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, concentrated, and purified by column chromatography (silica gel, 60% CHCl₃/hexane) to afford 3-oxo-2-(4,4,5,5,5-pentafluoropentyl)-dec-9-enoic acid ethyl ester (4.46 g, 59%).

[1448]¹H-NMR (270 MHz, CDCl₃) δ: 5.87-5.71 (1H, m, —CH═CH₂), 5.15-4.90 (2H, m, CH═CH ₂), 4.20 (2H, q, J=7.3 Hz, —OCH ₂CH₃), 3.44 (1H, t, J=7.3 Hz, —COCHCO—), 3.66-3.40 (2H, m, Alkyl-H), 2.18-1.82 (6H, m, Alkyl-H), 1.70-1.44 (4H, m, Alkyl-H), 1.43-1.21 (4H., m. Alkyl-H), 1.27 (3H, t, J=7.3 Hz, —OCH₂ CH ₃)

[1449] Step 2) (3RS,4RS)-4-(10-ethoxycarbonyl-9-oxo 14,14,15,15,15-pentafluoro) pentadecyl-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[1450] 1) The mixture of (3RS,4RS)-4-allyl-7-methoxymethoxy-3-(4-methoxy methoxyphenyl)-3-methyl-chroman (500 mg, 1.30 mmol), 3-oxo-2-(4,4,5,5,5-pentafluoropentyl)dec-9-enoic acid ethyl ester (968 mg, 2.60 mmol), benzylidene bis(tricyclohexylphosphine)-dichlororuthenium (53 mg, 0.064 mmol) and CH2Cl2 (1₀ ml) was refluxed under nitrogen for 4 hr. This resulting mixture was concentrated, and then this crude mixture was purified by column chromatography (silica gel, 17% AcOEt/hexane) to afford (3RS,4RS)-4-[(10-ethoxycarbonyl-9-oxo-14,14,15,15,15-pentafluoro)pentadec-2-enyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (638 mg) as a E/Z mixture.

[1451] 2) To a solution of (3RS,4RS)-4-[(10-ethoxycarbonyl-9-oxo-14,14, 15,15,15-pentafluoro)pentadec-2-enyl]-7-methoxymethoxy-3-(4-methoxymethoxy phenyl)-3-methylchroman (638 mg) in AcOEt/EtOH (1:1, 10 ml) was added 10% Pd on C (53 mg, 0.050 mmol). The reaction flask was flushed with nitrogen, and hydrogen gas was introduced. The black slurry was stirred at room temperature under 1 atm of H₂ for 2 days. The reaction mixture was filtered through a small pad of Celite, and the filter was concentrated. The residue was purified by column chromatography (silica gel, 18% AcOEt/hexane) to afford (3RS,4RS)₄ (10-ethoxycarbonyl-9-oxo-14,14,15,15,15-pentafluoro) pentadecyl-7-methoxy-methoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (590 mg, 62%).

[1452]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (2H, d, J=8.6 Hz, Ar—H), 7.02 (2H, d, 1=8.6 Hz, Ar—H), 6.94 (1H, d, J=9.2 Hz, Ar—H), 6.59-6.53 (2H, m, Ar—H), 5.18 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, OCH ₂OCH₃), 4.52 (1H, d, 1=10.2 Hz, C2-H), 4.26 (1H, d, J=10.2 Hz, C2-H), 4.19 (2H, q, J=7.3 Hz, —OCH ₂CH₃), 3.49 (3H, s, —OCH₃), 3.49 (3H, s, —OCH₃), 3.42 (1H, t, J=7.3 Hz, —COCHCO—), 2.68-2.61 (1H, m, C4-H), 2.60-2.36 (2H, m, Alkyl-H), 2.17-1.83 (4H, m, Alkyl-H), 1.63-1.45 (4H, m, Alkyl-H), 1.37-0.97 (12H, m, Alkyl-H), 1.26 (3H, t, J=7.3 Hz, —OCH₂ CH ₃), 1.24 (3H, s, C3-CH ₃)

[1453] Step 3) (3RS,4RS)-4-(10-ethoxycarbonyl-9-oxo-14,14,15,15,15-pentafluoro) pentadecyl-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman

[1454] To the solution of (3RS,4RS)-4-(10-ethoxycarbonyl-9-oxo-14,14,15,15,15-pentafluoro)pentadecyl -7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylch roman (618 mg, 0.846 mmol) in EtOH (4 ml) was added 6N HCl (0.7 ml, 4.2 mmol). The resulting solution was stirred at room temperature for 1 day and between 40 and 45° C. for 2 hr, and then poured into H₂O. The mixture was extracted with AcOEt. The organic layer was washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, concentrated, and purified by column chromatography (silica gel, 33% AcOEt/hexane) to afford (3RS,4RS)-4-(10-ethoxycarbonyl-9-oxo-14,14,15,15,15-pentafluoro)pentadecyl-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman (421 mg, 77%).

[1455]¹H-NMR (270 MHz, CDCl₃) δ: 7.08 (2H, d, J=8.6 Hz, Ar—H), 6.89 (1H, d, J=8.6 Hz, Ar—H), 6.84 (2H, d, J=8.6 Hz, Ar—H), 6.42-6.32 (2H, m, Ar—H), 5.61 (1H, s, OH), 4.94-4.91 (1H, m, OH), 4.50 (1H, d, J=6.9 Hz, C2-H), 4.29-4.15 (3H, m, C2-H and —OCH ₂CH₃), 3.46 (1H, t, J=6.9 Hz, —COCHCO—), 2.63-2.35 (3H, m, C4-H and alkyl-H), 2.16-1.85 (4H, m, alkyl-H), 1.70-1.40 (4H, m, alkyl-H), 1.34-0.95 (12H, m, alkyl-H), 1.28 (3H, t, J=6.9 Hz, —OCH₂ CH ₃), 1.25 (3H, s, C3-CH ₃)

[1456] Step 4) (3RS,4PS)-7-hydroxy-344-hydroxyphenyl 9-oxo-14,14,15,15,15-pentafluoro)pentadecyl-3-methylchroman]

[1457] To a solution of (3RS,4RS)-4-(10-ethoxycarbonyl-9oxo-14,14,15,15,15-pentafluoro)pentadecyl-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman (115 mg, 0.179 mmol) in THF (3 ml) at 0° C. was added aqueous 1N NaOH (3.0 ml, 3.0 mmol). The resulting solution was stirred at 0° C. for 15 min and at room temperature for 19 hr, and then poured into H₂O. The mixture was extracted with AcOEt. The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, concentrated, and purified by column chromatography (silica gel, 33% AcOEt/hexane) to afford (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-(9oxo-14,14,15,15,15-pentafluoro)pentadecyl-3-methylchroman (88.9 mg, 87%).

[1458]¹H-NMR (270 MHz, CDCl₃) δ: 7.08 (2H, d, J=8.6 Hz, Ar—H), 6.92-6.83 (3H, m, Ar—H), 6.40-6.34 (2H, m, Ar—H), 5.78 (1H, s, OH), 4.80 (1H, s, OH), 4.50 (1H, d, J=10.6 Hz, C2-H), 4.294.21 (1H, m, C2-H), 2.62-2.53 (1H, m, C4-H), 2.48 (2H, t, J=6.6 Hz, —COCH₂—), 2.39 (2H, t, J=7.6 Hz, —COC—), 2.15-1.93 (2H, m, alklyl-H), 1.74-1.42 (6H, m, allyl-H), 1.33-0.98 (12H, m, alkyl-H), 1.26 (3H, s, C3-CH ₃)

EXAMPLE 59

[1459] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-9-hydroxy-10-hydroxycarbonyl-14,14,15,15,1 5pentanluoro)pentadecyl-3-methylchroman

[1460] 1) To a solution of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-9 oxo-14,14,15,15,15-pentafluoro)-pentadecyl-3-methylchroman (120 mg, 0.187 mmol) in MeOH (2 ml) at 0° C. was added sodium borohydride (9 mg, 0.238 mmol). The resulting mixture was stirred at 0° C. for 30 minutes, and then quenched with H₂O. This mixture was extracted with AcOEt. The organic layer was washed with, saturated aqueous NaCl, dried (Na₂SO₄), filtered, concentrated, and purified by column chromatography (silica gel, 40% AcOEt/hexane) to afford (3RS,4RS)-4-(10-ethoxycarbonyl-9-hydroxy-14,14,15,15,15-pentafluoro)pentadecyl-7-hydroxy-3-(4-hydroxyphenyl)>3-methylchroman (109 mg).

[1461] 2) To the solution of (3RS,4RS)-4-10-ethoxycarbonyl-9-hydroxy-14,14,15,15,15-pentafluoro)-pentadecyl-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-chroman (100 mg) in THF (3 ml) at 0° C. was added aqueous 1N NaOH (3 ml). The resulting solution was stirred at room temperature for 19 hr, and then acidified with 2N HCl (pH 1). The mixture was extracted with AcOEt. The organic layer was washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, concentrated, and purified by column chromatography (silica gel, 10% MeOH/CHCl₃) to afford (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-(9-hydroxy-10-hydroxycarbonyl-14,14,15,15,15-pentafluoro)pentadecyl-3-methylchroman (85.7 mg, 74%).

[1462]¹H-NMR (270 MHz, DMSO-d-6) δ: 9.18 (1H, brs, —CO2H), 7.06 (2H, d, J=8.3 Hz, Ar—H), 6.81 (1H, d, J=8.2 Hz, Ar—H), 6.73 (2H, d, J=8.3 Hz, Ar—H), 6.27 (1H, dd, J=8.2 and 2.0 Hz, Ar—H), 6.19 (1H, d, J=2.0 Hz, Ar—H), 4.40 (1H, d, J=10.6 Hz, C2-H), 4.16 (1H, d, J=10.6 Hz, C2-H), 4.584.40 (1H, m, —CHOH), 2.62-2.52 (1H, m, C4-H), 2.32-2.03 (4H, m, alkcyl-H), 1.6440.81 (19H, m, alkyl-H), 1.12 (3H, s, C3CH ₃)

EXAMPLE 60

[1463] Synthesis of (3RS,4RS)-7-hydroxy-4-[(10 ethoxycarbonyl-14,14,15,15,15-pentafluoro)pentadec-9-enyl]—(4-hydroxyphenyl)-3-methylchroman

[1464] Step 1) (3RS,4RS)-4-(10-ethoxycarbonyl-9-methanesulfonyloxy-14,14,15,15,15-pentafluoro)pentadecyl-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylch roman

[1465] 1) To the solution of (3RS,4RS)-4-(10-ethoxycarbonyl-9-oxo-14,14,15,15,15-pentafluoro)pentadecyl-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (250 mg, 0.342 mmol) in MeOH (4 ml) at 0° C. was added sodium borohydride (17 mg, 0.449 mmol). The resulting mixture was stirred at 0° C. for 1 hr, and then quenched with 14.20. This mixture was extracted with AcOEt. The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, concentrated.

[1466] 2) To this crude mixture was added triethylamine (0.144 ml, 1.02 mmol) and CH₂Ck₂ (4 ml), and then methanesulfonyl chloride (0.04 ml, 0.517 mmol) was added at 0° C. This resulting mixture was stirred at 0° C. for 1 hr, and then quenched with H₂O. The mixture was extracted with CH₂Cl₂. The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, concentrated, and purified by column chromatography (silica gel, 25% AcOEt/hexane) to afford (3RS,4RS)-4-10-ethoxycarbonyl-9-methanesulfonyloxy-14,14,15,15,15-pentafluoro)pentadecyl-7-methoxymethoxy-3-(4-methoxymethoxyphe nyl)-3-methylchroman (254 mg, 92%).

[1467]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (2H, d, J=8.9 Hz, Ar—H), 7.02 (2H, d, J=8.9 Hz, Ar—H), 6.94 (1H, d, J=9.2 Hz, Ar—H), 6.59-6.54 (2H, m, Ar—H), 5.18 (2H, s, —OCH ₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.95-4.84 (1H, m, —CHOMs), 4.52 (1H, d, J=10.6 Hz, C2-H), 4.26 (1H, d, J=10.6 Hz, C2-H), 4-18 (2H, q, J=6.9 Hz, —OCH ₂CH₃), 3.50 (3H, s, —OCH ₂OCH₃), 3.49 (3H, s, —OCH₂OCH ₂), 3.02 and 2.99 (total 3H, s, —OSO₂CH₃), 2.87-2.77 (1H, m, —CHCO₂Et), 2.65-2.60 (1H, m, C4-H), 2.18-1.93 (2H, m, alkyl-H), 1.83-1.50 (6H, m, alkyl-H), 1.41-0.98 (14H, m, alkyl-H), 1.27 (3H, t, J=6.9 Hz, —OCH₂CH₃) 1.24 (3H, s, C3-CH₃)

[1468] Step 2) (3RS,4RS)-4-[(10-ethoxycarbonyl-14,14,15,15,15-pentafluoro)pentadec-9-enyl]-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman

[1469] To a solution of (3RS,4RS)-4-10-ethoxycarbonyl-9-methanesulfonyl oxy-14,14,15,15,15-pentafluoro)pentadecyl-7-methoxymethoxy-3-(4-methoxy-metho xyphenyl)-3-methylchroman (236 mg, 0.291 mmol) in CH₂Ck₂ (3 ml) at 0° C. under nitrogen was added 1,8-diazabicyclo[5,4,0]undec-7-ene (0.32 ml, 2.14 mmol). This resulting mixture was stirred at room temperature for 5 hr, and then poured into H₂O. The mixture was extracted with CH₂Cl₂. The organic layer was washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, concentrated, and purified by column chromatography (silica gel, 25% AcOEt/hexane) ta afford (3RS,4RS)-4-[(10-ethoxycarbonyl-14,14,15,15,15-pentafluoro)pentadec-9-enyl]-7-me thoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (184 mg, 88%) as a E/Z mixture.

[1470]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (2H, d, J=8.9 Hz, Ar—H), 7.02 (2H, d, J=8.9 Hz, Ar—H), 6.94 (1H, d, J=9.2 Hz, Ar—H), 6.80 (0.65H, t, J=7.3 Hz, —CH═CCO₂Et- of E isomer), 6.606.52 (2H, m, Ar—H), 5.88 (0.351, t, J=6.6 Hz, —CH═CCO₂Et- of Z isomer), 5.18 (2H, S, —OCH₂OCH₃), 5.15 (2H, s, —OCH ₂OCH₃), 4.52 (1H, d, J=10.2 Hz, C2-H), 4.26 (1H, d, J=10.6 Hz, C2-H), 4.20 (21H, q, J=7.3 Hz, —OCH ₂CH₃), 3.49 (6H s, —OCH₂OCH ₂×2), 2.69-2.60 (1H, m, C4-H), 2.43-2.27 (2H, m, alkyl-H), 2.19-1.89 (4H, m, alkyl-H), 1.80-1.63 (2H, m, alkyl-H), 1.65-0.98 (14H, m, alkyl-H), 1.29 (3H, t, J=7.3 Hz, —OCH₂ CH ₃), 1-25 (3H, s, C3-CH₃)

[1471] Step 3) (3RS,4kS)-7-hydroxy-4-[(10-ethoxycarbonyl-14,14,15,15,15-pentafluoro) pentadec-9-enyl]-3-(4-hydroxyphenyl)-3-methylchroman

[1472] 1) To a solution of (3RS,4RS)-4-[(10-ethoxycarbonyl-14,14,15,15,15-pentafluoro)pentadec-9-enyl]-7-methoxymethoxy-3-(4-methoxymethoxy phenyl)-3-methylchroman (E/Z=c.a. ½, 173 mg, 0.242 mmol) in EtOH (3 ml) was added 6N HCl (0.3 ml, 1.8 mmol). The resulting solution was stirred at room temperature for 2.5 days and at 35 C for 4 hr, and then poured into H₂O. The mixture was extracted with AcOEt- The organic layer was washed with saturated aqueous NaCl, dried (Na₂SO₄), filtered, concentrated, and purified by column chromatography (silica gel, 25% AcOEt/hexane) to afford (3RS,4RS)-7-hydroxy-4-[(10-ethoxycarbonyl-14,14,15,15,15-pentafluoro)pentadec-9-enyl]-3-(4-hydroxyphenyl)-3-methylchroman (134 mg).

[1473] 2) To the solution of (3RS,4RS)-7-hydroxy-4-[(10-ethoxycarbonyl-14,14,15,15,15-pentafluoro)-pentadec-9-enyl]-3-(4-hydroxyphenyl)-3-methylchroman (123 mg) in MeOH (3 ml) at 0° C. was added the solution of KOH (85%, 150 mg, 2.27 mmol) in H₂O (3 ml). The resulting solution was stirred at room temperature for 4 hr, and then acidified with 2N HCl (pH 1). The mixture was extracted with AcOEt The organic layer was washed with saturated aqueous NaCl, dried over Na₂SO₄, filtered, concentrated, and purified by column chromatography (silica gel, 66% AcOEt/hexane) to afford (3RS,4RS)-7-hydroxy-4-[(10-hydroxycarbonyl-14,14,15,15,15-pentafluoro)-pentadec-9-enyl]-3-(4-hydroxyphenyl)-3-methylchroman (52.1 mg, 36%) as E1Z mixtures.

[1474]¹H-NMR (270 MHz, CDCl₃) δ: 7.08 (2H, d, J=8.9 Hz, Ar—H), 6.98 (0.85H, t, J=7.6 Hz, —CH═CCO₂Et- of E isomer), 7.90 (1H, d, J=8.9 Hz, Ar—H), 6.83 (2H, d, J=8.9 Hz, Ar—H), 6.42-6.33 (2H, m, Ar—H), 6.09 (0.15H, t, J=7.3 Hz, —CH═CCO₂Et- of Z isomer), 4.51 (1H, d, J=10.6 Hz, C2-H), 4.24 (15H, d, J=10.6 Hz, C2-H), 2.65-2.56 (1H, m, C4-H), 2.43-2.29 (2H, m, alkyl-H), 2.23-1.91 (4H, m, alkyl-H), 1.85-1.62 (2H, m, alkyl-H), 1.48-0.93 (14H, m. alkyl-H), 1.24 (3H, s, C3-CH3)

EXAMPLE 61

[1475] Synthesis of 1,1,1,2,2-pentafluoro-14-[(3RS,4RS)-7-hydroxy-3-(4hydroxy phenyl)-3-methylchroman-4-yl]-5-tetradecanone.

[1476] Step 1) Synthesis of 4,4,5,5,5-pentafluoropentanoic Acid.

[1477] To a stirred solution of Jones reagent (20 ml, 160 mmol) in acetone (20 ml), cooled in an ice bath, a solution of 4,4,5,5,5-pentafluoro-1-pentanol (7.12 g, 40 mmol) in acetone (30 ml) was added dropwise. After remaining ice bath, the mixture was stirred continuously at room temperature for 1 h. The mixture was poured into ice/water and extracted with diethyl ether. Crude ether washed was extracted with aqueous 2 N sodium hydroxide. On the inorganic layer was acidified with aqueous 6 N hydrochloric acid and the organic layer was extracted with diethyl ether. The final extract was washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give crude 4,4,5,5,5-pentafluoropentanoic acid as colorless liquid (6.31 g, 82%), which was used in the next step without further purification.

[1478]¹H NMR (300 MHz, CDCl₃) δ: 11.5-9.5 (1H, br.s, CO2H), 2.70 (2H, t, J=7.8 Hz, C2-H), 2.53-2.33 (2H, m, C3-H).

[1479] Step 2) Synthesis of 4,4,5,5,5-pentafluoropentanoyl Chloride.

[1480] A mixture of 4,4,5,5,5-pentafluoropentanoic acid (7:44 g, 38.7 mmol) and thionyl chloride (23.0 g, 194 mmol) was stirred at reflux for 2 h. Excess thionyl chloride was removed by heating at normal pressure and the residue was distilled in vacuum using effective Vigreux column to give 4,4,5,5,5-pentafluoropentanoyl chloride as colorless liquid(62° C./103 mmHg, 4.41 g, 54%).

[1481]¹H NMR (300 MHz, CDCl₃) δ: 3,23 (2H, t, J=7.6 Hz, C2-H), 2.58-2.38 (2H, m, C3-H).

[1482] Step 3) Synthesis of ethyl 6,6,7,7,7-pentafluoro-3-oxoheptanoate.

[1483] To a stirred solution of ethyl acetate enolate, prepared from ethyl acetate (4.4.g, 50 mmol) and sodium hexamethyldisilazide (50 mmol) in THF at −70° C., was added neat 4,4,5,5,5-pentafluoropentanoyl chloride (2.1 g, 10 mmol) at −70° C. Cooling bath was removed and the reaction mixture was allowed to warm to room temperature. The mixture was diluted with diethyl ether and quenched with water. The organic layer was separated, washed with aqueous 2 N hydrochloric acid, saturated sodium bicarbonate solution, brine, dried over anhydrous sodium sulfate and concentrated in vacuum. The crude product was purified by flash chromatography on -silica gel (hexane ethyl acetate 5:1) to give ethyl 6,6,7,7,7-pentafluoro-3-oxoheptanoate as colorless oil. yield 1.46 g (56%).

[1484]¹H NMR (300 MHz, CDCl₃) δ: 4.22 (2H, q, J=7.1 Hz, OCH ₂Me), 3.50 (2H, s, C2-H), 2.89 (2H, m, C4-H), 2.50-2.30 (2H, m, C5-H), 1.29 (3H, t, J=7.1 Hz, MeCH₂O).

[1485] Step 4) Synthesis of 8-iodo-1-octene.

[1486] A mixture of 8-bromo-1-octene (1.34 g, 7 mmol) and sodium iodide (5.25 g, 35 mmol) in 2-butanone (15 ml) was stirred under reflux for 1 h. The mixture was concentrated in vacuo to a half of its original volume and hexane and water was added. Organic layer was washed with 5% aqueous sodium thiosulfate, saturated sodium bicarbonate and brine, dried over anhydrous sodium sulfate and concentrated in vacuum. Purification by flash chromatography on silica gel (hexane) gave 8-iodo-1-octene as colorless oil. yield 1.54 g (92%).

[1487]¹H NMR (300 MHz, CDCl₃) δ: 5.88-5.73 (1H, m, C2-H), 5.054.91 (2H, m, C1-H), 3.19 (2H, t, J=7.0 Hz, C8-H), 2.05 (2H, m, C3-H), 1.81 (2H, m, C7-H), 1.47-1.24 (6H, m, alkyl-H).

[1488] Step 5) Synthesis of ethyl 2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-9-decenoate.

[1489] To a stirred solution of ethyl 6,6,7,7,7-pentafluoro-3-oxoheptanoate (262 mg, 1 mmol) in anhydrous THF (4 ml), potassium tret-butoxide (112 mg, 1 mmol) was added as a solid and the mixture was stirred at room temperature for 30 min. Then to a solution of 8-iodo-1-octene (357 mg, 1.5 mmol) in anhydrous THF (1 ml) was added and the mixture was stirred at room temperature continued for 3 days. The mixture was concentrated, diluted with diethyl ether, washed with water, brine, dried over anhydrous sodium sulfate and concentrated in vacuum. Crude product was purified by flash chromatography on silica gel (hexane:ethyl acetate 10:1) to give ethyl 2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-9-decenoate as a colorless oil. yield 200 mg (54%).

[1490]¹H NMR (300 MHz, CDCl₃) δ: 5.88-5.71 (1H, m, C9-H), 5.03-4.88 (2H, m, C10-H), 4.20 (2H, q, 1=7.1 Hz, OCH ₂Me), 3.46 (11H, t, J=7.4 Hz, C2-H), 2.97-2.69 (2H, m, C2′-H), 2.48-2.28 (2H, m, C3′-H), 2.03 (2H, m), 1.86 (2H, m), 1.42-1.23 (6H, m), 1.27 (3H, t, 1=7.1 Hz, MeCH₂O).

[1491] Step 6) Synthesis of ethyl (E,Z)-2-4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]-9-undecenoate.

[1492] A solution of (3RS,4RS)-4-allyl-7-methoxymethoxy-3-(4-methoxy methoxyphenyl)-3-methylchroman (346 mg, 0.9 mmol), ethyl 2-4,4,5,5,5-pentafluoro-1-oxopentyl)-9-decenoate (667 mg, 1.8 mmol) and benzylidene bis(tricyclohexylphosphine)-dichlororuthenium (41 mg, 0.05 mmol) in methylene chloride (10 ml) was stirred under -reflux for 2 h. The mixture was concentrated and crude product was purified directly by flash chromatography on silica gel (hexane:ethyl acetate 5:1) to give ethyl (E,Z)-2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxy phenyl)-3-methylchroman-4-yl]-9-undecenoate as a colorless oil. yield 483 mg (74%).

[1493]¹H NMR (300 MHz, CDCl₃) δ: 7.20-6.90 (5H, m, Ar-4), 6.60-6.50 (2H, m, Ar—H), 5.27-4.97 (6H, mn, OCH ₂OMe and C9-H, C10-H), 4.59-4.47 (1H, m, C2″-H), 4.30-4.15 (3H, n, C2″-H and OCH ₂Me), 3.51-3.41 (7H, m, C2-H and MeOCH₂O), 2.97-2.69 (3H, m, C4″-H and C2′-H), 2.48-2.28 (2H, m, C3′-H), 1.94-1.46 (6H, m), 1.36-1.16 (14H, m, alkyl-H).

[1494] Step 7) Synthesis of ethyl 2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]undecanoate.

[1495] To a solution of ethyl (E,Z)-2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl}3-methylchroman-4-yl]-9-undecenoate (483 mg, 0.66 mmol) in ethyl acetate (30 ml), 10% Pd/C (120 mg) was added and the reaction mixture was stirred under H₂ at normal pressure at room temperature for 1 h. Catalyst was filtered out and filtrate was concentrated in vacuum to give ethyl 2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]undecanoate as a colorless oil, which was used in the next step without further purification. yield 483 mg (quant.).

[1496]¹H NMR (300 MHz, CDCl₃) δ: 7.17-6.92 (5H, m, Ar—H), 6.60-6.53 (2H, m, Ar—H), 5.18 and 5.15 (2H each, s, OCH₂OMe), 4.52 (1H, d, JAB=10.1 Hz, C2″-H), 4.26 (1H, dd, JAB=10.1 Hz, J=1.7 Hz, C2″-H), 4.19 (2H, q, J=7.1 Hz, OCH ₂Me), 3.50 and 3.49 (3H each, s, MeOCH₂O), 3.44 (1H, t, J=7.4 Hz, C2-H), 2.96-2.69 (2H, m, C2′-H), 2.64 (1H, m, C4″-H), 2.48-2.27 (2H, m, C3′-H), 1.92-1.75 (2H, m), 1.31-1.02 (22H, m, alkyl-H).

[1497] Step 8) Synthesis of ethyl 2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]undecanoate.

[1498] To a stirred solution of ethyl 2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)₃-methylchroman-4-yl]undecanoate (128 mg, 0.17 mmol) in ethyl alcohol (5 ml), was added concentrated aqueous hydrochloric acid (10 drops) at room temperature under N₂ atmosphere. The mixture was stirred at room temperature continued for 2.5 days and diluted with ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate and brine, dried over anhydrous sodium sulfate and concentrated in vacuum. Crude product was purified by flash chromatography on silica gel (hexane:ethyl acetate=3:2) to give ethyl 2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]undecanoate as a colorless glassy oil. yield 102 mg (94%).

[1499]¹H NMR (300 MHz, CDCl₃) δ: 7.13-6.80 (5H, m, Ar—H), 6.41-6.34 (2H, m, Ar—H), 5.45 and 4.95 (1H each, s, OH), 4.51 (1H, d, JAB=10.4 Hz, C2″-H), 4.28-4.17 (3H, m, C2″-H and OCH ₂Me), 3.49 (1H, t, J=7.4 Hz, C2-H), 2.99-2.69 (2H, m, C2′-H), 2.60 (1H, m, C4″-H), 2.51-2.29 (2H, m, C3′-H); 1.95-1.76 (2H, m), 1.28 (3H, t, J=7.1 Hz, MeCH₂O), 1.27-0.98 (22H, m, alkyl-H).

[1500] Step 9) Synthesis of 1,1,1,2,2-pentafluoro-14-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-5-tetradecanone.

[1501] To a solution of ethyl 2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]undecanoate (102 mg, 0.16 mmol) in THF (2.5 ml), 1 N aqueous sodium hydroxide solution (2.5 ml) was added at room temperature under N₂ atmosphere. The solution was stirred at room temperature for 16 h and at 50° C. for 2 h. The mixture was cooled to room temperature, diluted with water and extracted with methylene chloride. Organic extracts were dried over anhydrous potassium sulfate and concentrated in vacuum. Crude product was purified by flash chromatography on silica gel (hexane:ethyl acetate=2:1) to give 1,1,1,2,2-pentafluoro-14-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchrom an-4-yl]-5-tetradecanone as colorless oil. yield 96 mg (quant.).

[1502]¹H NMR (300 MHz, CDCl₃) δ: 7.12-6.80 (5H, m, Ar—H), 6.42-6.34 (2H, m, Ar—H), 5.48 and 4.99 (1H each, s, OH), 4.51 (K1, d, JAB=10.2 Hz, C2′-H), 4.24 (1H, dd, JAB=10.2 Hz, J=1.9 Hz, C2′-H), 2.74 (2H, m, C4-H), 2.61 (1H, m, C4′-H), 2.48 (2H, t, J=7.4 Hz, C6-H), 2-47-2.27 (2H, m; C3-H), 1.65-1.50 (2H, m), 1.30-0.98 (19H, m, alkyl-H).

[1503]¹³C NMR (75 MHz, CDCl₃) δ: 208.3, 154.9, 153.8, 153.0, 137.4, 131.2, 126.3, 118.2, 115.27, 107.14, 102.7, 69.4, 45.4, 43.0, 38.3, 34.5, 33.5, 29.3, 29.2, 29.1, 29.0, 27.6, 26.7, 23.8.

EXAMPLE 62

[1504] Synthesis of (E)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS)-7-hydroxy-3-(4-hydroxy phenyl)-3-methylchroman-4-yl]nonyl}-2-heptenoic Acid

[1505] Steps 1)-7) see above in Example 61.

[1506] Step 8) Synthesis of ethyl 2-(4,4,5,5,5-pentafluoro-1-hydroxypentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]undecanoate.

[1507] To a stirred solution of ethyl 2-(4,4,5,5,5-pentafluoro-1-oxopentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyls-3-methylchroman-4-yl]undecanoate (300 mg, 0.41 mmol) in methyl alcohol, (15 ml), cooled to 0-5° C. on ice bath, sodium tetrahydroborate (62 mg, 1.64 mmol) was added as a solid under N₂ atmosphere and stirring at 0-5° C. continued for 1.5 h. The mixture was partitioned between ethyl acetate and water, organic layer was separated, washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuum. Crude product was purified by flash chromatography on silica gel (hexane:ethyl acetate=5:2) to give ethyl 2-(4,4,5,5,5-pentafluoro-1-hydroxypentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]undecanoate as a colorless oil (mixture of anti and syn isomers at C2/C1′). yield 279 mg (93%)

[1508] Syn Isomer (Major):

[1509]¹H NMR (300 MHz, CDCl₃) δ: 7.17-6.91 (5H, m, Ar—H), 6.60-6.53 (2H, m, Ar—H), 5.18 and 5.15 (2H each, s, OCH ₂OMe), 4.53 (1H, d, J_(AB)=10.4 Hz, C2″-H), 4.26 (1H, dd, J_(AB)=10.4 Hz, J=1.9 Hz, C2″-H), 4.19 (2H, q, J=7.1 Hz, OCH ₂Me), 3.67 (1H, m, C1′-H), 3.50 and 3.49 (3H each, s, MeOCH₂O), 2.82 (1H, d, J=8.5 Hz, C2-H), 2.65 (1H, m, C4″-H), 2.47-1.97 (4H, m), 1.84-1.55 (4H,, m), 1.28 (3H, t, J=7.1 Hz, MeCH₂O), 1.27-1.02 (17H, m, alkyl-H).

[1510] Anti Isomer (Minor):

[1511]¹H NMR (300 MHz, CDCl₃) δ: 7.17-6.91 (5H, m, Ar—H), 6.60-6.53 (2H, m, Ar—H), 5.18 and 5.15 (2H each, s, OCH ₂OMe), 4.53 (1H, d, JAB=10.4 Hz, C2″-H), 4.26 (1H, dd, J_(AB)=10.4 Hz, J=1.9 Hz, C2″-H), 4.18 (2H, q, J=7.1 Hz, OCH ₂Me), 3.80 (1H, m, C1′-H), 3.50 and 3.49 (3H each, s, MeOCH₂O), 2.69-2.59 (2H, m), 2.49-1.93 (4H, m), 1.77-1.61 (2H, m), 1.28 (3H, t, J=7.1 Hz, MeH₂O), 1.32-1.02 (17H, m, alkyl-H).

[1512] Step 9) Synthesis of ethyl (E,Z)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]nonyl}-2-heptenoate.

[1513] To a stirred solution of ethyl 2-4,4,5,5,5-pentafluoro-1-hydroxypentyl)-11-[(3RS,4RS)-7-methoxymethoxy-3-4methoxymethoxyphenyl)-3-methylchroman-4-yl]undecanoate (279 mg, 0.38 mmol) and triethylamine (61 mg, 0.6 mmol) in methylene chloride (2 ml), methane sulfonyl chloride (52 mg, 0.45 mmol) was added at room temperature and the reaction mixture was stirred at room temperature for 3 h. After-1,8-diazabicyclo[5.4.0]undec-7-ene (0.2 ml) was added- The mixture was stirred continued at room temperature for 16 h The mixture was diluted with diethyl ether and washed with 2 N aqueous hydrochloric acid, saturated sodium hydrogen carbonate and brine, dried over anhydrous sodium sulfate and concentrated in vacuum. Crude product was purified by flash chromatography on silica gel (hexane:ethyl acetate=4:1) to give ethyl (E,Z)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]nonyl}-2-heptenoate as a colorless oil. yield 235 mg (86%).

[1514] E Isomer (Major):

[1515]¹H NMR (300 MHz, CDCl₃) δ: 7.17-6.92 (5H, m, Ar—H), 6.63 (1H, t, J=7.4 Hz, C3-H), 6.60-6.53 (2H, m, Ar—H), 5.18 and 5.15 (2H each, s, OCH ₂OMe), 4.52 (1H, d, J_(AB)=10.2 Hz, C2″-H), 4.26 (1H, dd, J_(AB)=10.2 Hz, J=1.6 Hz, C2″-H), 4.19 (2H, q, J=7.2 Hz, OCH₂Me), 3.50 and 3.49 (3H each, s, MeOCH₂O), 2.64 (1H, m, C4″-H), 2.50-2.40 (2H, m), 2.34-2.04 (4H, m), 1.27 (3H, t, J=7.1 Hz, MeCH₂O), 1.32-0.98 (19H, m, alkyl-H).

[1516] Z-Isomer (Minor):

[1517]¹H NMR (300 MHz, CDCl₃) δ: 7.17-6.92 (5H, m, Ar—H), 6.60-6.53 (2H, m, Ar—H), 5.80 (1H, t, J=7.4 Hz, C3-H), 5.18 and 5.15 (2H each, s, OCH ₂OMe), 4.52 (1 μl, d, J_(AB)=10.2 Hz, C2″-H), 4.26 (1H, dd, JAB=10.2 Hz, J=1.6 Hz, C2″-H), 4.20 (2H, q, 3=7.2 Hz, OCH ₂Me), 3.50 and 3.49 (3H each, s, MeOCH₂O), 2.70-2.59 (3H, m), 2.20-2.02 (4H, m), 1.30 (3H, t, J=7.2 Hz, MeCH₂O), 1.32-0.98 (19H, m, alkyl-H).

[1518] Step 10) Synthesis of (E)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]nonyl}-2-heptenoic acid.

[1519] To a stirred solution of ethyl (E)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]nonyl}-2-h eptenoate (116 mg, 0.16 mmol) in ethyl alcohol (5 ml), 5 N aqueous potassium hydroxide solution was added and the mixture was stirred under- N₂ atmosphere at 70° C. for 5 h. After cooling to room temperature the reaction mixture was acidified by 6 N aqueous hydrochloric acid and extracted with methylene chloride. Extracts were dried over anhydrous sodium sulfate and concentrated in vacuum to give crude (E)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]nonyl}-2-heptenoic acid as a colorless oil. yield 111 mg (quant.). The sample was used in the following step without further purification.

[1520]¹H NMR (300 MHz, CDCl₃) δ: 7.17-6.92 (5H, m, Ar—H), 6.79 (1H, t, J=7.3 Hz, C3-H), 6.60-6.53 (2H, m, Ar—H), 5.18 and 5.15 (2H each, s, OCH ₂OMe), 4.53 (1H, d, JAB=10.7 Hz, C2″-H), 4.26 (1H, dd, JAB=10.7 Hz, J=1.9 Hz, C2″-H), 3.49 (6H, s, MeOCH₂O), 2.65 (1H, m, C4″-H), 2.55-2.44 (2H, m), 2.34-2.07 (4H, m), 1.44-0.98 (19H, m, alkyl-H).

[1521] Step 11) Synthesis of (E)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS) 7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]nonyl}-2-heptenoic acid.

[1522] To a stirred solution of (E)-6,6,7,7,7-pentafluoro-2-(9-[(3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]nonyl)-2-h eptenoic acid (111 mg, 0.16 mmol) in ethyl alcohol (5 ml), was added 6 N aqueous solution of hydrochloric acid (30 drops) and the reaction mixture was stirred at 40° C. for 6 h. The reaction mixture was diluted with water and extracted with methylene chloride. Organic extracts were dried over anhydrous sodium sulfate and concentrated in vacuum. Crude product was purified by flash chromatography on silica gel (hexane:ethyl acetate : methyl alcohol=10:10:1), and then additionally by preparative thin-layer chromatography on Merck Silica-gel 60 plates (hexane:ethyl acetate : methyl alcohol =5:5:1) to give (E)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl) 3-methychroman-4-yl nonyl}-2-heptenoic acid as a colorless amorphous solid. yield 47.4 mg (49%)

[1523]¹H NMR (300 MHz, CDCl₃) δ: 7.12-6.80 (6H, m, Ar—H and C3-H), 6.41-6.35 (2H, m, Ar—H), 4.51 (1H, d, J_(AB)=10.4 Hz, C2″-H), 4.24 (1H, dd, J_(AB)=10.4 Hz, J=1.6 Hz, C2″-H), 2.61 (1H, m, C4″-H), 2.56-2.44 (2H, m), 2.35-2.07 (4H, m), 1.44-0.99 (19H, m, alkyl-H).

EXAMPLE 63

[1524] Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]chroman

[1525] Step 1) Synthesis of (3RS,4RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylamino)nonyl]chroman

[1526] 4-(9-aminononyl)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman (82.3 mg, 0.17 mmol) was dissolved in 5 ml of methylenechloride under argon atmosphere, which was then cooled down to 0 C. 4,4,5,5,5-pentafluoropentylsulfonyl chloride (1 10.4 mg, 0.42 mmol) in 1 ml of methylene chloride and triethylamine (0.07 ml, 0.5 mmol) was added thereto, and the mixture was stirred at the same temperature for 30 minutes. The reaction was quenched with water, and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate, and concentrated. The residue was subject to flash chromatography in silica gel (n-hexane:ethyl acetate=5:1) to give the title compound (81 mg, yield 67%) as a colorless oil.

[1527]¹H-NMR (270 MHz, CDCl₃) δ: 7.13 (d, 3=8.9 Hz, 2H, Ar—H), 7.03 (d, J=8.9 Hz, 2H, Ar—H), 6.95-(d, J=9.2 Hz, 1H, C5-H), 6.58-6.54 (in, 2H, Ar—H), 5.18 (s, 2H, OCH ₂CH₃), 5.15 (s, 2H, OCH ₂CH₃), 4.53 (d, J=10.2 Hz, 1H, C2-H), 4.26 (d, J=10.6 Hz, 1H, C2-H), 4.25 (brs, 1H, NH), 3.06-3.13 (m, 4H, CH ₂—NH and SO₂ CH ₂), 3.50 (s, 3H, OCH₂ CH ₃), 3.49 (s, 3H, OCH₂ CH ₃), 2.6-2.7 (m, 1H, C4-H), 2.38-2.05 (m, 4H, CH ₂ CH ₂CF₂CF₃) 1.58-0.94 (m, 19H, C3-CH. and alkyl-H)

[1528] Step 2) Synthesis of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-r[94,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]-chroman

[1529] A mixture of (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]chroman (81 mg, 0.011 mmol) and 9-10% HCl/MeOH(0.5 ml) was stirred at room temperature for 1 h. To the mixture was added 9-10% HCl/MeOH(0.5 ml) and stirred at room temperature for 24h. The reaction was quenched with saturated sodium hydrogen carbonate solution and the resulting mixture was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and concentrated. The residue was separated by preparetive TLC (chloroform:MeOH=9: 1) to give the title compound (82 mg, yield 82%) as a colorless oil.

[1530]¹H-NMR (270 MHz, CDCl₃) δ: 7.08 (d, J=8.6 Hz, 2H, Ar—H), 6.90 (d, J=7.9 Hz, 1H, C5-H), 6.84 (d, J=8.6 Hz, 2H, Ar—H), 6.40-6.37 (m, 2H, Ar—H), 5.56 (brs., 1H, Ar—OH), 5.10 (brs., 1H, Ar—OH), 4.53-4.42 (m, 2H, C2-H and NH), 4.23 (d, J=10.6 Hz, 1H, C2-H), 3.14-3.07 (m, 4H, CH NH and SO₂CH₂), 2.65-2.56 (m, 1H, C4-H), 2.38-2.05 (m, 4H, CH ₂ CH ₂CF₂CF₃) 1.58-0.95 (m, 19H, C3-CH and alkyl-H)

EXAMPLE 64

[1531] Synthesis of (3′RS,4′RS-(E)-3-{4-[7-hydroxy-3-(4-hydroxyphenyl)thiochromen-4-yl]phenyl}propeneoic Acid

[1532] Step 1) Synthesis of 4-(Bromophenyl)-(1,3)-dioxolane.

[1533] In a round-bottomed flask equipped with a Dean Stark trap and a condenser, was added a solution of p-Bromobenzaldehyde (5 g, 27 mmol) in toluene (25 mL). To this mixture were then added p-toluenesulfonic acid (50 mg, 0.26 mmol) and etylene glycol (1.84 g, 29.7 mmol). The mixture was heated to reflux under nitrogen atmosphere for 8 h. The progress of the reaction was monitored by TLC. When the reaction was complete, the mixture was cooled down, the solvent was removed under reduced pressure, the residue material was distilled to give an oil (5.49 g, 89%).

[1534]¹H-NMR (300 MHz, CDCl₃) δ: 7.50 (2H, d, J=8.3 Hz, Ar—H), 7.34 (2H, d, J=8.3HY, Ar—H), 5.77 (s, 1H, Ar—CH), 4.03 (m, 4H, O—CH₂)

[1535] Step 2) Synthesis of (3′RS,4′RS)-{[4-(1,3-dioxolane)-2-ylphenyl]-7-methoxy-3-(4-methoxyphenyl)thiochroman-4-ol

[1536] To a solution of 2-[4-(bromophenyl)]-1,3-dioxolane (687 mg, 3 mmol) in THF (15 mL) at 78° C. under nitrogen was added n-Butyllithium (1.61 M solution in hexane, 3.3 mmol, 2.04 mL) dropwise. The reaction mixture was stirred at that temperature for 45 minutes. Chromanone derivative (840 mg, 2.8 mmol) in THF (10 mL) was then added. The reaction mixture was gradually warmed up to room temperature and stirred overnight. Water was added and the organic layer was extracted by ethyl acetate, washed with brine, dried, concentrated under reduced pressure to give 1.51 g of crude mixture. Column chromatography of the mixture (hexane/ethyl acetate:3/1) gave 995 g of the title compound (73%).

[1537]¹H-NMR (300 MHz, CDCl₃) δ: 7.3 (2H, d, J=9 Hz, Ar—H), 7.2 (2H, d, J=9 Hz, Ar—H), 6.8-6.4 (7H,m, Ar—H), 5.7 (1H, s, Ar—CH—O), 4.1 (4H, m, oxalane), 3.8 (3H, s, Ar—OMe), 3.7 (4H, m, C2H,Ar—OMe), 3.51 (1H, d, J=10.8 Hz, C3H), 2.86 (1H, dd, J=13, 2.3 Hz, C2H), 2.1 (1H, s, OH)

[1538] Step 3) Synthesis of (3′RS,4′RS)-{4-[7-methoxy-3-(4-methoxyphenyl) thiochroman-4-yl]phenyl}benzaldehyde

[1539] To a solution of chromanol derivative (1 g, 2.2 mmol) in methylene chloride (10 mL) at room temperature was slowly added methaesulfonic acid. The reaction mixture turned red. After about 15 minutes TLC showed the completion of the reaction. Water was added and the aqueous layer was extracted by ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, saturate sodium chloride, dried, concentrated to give 1.31 g of the crude product. Flash chromatography of the crude mixture (Hexane/ethyl acetate: 5/1) formed 0.83 g (97%) of the pure title compound. Spectroscopic analysis of the product showed that both dehydration and deprotection had taken place.

[1540]¹H-NMR (300 MHz, CDCl₃) δ: 9.95 (1H, s, aldehyde), 7.72 (2H, d, J=8.3 Hz, Ar—H), 7.2 (2H, d, J=7.9 Hz, Ar—H); 6.9 (3H, m, Ar—H), 6.64 (3h, d, J=8.6 Hz, Ar—H), 6.54 (1H, m, Ar—H), 3.8 (3H, s, Ar—OMe), 3.76 (2H, s, C2H), 3.73 (3H, s, Ar—OMe).

[1541] Step 4) Synthesis of (3′RS,4′RS)-(E)-3-{4-[7-methoxy-3-(4-methoxyphenyl) thiochromene-4-yl]phenyl}propeneoic Acid

[1542] To a solution of thiochromene aldehyde derivative (0.39 g, 1.02 mmol) in pyridine (8 mL), was added malonic acid (321 mg, 3.07 mmol) and piperidine (87.1 mg, 1.02 mmol). The mixture was heated up and stirred at 60° C. for 1 h and at 100° C. for 1.5 h after which TLC showed completion. Ice water was added and the mixture was acidified by 2N HCl to pH 2-3. The reaction mixture was extracted three times by ethyl acetate and the organic layer was washed with brine, dried, concentrated under reduced pressure to give 0.55 g of crude product which was purified by flash chromatography (ethyl acetate) to form 0.43 g (97%) of the desired compound.

[1543]¹H-NMR (300 MHz, CDCl₃) δ: 7.25 (1H, d, J=16 Hz, vinyl), 7.4 (2H, d, J=8.2 Hz, Ar—H), 7.06 (2H, d, J=8.2, Ar—H), 6.94 (3H, m, Ar—H), 6.68 ((3H, m, Ar—H), 6.54 (1H, m, Ar—H), 6.4 ((1H, d, i=16 Hz, vinyl), 3.83 (3H, s, Ar—OMe), 3.75 (2H, s, C2H), 3.73 (3H, s, Ar—OMe).

[1544] Step 5) Synthesis of (3′RS,4′RS)(E)-3-{4-[7-hydroxyoxy-3-(4-hydroxy oxyphenyl)thiochromene-4-yl]phenyl)propeneoic acid

[1545] To a solution of thiochrmene acid derivative (200 mg, 0.46 mmol) in methylene chloride (5 mL) at 10° C. under nitrogen was added a solution of phosphorus tribromide in methylene chloride (1 M, 1.86 mL). The reaction mixture was stirred at 0° C. for 3 h. When TLC analysis showed the completion of the reaction, water was added and the mixture was acidified to pH 3 with 0.5 N HCl, extracted by ethyl acetate and dried, concentrated to give 0.23 g of the crude mixture. Purification by flash chromatography (MeOH/CH₂Cl₂: 1/10) produced 136.5 mg (73%) of the title compound.

[1546]¹H-NMR (300 MHz, CDCl₃) δ: 7.63 (1H, d, J=16 Hz, vinyl), 7.54 (2H, d, J=8.0 Hz, Ar—H), 7.06 (2H, d, J=8.0 Hz), 6.9 (3H, m, Ar—H), 6.87 (1H, s, Ar—H), 6.6-6.4 (6H, Ar—H, Ar—OH, vinyl), 3.7 (2H, s, C2H).

EXAMPLE 65

[1547] Synthesis of (3′RS,4′RS)-(E-3-1s[7-hydroxy-3-(4-hydroxyphenyl) thiochroman-4-yl]phenyl)propeneoic Acid

[1548] Step 1) Synthesis of (4-bromo-benzyloxy)tert-butyl-dimethyl-silane

[1549] To a solution of p-bromobenzyl alcohol (5.0 g, 26.7 mmol) in DMF (10 mL) was added imidazole (4.54 g, 66.7 mmol) followed by addition of tert-butyldimethylsilyl chloride (6.01 g, 40 mmol). The progress of the reaction was monitored by TLC. When the reaction was complete (about 2 h), methanol was added and diluted by 20% ethyl acetate in hexane. The organic layer was washed several times with water and then with brine, dried, concentrated under reduced pressure to give 7.5 g of the crude product which was passed through a short column chromatography to give 7.3g (91%) of the desired compound.

[1550]¹H-NMR (300 MHz, CDCl₃) δ: 7.44 (2H, d, J=8.5 Hz, Ar—H), 7.19 (2H, d, J=8.5 Hz, Ar—H), 4.68 (2H, s, benzyl), 0.94 (9H, s, t-Bu), 0.09 (6H, s, Me).

[1551] Step 2) Synthesis of (3′RS,4′RS)-4-{[7-methoxy-3-(4-methoxyphenyl)thio chroman-4-yl]phenyl}methanol

[1552] To a solution of (4-bromobenzyloxy tert-butyldimethylsilane (0.99 c, 3.32 mmol) in THF (15 mL) at 78° C. under nitrogen was added n-butyllithium (1.61 M solution in hexane, 3.32 mmol, 2.06 mL) dropwise. The reaction mixture was stirred at that temperature for 45 minutes chromanone derivative (0.5 g, 1.66 mmol) in THF (10 mL) was then added. The reaction mixture was gradually warmed up to room temperature and stirred overnight. Water was added and the organic layer was extracted by ethyl acetate washed with brine, dried, and concentrated under reduced pressure to give 1.41 g of crude mixture. After passing through a short column., the mixture which contained the desired product, starting material and some deoxygenated chromenone, was treated with zinc iodide (794 mg, 2.49 mmol) and sodium cyanoborohydride (617 mg, 9.9 mmol) in 1,2-dichloroethane (10 mL). After completion of-the reaction, saturated ammonium chloride was added and extracted by 50% ethyl acetate in hexane. Since the desired product and the small impurities were not separated, the mixture was dissolved in THF (10 mL) and treated with a solution of tetrabutylammonium fluoride (1 M in TBF). When the reaction was complete, the desired product was separated from the by-products by flash chromatography (methylene chloride/ethyl acetate: 25/1) to give 378 mg (55%) of the title compound.

[1553]¹H-NMR (300 MHz, CDCl₃) δ: 7.08 (2H, d, J=8 Hz, Ar—H), 6.9-6.7 (2H, m, Ar—H), 6.6-6.45 (7H, m, Ar—H), 4.6 (2H, s, benzyl-O ), 4.2 (1H, d, J=4.5 Hz, C4H), 3.78 (6H, s, Ar—OMe), 3.75-3.54 (2H, m, C2H), 2.8 (1H, d, J=12, C3H).

[1554] Step 3) Synthesis of (3′RS,4′RS)-4-[7-methoxy-3-(4-methoxyphenyl)-thiochroman-4-yl]benzaldehyde

[1555] To a solution of chroman derivative (320 mg, 0.82 mmol) in methylene chloride (8 mL) was added manganese (IV) oxide (568 mg, 6.5 mmol). The reaction mixture was stirred at room temperature for 5 h. When the reaction was complete, the mixture was diluted with methylene chloride and filtered through a short path of celite. The solvent was removed under reduced pressure to give 312 mg (97%) of the desired compound

[1556]¹H-NMR (300 MHz, CDCl₃) δ: 9.9 (1H, s, aldehyde), 7.6 (2H, d, J=8.24 Hz, Ar—H), 6.8-6.4 (9H, m, Ar—H), 4.25 (1H, d, J=4.3 Hz, C4H), 3.79 (6H, s, Ar—OMe), 3.60-3.30 (2H, m, C2H), 2.85 (1H, d, J=12.0 Hz, C3H).

[1557] Step 4) Synthesis of (3 methoxyphenyl) thiochroman-4-yl]phenyl}propeneoic Acid

[1558] To a solution of chromene aldehyde derivative (312 mg, 0.8 mmol) in pyridine (7 mL), was: added malonic acid (256 mg, 2.44 mmol) and piperidine (69.0 mg, 0.81 mmol). The mixture was heated up and stirred at 60° C. for 1 h and at 100° C. for 2 h after which TLC showed completion. Ice- water was added and the mixture was acidified by 2N HCl to pH 2 3. The reaction mixture was extracted three times by ethyl acetate and the organic layer was washed with brine, dried, concentrated under reduced pressure to give 0.55 g of crude product which was purified by flash chromatography (ethyl acetate) to form 0.283g (82%) of the desired compound.

[1559]¹H-NMR (300 MHz, CDCl) δ: 7.68 (1H, d, J=16H, vinyl), 6.8-6.5 (111H, m,Ar—H), 6.3 (1H d, , J=16, vinyl), 4.22 (1H, d, J=3.6, C4H), 3.79 (6H, s, Ar—OMe), 3.55 (1H, m, C2H), 3.4 (1H, t, J=12 Hz, C2H ), 2.82 (1H, d, J=12 Hz, C3H).

[1560] Step 5) Synthesis of (3′RS,4′RS)-(E)-3-{4-[7-hydroxy-3-(4-hydroxyphenyl) thiochroman-4-yl]phenyl}propeneoic Acid

[1561] To a solution of chroman acid derivative (250 mg, 0.58 mmol) in methylene chloride (7.5 mL) at 10° C. under nitrogen was added a solution of phosphorus tribromide in methylene chloride (1 M, 2.32 mL). The reaction mixture was stirred at 0° C. for 3 h. When TLC analysis showed the completion of the reaction, water was added and the mixture was acidified to pH 3 by 0.5 N HCl, extracted by ethyl acetate, dried, and concentrated to give 0.23 g of the crude mixture. Purification by flash chromatography (MeOH/CH₂Cl₂: 1/10) produced 220 mg (94%) of the final product.

[1562]¹H-NMR (300 MHz, CDCl₃) δ: 7.68 (1H, d, J=16 Hz, vinyl),), 7.6-7.4 (3H, m, Ar—H), 7.15-6.6 (10H, m, Ar—H, Ar—OH) 6.3 (1H d, J=16 Hz, vinyl), 4.32 (1H, d, J=3.6, C4H), ), 3.55 (1H, m, C2H), 3.4 (1H, t, J=12 Hz, C2H ), 2.85 (1H, d, J=12 Hz, C4H).

EXAMPLE 66

[1563] Synthesis of (3′RS,4′RS)-(E)-3-{4-[7-hydroxy-3-(4-hydroxyphenyl)₃methylthio chroman-4-yl]phenyl}Propeneoic Acid

[1564] Step 1) Synthesis of (3′RS,4′RS)-4-{[(tert-butyl-dimethyl-silanyloxy)methyl phenyl]-7-methoxy-3-(4-methoxyphenyl)}-3-methylthiochroman

[1565] To a solution of (4-bromobenzyloxy) (tert-butyl) (dimethyl) silane(1.8 g, 6.0 mmol) in THF (30 mL) at 78° C. under nitrogen was added n-butyllithium (1.61 M solution in hexane, 6.0 mmol, 3.72 mL) dropwise. The reaction mixture was stirred at that temperature for 45 minutes. Chromanone derivative (0.94 g, 3.0 mmol) in THF (30 mL) was then added. The reaction mixture was gradually warm up to room temperature and stirred overnight. Water was added and the organic layer was extracted by ethyl acetate, washed with brine, dried, and concentrated under reduced pressure to give 2.53 g of the crude mixture. The crude mixture was purified by column chromatography (25% ethyl acetate-hexane) to remove the starting material and by-products and obtain 1.45 g (79%) of the desired compound- A portion of this compound (0.8 g, 1.5 mmol) was treated with zinc iodide (620 mg, 1.94 mmol) and sodium cyanoborohydride (612 mg, 9.7 mmol) in 1,2-dichloro ethane (25 mL). After completion of the reaction, saturated ammonium chloride was added and extracted by 50% ethyl acetate-hexane to form 0.82 g of the crude product which was a mixture of cis and trans compounds. Separation of the mixture by flash chromatography (hexane:ethyl acetate 10;1) gave 390 mg of the major (trans) and 180 mg of the minor (cis) compound (desired).

[1566]¹H-NMR (cis) (300 MHz, CDCl₃) δ: 7.35 (2H d, J=9.0H -Ar—H), 7.17 (2H, d, J=7.7 Hz, Ar—H), 7.12 (2H, d, J=8.2 Hz, Ar—H), 6.85 (2H, d, J=8.8 Hz), 6.79-6.69 (3H, m, Ar—H), 4.71 (1H, s, C4H), 3.75 (3H, s, Ar—OMe), 3.68 (3H, s, Ar—OMe), 3.21 (1H, d, J=12 Hz, C2H), 3.08 (1H, d, J=12 Hz, C2H), 1.17 (3H, s, C3Me), 0.94 (9H, s, t-Bu), 0.09 (6H, s, Si(Me)₂).

[1567] Step 2) synthesis of (3′RS,4′RS)-4-{[7-methoxy-3-(4methoxyphenyl)-3-methylthiochroman-4-yl]phenyl}methanol

[1568] The minor (cis) compound obtained in the previous experiment (180 mg, 0.3 mmol) was dissolved in THF (5 mL) and treated with a 1 mL of a solution of tetrabutylammonium fluoride (1 M in THF). When the reaction was complete, the desired product was separated from the by-products by flash chromatography (hexane/ethyl acetate: 3/2) to give 93 mg (76%) of the desired compound

[1569]¹H-NMR (300 MHz, CDCl₃) δ: 7.02 (2H, d, J=9.1 Hz Ar—H), 6.94 (2H, d, J=8.2 Hz, Ar—H), 6.85 (2H, d, J=8.5 Hz, Ar—H), 6.79-6.73 (3H, m, Ar—H), 4.49 (2H, s, benzyl-O), 3.76 (6H, s, Ar—OMe), 3.69 (11H, d, J=12.3 Hz, C2H), 2.71 (1H, d, J=12.3 Hz, C2H), 1.61 (31H, s, C3Me).

[1570] Step 3) Synthesis of (3′RS,4′RS)-4-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]benzaldehyde

[1571] To a solution of alcohol chroman derivative (930. mg, 0.23 mmol) in methylene chloride (2 mL) was added manganese (IV) oxide (160 mg, 1.84 mmol). The reaction mixture was stirred at room temperature for 5 h. When the reaction was complete, the mixture was diluted with methylene chloride and filtered through a short path of celite. The solvent was removed under reduced pressure to give 88 mg (96%) of the desired compound

[1572]¹H-NMR (300 MHz, CDCl₃) δ: 9.83 (1H, s, aldehyde), 7.47 (2H, d, J=8.3 Hz, Ar—H), 7.01 (2H, d, J=9-1 Hz Ar—H), 6.85-6.72 (6H, , m, Ar—H), 6.53 (1H, d, J=8.51 Hz, Ar—H), 4.07 (1H, s, C4H), 3.79 (3H, s, Ar—OMe), 3.77 (3H, s, Ar—OMe), 3.67 (1H, d, J=14.0 Hz, C2H), 2.74 (1H, d, J=14.0 Hz, C2H), 1.58 (3H, s, C3Me).

[1573] Step 4) Synthesis of (3′RS,4′RS)(E)-3-{4-[7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman-4-yl]phenyl}propeneoic Acid

[1574] To a solution of chromene aldehyde derivative (88 mg, 0.23 mmol) in pyridine (2 mL), were added malonic acid (256 mg, 2.44 mmol) and piperidine (68.0 mg, 0.6 mmol). The mixture was heated-up and stirred at 60° C. for 1 h and at 100° C. for 2 h after which TLC showed completion. Ice-water was added and the mixture was acidified by 2N HCl to pH 2-3. The reaction mixture was extracted three times with ethyl acetate and the organic layer was washed with brine, dried, and concentrated under reduced pressure to give 91 mg of crude product which was purified by flash chromatography(ethyl acetate) to provide 91 mg (94%) of the desired compound.

[1575]¹H-NMR (300 MHz, CDCl₃) δ: 7.59 (1H, d, J=16 Hz, vinyl), 7.14 (2H, d, J=9.0 Hz, Ar—H), 7.03 (2H, d, J=9.1 Hz Ar—H), 6.86-6.74 (4H, , m, Ar—H), 6.60-6.54 (3H, , m, Ar—H), 6.27 (1H, d, J=16 Hz, vinyl), 4.01 (1H, s, C4H), 3.78 (6H, s, Ar—OMe), 3.69 (1H, d, J=12.2 Hz, C2H), 2.74 (1H, d, J=12.2 Hz, C2H), 1.58 (3H, s, C3-Me).

[1576] Step 5) Synthesis of (3′RS,4′RS-(E-3-14-[7-hydroxy-3-4hydroxyphenyl)-3-methylthiochroman-4-yl]phenyl)propeneoic Acid

[1577] To a solution of chroman acid derivative (90 mg, 0.2 mmol) in methylene chloride (2.5 mL) at 10° C. under nitrogen was added a solution of phosphorus tribromide in methylene chloride (1 M, 0.8 mL). The reaction mixture was stirred at 0° C. for 3 h. When TLC analysis showed the completion of the reaction , water was added and the mixture was acidified to pH 3 with 0.5 N HCl, extracted by ethyl acetate, dried, and concentrated to give 88.0 mg of the crude mixture. Purification by flash chromatography (MeOH/CH₂Cl₂: 1/10) produced 71 mg (85%) of the final product.

[1578]¹H-NMR (300 MHz, CDCl₃) δ: 8.15 (1H, s, Ar—OH), 7.69-7.60 (3H, m, Ar—H, vinyl), 7.43-7.34 (4H, m, Ar—H), 6.83 (1H, d, J=8.24 Hz, Ar—H), 6.69 (2H, d, 15 Hz, Ar—H), 6.50 (2H, m, Viny, Ar—OH), 6.37 (1H, dd, J=6.9, 3 Hz, Ar—H), 4.68 (1H, s, C4H), 3.22 (2H, m,C2H), 1.16 (3H, s, C3Me).

EXAMPLE 67

[1579] Synthesis of (3′RS,4′RS)-N-[2-4,4,5,5,5pentafluoropentylsulfinyl)lethyl-4-{4-[7-hydroxy-3-(4-hydryoxyphenyl)₃methylchroman-4-yl]butyl}phenyl-N-methylamine

[1580] Step 1) Synthesis of 2-[(4-bromophenyl)methylamino]ethanol

[1581] To a solution of 2-(N-methylanilino)ethanol (0.76 g, 5 mmol) in methylene chloride (5 mL) were added tetraethylammonium chloride (83.0 mg, 0.5 mmol) and 0.1 mL of methanol. While stirring, a solution of bromine(0.8 g, 5 mmol) in methylene chloride (5 mL) was added slowly in a period of 5 minutes. When the color of the bromine persisted, triethylamine (0.75 mL) was added dropwise. The reaction mixture was diluted by ethyl acetate, washed with saturated sodium bicarbonate and brine, dried, and concentrated under reduced pressure to give 1.31 g of crude product which contained some 2,6-dibromo derivative. Flash chromatography of the crude mixture(35% ethyl acetatethexane) gave 0.87 g (75%) of the desired product.

[1582]¹H-NMR (300 MHz, CDCl₃) δ: 7.28 (2H, d, 9 Hz, Ar—H), 6.65 (2H, d, J=9 Hz, Ar—H), 3.79 (2H, t, 1=5.5 Hz, N—CH₂), 3.45 (2H, t, J=5.5 Hz, O—CH₂), 2.94 (3H, s, N-Me), 1.64 (1H, br s, OH).

[1583] Step 2) Synthesis of (4-bromophenyl)methyl[(tert-bytyldimethylsilanyloxy)ethyl]amine

[1584] To a solution of 2-(N-methyl-4-bromoamino)ethanol (0.62 g, 2.7 mmol) in DMF (1.5 mL) was added imidazole (0.46 g, 6-7 mmol) followed by addition of tert-butyldimethylsilyl chloride (0.48 g, 3.2 mmol). The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by TLC. When the reaction was complete (about 2 h), methanol was added and diluted by 20% ethyl acetate-hexane. The organic layer was washed with water several times and brine, dried, and concentrated under reduced pressure to give 0.99 g of the crude product which was purified by flash chromatography (5% ethyl acetate in hexane) to give 0.88 g (95%) of the desired compound.

[1585]¹H-NMR (300 MH, CDCl₃) δ: 7.27 (2M d, 9 Hz, Ar—H), 6.57 (2H, d, J=9 Hz, ArH), 3.79 (2H, t, J=6.0 Hz, N—CH₂), 3.45 (2H, t, J=6.0 Hz,O— CH₂), 2.95 (3H, s, N—Me), 0.87 (9H, s, t-BuSi), 0.01 (6H, s, Me—Si).

[1586] Step 3) Synthesis of [4-allylphenyl-N-tert-butyldimethylsilanyloxy) ethyl-N-methyl]Amine

[1587] To a solution of bromoaniline derivative (344 mg, 1 mmol) in THF (10 mL) at 78° C. under nitogen, was added n-butyllithium (1.54 M solution in hexane, 0.71 mL, 1-1 mmol) and stirred at that temperature for 45 minutes. Solid copper (II) bromide-dimehylsulfide complex (205.6 mg, 1 mmol) was added and the reaction mixture was stirred at 78° C. for 2 h. Allyl bromide (241 mg, 2 mmol) in THF (2 mL) was added dropwise and when the addition was complete, the reaction mixture was warmed up to room temperature and saturated ammonium chloride was added and was extracted by 50% ethyl acetate in hexane. The, organic layer was washed with brine and dried over magnesium sulfate and concentrated under reduced pressure to give 390 mg of a crude mixture. Flash chromatography of (5% ethyl acetate in hexane) produced 256 mg (84%) of the desired compound.

[1588]¹H-NMR (300 MHz, CDCl₃) δ: 7.05 (2H, d, 9.0 Hz, Ar—H), 6.66 (2F, d, J=9.0 Hz, Ar—H), 5.95 (1H, allyl), 5.03 (2H, allyl), 3.76 (2H, t, J=6.3 Hz, N—CH₂), 3.44 (2H, t, J=6.3 Hz, O—CH₂), 3.35 (d, J=6.6 Hz, Ar—CH₂), 2.96 (3H, s, N—Me), 0.89 (9H, s, t-BuSi), 0.02 (6H, s, Me—Si).

[1589] Step 4). Synthesis of N-[2-(tert-butyldimethylsilanyloxy)]ethyl-N-methyl-4-{(3′RS,4′RS)-4-[7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]butyl}phenyl amine

[1590] A solution of allyl chroman derivative (154 mg, 0.4 mmol), ally aniline (247 mg, 0.8 mmol) and benzylidine-bis(tricyclohexylphosphine{dichlororuthenium (15 mg, 10 mol %) in methylene chloride (5 mL) was refluxed under nitrogen. When the starting material disappeared, the solvent was removed. Flash chromatography of the crude mixture gave 355 mg (83%) of the desired compound as the main product. To this compound in ethyl acetate (2 mL) was added 10% palladium on charcoal(180 mg, 50% w/w). The reaction mixture was stirred at room temperature for 2 h. When the reaction was complete, it was diluted by ethyl acetate and filtered through celite. The solvent was removed under reduced pressure to give 346 mg (81% overall) of the desired product.

[1591]¹H-NMR (300 MHz, CDCl₃) δ: 7.12 (2H, d, J=9.0 Hz, Ar—H), 7.023 (2H, d, J=9.0 Hz, Ar—H), 6.9 (3H, m, Ar—H), 6.6-6.4 (4H, m, Ar—H), 5.18 (2H, s, Ar—OCH₂), 5.15 (2H, s, Ar—OCH₂), 4.53 (1H, d, J=10.4 Hz —OCH₂), 4.24 (1H, d, J=10.4 Hz-C2H), 3.72 (2H, t, J=6.6, 6.6 Hz, N—CH₂), 3.51 (6H, s, OMe), 3.41 (21 t, J=6.6 Hz, 6.6 Hz, —SiOCH₂), 2.95 (3H, s, N—Me), 2.64 (1H, brs, C4H), 2.31 (2H, brm, N—Ar—CH₂—), 1.28 (61H, m, (CH₂)₂, 0.89 (9H, s, t-BuSi), 0.02 (6H, s, Me—Si).

[1592] Step 5) Synthesis of 4-{(3′RS,4′RS)-4-[7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]butyl}phenyl-N-methylamino ethanol

[1593] A solution of the chroman derivative (550 mg, 0.83 mmol) was dissolved in THF (5 mL) and treated with a 1 7 mL of a solution of tetrabutylammonium fluoride (1 M in THF). When the reaction was complete, the reaction mixture was diluted with ethyl acetate. Aa column chromatography gave 390 mg (86%) of the desired compound.

[1594]¹H-NMR (300 MHz CDCl₃) δ: 7.19 (2H, d, J=9.0 Hz, Ar—H), 7.03 (2H, d, J=9.0 Hz, Ar—H), 6.9 (3H, m, Ar—H), 6.72 (2H, d, J=9 Hz, Ar—H), 6.55 (2H, m, Ar—CH), 5-18 (2H, s, Ar—OCH₂), 5.15 (2H, s, Ar—OCH₂) 4.53 (1H, d, J=10.4 Hz.—C2H), 4.24 (1H, d, J=10.4 Hz-C2H), 3.75 (2H, t, J=6.6 Hz, N—CH₂),3.50 (6H, s, OMe), 3.41 (2H, t, J=6.6 Hz, OCH₂), 2.95 (3H, s, NMe), 2.62 (1H, brs, C4H), 2.39 (2H, brm, N—Ar—CH2-), 1.28 (6H, m, (CH2)2.

[1595] Step 6) Synthesis of 4-{(3′RS,4RS)-4-[7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-yl]butyl phenyl-N-methylaminoethyl sulfonate

[1596] To a solution of chroman alcohol derivative (390 mg, 0.71 mmol) in ether (3.5 mL) at 0° C. was added triethylamine (135,S, 0.97 mmol) followed by addition of methanesulfonyl chloride (64 μl 0.83 mmol). After 30 minutes the reaction was complete. The reaction was quenched with water and extracted with ether, washed with 1N HCl, saturated sodium bicarbonate, and brine. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give 412 mg of the crude product which was passed through a short column (50% ethyl acetate in hexane) to give 401 mg (92%) of the mesylated compound

[1597]¹H-NMR (300 MHz, CDCl₃) δ: 12 (2H, d, J=8.8 Hz, Ar—H), 7.03 (2H, d, J=9.0 Hz, Ar—H), 6.8 (3H, m, Ar—H), 6.64 (2H, d, J=8.8 Hz Ar—H), 6.54 (2H, m, Ar—H), 5.18 (2H, s, Ar—OCH₂), 5.15 (2H, s, Ar—OCH₂), 4.53 (1H, d, J=10.4 Hz-C2H), 4.35 (2H, t, 6.0 Hz, Ar—N—CH₂) 4.25 (1H, d, J=10.4 Hz-C2H), 3.5 (2H, t, J=6.0 Hz, Ms OCH₂), 3.49 (6H, s,OMe), 2.96 (3H, s, NMe), 2.96 (3H, s, CH₃-methane), 2.63 (1H, brd, C4H), 2.32 (2H, brt, J=6.9 Hz, N—Ar—CH₂—), 1.26 (6H, m, (CH₂)₂.

[1598] Step 7) Synthesis of N-f-244,4,5,5,5-pentafluoropentylsulfano)ethyl-4-{4-[(3′RS,4′RS)-7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-y l]butyl}phenyl-N-methylamine

[1599] To a solution of thioacetate (0.87 g, 3.66 mmol) in methanol (2 mL) at room temperature under nitrogen was added a 1 M solution of sodium methoxide (1.28 mL) and the mixture was stirred for 30 minutes. A solution of previously prepared mesylate (0.401 g, 0.64 mmol) in TBF (2 mL) was added to the above solution dropwise in a period of 10 minutes. The reaction mixture was stirred overnight. Wen the reaction was complete, the mixture was diluted with ethyl acetate and was adjusted to pH 6 using 50% aqueous aetic acid. The reaction mixture was then poured into ice-water and extracted with ethyl acetate. The organic layer was washed with brine, dried, and concentrated under reduced pressure to give 430 g of the crude product. Flash chromatography (25% ethyl acetate in hexane) resulted in 0.38 g (81%) of the pure product.

[1600]¹H-NMR (300 MHz, CDCl₃) δ: 7.19 (2H, d, J=8.2 Hz, Ar—H), 7.03 (2H, d, J=8.9 Hz, Ar- H), 6.91 (3H, m, Ar—H), 6.57 (4H, m, Ar—H), 5.18 (2H, s, Ar—OCH₂), 5.15 (2H, s, Ar—OCH₂), 4.53 (1H, d, J=9.9 Hz-C2H), 4.31 (1H, d, J=9.9 Hz-C2H), 3.52-3.46 (8H, m), 2.93 (3H, s, N—Me), 2.71-2.61 (6H, m), 2.4-1.8 (9H, m), 1.25 (4H, m).

[1601] Step 8) Synthesis of N-[2-(4,4,5,5,5-pentafluoro-pentylsulfenyl)]ethyl-4-(3′RS,4′RS)-4-[7-hydroxy-3-(4-hydryoxyphenyl)-3-methylchroman-4-yl]butyl}ph enyl-N-methylamine

[1602] To a solution of the sulfide (302 mg, 0.42 mmol) in methanol (4 mL) was added concentrated hydrochloric acid (138#t, 1.66 mmol) and the reaction mixture was warmed up gradually to 50° C. After 5 h the reaction was quenched by adding water. The organic layer extracted with ethyl acetate was washed with brine, dried and concentrate to afford 370 mg of a crude mixture. Flash chromatography (30% ethyl acetate in hexane) resulted in 261 mg (98%) of the pure product.

[1603]¹H-NMR (300 MHz, CDCl₃) δ: 7.05 (2H, d, J=8.8 Hz, Ar—H), 6.90 (2H, d, J=8.5 Hz, Ar—H), 6.82 (3H, m, Ar—H), 6.60 (2H, d, J=8.8 Hz Ar—H), ), 6.34 (2H, m, Ar—H), 4.80 (1H, brs, OH, Ar—OH), 4.75 (1H, brs, Ar—OH), 4.50 (1H,, d, J=10.4 Hz-C2H), 4.22 (1H, d, J=10.4 Hz, —C2H), 3.49 (2H, m), 2.93 (3H, s, N-Me), 2.63 (5H, m), 2.40 1.8 (6H, m), 1.4-1.1 (6H, m, alkyl, C3Me)

[1604] Step 9) Synthesis of N-[2-4,4,5,5,5-pentafluoropentylsulfinyl)]ethyl-4-{(3′RS,4′RS)-4-[7-hydroxy-3-(4-hydryoxyphenyl)-3-methylchroman-4-yl]butyl} phenyl-N-methylamine

[1605] To a solution of sulfide (189 mg, 0.3 mmol) in- methanol (3 mL) and water (0.6 mL) was added solid sodium periodate (127 mg, 0.6 mmol) and the reaction was stirred for 1.5 hour at room temperature. When the starting material disappeared, the solvent was removed under reduced pressure. Saturated ammonium chloride was added and the reaction mixture was extracted by ethyl acetate. The organic layer was dried over magnesium sulfate and concentrated under reduced pressure to give 192 mg of a crude product, which was purified by flash chromatography to give 180 mg (95%) of the final product.

[1606]¹H-NMR (300 MHz, CDCl₃) δ: 7.04 (2H, d, J=8.2 Hz, Ar—H), 6.85 (2H, d, J=8.8 Hz, Ar- H), 6.83-6.63 (7H, m, Ar—H#Ar—OH, 6.44-6.28 (3HmAr—H+Ar—OH), 6.07 (½ H, brs, Ar—OH), 5.67 (12H, brs, Ar—OH), 4.54 (1H, d, J=10.5 Hz, C2H), 4.24 (1H, d, J=10.5 Hz, C2H), 3.80 (2H, m, CH ₂CF₂), 3.01-2.2 (14H, m, N-Me, alkyl, CH₂—SO), 1.4-1.1 (9H, m, alkyl, C3-Me).

EXAMPLE 68

[1607] Synthesis of 6-(4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)₃methyl chroman-4-yl]phenoxy)-2-(4,4,5,5,5-pentafluoropentyl)hexanoic acid

[1608] Step 1) Synthesis of (4,4,5,5,5--pentafluoropentyl)malonic Acid Diethyl Ester

[1609] To a solution of 1-iodo-4,4,5,5,5-pentafluoropentane (18.0 g, 0.06 mol) in tetrahydrofuran (180 ml) was added sodium hydride (3.5 g, 0.08 mol), which was then stirred for 30 minutes at room temperature. Diethylmalonate (15.0 g, 0.09 mol) was added to this reaction mixture and the reaction mixture was stirred overnight at room temperature. When the reaction was completed, water was added to the reaction mixture and extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=15:1) to give the title compound (16.3 g, yield 82%) as a colorless liquid.

[1610]¹H-NMR (270 MHz, CDCl₃) δ: 3.94 (q, J=7.0 Hz, 4H), 3.07 (t, J=7.2 Hz, 1H), 1.88-1.66 (m, 4H), 1.43-1.32 (m, 2H), 1.06-0.95 (t, J=7.0 Hz, 6H)

[1611] Step 2) Synthesis of (4-chlorobutyl)(4,4,5,5,5-pentafluoropentyl)-malonic Acid Diethyl Ester

[1612] The title compound was prepared from 1-bromo-4-chlorobutane according to the same procedure as step 1 of Example 71.

[1613]¹H-NMR (270 MHz, CDCl₃) δ: 4.18 (q, J=7.0 Hz, 4H), 3.51 (t, J=6.6 Hz, 2H), 2.12-1.83 (m, 6H), 1.82-1.72 (m, 2H), 1.57-1.25 (m, 4H), 1.23 (t, J=7.0 Hz, 6H) step 3) Synthesis of 4-iodobutyl-(4,4,5,5,5-pentafluoropentyl)malonic acid diethyl ester

[1614] The title compound was prepared from 4-chlorobutyl-4,4,5,5,5-pentafluoropentyl)malonic acid diethyl ester according to the same procedure as step 2 of Example 71.

[1615]¹H-NMR (270 MHz, CDCl₃) δ: 4.18 (q, J=7.2 Hz, 4H), 3.17 (t, J=6.6 Hz, 2H), 2.13-1.76 (m, 8H), 1.54-1.42 (m, 2H), 1.36-1.21 (m, 8H)

[1616] Step 4) Synthesis of (3RS,4RS)-4[4-(t-butyldimethylsilyloxy)phenyl]-7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman

[1617] The title compound was prepared from 7-methoxymethoxy-3-(4-methoxymethoxyphenyl)-3-methylchroman-4-one according to the same procedure as Step-4 of Example 3.

[1618]¹H-NMR (270 MHz, CDCl₃) δ: 6.8 (m, 5H, Ar—H), 6.6 (d, J=2.3 Hz, 1H, Ar—H), 6.53 (m, 1H, Ar—H), 6.44 (m, 4H, Ar—H), 5.16 (s, 2H, OCH ₂OCH₃), 5.1 (s, 2H, OCH ₂OCH₃), 4.56 (d, 1H, C2-H), 3.99 (d, 1H, C2-H), 3.88 (s, 1H, C4-H), 3.50 (s, 3H, OCH₂OCH ₃), 3.44 (s, 3H, OCH₂OCH ₃), 1.55 (s, 3H, C3CH₃), 0.91 (s, 9H, t-butyl-H), 0.08 (s, 6H, 2×CH₃)

[1619] Step 5) Synthesis of diethyl 2-4,4,5,5,5-pentafluoropentyl)-2-(4-((3RS,4RS)-4-(3-methyl-7-(methyloxymethyloxy)-3-(4-(methyloxymethyloxy)pheryl)chroman-4-yl) phenyloxy)butyl)propane- 1,3-dioate

[1620] To a solution of (3RS,4RS)-4-[4-(t-butyldimethylsilyloxy)phenyl]-7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman (1.1 g, 1.99 mmol) in tetrahydrofuran (10 ml) was added 1N-tetrabutylammoniumfluoride (3.99 ml, 3.99 mmol) in tetrahydrofuran and stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was treated with-water and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to chromatography on silica gel (n-hexane:ethyl acetate 2:1) to give the title compound (0.84 g, 96.4%) as a foamy oil. To a solution of (3RS,4RS)-4-(4-hydroxyphenyl)-7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman (0.31 g, 0.71 mmol) in dimethylformamide (6 ml) was added potassium carbonate (0.39 g, 2.84 mmol) and 5,5-di-ethoxycarbonyl)-1-iodo-5-(4,4,5,5,5-pentafluoropentyl)butane (0.54 g, 1.07 mmol) and stirred at 80° C. for 3 hours. After the reaction was completed, the reaction mixture was treated with water and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to chromatography on silica gel (n-hexane:ethyl acetate=4:1) to give the title compound (0.552 g, 96%) as a foamy oil.

[1621]¹H-NMR (270 MHz, CDCl₃) δ: 6.93-6.71 (m, 5H, Ar—H), 6.66 (d, 1H, Ar—H), 6.58-6.42 (m, 51, Ar—H), 5.16 (s, 2H, OCH ₂OCH₃), 5.11 (s, 2H, OCH ₂OCH₃), 4.58 (d, 1H, C2-H), 4.25-4.09 (q, 4H, 2×CH ₂ CH₃), 4.03 (d, 1H, C2-H), 3.91 (s, 1H, C4-H), 3.81 (m, 2H, OCH ₂-alkyl), 3.5 (s, 3H, OCH ₂OgH₃), 3.45 (s, 3H, OCH₂OCH ₃), 2.15-1.84 (m, 6H, alkyl-H), 1.81-1.64 (m, 2H, alkyl-H), 1.54-1.41 (m, 5H, C3-CH₃ and alkyl-H), 1.39-1.15 (m, 8H, 2×CH₂ CH ₃ and alkyl-H)

[1622] Step 6) Synthesis of (4,4,5,5,5-pentafluoropentyl)(4-(4-((3RS,4RS)-3-methyl-7-(methyloxymethyloxy)-3-(4-methyloxymethyloxy)phenyl)chroman-4-yl)phenyloxy)butyl)methane-1,1dicarboxylic Acid

[1623] To a solution of diethyl 2-(4,4,5,5,5-pentafluoropentyl)-244-(3RS,4RS)-4-(3-methyl-7-(methyloxymethyloxy)-3-(4-(methyloxymethyloxy)phenyl)chroman-4-yl)phenyloxy)butyl)propane-1,3-dioate (0.552 g, 0.68 mmol) in ethanol (10 ml) was added the solution of potassium hydroxide (1.53 g, 27.23 mmol) in water (5 ml) and the mixture was stirred at refluxed overnight. After the reaction was completed, the reaction mixture was treated with 2N—HCl solution (pH=4) and extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to give the title compound (0.513 g, quantitative) as a foamy oil.

[1624]¹H-NMR (270 MHz, CDCl₃) δ: 6.87-6.7 (m, 5H, Ar—H), 6.65 (d, 1H, Ar—H), 6.5 (dd, 1H, Ar—H), 6.43 (s, 4H, Ar—H), 5.23-5.04 (m, 4H, 2×OCH ₂OCH₃), 4.55 (d, 1H, C2-H), 3.97 (d, 1H,C2-H), 3.91-3.73 (m, 3H, C4-H and OCH ₂-alkyl), 3.4B(d, 6H, 2×OCH₂OCH ₃), 2.13-1.84 (brs, 6H, alkyl-H), 1.81-1.14 (brs, 9H, C3-CH₃ and alkyl-H)

[1625] Step 7) Synthesis of (4,4,5,5,5-pentafluoropentyl)(4-((3RS,4RS)-4-(7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl)phenyloxy)butyl)methane-1,1-dicarboxyl ic Acid

[1626] The title compound was prepared from (4,4,5,5,5-pentafluoropentyl)(4-4-((3RS,4RS)-3-methyl-7-(methyloxymethyloxy)-34-(methylo xymethyloxy)phenyl)chroman-4-yl)phenyloxy)butyl)methane-1,1-dicarboxylic acid according to the same procedure as Step 10 of Example 9

[1627]¹H-NMR (270 MHz, CD₃OD) δ: 6.8-6.15 (brs, 1H. Ar—H), 4.57-4.42 (m, 1H, C2-H), 4.1-3.7 (m, 4H, C2-H and C4-H, OCH₂-alkyl). 2.2-1.8 (brs, 6H, alkyl-H), 1.75-1.1 (brs, C3-H and alkyl-H)

[1628] Step 8) Synthesis of 6-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl chroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)hexanoic Acid

[1629] A solution of (4,4,5,5,5-pentafluoropentyl)(4-(4-(7-hydroxy-3-(4-hydroxy phenyl)-3-methyl chroman-4--yl)phenyloxy)butyl)methane-1,1-dicarboxylic acid (0.19 g, 0.285 mmol) in dimethylsulfoxide(7.6 ml) was stirred at 125° C. for 3 hours. After the reaction was completed, the reaction mixture was treated with saturated NaCl solution and extracted with ethyl acetate:hexane=1:1. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to chromatography on silica gel (n-hexane:ethyl acetate=2:1) to give the title compound (0.12 g, 67.6%) as a white foamy solid.

[1630]¹H-NMR (270MRz, CDCl₃) δ: 6.78 (m, 3H, Ar—H), 6.61 (d, J=8.91, 2H, Ar—H), 6.49 (d, J=1.98, 4H, Ar—H), 6.46 (d, 1H, Ar—H), 6.35 (dd, 1H, Ar—H), 4.59 (d, 1H, C2-H), 4.02 (d. 1H, C2-H), 3.86 (m, 3H, C4-H and OCH2-alkyl), 2.43 (m, 1H), CH—COOH), 2.18-1.90 (m, 2H, alkyl-H),, 1.87-1.38 (brs, 13H, C3-H, and alkyl-H)

EXAMPLE 69

[1631] Synthesis of 7-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl-3-methyl chroman-4-yl]phenoxy)-2-(4,4,5,5,5-pentafluoropentyl)heptanoic Acid

[1632] Step 1) Synthesis of 7-(t-butyldimethylsilyloxy)heptyl Bromide

[1633] To a solution of 7-bromoheptanol (50 g, 25.6 mmole) and imidazole (4.2 g, 61.5 mmole) in dry tetrahydrofuran (80 ml) was added t-butyldimethylsilyl chloride (4.6 g, 30.8 mmole) dropwise during 1 hour at room temperature. Then the reaction mixture was stirred overnight. at room temperature. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with. column chromatography (n-hexane:ethyl acetate=20:1) to give 5.7g (yield: 72%) of the title compound as a colorless oil.

[1634]¹H-NMR (270 MHz, CDCl₃) δ: 3.61 (t, 2H, OCH₂), 3.41 (t, 2H, BrCH₂), 1.85 (q, 2H, CH₂), 1.61-1.30 (m,8H, alkyl-H), 0.90 (s, 9H, t-butyl), 0.10 (s, 6B, dimethyl)

[1635] Step 2) Synthesis of ethyl [2-(ethoxycarbonyl)-2-4,4,5,5,5-pentafluoropentyl)-9-(t-butyldimethylsilyloxy)]nonanoate

[1636] To a solution of ethyl , [2-(ethoxycarbonyl)-5-(1,1,2,2,2-pentafluoroethyl)]pentanoate (1.0 g, 0.3.1 mmole) in dry tetrahydrofuran (5.0 ml) was added 60% sodium hydride in oil (136 mg, 3.41 mmole) under nitrogen stream at room temperature. After 30 minutes, to reaction mixture was added 7-(t-butyldimethylsilyloxy)heptyl bromide at room temperature. Then the reaction mixture was stirred overnight at room temperature. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=30:1) to give 910 mg (yield: 54%) of the title compound as a colorless oil.

[1637]¹H-NMR (270 MHz, CDCl₃) δ; 4.20 (q, 4H, COOCH₂×2). 3.60 (t, 2H, OCli₂), 2.15-1.04 (m,24H, alkyl-H, CH—X 2), 0.94 (s, 9H, t-butyl), 0.10 (s, 6H, dimethyl)

[1638] Step 3) Synthesis of diethyl 2-4,4,5,5,5-pentafluoropentyl)-2-(7-hydroxyheptyl) propane-1,3-dioate

[1639] To a solution of ethyl [2-(ethoxycarbonyl)-2-(4,4,5,5,5-pentafluoro pentyl)-9-t-butyldimethylsilyloxy)]nonanoate (900 mg, 1.64 mmole) and dry tetrahydrofuran (20 ml) was added 11.0M tetra-butylammonium fluoride in THF at room temperature. Then the reaction mixture was stirred for 4 hours at room temperature. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. And the organic layer was washed with sat. sodium bicarbonate soln. and sat. sodium chloride soln. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=4:1) to give 700 mg (yield: 98%) of the title compound as a colorless oil.

[1640]¹H-NMR (270 MHz, CDCl₃) δ: 4.20 (q, 4H, COOCH₂×2), 3.64 (t, 2H, OCH₂), 2.18-1.06 (m.24H, alkyl-H, CH₃×2) step 4) Synthesis of diethyl 2-(4,4,5,5,5-pentafluoropentyl)-2-(6-methyl sulfinyloxy)hexyl)propane-1,3-dioate

[1641] To a solution of diethyl 2-(4,4,5,5,5-pentafluoropentyl)-2-(7-hydroxyheptyl)propane-1,3-dioate (710 mg, 1.63 mmole) in methylene chloride (10mi) was added triethylamine (0.68 ml, 4.90 mmole) at room temperature. After 10 minute, to reaction mixture was added methanesulfonyl chloride at room temperature. Then the reaction mixture was stirred for 1 hour at room temperature. When the reaction was completed, water was added to the reaction solution which was then extracted with ethyl acetate. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=4:1) to give 840 mg (yield: 99%) of the title compound as a colorless oil.

[1642]¹H-NMR (270 MHz, CDCl₃) δ: 4-234.08 (m, 6H, OCH₂,COOCH₂×2), 3.02 (s, 3H, SO₂CH₃), 2.18-1.05 (m, 24H, alkyl-H, CH₃X₂)

[1643] Step 5) Synthesis of 7-iodoheptyl-(4,4,5,5,5-pentafluoropentyl)malonic Acid Diethyl Ester

[1644] To a solution of diethyl 2-(4,4,5,5,5-pentafluoropentyl)-2-(6-methyl sulfinyloxy)hexyl)propane-1,3-dioate (830 mg, 1.62 mmole) in dry acetone (20 ml) was added sodium iodide (3.6 g, 24.30 mmole) at room temperature. Then the reaction mixture was refluxed for 3.5 hours- When the reaction was completed, water was added to the reaction solution, which was then extracted with ethyl acetate. And the organic layer was washed with 2N hydrochloride soln. and sat. sodium chloride soln. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was purified with column chromatography (n-hexane:ethyl acetate=40:1) to give 780 mg (yield: 89%) of the title compound as a colorless oil.

[1645]¹H-NMR (270 MHz, CDCl₃) δ: 4.20 (q, 4H, COOCH₂×2), 3.18 (t, 2H, ICH₂), 2.17-1.07 (m, 24H, alkyl-H, CH₃×2)

[1646] Step 6) Synthesis of 7-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl chroman-4-yl]phenoxy )-2-(4,4,5,5,5-pentafluoropentyl)heptanoic acid

[1647] The title compound was prepared according to the same procedure as synthesis of Example 68 from (3RS,4RS)-44-hydroxyphenyl)-7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman.

[1648]¹H-NMR (270 MHz, CDCl₃) δ: 6.81 (d, 2H, Ar—H), 6.72 (d, 1H, Ar—H), 6.62 (d, 2H, Ar—H), 6.59-6.43 (m, 5H, Ar—H), 6.35 (dd, 1H, Ar—H), 4.56 (d, 1H, C2-H), 4.00 (dd, 1H, C2-H), 3.86 (s, 1H, C4H), 3.84 (t, 2H, OCH2), ₂.40 (m, 1H, CHCOO), 2.03 (m, 2H, CH2CF2), ₁.85-1.21 (m, 19H, C3-CH3, alkyl-H)

EXAMPLE 70

[1649] Synthesis of 8-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phenoxy}-2-4,4,5,5Spentafluoropentyl)octanoic Acid

[1650] Step 1) Synthesis of 5-chloropentyl-{4,4,5,5,5-pentafluoropentyl)malonic Acid Diethyl Ester

[1651] The title compound was prepared from 1-bromo-5-chloropentane according to the same procedure as step 1 of Example 71.

[1652]¹H-NMR (270 MHz CDCl₃) δ: 4.17 (q, J=7.3 Hz, 4H), 3.49 (t, J=6.6 Hz, 2H), 2.12-1.82 (m, 6H), 1.81-1-72 (m, 2H), 1.58-1.38 (m, 4H), 1.26-1.13 (m, 8H)

[1653] Step 2) Synthesis of 5-iodopentyl-(4,4,5,5,5-pentafluoropentyl)malonic Acid Diethyl Ester

[1654] The title compound was prepared from 5-chloropentyl-(4,4,5,5,5-pentafluoropentyl)malonic acid diethyl ester according to the same procedure as step 2 of Example 71.

[1655]¹H-NMR (270 MHz, CDCl₃) δ: 4.17 (q, J=7.2 Hz, 4H), 3.16 (t, J=6.6 Hz, 2H), 2.13-1.77 (m, 8H), 1.57-1.38 (m, 4H), 1.25-1.12 (m, 8H)

[1656] Step 3) Synthesis of 8-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl chroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)octanoic Acid

[1657] The title compound was prepared according to the same procedure as synthesis of Example 68 from (3RS,4RS)-4-(4-hydroxyphenyl)-7-(methoxymethoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman.

[1658]¹H-NMR (270 MHz, CD₃OD) δ: 6.80-6-67 (m, 3H), 6.57 (d, J=8.6 Hz, 2H), 6.48-6.42 (m, 5H), 6.32 (m, 1H), 4.54 (m, 1H), 3.96 (m, 1H), 3.86-3.78 (m, 3H), 2.42-2.35 (m, 1H), 2.11-191 (m, 2H), 1.77-1.23 (m, 15H)

EXAMPLE 71

[1659] Synthesis of 9-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)nonanoic Acid

[1660] step 1) Synthesis of 6-chlorohexyl-(4,4,5,5,5-pentafluoropentyl)malonic Acid Diethyl Ester

[1661] To a solution of (4,4,5,5,5-pentafluoropentyl)malonic acid diethyl ester (1 g, 3.12 mmol) in tetrahydrofuran (15 ml) was added sodium hydride (175 mg, 4.37 mmol), which was then stirred for 30 min at rt. 1-Bromo-6-chlorohexane (0.7 ml, 4.68 mmol) was added to this reaction mixture and the reaction mixture was refluxed overnight. When the reaction was completed, water was added to the reaction mixture and extracted with ethyl acetate. Then, the organic layer was washed with water and saturated sodium chloride solution. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=30:1) to give the title compound (760 mg, yield 56%) as a colorless liquid.

[1662]¹H-NMR (270 MHZ, CDCl₃) δ: 4.17 (q, J=7.2 Hz, 4H), 3.50 (t, J=6.6 Hz, 2H), 2.12-1.82 (m, 6H), 1.81-1.72 (m, 2H), 1.57-1.12 (m, 14H)

[1663] Step 2) Synthesis of 6-iodohexyl-(4,4,5,5,5-pentafluoropentyl)malonic Acid Diethyl Ester

[1664] To a solution of 6-chlorohexyl-(4,4,5,5,5-pentafluoropentyl)malonic acid diethyl ester (743 mg, 1.69 mmol) in acetone (5 ml) was added sodium iodide (761 mg, 5.08 mmol), which was then refluxed for 4h. When the reaction was completed, water was added to the reaction mixture and extracted with ethyl acetate. Then, the organic layer was washed with wafer and saturated sodium chloride solution. The extract was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography (n-hexane:ethyl acetate=15:1) to give the title compound (801 mg, yield 89%) as a colorless liquid.

[1665]¹H-NMR (270 MHz, CDCl₃) δ: 4.17 (q, J=7.0 Hz, 4H), 3.15 (t, J=7.0 Hz, 2H), 2.13-1.72 (m, 8H), 1.58-1.12 (m, 14H)

[1666] Step 3) Synthesis of 9-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl chroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)nonanoic Acid

[1667] The title compound was prepared according to the same procedure as synthesis of Example 68 from (3RS,4RS)-4-(4-hydroxyphenyl)-7-(methoxy methoxy)-3-[4-(methoxymethoxy)phenyl]-3-methylchroman.

[1668]¹H-NMR (270 MHz, CD₃OD) δ: 6.77 (d, J=8.5 Hz, 2H), 6.69 (d, J=8.2 Hz, 1H), 6.57 (d, J=8.5 Hz, 2H), 6.47-6.43 (m, 5H), 6.33 (m, 1H), 4;54 (m, 1H), 3.96 (m, 1H), 3.87-3.78 (m, 3H), 2.42-2.34 (m, 1H), 2.11-1.92 (m, 2H), 1.76-1.22 (m, 17H)

[1669] The following compounds of Examples 72 to 205 were prepared according to the similar procedures as Examples 1 to 71. These compounds are represented in the following Table 1 TABLE 1 COM. PHYSICAL NO. NAME STRUCTURE DATA 72 (3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)- 4-{9-{{[(4,4,5,5,5- pentafluoropentyl)amino]- iminomethyl}amino}nonyl}- 3-methylchroman

¹H-NMR(300 MHz, DMSO-d₆) δ: 0.8-1.3(m, 16H), 1.11(s, 3H), 1.45(m, 2H), 1.73(m, 2H), 1.73(m, 2H), 2.26(m, 2H), 2.58(d, 1H), # 3.08(m, 2H), 3.2(m, 2H), 4.15(d, 1H), 4.4(d, 1H), 6.2(d, 1H), 6.28(dd, 1H), 6.7(d, 2H), 6.8(d, 1H), 7.05(d, 2H), 7.4(brs, 1H), 7.63(brs, 1H), 7.56(brs, 1H), 9.15(brs, 1H), 9.3(brs, 1H) Mass(ESI): 600(M + 1) 73 N-n-butyl-11-[(3RS,4RS)- 7-hydroxy-3-(4-hydroxyphenyl)- 3-methylchroman-4-yl]- N-methylundecaneamide

¹H-NMR(300 MHz, CDCl₃) δ: 0.95-1.70(brs, 26H), 2.36(m, 2H), 2.60(m, 1H), 2.99(s, 1.5H), 3.03(s, 1.5H), 3.31(t, 1H), 3.43(t, 1H), 4.27(d, 1H), 4.55(d, 1H), 6.14(s, 1H), 6.93(m, 3H), # 7.09(d, 2H), 8.07(s, 1H) 74 (3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)-4-{9- [(4,4,5,5,5-pentafluoropentyl)- carbamoylamino]nonyl}- 3-methylchroman

¹H-NMR(300 MHz, CDCl₃) δ: 0.9-1.2(m, 18H), 1.3(s, 2H), 1.65(m, 2H), 1.9-2.1(m, 2H), 3.0(m, 2H), 3.15(m, 2H), 4.1(d, 1H), 4.35(d, 1H), 5.15(s, 1H), 5.35(s, 1H), # 6.25(t, 2H), 6.7(t, 3H), 6.9(d, 2H), 8.2(s, 1H), 8.6(s, 1H) Mass(ESI): 601(M + 1) 75 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl-4- [2-(5-(4-(4,4,5,5,5-pentafluoro- pentylsulfinyl)butyl)fur-2- yl)ethyl]chroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.55(d, J=22.99 Hz, 1H), 7.00-6.78(m, 5H), 6.39-6.35(m, 2H), 5.84-5.81(m, 2H), 5.32(d, J=15.45 Hz, 1H), # 4.50(d, J=10.18 Hz, 1H), 4.25(d, J=10.55 Hz, 1H), 2.88-2.10(m, 12H), 1.90-1.60(m, 5H), 1.34-1.13(m, 4H) Mass(ESI): 615(M + 1) 76 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl-4- [5-((3-(4,4,5,5,5-pentafluoro- pentylsulfinyl)propyl)- methoxyamino)pentyl]chroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.40(br, 1H), 7.04(d, 2H, J=9 Hz), 6.86(d, 1H, J=8 Hz), 6.82(d, 2H, J=9 Hz), 6.37(m, 2H), 6.03(br, 1H), # 4.47(d, 1H, J=11 Hz), 4.20(d, 1H, J=11 Hz), 3.43(s, 3H), 2.84(m, 4H), 2.65(m, 2H), 2.55(br, 1H), 2.45(m, 2H), 2.26(m, 2H), 2.18(m, 2H), 1.98(m, 2H), 0.98-1.29(m, 11H) Mass(ESI): 622(M + 1) 77 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl-4- (9-(4,4,5,5,5-pentafluoro- pentyl)-2, 2-dioxo-2, 1, 3- thiadizolidinyl)nonylchroman

¹H-NMR(300 MHz, CDCl3) δ: 7.05(d, 2H, J=8.66 Hz), 6.87(d, 1H, J=7.91 Hz), 6.82(d, 2H, J=9.04 Hz), 6.34(m, 2H), 4.48(d, 1H, J=10.55 Hz), # 4.21(dd, 1H, J=10.55 Hz), 3.31(s, 4H), 3.13(t, 2H, J=6.78 Hz), 3.01(t, 2H, J=7.16 Hz), 2.57(d, 1H, J=7.46 Hz), 2.25-2.09(m, 2H), 1.99-1.90(m, 2H), 1.60-1.54(m, 2H), 1.32-0.98(m, 17H) Mass(ESI): 663(M + 1) 78 (3RS,4RS)-7-hydroxy-3- methyl-3-(4-hydroxyphenyl)- 4-(9-(((((4,4,5,5,5-pentafluoro- pentyl)amino)-N-carbamoyl- imino)methyl)amino)nonyl- chroman

¹H-NMR(300 MHz, CD₃OD) δ: 6.98(d, 2H, J=8.7 Hz, Ar—H), 6.75(d, 2H, J=8.24 Hz, Ar—H), # 6.68(d, 2H, J=8.7 Hz), 6.21(dd, 1H, J=2.5 Hz, J=8.24 Hz), 6.14(d, 1H, J=2.6 Hz), 4.39(d, 1H, J=10.5 Hz, C2-H), 4.1(d, 1H, J=10.5 Hz, C2-H), 3.06(t, 2H, J=6.9 Hz), 2.51(m, 1H), 2.1(m, 2H), 1.7(m, 2H), 1.5(m, 2H), 1.09(s, 3H, C3-CH₃), 0.9-1.2(m, 14H) 79 (3RS,4RS)-7-hydroxy-3- methyl-3-(4-hydroxyphenyl)- 4-(9-((((4,4,5,5,5-pentafluoro- pentyl)amino)-N-cyanoimino- methyl)amino)nonyl)- thiochroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.23(d, 2H, J=8.7 Hz, Ar-H), 6.85(d, 1H, J=8.2 Hz, Ar-H), # 6.77(d, 2H, J=8.7 Hz), 6.55(d, 1H, J=2.47 Hz), 6.43(dd, 1H, J=8.2 Hz, J=2.47 Hz), 3.6(d, 1H, J=11.6 Hz, C2-H), 3.3(t, 2H), 3.15(t, 2H, J=7.1 Hz), 2.94(d, 1H, J=11.6 Hz, C2-H), 2.73(m, 1H), 2.1(m, 2H), 1.8(m, 2H), 1.5(m, 2H), 1.1(s, 3H, C3-CH₃), 0.9-1.3(m, 14H) 80 (3RS,4RS)-7-hydroxy-3- methyl-3-(4-hydroxyphenyl)- 4-(3-(4-(3-(4,4,5,5,5-penta- fluoropentylsulfinyl)- propyl)piperazinyl)- propyl)chroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.0(d, 2H, J=8.7 Hz, Ar-H), 6.79(d, 2H, J=8.3 Hz, Ar—H), 6.68(d, 2H, J=8.7 Hz), # 6.21(dd, 1H, J=2.4 Hz, J=8.3 Hz), 6.14(d, 1H, J=2.4 Hz), 4.4(d, 1H, J=10.6 Hz, C2-H), 4.11(d, 1H, J=10.6 Hz, C2-H), 2.75(m, 4H), 2.6(m, 1H), 2.3(m, 12H), 2.0(m, 4H), 1.75(m, 2H), 1.1(s, 3H, C3-CH₃), 0.9-1.2(m, 4H) Mass(ESI): 633(M + 1) 81 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-[9-((2-piperidinoethyl)- sulfinyl)nonyl]chroman

¹H-NMR(300 MHz, CDCl₃) δ: 6.97(d, 2H, J=9 Hz), 6.76(d, 1H, J=8 Hz), 6.68(d, 2H, J=9 Hz), 6.22(dd, 1H, J=8 Hz, J=3 Hz), 6.15(d, 1H, J=2 Hz), # 4.39(d, 1H, J=10 Hz), 4.12(d, 1H, J=7 Hz), 2.68(m, 4H), 2.52(br, 1H), 2.40(m, 4H), 1.63(t, 2H, J=7 Hz), 1.50(m, 4H), 1.33(m, 4H), 0.85-1.22(m, 17H) Mass(ESI): 542(M + 1) 82 (3RS,4RS)-4-[9-(2-(3- cyanophenyl)ethyl)sulfinyl- nonyl]-7-hydroxy-3-(4- hydroxyphenyl)-3-methyl- thiochroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.40-7.58(m, 4H), 7.21(d, 2H, J=9 Hz), 6.84(m, 3H), 6.65(d, 2 Hz), 6.48(dd, 1H, J=8 Hz, J=2 Hz), 5.71(s, 1H), 5.58(s, 1H), # 3.61(dd, 1H, J=10 Hz, J=3 Hz), 3.17(t, 2H, J=8 Hz), 3.04(m, 1H), 2.71-2.96(m, 3H), 2.62(m, 2H), 1.71(m, 2H), 1.27(m, 4H), 0.85-1.21(m, 13H) Mass(ESI): 576(M + 1) 83 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-[4-(3-(2-(4,4,5,5,5-penta- fluoropentylsulfinyl)ethoxy)- propoxy)phenyl]chroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.06(s, 1H), 6.75(m, 3H), 6.62(d, 2H, J=9 Hz), 6.53(m, 5H), 6.37(dd, 1H, J=8 Hz, J=2 Hz), 5.97(s, 1H), # 4.58(d, 1H, J=11 Hz), 3.96(m, 3H), 3.85(m, 3H), 3.62(t, 2H, J=6 Hz), 2.99(m, 2H), 2.86(t, 2H, J=7 Hz), 2.17(m, 4H), 1.97(t, 2H, J=6 Hz), 1.52(s, 3H) Mass(ESI) 643(M + 1) 84 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-[5-((3-(4,4,5,5,5-pentafluoro- pentylsulfinyl)propyl)- phenylmethoxyamino)pentyl]- chroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.46(br, 1H), 7.28(m, 5H), 7.03(d, 2H, J=8 Hz), 6.87(d, 1H, J=8 Hz), # 6.82(d, 2H, J=8 Hz), 6.38(d, 1H, J=3 Hz), 6.35(s, 1H), 5.94(br, 1H), 4.57(s, 2H), 4.48(d, 1H, J=11 Hz), 4.20(m, 1H), 2.68(m, 5H), 2.55(m, 4H), 2.27(m, 2H), 2.14(m, 2H), 1.88(m, 2H), 0.95-1.33(m, 11 Hz) Mass(ESI) 698(M + 1) 85 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-[4-(2-((3-(4,4,5,5,5-penta- fluoropentylsulfinyl)propyl)- methylamino)ethoxy)phenyl]- chroman

¹H-NMR(300 MHz, CDCl₃) δ: 6.69(m, 3H), 6.58(d, 1H, J=2 Hz), 6.55(d, 1H, J=2 Hz), 6.45(s, 4H), # 6.43(d, 1H, J=3 Hz), 6.32(m, 1H), 4.53(dd, 1H, J=11 Hz, J=3 Hz), 3.96(m, 3H), 3.80(s, 1H), 2.78(m, 4H), 2.70(m, 2H), 2.56(m, 2H), 2.30(s, 3H), 2.14(m, 4H), 1.90(m, 2H), 1.48(d, 3H, J=3 Hz) Mass(ESI) 656(M + 1) 86 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-[6-aza-6-(4,4,5,5,5-penta- fluoropentylsulfinyl)-ethoxy- 5-hexenyl]chroman

¹H-NMR(300 Hz, CDCl₃) δ: 7.25(m, 0.5H), 7.17(d, J=8.64 Hz, 2H), 6.98(m, 3H), 6.65(t, 0.5H), 6.46(m, 2H), 4.62-4.23(m, 4H), # 3.25-3.00(m, 2H), 3.00-2.75(m, 2H), 2.73(brs, 1H), 2.37-1.94(m, 6H), 1.47-0.90(m, 9H) Mass(ESI): 592(M + 1) 87 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-[9-carboxy-9-(4,4,5,5,5- pentafluoropentylthio)- nonyl]chroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.10(d, 2H), 6.95-6.75(m, 3H), 6.40-6.28(m, 2H), 4.45(d, J=10.57 Hz, 1H), 4.12(d, J=10.41 Hz, 1H), 4.22(t, J=6.47 Hz, 1H), # 2.80-2.54(m, 3H), 2.30-2.02(m, 2H), 2.00-0.90(m, 2H) Mass(ESI): 619(M + 1) 88 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-[9-carboxy-9-(4,4,5,5,5- pentafluoropentyl- sulfinyl)nonyl]chroman

¹H-NMR(300 MHz, MeOH-d₄) δ: 6.98(d, J=8.71 Hz, 2H), 6.81-6.69(m, 3H), 6.25-6.08(m, 2H) 4.34(d, J=10.39 Hz, 1H), 4.08(d, J=10.42 Hz, 1H), # 3.40-3.10(m, 1H), 3.00-2.65(m, 3H), 2.49(d, J=7.83 Hz, 1H), 2.33-2.10(m, 2H), 2.10-0.81(m, 21H) Mass(ESI): 657(M + Na) 89 (3RS,4RS)-7-hydroxyphenyl- 3-(4-hydroxyphenyl)- 4-[4-methyloxycarbonyl- propyloxy)phenyl]-3-methyl- chroman

¹H-NMR(300 MHz, CDCl₃) δ: 6.74(d, 2H), 6.67(d, 1H), 6.55(d, 2H), 6.48-6.40(m, 5H), 6.28(dd, 1H), 4.51(d, 1H, J=10.6 Hz), 3.96(d, 1H, J=10.6 Hz), # 3.84(t, 2H), 3.82(s, 1H), 3.65(s, 3H), 2.42(t, 2H, J=7.3 Hz), 2.02-1.93(m, 2H), 1.46(s, 3H). Mass(ESI): 449(M + 1), 471(M + Na) 90 (3RS,4RS)-4-{4-[7-hydroxy- 3-(4-hydroxyphenyl)- 3-methylchroman-4-yl]- phenoxy}butanoic acid

¹H-NMR(300 MHz, MeOH-d₄) δ: 6.71(d, 2H), 6.50(d, 1H), 6.43(d, 2H), 6.41-6.36(m, 4H), 6.29-6.14(m, 2H), 4.46(d, 1H, J=10.6 Hz), 3.86(d, 1H, J=10.6 Hz), 3.81-3.75(m, 3H), # 2.30(t, 2H, J=7.3 Hz), 1.93-1.85(m, 2H), 1.34(s, 3H) Mass(ESI): 435(M + 1), 457(M + Na) 91 (3RS,4RS)-ethyl-1-{4-{4- [7-hydroxy-3-(4-hydroxy- phenyl)-3-methylchroman-4-yl]- phenoxy}butyl}piperidine- 2-carboxylate

¹H-NMR(300 MHz, CDCl₃ + MeOH-d₄) δ: 6.73(d, 2H), 6.62(d, 1H), 6.55(d, 2H), 6.44-6.37(m, 5H), 6.29(dd, 1H), # 4.50(d, 1H, J=10.6), 4.12(q, 2H, J=6.8 Hz), 3.93(d, 1H, J=10.6 Hz), 3.82(s, 1H), 3.76(t, 2H), 3.02-2.96(m, 2H), 2.55-2.48(m, 1H), 2.30-2.24(m, 1H), 2.12-2.08(m, 1H), 1.78-1.53(m, 10H), 1.42(s, 3H), 1.19(t, 3H, J=6.8 Hz) Mass(ESI): 560(M + 1) 92 (3RS,4RS)-1-{4-{4-[7- hydroxy-3-(4-hydroxyphenyl)- 3-methylchroman-4-yl]- phenoxy}butyl}piperidine- 2-carboxylic acid

¹H-NMR(300 MHz, MeOH-d₄) δ: 6.96(d, 2H), 6.78(d, 1H), 6.71(d, 2H), 6.68(m, 4H), 6.50(d, 1H), 6.43(dd, 1H), 4.71(d, 1H, J=10.6 Hz), # 4.12(d, 1H, J=10.6 Hz), 4.06(s, 1H), 4.04(t, 2H), 3.77-3.68(m, 1H), 3.61-3.55(m, 1H), 3.47-3.40(m, 1H), 3.26-3.00(m, 2H), 2.39-2.30(m, 1H), 2.08-1.88(m, 9H), 1.68(s, 3H) Mass(ESI): 532(M + 1), 554(M + Na) 93 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-{4-{4-{methyl[3-(4,4,5,5,5- pentafluoropentylthio)propyl]- amino}butoxy}phenyl}chroman

¹H-NMR(300 MHz, MeOH-d₄) δ: 6.87(d, 2H), 6.68(d, 1H), 6.58(d, 2H), # 6.56(m, 4H), 6.42(d, 1H), 6.34(dd, 1H), 4.63(d, 1H, J=10.6 Hz), 4.01(d, 1H, J=10.6 Hz), 3.96(s, 1H), 3.90(t, 2H), 2.70-2.48(m, 8H), 2.39-2.22(m, 2H), 2.32(s, 3H), 1.96-1.64(m, 8H), 1.52(s, 3H) Mass(ESI): 669(M + 2) 94 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-{[7-(4,4,5,5,5-pentafluoro- pentylsulfinyl)heptyloxy]- methyl}chroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.08(d, 2H), 6.99(d, 1H), 6.80(d, 2H), 6.43-6.36(m, 2H), 4.66(dd, 1H), 4.13(d, 1H), 3.23-3.08(m, 2H), 3.08-2.92(m, 2H), # 2.87-2.72(m, 4H), 2.68-2.57(m, 1H), 1.78-1.06(m, 10H), 1.30(s, 3H) Mass(ESI): 593(M + 1), 615(M + Na) 95 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- 4-{[6-(4,4,5,5,5-pentafluoro- pentylsulfinyl)hexyloxy]- ethyl}chroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.08(d, 2H), 6.91(d, 1H), 6.83(d, 2H), 6.39-6.36(m, 2H), 4.47(d, 1H), 4.26(dd, 1H), 3.37-3.10(m, 4H), # 2.88-2.58(m, 5H), 2.36-2.14(m, 4H), 1.88-1.77(m, 2H), 1.55-1.18(m, 8H), 1.26(s, 3H) Mass(ESI): 593(M + 1) 96 (3RS,4RS)-2-{{5-[7-hydroxy- 3-(4-hydroxyphenyl)-3-methyl- chroman-4-yl]pentyl}{3- [(4,4,5,5,5-pentafluoropentyl)- sulfinyl]propyl}amino}- acetic acid

¹H-NMR(300 MHz, MeOH-d₄) δ: 7.10(d, 2H), 6.88(d, 1H), 6.79(d, 2H), 6.33(d, 1H), 6.25(s, 1H), 4.52(d, 1H), # 4.21(d, 1H), 3.57(s, 2H), 3.23(t, 1H), 3.02-2.85(m, 6H), 2.69-2.63(m, 1H), 2.47-2.28(m, 2H), 2.22-2.06(m, 4H), 1.58-1.07(m, 8H), 1.21(s, 3H) Mass(ESI): 650(M + 1) 97 (3RS,4RS)-3-(4-hydroxy- phenyl)-3-methyl-4-{5-{4- [(4,4,5,5,5-pentafluoropentyl- sulfinyl)methyl]piperidyl}- pentyl}chroman-7-ol

¹H-NMR(300 MHz, MeOH-d₄) δ: 6.95(d, 2H), 6.70(d, 1H), 6.61(d, 2H), 6.15(d, 1H), 6.10(s, 1H), 4.38(d, 1H), 4.09(d, 1H), # 3.05-2.51(m, 6H), 2.33-1.64(m, 10H), 1.41-0.97(m, 11H), 1.05(s, 3H) Mass(ESI): 632(M + 1) 98 7-hydroxy-3-[4-hydroxy-2- (methyloxymethyloxy)phenyl]- 4-(4,4,5,5,5-pentafluoropentyl- sulfinyloctyloxy)-2H-chromene

¹H-NMR(300 MHz, CDCl₃); δ7.85(d, J=8.67 Hz, 1H), 7.28(d, J=7.92 Hz, 1H), 6.68(s, 1H), 6.58(dd, J=2.26 and 8.67 Hz, 1H), 6.43(dd, J=2.26 # and 4.14 Hz, 1H), 6.35(dd, J=2.26 and 8.29 Hz, 1H), 6.21(d, J=2.26 Hz, 1H), 4.75(d, J=10.92 Hz, 1H), 4.45(d, J=10.92 Hz, 1H), 3.94(d, J=9.8 Hz, 1H), 3.82(d, J=9.79 Hz, 1H), 3.64(t, 2H), 3.47(s, 3H), 2.70-2.84(m, 4H), 2.20-2.26(m, 4H), 1.76-1.79(m, 4H), 0.94-1.42(m, 8H) Mass(ESI): 637(M + 1) 99 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4-(4-(N- methyl-N-4-(4,4,5,5,5-penta- fluoropentylsulfinyl)butyl- amino)butyl)-3-methylchroman

¹H-NMR(300 MHz, MeOH-d₄) δ: 7.13(d, 2H, J=8.7 Hz), 6.90(d, 1H, J=8.25 Hz), 6.81(d, 2H, J=8.77 Hz), 6.34(dd, 1H, # J=8.2 Hz), 6.28(d, 1H, J=2.44 Hz), 4.53(d, 1H, J=10.64 Hz), 4.23(d, 1H, J=10.59 Hz), 2.93-2.83(m, 4H), 2.68(d, 1H, J=7.46 Hz), 2.58(t, 2H), 2.44-2.29(m, 7H), 2.11(m, 2H), 1.81-1.63(m, 4H), 1.40-1.09(m, 9H) Mass(ESI): 606(M + 1) 100 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4-(4-(N- methyl-N-4-(4,4,5,5,5-penta- fluoropentylsulfonyl)butyl- amino)butyl)-3-methylchroman

¹H-NMR(300 MHz, MeOH-d₄) δ: 7.01(d, 2H, J=8.76 Hz), 6.77(d, 1H, J=8.25 Hz), 6.69(d, 2H, J=8.76 Hz), 6.22(dd, 1H, J=8.15 Hz), 6.15(d, # 1H, J=2.45 Hz), 4.40(d, 1H, J=10.64 Hz), 4.13(d, 1H, J=10.59 Hz), 3.10(t, 2H, J=7.53 Hz), 3.03(t, 2H, J=7.48 Hz), 2.68(d, 1H, J=7.46 Hz), 2.56(t, 2H, J=7.86 Hz), 2.40(t, 2H), 2.34-2.19(m, 7H), 2.06-2.00(m, 2H), 1.76-1.65(m, 2H), 1.60-1.49(m, 2H), 1.27-0.96(m, 9H) Mass(ESI): 622(M + 1) 101 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4-(5-(N- methyl-N-3-(4,4,5,5,5-penta- fluoropentylsulfonyl)propyl- amino)pentyl)-3-methylchroman

¹H-NMR(300 MHz, MeOH-d4) δ: 7.08(d, 2H, J=9.05 Hz), 6.84(d, 1H, J=8.29 Hz), 6.75(d, 2H, J=9.04 Hz), 6.29(dd, 1H, J=8.28 Hz), 6.23(d, 1H, # J=2.26 Hz), 4.47(d, 1H, J=10.92 Hz), 4.17(dd, 1H, J=10.55 Hz), 3.18(t, 2H, J=7.54 Hz), 3.08(t, 2H, J=7.54 Hz), 2.62(d, 1H, J=8.29 Hz), 2.45(t, 2H, J=7.92 Hz), 2.35(m, 7H), 2.24(t, 2H, J=7.91 Hz), 2.17(s, 3H), 2.13-2.05(m, 2H), 1.96-1.88(m, 2H), 1.29-0.98(m, 11H) Mass(ESI): 622(M + 1) 102 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4-(3-(N- methyl-N-5-(4,4,5,5,5-penta- fluoropentylsulfinyl)- pentylamino)propyl)-3- methylchroman

¹H-NMR(300 MHz, MeOH-d4) δ: 7.07(d, 2H, J=8.67 Hz), 6.86(d, 1H, J=8.29 Hz), 6.75(d, 2H, J=8.67 Hz), 6.29(dd, 1H, # J=7.91, 2.63 Hz), 6.22(d, 1H, J=2.63 Hz), 4.47(d, 1H, J=10.55 Hz), 4.17(d, 1H, J=10.55 Hz), 2.89-2.73(m, 4H), 2.64(d, 1H, J=7.53 Hz), 2.40-2.23(m, 4H), 2.14-2.02(m, 7H), 1.71(m, 2H), 1.47-0.98(m, 11H) Mass(ESI): 605(M + 1) 103 (3RS,4RS)-4-[4-(4-cyano- propyloxy)phenyl]-7- hydroxy)-3-(4-hydroxyphenyl)- 3-methylchroman

¹H-NMR(300 MHz, MeOH-d4) δ: 7.2(dd, 2H), 6.9˜6.7(d, 7H), 6.4(t, 1H), 6.3(d, 1H), 4.45(dd, J=10.3 Hz, 1H), 4.12(dd, J=10.4 Hz, 1H), 4.02(s, 1H), 3.9(t, 2H), 2.64(t, 2H), # 2.15(m, 2H), 1.18(s, 3H) Mass(ESI): 416(M + 1) 104 (3RS,4RS)-7-hydroxy-3- (4-(hydroxyphenyl)-4- [4-(4-piperidylbutyloxy)phenyl]- chroman

¹H-NMR(300 MHz MeOH-d4) δ: 6.59(dd, 2H), 6.54(m, 7H), 6.2(t, 2H), 4.0(m, 1H), 3.85(t, 2H), 3.36(m, 1H), 3.1˜2.82(m, 7H), 1.7(m, 8H), 1.55(s, 3H) 105 (3RS,4RS)-7-hydroxy-3- (4-(hydroxyphenyl)-3- methyl-4-[4-(5-N-oxy- piperidylpentyloxy)phenyl]- chroman

¹H-NMR(300 MHz, MeOH-d4) δ: 7.07(dd, 2H), 6.68(d, 1H), 6.46(dd, 2H), 6.4(m, 4H), 6.28(s, 1H), 6.1(d, 1H), 4.28(dd, J=10.2 Hz, 1H), # 4.1(dd, J=10.5 Hz, 1H), 3.75(m, 2H), 3.7(s, 1H), 3.1(m, 6H), 2.0(m, 2H), 1.88˜1.26(m, 10H), 0.95(s, 3H) Mass(ESI): 518(M + 1) 106 (3RS,4RS)-7-hydroxy-3- (4-(hydroxyphenyl)-4- [11-(4,4,5,5,5-pentylfluoro- pentyl)sulfonylamino-11- iminoundecyl]chroman

¹H-NMR(300 MHz, MeOH-d4) δ: 7.23(dd, 2H), 6.85(d, 1H), 6.79(dd, 2H), 6.58(s, 1H), 6.45(d, 1H), 3.6(dd, J=11.6 Hz, 1H), 3.2(broad, 1H, NH), # 3.15(t, 2H), 2.93(dd, J=11.5 Hz, 1H), 2.75(m, 1H), 2.45˜2.23(m, 4H), 2.07(m, 2H), 1.65(m, 2H), 1.39˜0.9(m, 19H) Mass(ESI): 679(M + 1) 107 (3RS,4RS)-7-hydroxy-3- (4-(hydroxyphenyl)-4- [5-N-methyl-N-8,8,9,9,9-penta- fluoro-4-carboxyl-nonylamino]- chroman

¹H-NMR(300 MHz, MeOH-d4) δ: 7.0(dd, J=8.7 Hz, 2H), 6.78(d, 1H), 6.66(dd, J=8.7 Hz, 2H), 6.2(d, 1H), 6.12(s, 1H), # 4.4(dd, J=10.5 Hz, 1H), 4.08(dd, J=10.6 Hz, 1H), 2.87(m, 2H), 2.75(m, 2H), 2.55(m, 4H), 2.25˜1.85(m, 3H), 1.7˜0.89(m, 18H) Mass(ESI): 616(M + 1) 108 (3RS,4RS)-7-hydroxy-3- (4-(hydroxyphenyl)-3- methyl-4-[5-oxa-9-(4,4,5,5,5- pentafluoropentylsulfonyl- amino)nonyl]chroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.08(dd, J=8.6 Hz, 2H), 6.80(m, 3H), 6.32(d, 2H), 6.0(dd, J=8.2 Hz, 1H), 5.08(t, 1H), # 4.52(dd, J=10.2 Hz, 1H), 4.25(dd, J=10.6 Hz, 1H), 3.30(m, 4H), # 3.09(m, 4H), 2.63(dd, J=8.9 Hz, 1H), 2.38˜1.92(m, 4H), 1.52˜0.61(m, 15H) 109 (5-(7-hydroxy-3- (4-hydroxyphenyl)-3- methylchroman-4-yl)pentyl)- (methylsulfonyl)(3-(4,4,5,5,5- pentafluoropentylsulfinyl)- propyl)amine

¹H-NMR(300 MHz, CD₃OD) δ: 7.0(d, 2H), 6.84(d, 1H), 6.7(d, 2H), 6.2(m, 2H), 4.4(d, 1H), 4.1(d, 1H), # 3.1(m, 2H), 2.9(m, 2H), 2.75(m, 7H), 2.55(d, 1H), 2.25(m, 2H), 1.9(m, 4H), 1.3˜1.1(m, 11H) Mass(ESI): 670(M + 1) 110 8-(3-methyl-8-methyloxy-3- (4-methyloxyphenyl)-5- thiabicyclo[4,4,0]deca-1(6),7,9- trien-2yl)-2-(4,4,5,5,5-penta- fluoropentyl)octanoic acid

¹H-NMR(300 MHz, CD₃OD) δ: 7.1(d, 2H), 6.7(d, 1H), 6.6(d, 2H), 6.45(d, 1H), 6.35(dd, 1H), 3.5(d, 1H), 2.9(d, 1H), # 2.65(bs, 1H), 2.1(m, 3H), 1.5(m, 4H), 1.3˜1.0(m, 15H) Mass(ESI): 575(M + 1) 111 (3RS,4RS)-10-[7-hydroxy-3- (4-hydroxyphenyl)-3- methylchroman-4-yl]-2- (4,4,5,5,5-pentafluoropentyl)- decanoic acid

¹H-NMR(300 MHz, CDCl₃) δ: 7.00(d, 2H, J=8.7 Hz), 6.82(d, 1H, J=6.7 Hz), 6.76(d, 2H, J=8.5 Hz), 6.30(m, 2H), 4.43(d, 1H, # J=10.4 Hz), 4.16(d, 1H, J=10.4 Hz), 2.53(bd, 1H), 2.33(m, 1H), 1.96(m, 2H), 1.55(s, 6H), 1.19(s, 3H), 1.21˜1.06(m, 14H) Mass(ESI): 587(M + 1) 112 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{5-{N-methyl-N- [1-hydroxycarbonyl-3- (4,4,5,5,5-pentafluoropentyl)- sulfinyl]propyl}amino- pentyl}chroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.56(m, 2H), # 7.00(m, 1H), 6.73(m, 2H), 6.21(m, 1H), 6.15(m, 1H), 4.40(m, 1H), 4.10(m, 1H), 3.23(m, 1H), 2.92-2.82(m, 6H), 2.65(s, 3H), 2.53(m, 1H), 2.28-1.96(m, 6H), 1.43-1.05(m, 11H) Mass(ESI): 650(M⁺ + 1) 113 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{5-{N-methyl-N- [3-(4,4,5,5,5-pentafluoropentyl)- sulfinyl]propionyl}amino- pentyl}chroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.75-7.09(m, 1H), 6.96(m, 2H), 6.86(m, 3H), 6.37(m, 2H), # 5.98-5.76(m, 1H), 4.47(m, 1H), 4.12(m, 1H), 3.48-2.45(m, 10H), 2.34-2.05(m, 4H), 1.34-0.88(m, 13H) Mass(ESI): 620(M⁺ + 1) 114 (3RS,4RS)-4-[9-(N-cyano)- aminononyl]-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl- thiochroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.15(m, 2H), 6.77-6.67(m, 3H), 6.47(m, 1H), 6.35(m, 1H), 3.51(m, 1H), 2.86(m, 3H), 2.64(m, 1H), # 1.46-1.38(m, 2H), 1.18-0.99(m, 17H) Mass(ESI): 439(M⁺ + 1) 115 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{5-{N-methyl-N-oxo- N-[3-(4,4,5,5,5-pentafluoro- pentyl)sulfinyl]propyl}amino- pentyl}chroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.01(m, 2H), 6.81(m, 1H), 6.66(m, 2H), # 6.25-6.13(m, 2H), 4.42(m, 1H), 4.11(m, 1H), 3.08-2.63(m, 9H), 2.52(m, 1H), 2.32-1.89(m, 6H), 1.53-1.36(m, 2H), 1.32-0.92(m, 11H) Mass(ESI): 622(M⁺ + 1) 116 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{10-{N-[(5- hydroxycarbonyl)pentyl]-N- cyano}aminodecyl}thiochroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.13(m, 2H), 6.78-6.66(m, 3H), 6.47(m, 1H), 6.32(m, 1H), 3.47(m, 1H), # 3.01-2.83(m, 5H), 2.62(m, 1H), 2.22(m, 2H), 1.62-1.43(m, 6H), 1.28-0.92(m, 19H) Mass(ESI): 553(M⁺ + 1) 117 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4- {2-{2-[4-(4,4,5,5,5-penta- fluoropentylsulfinyl)-n- butyl]oxazolinyl}ethyl}- 3-methylchroman

¹H-NMR(300 MHz, CD₃OD) δ: 6.95(d, 2H), 6.75(d, 1H), 6.68(d, 2H), # 6.45(s, 1H), 6.24(dd, 1H), 6.17(d, 1H), 4.43(d, 1H), 4.14(d, 1H), 2.8˜2.5(m, 7H), 2.39(t, 2H), 2.3˜2.1(m, 2H), 1.98(m, 2H), 1.73(m, 4H), 1.5(m, 1H), 1.25(m, 1H), 1.1(s, 3H) Mass(ESI): 616(M + 1) 118 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4- {5-[4-(4,4,5,5,5-pentafluoro- pentylsulfinyl)piperidinyl]- pentyl}-3-methylchroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.01(d, 2H), 6.76(d, 1H), 6.68(d, 2H), 6.22(dd, 1H), 6.15(d, 2H), 4.4(d, 1H), # 4.09(d, 1H), 2.9˜2.5(m, 6H), 2.3˜2.09(m, 4H), 2.05˜1.91(m, 5H), 1.8˜1.5(m, 3H), 1.2˜0.8(m, 11H). Mass(ESI): 618(M + 1) 119 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4- {9-[N-hydroxy-N-(4,4,5,5,5- pentafluoropentyl)carbamoyl- amino]nonyl}-3-methylchroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.05(t, 3H), 6.67(m, 3H), 6.48(d, 1H), 6.31(dd, 1H), 5.92(s, 1H), # 5.78(s, 1H), 5.1(s, 1H), 3.5˜3.15(m, 6H), 2.75(d, 1H), 2.5(d, 1H), 1.89(m, 2H), 1.67(m, 2H), 1.01˜0.76(m, 16H). Mass(ESI): 634(M + 1) 120 (3RS,4RS)-4-[9-(carbamoyl- amino)nonyl]-7-hydroxy-3- (4-hydroxyphenyl)-3- methylchroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.11(d, 2H), 6.87(d, 1H), 6.8(d, 2H), 6.33(dd, 1H), 6.27(d, 1H), 4.51(d, 1H), 4.24(d, 1H), 3.08(t, 2H), 2.65(d, 1H), # 1.44(m, 2H), 1.31˜1.11(m, 17H). Mass(ESI): 441(M + 1) 121 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4- {9-{[(4,4,5,5,5-pentafluoro- pentyl)sulfonyl]carbamoyl- imino}nonyl}-3- methylthiochroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.14(d, 2H), 6.76(d, 1H), 6.68(d, 2H), 6.42(d, 1H), 6.34(dd, 1H), # 3.52(d, 1H), 3.4(t, 2H), 3.03(t, 2H), 2.87(d, 1H), 2.65(d, 1H), 2.2(m, 2H), 1.96(m, 2H), 1.35(m, 2H), 1.19˜0.97(m, 17H). Mass(ESI): 703(M + 23) 122 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4- {2-{2-[4-(4,4,5,5,5-penta- fluoropentylsulfinyl]-n-butyl]- oxazolinyl}ethyl}- 3-methylthiochroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.16(d, 2H), 6.8(d, 1H), 6.64(d, 2H), # 6.48(d, 2H), 6.38(dd, 1H), 3.54(d, 1H), 2.89(d, 1H), 2.8˜2.55(m, 7H), 2.35˜2.1(m, 4H), 1.99(m, 2H), 1.71(m, 4H), 1.35(m, 2H), 1.01(s, 3H). Mass(ESI): 632(M + 1) 123 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4- {7-[(4,4,5,5,5-pentafluoro- pentyl)sulfonylamino]-heptyl}- 3-methylchroman

¹H-NMR(300 MHz, CDCl₃) δ: 6.99(d, 2H), 6.76(d, 1H), 6.68(d, 2H), 6.22(dd, 1H), 6.15(d, 1H), 4.39(d, 1H), # 4.1(d, 1H), 3.02(t, 2H), 2.87(t, 2H), 2.52(d, 1H), 2.21(m, 2H), 1.94(m, 2H), 1.33(m, 2H), 1.16˜0.9(m, 13H). Mass(ESI): 594(M + 1) 124 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4- {5-{N-methyl-N-[2-(4,4,5,5,5- pentafluoropentylsulfinyl)ethyl]- sulfonylamino}pentyl}-3- methylchroman

¹H-NMR(300 MHz, CDCl₃) δ: 7.01(d, 2H), 6.78(d, 1H), # 6.68(d, 2H), 6.22(dd, 1H), 6.14(d, 1H), 4.4(d, 1H), 4.12(d, 1H), 3.29˜3.1(m, 3H), 3.02˜2.9(m, 3H), 2.85˜2.8(m, 2H), 2.69(s, 3H), 2.55(d, 1H), 2.3˜2.1(m, 2H), 2.05˜1.95(m, 2H), 1.3˜0.9(m, 1H). Mass(ESI): 656(M + 1) 125 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4- {[11-carboxyl-11-(4,4,5,5,5- pentafluoropentyl)]undecyl}- 3-methylthiochroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.13(d, 2H), 6.71(d, 1H), 6.68(d, 2H), 6.47(d, 1H), 6.35(dd, 1H), #3.52(d, 1H), 2.86(d, 1H), 2.6(m, 1H), 2.23(m, 1H), 2.05(m, 2H), 1.56˜1.03(m, 27H). Mass(ESI): 631(M + 1) 126 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-4- {[11-carbamoyl-11-(4,4,5,5,5- pentafluoropentyl)]undecyl}- 3-methylthiochroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.15(d, 2H), 6.76(d, 1H), 6.68(d, 2H), 6.42(d, 1H), 6.35(dd, 1H), # 3.51(d, 1H), 2.85(d, 1H), 2.63(m, 1H), 2.2˜1.9(m, 3H), 1.52˜1.02(m, 27H). Mass(ESI): 630(M + 1) 127 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-[9-(4,4,5,5,5-penta- fluoropentyl)-9-(hydroxy- carbonyl)-nonyl]chroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.12(d, 2H, Ar—H), 6.90(d, 1H, Ar—H), 6.82(d, 2H, Ar—H), # 6.34(dd, 1H, Ar—H), 6.28(d, 1H, Ar—H), 4.53(d, 1H, C2-H), 4.22(dd, 1H, C2-H), 2.65(brs, 1H, C4-H), 2.37(m, 1H, CHCOO), 2.15(m, 2H, CH₂CF₂), 1.75-0.98(m, 25H, C3-CH₃, alkyl-H) 128 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-[9-(4,4,5,5,5-penta- fluoropentyl)-9-(hydroxy- carbonyl)-nonyl]thiochroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.34(d, 2H, Ar—H), 6.96(d, 1H, Ar—H), 6.88(d, 2H, Ar—H), # 6.67(d, 1H, Ar—H), 6.55(dd, 1H, Ar—H), 3.70(d, 1H, C2-H), 3.05(d, 1H, C2-H), 2.85(brs, 1H, C4-H), 2.42(m, 1H, CHCOO), 2.20(m, 2H, CH₂CF₂), 1.83-1.07(m, 25H, C3-CH₃, alkyl-H) 129 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{9-[4,4,5,5,5- pentafluoropentanesulfonyl- (N-hydroxycarbonylmethyl)- amino]-nonyl]thiochroman

¹H-NMR(300 MHz, CD₃OD) δ: 7.34(d, 2H, Ar—H), # 6.98(d, 1H, Ar—H), 6.88(d, 2H, Ar—H), 6.67(d, 1H, Ar—H), 6.55(dd, 1H, Ar—H), 4.10(s, 2H, CH₂COO), 3.72(d, 1H, C2-H), 3.38(t, 2H, NCH₂), 3.06(d, 1H, C2-H), 2.85(brs, 1H, C4-H), 2.43(m, 2H, CH₂SO₂), 2.21(m, 2H, CH₂CF₂), 1.75-0.90(m, 21H, C3-CH₃, alkyl-H) 130 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-[8-(4,4,5,5,5-penta- fluoropentylsulfonyl) octylchroman

¹H-NMR(CDCl₃, 270 MHz); δ7.08(d, J=8.58 Hz, 1H), 6.90(d, J=7.92 Hz, 1H), 6.83(d, J=8.58 Hz, 2H), 6.38(m, 2H), # 5.43-5.35(br, 1H), 4.93(br, 1H), 4.51(d, J=10.23 Hz, 1H), 4.24(d, J=10.55 Hz, 1H), 3.10-2.97(m, 4H), 2.60(m, 1H), 2.35-2.18(m, 4H), 1.83(m, 2H), 1.60(m, 2H), 1.43-0.98(m, 17H) 131 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{6-[N-methyl-N-2- (4,4,5,5,5-pentafluoropentyl- thio)ethylamino]hexyl}- chroman. HCl salt

¹H-NMR(CD₃OD, 270 MHz); δ7.06(d, 2H), 6.84(d, 1H), 6.75(d, 2H), 6.28(dd, 1H), 6.23(d, 1H), # 4.46(d, 1H), 4.17(d, 1H), 3.16-2.73(m, 7H), 2.73-2.49(m, 3H), 2.36-2.07(m, 2H), 1.97-1.73(br, 2H), 1.66-1.43(br, 2H), 1.37-0.89(m, 13H) 132 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{6-[N-methyl-N-2- (4,4,5,5,5-pentafluoropentyl- sulfinyl)ethylamino]- hexyl}chroman

¹H-NMR(CD₃OD, 270 MHz); δ7.06(d, 2H), 6.89(d, 1H), 6.66(d, 2H), 6.35(dd, 1H), 6.14(d, 1H), 4.47(d, 1H), 4.17(d, 1H), # 3.09-2.53(m, 7H), 2.46-2.11(m, 7H), 2.04(m, 2H), 1.44-0.85(m, 13H) 133 (3RS,4RS)-3-(4,4,5,5,5-penta- fluoropentyl)-12-(7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl)- dodecanoic acid

¹H-NMR(300 MHz, CD₃OD) δ: 6.98(d, 2H, J=8.75 Hz), 6.75(d, 1H, J=8.26 Hz), 6.67(d, 2H, J=8.76 Hz), 6.2(dd, 1H, J=2.55 Hz, 8.23 Hz), # 6.13(d, 1H, J=2.55 Hz), 4.39(d, 1H, J=10.3 Hz), 4.1(d, 1H, J=10.3 Hz), 2.53(bd, 1H), 2.0(m, 4H), 1.21˜1.06(m, 26H) Mass(ESI): 615(M + 1) 134 (3RS,4RS)-4-allyl-7- methoxymethoxy-3-(4- methoxymethoxyphenyl)-3- methylchroman

¹H-NMR(270 MHz, CDCl₃) δ: 7.15(d, 2H, J=8.9 Hz, Ar—H), 7.03(d, 2H, J=8.9 Hz, Ar—H), 6.96(d, 1H, J=7.9 Hz, Ar—H), 6.57(s, 1H, Ar—H), # 6.5˜6.6(m, 1H, Ar—H), 5.5˜5.7(m, 1H, vinyl-H), 5.18(s, 2H, OCH₂OMe), 5.15(s, 2H, CH₂OMe), 4.86(d, 1H, J=9.9 Hz, vinyl-H), 4.71(dd, 1H, J=17.2 Hz, 1.7 Hz, vinyl-H), 4.52(d, 1H, J=10.7 Hz, C2-H), 4.25(dd, 1H, J=10.6, 1.7 Hz, C2-H), 3.50(s, 3H, OCH₃), 3.49(s, 3H, OCH₃), # 2.7˜2.9(m, 1H, C4-H), 2.0˜2.1(m, 1H, allylic-H), 1.8˜1.9(m, 1H, allylic-H), 1.29(s, 3H, C3-Me) 135 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{9-[3-(methoxy)- propylsulfinyl]nonyl}- thiochroman

¹H-NMR(270 MHz, CD₃OD) δ: 7.18(d 2H, J=9 Hz, Ar—H), 6.79(d, 1H, J=8 Hz, Ar—H), 6.71(d, 2H, J=9 Hz, Ar—H), 6.49(d, 1H, J=2 Hz, Ar—H), # 6.37(dd, 1H, J=8 and 2 Hz, Ar—H), 3.55(d, 1H, J=12 Hz, C2-H), 3.45(t, 2H, J=5 Hz, —CH₂OCH₃), 3.27(s, 3H, —CH₂OCH₃), 2.91˜2.65(m, 6H, C2-H, C4-H and —CH₂SOCH₂—), 1.98˜1.88(m, 2H, alkyl-H), 1.66˜1.58(m, 2H, alkyl-H), 1.30˜0.90(m, 14H, alkyl-H), # 1.05(s, 3H, C3-CH₃) 136 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{6-[3-(4,4,5,5,5- pentafluoropentylsulfinyl)- propylsulfinyl]hexyl}- thiochroman

¹H-NMR(270 MHz, CD₃OD) δ: 7.18(d, 2H, J=9 Hz, Ar—H), 6.80(d, 1H, J=8 Hz, Ar—H), 6.71(d, 2H, J=9 Hz, Ar—H), # 6.49(d, 1H, J=2 Hz, Ar—H), 6.37(dd, 1H, J=8 and 2 Hz, Ar—H), 3.55(d, 1H, J=12 Hz, C2-H), 2.98˜2.58(m, 10H, C2-H, C4-H and —CH₂SOCH₂CH₂CH₂SOCH₂—), 2.38˜1.96(m, 6H, CF₃CF₂CH₂CH₂CH₂SOCH₂CH₂—), 1.53(m, 2H, alkyl-H), # 1.30˜0.90(m, 8H, alkyl-H), 1.06(s, 3H, C3-CH₃) 137 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methyl-4-{6-[2-(4,4,5,5,5- pentafluoropentylsulfinyl)- ethylsulfinyl]hexyl}- thiochroman

¹H-NMR(270 MHz, CD₃OD) δ: 7.18(d, 2H, J=9 Hz, Ar—H), 6.80(d, 1H, J=8 Hz, Ar—H), 6.71(d, 2H, J=9 Hz, Ar—H), # 6.49(d, 1H, J=3 Hz, Ar—H), 6.37(dd, 1H, J=8 and 3 Hz, Ar—H), 3.56(d, 1H, J=12 Hz, C2-H), 3.23˜2.65(m, 10H, C2-H, C4-H and —CH₂SOCH₂CH₂SOCH₂—), 2.39˜2.20(m, 2H, CF₃CF₂CH₂—), 2.08˜1.99(m, 2H, CF₃CF₂CH₂CH₂—), # 1.55(br, 2H, alkyl-H), 1.30˜1.00(m, 8H, alkyl-H), 1.06(s, 3H, C3-CH₃) 138 2-{4-[(3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methylchroman-4-yl]butoxy}- 5-(4,4,5,5,5-pentafluoropentyl- sulfinyl)pentanoic acid

¹H-NMR(270 MHz, CD₃OD) δ: 7.03(d, 2H, J=9 Hz, Ar—H), 6.82˜6.80(m, 1H, Ar—H), 6.71(d, 2H, J=9 Hz, Ar—H), # 6.27˜6.17(m, 2H, Ar—H), 4.44(d, 1H, J=11 Hz, C2-H), 4.14(d, 1H, J=11 Hz, C2-H), 3.66(br, 1H, CH(CO₂H)-), 3.40(br, 1H, CH₂O—), 3.08(br, 1H, CH₂O—), 2.80˜2.58(m, 5H, C4-H and —CH₂SOCH₂—), 2.37˜2.18m, (2H, CF₃CF₂CH₂—), # 2.06˜1.98(m, 2H, CF₃CF₂CH₂CH₂—), # 1.75(br, 4H, alkyl-H), 1.30˜0.97(m, 6H, alkyl-H), 1.13(s, 3H, C3-CH₃) 139

¹H-NMR(270 MHz, CDCl₃): δ: 8.01(d, J=8.6 Hz, 2H, Ar—H), 7.29(d, J=8.6 Hz, 2H, Ar—H), 6.87(d, J=7.9 Hz, 1H, Ar—H), 6.79(brs, 1H, OH), 6.71(brs, 1H, OH), 6.42(m, 2H, Ar—H), 4.56(d, J=10.5 Hz, 1H, C2-H), 4.28(d, J=10.5 Hz, 1H, C2-H), 3.91(s, 3H, COOCH₃), # 2.76˜2.58(m, 5H, C4-H, and 2xS(O)CH₂), 2.18(m, 4H, alkyl-H), 1.72(m, 2H, alkyl-H), 1.27˜0.98(m, 17H, C3-CH₃ and alkyl-H) 140

¹H-NMR(270 MHz, CD₃OD): δ: 7.21(d, J=8.5 Hz, 2H, Ar—H), 7.06(brd, J=not resolved, 2H, Ar—H), 6.95(d, J=8.6 Hz, 2H, Ar—H), 6.75(m, 3H, Ar—H), 6.23(m, 2H, Ar—H), 46˜4.05(m, 6H, PhCH₂CH₂S(O), C4-H and 2xC2-H), 3.39˜2.93(m, 6H, 2xS(O)CH₂ and C2-CH₂), # 2.84(brt, 1H, C4-H), 2.35(m, 2H, alkyl-H), 2.10(m, 2H, alkyl-H), 1.23(m, 5H, C3-CH₃ and alkyl-H) 141 methyl(3RS,4RS)-6-[7-hydroxy- 3-(4-hydroxyphenyl)-3-methyl- thiochroman-4-yl]octanoate

¹H-NMR(270 MHz, CDCl₃) δ: 7.24(d, J=9 Hz, 2H, Ar—H), 6.85(d, J=8 Hz, 1H, Ar—H), 6.83(d, J=9 Hz, 2H, Ar—H), 6.67(d, J=2 Hz, 1H, Ar—H), 6.50(dd, J=8, 2 Hz, 1H, Ar—H), 5.58(brs, 1H, ArOH), # 4.88(brs, 1H, ArOH), 3.69(s, 3H, CO₂CH₃), 3.64(d, J=11 Hz, 1H, C2-H), 2.92(d, J=11 Hz, 1H, C2-H), 2.67(brs, 1H, C4-H), 2.23(t, J=7 Hz, 2H, CH₂CO₂CH₃), 1.65˜1.45(q, J=7 Hz, CH₂CH₂CO₂CH₃), 1.30˜0.90(m, 13H, alkyl-H). 142 (3RS,4RS)-7-hydroxy-4- [4-hydroxy-9-(4,4,5,5,5-penta- fluoropentylsulfinyl)non-1-yl]- 3-hydroxyphenyl-3-methyl- chroman

¹H-NMR(270 MHz, CD₃OD) δ: 7.08(d, J=9 Hz, 2H, Ar—H), 6.88(d, J=8 Hz, 1H, Ar—H), 6.77(d, J=9 Hz, 2H, Ar—H), 6.31(dd, J=8, 2 Hz, 1H, Ar—H), # 6.24(d, J=2 Hz, 1H, Ar—H), 4.50(d, J=11 Hz, 1H, C2-H), 4.20(d, J=11 Hz, 1H, C2-H), 3.30(brs, 1H, CHOH), 2.95-2.70(m, 4H, CH₂SOCH₂), 2.65(m, 1H, C4-H), 2.45˜2.20(m, 2H, CH₂CF₂), 2.15˜2.00(m, 2H, CH₂CH₂CF₂), 1.85˜1.65(m, 2H, CH₂CH₂SO), 1.50˜1.00(m, 15H, alkyl-H) 143 (3RS,4RS)-7-hydroxy-3- hydroxyphenyl-4-[4-oxo-9- (4,4,5,5,5-pentafluoropentyl- sulfinyl)non-1-yl]-3- methylchroman

¹H-NMR(270 MHz, CDCl₃) δ: 7.64, 7.52(each s, total 1H, ArOH), 7.05(d, J=9 Hz, 2H, Ar—H), 6.88(d, J=8 Hz, 1H, Ar—H), 6.84(d, J=9 Hz, 2H, Ar—H), # 6.39˜6.33(m, 2H, Ar—H), 5.45, 5.38(each s, tatal 1H, Ar—OH), 4.48(d, J=11 Hz, 1H, C2-H), 4.22(d, J=11 Hz, 1H, C2-H), 2.95˜2.70(m, 4H, CH₂SOCH₂), 2.59(m, 1H, C4-H), 2.35˜2.05(m, 8H, CH₂COCH₂ and CH₂CH₂CF₂), 2.15˜2.00(m, 2H, CH₂CH₂CF₂), 1.85˜1.70(m, 2H, # CH₂CH₂SO), 1.50˜1.00(m, 11H, alkyl-H) 144 (3RS,4RS)-4-[7,7-difluoro-5- oxa-9-(4,4,5,5,5-pentafluoro- pentylsulfinyl)non-1-yl]-7- hydroxy-3-hydroxyphenyl-3- methylchroman

¹H-NMR(270 MHz, CD₃OD) δ: 7.14(d, J=9 Hz, 2H, Ar—H), 6.91(d, J=8 Hz, 1H, Ar—H), 6.82(d, J=9 Hz, 2H, Ar—H), 6.35(dd, J=8, 2 Hz, 1H, Ar—H), # 6.28(d, J=2 Hz, 1H, Ar—H), 4.52(d, J=11 Hz, 1H, C2-H), 4.26(d, J=11 Hz, 1H, C2-H), 3.61(t, J=12 Hz, 2H, OCH₂CF₂), 3.40(t, J=6 Hz, CH₂CH₂O), 3.13˜2.85(m, 4H, CH₂SOCH₂), 2.70(m, 1H, C4-H), 2.50˜2.25(m, 4H, CH₂CF₂X₂), 2.15˜2.00(m, 2H, CH₂CH₂CF₂), # 2.15˜2.08(m, 2H, CH₂CH₂CF₂CF₃), 1.50˜1.05(m, 9H, alkyl-H) 145 (3RS,4RS)-1-[9-(7-hydroxy-3- (4-hydroxyphenyl-3-methyl- chroman-4-yl)]nonylcyclo- hexanecarboxylic acid

¹H-NMR(270 MHz, CDCl₃) δ: 7.07(d, J=9 Hz, 2H, Ar—H), 6.90(d, J=8 Hz, 1H, Ar—H), 6.83(d, J=9 Hz, 2H, Ar—H), 6.40˜6.30(m, 2H, Ar—H), 4.51(d, J=11 Hz, 1H, # C2-H), 4.23(d, J=11 Hz, 1H, C2-H), 2.60(m, 1H, C4-H), 2.13-2.03(m, 2H, CH₂CCO₂H), 1.65˜0.95(m, 29H, alkyl-H) 146 (3RS,4RS)-4-[6, 6-dimethyl-5- oxa-9-(4,4,5,5,5-pentafluoro- pentylsulfinyl)nonyl]-7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman

¹H-NMR(270 MHz, CDCl₃) δ: 7.19(s, 1H, —OH), 7.07(d, J=8.3 Hz, 2H, Ar—H), 6.91(d, J=4.0 Hz, 1H, Ar—H), 6.85(d, J=8.3 Hz, 2H, Ar—H), # 6.41˜6.36(m, 2H, Ar—H), 5.76 and 5.48(s, total 1H, —OH), 4.53˜4.49(m, 1H, C2-H), 4.25˜4.16(m, 1H, C2-H), 3.05˜3.00(m, 2H), 2.92˜2.68(m, 3H), 2.63˜2.50(m, 2H), 2.38˜2.18(m, 4H, —CH₂CH₂CF₂CF₃), 1.82˜1.63(m, 2H), 1.60˜1.39(m, 2H), 1.30˜1.21(m, 6H), 1.07(s, 3H, —CH₃), # 1.04(s, 3H, —CH₃), 1.02 and 1.01(s, total 3H, C3-CH₃) 147 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl-4- [N-methyl-6-aza-9-(4,4,5,5,5- pentafluoropentylsulfonyl- amino)nonyl]chroman

¹H-NMR(270 MHz, CDCl₃) δ: 7.07(d, J=8.6 Hz, 2H, Ar—H), 6.88(d, J=7.9 Hz, 1H, Ar—H), 6.82(d, J=8.6 Hz, 2H, Ar—H), 6.38˜6.34(m, 2H, Ar—H), # 4.48(d, J=10.6 Hz, 1H, C2-H), 4.23(d, J=10.6 Hz, 1H, C2-H), 3.78˜3.70(m, 2H, —CH₂N—), 3.54(t, J=7.3 Hz, 3H, —SO₂CH₂— and NH), 2.62˜2.58(m, 1H, C4-H), 2.38˜2.15(m, 8H, —CH₂NCH₂— and —CH₂CH₂CF₂CF₃), 2.13(s, 3H, —NCH₃), 1.91˜1.82(m, 2H), # 1.25(s, 3H, C3-CH3), 1.25˜1.18(m, 4H), 1.17-1.00(m, 4H) 148 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl-4- [4-methyl-5-oxa-9-(4,4,5,5,5- pentafluoropentylsulfinyl)- nonyl]chroman

¹H-NMR(270 MHz, CD₃OD) δ: 7.18(d, J=8.3 Hz, 2H, Ar—H), 6.87(dd, J=8.2 Hz and 1.6 Hz, 1H, Ar—H), 6.78(d, J=8.3 Hz, 2H, Ar—H), 6.31(dd, J=8.2 Hz # and 2.0 Hz, 1H, Ar—H), 6.24(d, J=2.0 Hz, 1H, Ar—H), 4.50(d, J=10.5 Hz, 1H, C2-H), 4.20(d, J=10.5 Hz, 1H, C2-H), 3.45-3.42(m, 1H, —CH₂CHO—CH₂—), 3.27-3.18(m, 2H, —CH₂CHO—CH₂—), 2.90˜2.78(m, 4H, —CH₂SCH₂—), 2.70˜2.60(m, 1H, C4-H), 2.45˜2.22(m, 2H, # —CH₂CH₂CF₂CF₃), 2.18˜2.02(m, 2H, —CH₂CH₂CF₂CF₃), 1.89˜1.54(m, 4H), 1.41˜1.01(m, 6H), 1.20(s, 3H, —CHCH₃), 1.01 and 0.98(s, total 3H, C3-CH₃) 149 (3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3-methyl-4- [4-(3-(4,4,5,5,5-pentafluoro- pentylsulfinyl)propyloxy) phenylpropyl]chroman

¹H-NMR(270 MHz, CDCl₃) δ: 7.24 and 7.22(s, total 1H, OH), 6.96˜6.65(m, 9H, Ar—H), 6.40˜6.33(m, 2H, Ar—H), 5.19(s, 1H, OH), # 4.45(1H, d, J=10.6 Hz, C2-H), 4.25˜4.09(m, 3H, —OCH₂— and C2-H), 3.13˜2.74(m, 5H), 2.57˜2.14(m, 9H), 1.74˜1.59(m, 1H), 1.43˜1.11(m, 1H), 1.21(s, 3H, C3-CH₃), 1.06˜0.85(m, 1H) 150 (Z)-6,6,7,7,7-pentafluoro- 2-{9-[(3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)-3-methyl- chroman-4-yl]nonyl}- 2-heptenoic acid

¹H-NMR(300 MHz, CDCl₃) δ: 7.12˜6.80(m, 5H, Ar—H), 6.41˜6.34(m, 2H, Ar—H), 5.99(t, 1H, J=7.7 Hz, C3-H), 4.51(d, 1H, J_(AB)=10.2 Hz, C2″-H), # 4.24(dd, 1H, J_(AB)=10.2 Hz, J=1.9 Hz, C2″-H), 2.84˜2.72(m, 2H), 2.61(m, 1H, C4″-H), 2.31-2.07(m, 4H), 1.46˜0.98(m, 19H, alkyl-H) 151 2-(4,4,5,5,5-pentafluoro- 1-hydroxypentyl)-11- [(3RS,4RS)-7-hydroxy-3- (4-hydroxyphenyl)-3- methylchroman-4-yl]- undecanoic acid

¹H-NMR(300 MHz, CDCl₃) δ: 7.12˜6.78(m, 5H, Ar—H), 6.41˜6.33(m, 2H, Ar—H), # 4.51(d, 1H, J_(AB)=10.2 Hz, C2″-H), 4.24(dd, 1H, J_(AB)=10.2 Hz, J=1.6 Hz, C2″-H), 3.89 and 3.78(m, 0.33H and 0.67H, C-1′-H, anti and syn), 2.60(m, 1H, C4″-H), 2.58-1.53(m, 9H), 1.41˜0.94(m, 17H, alkyl-H) 152 (E)-3-{4-[4-[(3RS,4RS)- 7-hydroxy-3-(4-hydroxy- phenyl)-3-methylthiochroman- 4-yl]-benzyl}propeneoic acid

¹H-NMR(300 MHz, CDCl₃) δ: 7.65(d, 1H, J=16 Hz, vinyl), 7.40˜7.2(m, 6H, Ar—H, Ar—OH), 6.80˜6.61(m, 5H, Ar—H, Ar—OH), # 6.25(d, 1H, J=16 Hz, Vinyl), 6.22(m, 1H, Ar—H), 6.08(d, 1H, J=8.2 Hz, Ar—H), 3.76(d, 1H, J=12 Hz, C2-H), 3.05(s, 1H, 12 Hz, C2-H), 2.95(d, 1H, J=10.5 Hz, benzyl(CH₂)), 2.49(d, 1H, J=10.5 Hz, benzyl(CH₂)), 2.29(dd, 1H, J=10.9, 1.3 Hz, C4-H), 1.26(s, 3H, C3-Me) 153 2-{2-[(3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]ethyl}5- {[4-(4,4,5,5,5-pentafluoropentyl- sulfinyl)butyl]}oxazole

¹H-NMR(300 MHz, Acetone-d6) δ: 8.02(s, 1H, oxazole), 7.06(m, 4H, Ar—H), 6.84(m, 2H, Ar—H), # 6.64(brs, 1H, Ar—OH), 6.42˜6.32(m, 2H, Ar—H, Ar—OH), 6.54(d, 1H, J=11 Hz, C2-H), 4.27(d, 1H, J=10.5 Hz, C2-H), 2.8˜2.1(m, 14H, CH₂, CF₂, Alkyl, CH₂SO), 1.8˜1.6(m, 5H, —(CH₂)_(n)), 1.20(s, 3H, C3-Me) 154 (3RS,4RS)-6-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]nonanoic acid

¹H-NMR(270 MHz, CD₃OD) δ: 7.22(d, J=9 Hz, 2H, Ar—H), 6.65(d, J=8 Hz, 1H, Ar—H), 6.50(d, J=9 Hz, 2H, Ar—H), 6.37(d, J=2 Hz, 1H, Ar—H), # 6.25(dd, J=8, 2 Hz, 1H, Ar—H), 3.22(AB q, J=11 Hz, 2H, C2-H), 2.91(brd, 1H, C4-H), 2.26(t, J=7 Hz, 2H, CH₂CO₂H), 1.60-1.40(q, J=7 Hz, CH₂CH₂—CO₂H), 1.30-0.90(m, 15H, alkyl-H) 155 (3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)-3- methyl-4-[10-(4,4,5,5,5-penta- fluoropentylsulfonyl)- amino)decyl]chroman

¹H-NMR(270 MHz, CDCl₃) δ: 7.07(d, J=8.6 Hz, 2H, Ar—H), 6.90(d, J=8.3 Hz, 1H, C5-H), 6.83(d, J=8.6 Hz, 2H, Ar—H), # 6.39-6.37(m, 2H, Ar—H), 5.51(brs, 1H, Ar—OH), 5.30(brs, 1H, Ar—OH), 4.62˜4.36(m, 2H, C2-H and NH), 4.23(d, J=10.6 Hz, 1H, C2-H), 3.14-3.07(m, 4H, CH₂—NH and SO₂CH₂), 2.65-2.56(m, 1H, C4-H), 2.38-2.05(m, 4H, CH₂CH₂CF₂CF₃), 1.58-0.95(m, 21H, C3-CH₃ # and alkyl-H) 156 9-{4-[(3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- phenoxy}-2-(4,4,5,5,5- pentafluoropentyl)nonanoic acid

157 8-{4-[(3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- phenoxy}-2-(4,4,5,5,5- pentafluoropentyl)octanoic acid

158 7-{4-[(3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- phenoxy}-2-(4,4,5,5,5-penta- fluoropentyl)heptanoic acid

159 6-{4-[(3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- phenoxy}-2-(4,4,5,5,5- pentafluoropentyl)hexanoic acid

160 5-{4-[(3RS,4RS)-7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- phenoxy}-2-(4,4,5,5,5-penta- fluoropentyl)pentanoic acid

161 5-{4-[(3′RS,4′RS)-7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- phenoxy}-2-(4,4,5,5,5- pentafluoropentyl)pentanoic acid

162 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-(4,4,5,5,5-pentafluoro- pentyl)undecanoic acid

163 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(4,4,5,5,5-pentafluoro- pentyl)undecanoic acid

164 (3′RS,4′RS)-12-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-(4,4,5,5,5-pentafluoro- pentyl)dodecanoic acid

165 (3′RS,4′RS)-12-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(4,4,5,5,5-pentafluoro- pentyl)dodecanoic acid

166 (3′RS,4′RS)-9-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-(4,4,5,5,5-pentafluoro- pentyl)nonanoic acid

167 (3′RS,4′RS)-9-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(4,4,5,5,5-pentafluoropentyl)- nonanoic acid

168 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(4,4,5,5,5-pentafluoropentyl)- decanoic acid

169 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-(4,4,5,5,5-pentafluoropentyl)- decanoic acid

170 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(4,4,5,5,5-pentafluorobutyl)- decanoic acid

171 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-(3,3,4,4,4-pentafluorobutyl)- decanoic acid

172 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(5,5,6,6,6-pentafluorohexyl)- decanoic acid

173 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-(5,5,6,6,6,-pentafluorohexyl)- decanoic acid

174 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(6,6,7,7,7-pentafluoroheptyl)- decanoic acid

175 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-(6,6,7,7,7-pentafluoroheptyl)- decanoic acid

176 (3′RS,4RS′)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(3,3,4,4,4-pentafluorobutyl)- undecanoic acid

177 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-(3,3,4,4,4-pentafluorobutyl)- undecanoic acid

178 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(5,5,6,6,6-pentafluorohexyl)- undecanoic acid

179 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methythiochroman-4-yl]- 2-(5,5,6,6,6-pentafluorohexyl)- undecanoic acid

180 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-(6,6,7,7,7-pentafluoroheptyl)- undecanoic acid

181 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-(6,6,7,7,7-pentafluoroheptyl)- undecanoic acid

182 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-methyl-2-(4,4,5,5,5-penta- fluoropentyl)undecanoic acid

183 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-methyl-2-(4,4,5,5,5-penta- fluoropentyl)undecanoic acid

184 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-methyl-2-(4,4,5,5,5-penta- fluoropentyl)decanoic acid

185 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-methyl-2-(4,4,5,5,5-penta- fluoropentyl)decanoic acid

186 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-ethyl-2-(4,4,5,5,5-pentafluoro- pentyl)undecanoic acid

187 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-ethyl-2-(4,4,5,5,5-pentafluoro- pentyl)undecanoic acid

188 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-ethyl-2-(4,4,5,5,5-pentafluoro- pentyl)decanoic acid

189 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-ethyl-2-(4,4,5,5,5-pentafluoro- pentyl)decanoic acid

190 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-methyl-2-(5,5,6,6,6-penta- fluorohexyl)undecanoic acid

191 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-methyl-2-(5,5,6,6,6-penta- fluorohexyl)undecanoic acid

192 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-methyl-2-(6,6,7,7,7-penta- fluoroheptyl)undecanoic acid

193 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-methyl-2-(6,6,7,7,7-penta- fluoroheptyl)undecanoic acid

194 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-ethyl-2-(5,5,6,6,6-penta- fluorohexyl)undecanoic acid

195 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-ethyl-2-(5,5,6,6,6-penta- fluorohexyl)undecanoic acid

196 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-ethyl-2-(6,6,7,7,7-penta- fluoroheptyl)undecanoic acid

197 (3′RS,4′RS)-11-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-ethyl-2-(6,6,7,7,7-penta- fluoroheptyl)undecanoic acid

198 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-methyl-2-(5,5,6,6,6-penta- fluorohexyl)decanoic acid

199 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-methyl-2-(5,5,6,6,6-penta- fluorohexyl)decanoic acid

200 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]-2- methyl-2-(6,6,7,7,7-pentafluoro- heptyl)decanoic acid

201 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-methyl-2-(6,6,7,7,7-penta- fluoroheptyl)decanoic acid

202 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-ethyl-2-(5,5,6,6,6-penta- fluorohexyl)decanoic acid

203 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-ethyl-2-(5,5,6,6,6-penta- fluorohexyl)decanoic acid

204 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylchroman-4-yl]- 2-ethyl-2-(6,6,7,7,7-penta- fluoroheptyl)decanoic acid

205 (3′RS,4′RS)-10-[7-hydroxy- 3-(4-hydroxyphenyl)-3- methylthiochroman-4-yl]- 2-ethyl-2-(6,6,7,7,7-penta- fluoroheptyl)decanoic acid

[1670] Experiment 1

[1671] Cell Growth Inhibiting Activity

[1672] In this experiment, the cell growth inhibiting activity was determined by using the compounds of Examples 1, 2, 3, 5, 22, 127 and 128 as the test compound and the known anti-estrogenic compound ZMI89154 having the following structure (see, EP0124369 B1) as the control compound, according to the method described hereinafter.

[1673] MCF-7 cell lines (ATCC) were incubated in MEM (minimum essential medium) which is supplemented by 3% DCC(dextran coated charcoal)-treated 5% FBS(fetal bovine serum) but does not contain phenol red, for one week. One day before drug administration, incubated MCF-7 cells were plated in 96well plate in the concentration of 5×10³ cells per well- After the 96well plate was incubated for one day, 0.1NM of estradiol and the test compound in the given concentration were added to each well. The plate was incubated for 7 days at 37° C. and then MTT solution(Sigma) was added to each well in the amount of 15a. and allowed to react for 2 hours at 37° C. After the reaction was completed, the solubilizing/stopping solution (constitution: SDS, acetic acid, N,N-dimethylformamide) was added to each well in the amount of 1001. Then, the absorption for each well at 570 nm was measured by means of a plate reader. IC₅₀ value for inhibiting cell growth of 50% was calculated from the results as measured and described in the following Table 2. TABLE 2 IC₅₀ value of the test compounds(nM) Test Com. I Com. II com. Ex. 1 of Ex. 2 of Ex. 2 Ex. 3 Ex. 5 Ex. 22 Ex. 127 Ex. 128 Zm189154 IC₅₀ 60.4 67.5 1000 54.5 387.4 850.5 3313 4993 77(trans) (nM)  9.2(cis)

[1674] Experiment 2

[1675] Anti-Estrogenic Activity (Subcutaneous Administration)

[1676] Anti-estrogenic activity of the test compound by subcutaneous administration was determined according to the method described hereinafter. In this experiment, the compounds of Examples 1, 2, 3, 4, 5, 22, 127 and 128 were used as the test compound and the known anti-estrogenic compound ZM189154 was used as the control compound as in Experiment 1.

[1677] The anti-estrogenic activity was determined by subcutaneously injecting 17β-estradiol-benzoate (Sigma) to mice (ICR, weight 30±2 g), which were ovariectomized two weeks before, in an amount of 0.1 μg/day, per mouse for 3 days and then measuring the degree that the test compound inhibits the increase of uterine weight by stimulus with estradiol. In this experiment, the test compound or the control compound was dissolved in peanut oil(Sigma) and injected subcutaneously for 3 days, once a day. After 24 hours from the last injection, the test animal was sacrificed and uterus was removed and weighed. The results as measured are described in the following Table 3 TABLE 3 Anti-estrogenic activity of the test compound in ovariectomized mice which were administered with 17 β-estradiol Test compound/dosage (s.c., 3 days) Inhibition (%) Compound of 30 μg/mouse 27.5 Example 1 Compound I of 30 μg/mouse 30.8 Example 2 Compound II of 30 μg/mouse −9.3 Example 2 Compound of 30 μg/mouse 11.7 Example 3 Compound of 30 μg/mouse 26.4 Example 4 Compound of 30 μg/mouse 9.8 Example 5 Compound of 30 μg/mouse 51.0 Example 22 Compound of 30 μg/mouse 40.0 Example 127 Compound of 30 μg/mouse 54.3 Example 128 Control compound 30 μg/mouse 73.8 ZM189154

[1678] From the results described in the above Table 3, it could be seen that the compounds of Examples 1, 2, 4, 22, 127 and 128 according to the present invention substantially inhibit the increase of uterine weight by estradiol.

[1679] Experiment 3

[1680] Anti-Estr Genic Activity (Oral Administration)

[1681] Oral anti-estrogenic activity in vivo of the test compound was determined according to the method described hereinafter. In this experiment, the compound of Example 3, 22, 127 and 128 were used as the test compound and the known anti-estrogenic compound ZM189154 was used as the control compound as in- Experiment 2.

[1682] Anti-estrogenic activity was determined by oral administration of 17β-estradiol-benzoate(Sigma) to mice (ICR, weight 30±2 g), which were ovariectomized 2 weeks before, in the amount of 0.1 μg/day, per mouse for 3 days and then measuring the degree that the test compound inhibits the increase in uterus weight by stimulus with estradiol. In this experiment, the test compound or the control compound was suspended in 5% arabic gum solution and orally administered for 3 days, once a day. After 24 hours from the last administration, the test animal was sacrificed and uterus was removed and weighed. The results as measured are described in the following Table 4. TABLE 4 Anti-estrogenic activity of the test compound in ovariectomized mice which were administered with 17 β-estradiol (oral administration, 3 days) Test compound/dosage (p.o., 3 days) Inhibition (%) Compound of 10 mg/kg 0.6 Example 3 Compound of 10 mg/kg 81.3 Example 22 Compound of 10 mg/kg 44.5 Example 127 Compound of 10 mg/kg 70.0 Example 128 ZM189154 10 mg/kg 41.7

[1683] From the results described in the above Table 4, it could be seen that the compound according to the present invention administered via oral route substantially inhibits the increase of uterine weight by estradiol. 

What is claimed is:
 1. A benzopyran or thiobenzopyran derivative represented by the following formula (1):

pharmaceutically acceptable salt or stereoisomer thereof, in which X represents O or S, R₁ represents hydrogen, hydroxy, or —OR₆ (wherein R₆ represents acyl or alkyl), R₂ represents phenyl which is optionally substituted by one or more substituents selected from a group consisting of hydroxy, lower alkyl, halogen, nitro, hydroxymethyl, carboxy, alkoxycarbonyl, —OR₆ (wherein R₆ represents acyl or alkyl) and amino which is optionally substituted by one or two lower alkyl; or represents 5- or 6-membered unsaturated heterocycle containing nitrogen, oxygen or sulfur as the hetero atom, R₃ represents hydrogen or lower alkyl, provided that R₃ does not exist when

is a double bond (wherein

represents a single bond or a double bond), R₄ represents hydrogen or lower alkyl, A represents hydrogen; hydroxyalkyl; carboxyalkyl; carboxyvinylphenyl; pyrrole substituted by carboxyvinylbenzyl; or represents a group selected from the following formulae (a) to (l);

in the above formulae (a) to (l) m₁ to m₃ independently of one another represent an integer of 0 to 15, n₁ to n₂ independently of one another represent an integer of 0, 1 or 2, R₅ represents cyano; alkyl; halogenoalkyl; alkoxy; hydroxy; carboxy; alkoxycarbonyl; carbamoyl; monoalkylamino; phenyl which is optionally substituted by one or more substituents selected from a group consisting of straight-chain or branched alkyl, carboxy and cyano; piperidinyl which is optionally substituted by one or more substituents selected from a group consisting of carboxy, alkyl and alkoxycarbonyl; cyclohexyl which is optionally substituted by carboxy; imidazolyl; dialkylamino; or piperidinyl oxide, D¹ and D² independently of one another represent a direct bond, or a group selected from the following:

wherein m, m₁ and m₂ independently of one another represent an integer of 0 to 15, and R₅ is defined as above.
 2. The compound of claim 1, wherein X represents O or S, R₁ represents hydroxy, R₂ represents phenyl which is optionally substituted by one or two substituents selected from a group consisting of hydroxy, lower alkyl and halogen; or represents 6-membered unsaturated heterocycle containing nitrogen as the hetero atom, R₃ represents lower alkyl, provided that R₃ does not exist when is a double bond, R₄ represents hydrogen, A represents a group selected from the following formulae (a) to (e), (k) and (l);

in the above formulae (a) to (e), (k) and (l) m₁ to m₃ independently of one another represent an integer of 0 to 15, n₁ to n₂ independently of one another represent an integer of 0, 1 or 2, R₅ represents alkyl; halogenoalkyl; alkoxy; hydroxy; carboxy; phenyl which is optionally substituted by one or two straight-chain or branched alkyl; or dialkylamino, D¹ and D² independently of one another represent a direct bond, or a group selected from the following:

wherein m₁ and m₂ independently of one another represent an integer of 0 to 15, and R₅ is defined as above.
 3. The compound of claim 2, which is selected from the group consisting of: 7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[4-(4,4,5,5,5-pentafluoro pentyl)piperazinyl]nonyl}chroman; (3RS,4RS)-7-hydroxy-4[(11-imino-11-N-butylamino)undecyl]-3-(4-hydroxy phenyl)-3-methylchroman; (3RS,4RS)-7-hydroxy-4-[(1-N-butylimino-1-N-butylamino)undecyl]-3-(4-hydroxyphenyl)-3-methylchroman; (3RS,4SR)-7-hydroxy-4-{4-{2-{4-{[3,5-bis(t-butyl)phenyl]methyl}piperazinyl}ethoxy}phenyl}-3-(4-hydroxyphenyl)-3-meth ychroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-{5-[N-methyl-N-3-(4,4,5,5,5-pentafluoropentylthio)-propylamino]pentyl}-3-methylchroman; 4-{4-{2-[2-(4,4,5,5,5-pentafluoropentylsulfinyl)ethoxy]ethoxy}phenyl}-7-hydroxy-3-(4-hydroxyphenyl)-2H-chromene; (3RS,4RS)-4-[9-(3-dimethylaminopropylsulfinyl)nonyl]-7-hydroxy-3-4-hydroxyphenyl)-3-methylthiochroman; (3RS,4RS)-4-[9-(N-4,4,5,5,5-pentafluoropentylaminosulfonylamino)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman; 6-{(3RS,4RS)-{9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]nonylsulfinyl}hexanoic acid; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2-methoxy ethoxy)ethylsulfinyl]nonyl)thiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2-hydroxy ethoxy)ethylsulfinyl]nonyl}thiochroman; (3RS,4RS)-7-hydroxy-3-(2-methylphenyl)-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentyl)sulfinylnonyl]thiochroman; (3RS,4RS)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-3-(4-pyridyl)chroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentylsulfonylamino)nonyl]thiochroman; (3RS,4RS)-3-(4-fluorophenyl)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentylsulfinyl)nonyl]thiochroman; (3RS,4RS)-3-(3-fluorophenyl)-7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentylsulfinyl)nonyl]thiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[N-5-(4,4,5,5,5-pentafluoropentylsulfinyl)pentylamino]propyl}chroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl 4-[9-(N-methyl-N-4,4,5,5,5-pentafluoropentyl)aminononyl]chroman; N-methyl-N-(4,4,5,5,5-pentafluoropentyl)-9-[(3RS,4RS)-7-hydroxy-3-4-hydroxyphenyl)-3-methylchroman-4-yl]nonylamine N-oxide; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-{4-[2-(4,4,5,5,5-pentafluoropentylsulfinyl)ethoxy]phenoxy}propyl}thiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[4-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(4,4,5,5,5-penta fluoropentylaminosulfonyl)nonyl]chroman; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid; (3′RS,4′RS)-{8-[7-hydroxy-3-(4-hyroxyphenyl)-3-methylthiochroman-4-yl]octyl}-(4,4,5,5,5-pentafluoropentyl)methane-1,1-dicarboxylic acid; methyl-(3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroma n-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoate; (3′RS,4′RS)-2-{8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]octyl}-2-(4,4,5,5,5-pentafluoropentyl)propane-1,3-diol; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-2-aza-2-carbonyl-1-(4,4,5,5,5-pentafluoropentylamino)ethenyl)aminononyl)thiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-(9-(1-((4,4,5,5,5-pentafluoropentyl)amino)-2-nitroethenyl)amino)nonyl)thiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[8-(4,4,5,5,5-penta fluoropentylsulfonylamino)octyl]chroman; (3RS,4RS)-7-hydroxy-3-(4-(hydroxyphenyl)-3-methyl-4-[4-4-piperidyl -butyl oxy)phenyl]chroman; (3RS,4RS)-7-hydroxy-3-methyl-3-(4-hydroxyphenyl)-444-(3-(2-4,4,5,5,5-pentafluoropentyl sulfinyl)ethoxy)-(R)-2-hydroxypropyloxy)phenyl)chroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{[4-(4,4,5,5,5-penta fluoropentylsulfinyl)butyloxy]butyl}chroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{5-{N-methyl-N-[3-(4,4,5,5,5-pentafluoropentyl)sulfiny]propyl}aminopentyl}chroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{5-{N-methyl-N-oxo-N-[3-(4,4,5,5,5-pentafluoropentyl)sulfiny]propyl}aminopentyl}chroman; (3′RS,4′RS)-2-4-(7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4yl) butyl(4-(4,4,5,5,5-pentafluoropentyl)sulfinyl)hexanoic acid; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-(N-cyano-N-pentylcarbonyl)aminononyl]thiochroman; (3RS,4RS)-7-hydroxy-3-(4-(hydroxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylsulfonylamino)nonyl]chroman; (3′RS,4′RS)-6,6,7,7,7-pentafluoro-2-(2-4-4-(7-hydroxy-3-(4-hydroxyphenyl)-3-meihylchroman-4-yl)butyl)phenyloxy)ethyl)heptanoic acid; (3RS,4RS)-4-allyl-7-methoxy-3-(4-methoxyphenyl)-3-methylthiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{9-[2-(2,2,2-trifluoro ethoxy)ethylsulfinyl]nonyl}thiochroman; (3′RS,4′RS)-8-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]octanoic acid; (3′RS,4′RS)-6-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]hexanoic acid; (3′RS,4′RS)-7-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]heptanoic acid; (3RS,4RS)-4-[4,7-dioxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[6-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[7-oxa-9-4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[5-oxa-9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]thiochroman; (3′RS,4′RS)-9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]nonanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]decanoic acid; (E)-3-[7-hydroxy-3-(4-hydoxyphenyl)-2H-chromen-4-yl]phenylacrylic acid; (3′RS,4′RS)-(E}3-[7-hydroxy-3-(4-hydoxyphenyl)thiochroman-4-ylphenyl acrylic acid; (3RS,4RS)-4-[9-(4-cyanobutylsulfinyl)nonyl]-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman; (3′RS,4′RS)-4-{7-hydroxy-3-methyl-4-[9-(4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]chroman-3-yl benzoic acid; (3′RS,4′RS)-4-{7-hydroxy-3-methylA-[9-4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]chroman-3-yl}benzyl alcohol; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[3-4,4,5,5,5-penta fluoropentylsulfinyl)propylphenoxy]-1-propyl)chroman,; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{3-[3-4,4,5,5,5-penta fluoropentylsulfonyl)propylphenoxy]-1-propyl}chroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl 4-{4-[4-(4,4,5,5,5-penta fluoropentylsulfinylethyloxy)phenyl]-1-butyl}chroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-{4-[4-(4,4,5,5,5-penta fluoropentylsulfonyl -ethyloxy)phenyl]-1-butyl}chroman; (3′RS,4′RS)-1-[7-hydroxy-4-(4-hydroxyphenyl)-3-methylchroman-4-yl]-14,14,15,15,15-pentafluoropentadecan-10-ol; (3RS,4RS)-7-hydroxy-3-methyl-4-[9-4,4,5,5,5-pentafluoropentylsulfinyl) nonyl]-3-(3-pyridyl)chroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-[9-(4,4,5,5,5-pentafluoropentyl sulfinyl)nonyl]chroman; (3RS,4RS)-7-hydroxy-3-{-4-hydroxyphenyl)-4-(9-oxo-11 4,14,15,15,15-penta fluoro)pentadecyl -3-methyl chroman; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-(9-hydroxy-10-hydroxy carbonyl-14,14,15,15,15-pentafluoro)pentadecyl-3-methylchroman; (3RS,4RS)-7-hydroxy-4-[(10-ethoxycarbonyl-14,14,15,15,15-pentafluoro) pentadec-9-enyl]-3-(4-hydroxyphenyl)-3-methylchroman; 1,1,1,2,2-pentafluoro-14-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-5-pentadecanone; (E)-6,6,7,7,7-pentafluoro-2-{9-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]nonyl)-2-heptenoic acid; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methyl-4-[9-4,4,5,5,5-penta fluoropentylsulfonylamino)nonyl]chroman; (3RS,4RS)-(E)-3-{4-[7-hydroxy-3-(4-hydroxyphenyl)thiochromen-4-yl]pheny l)propeneoic acid; (3RS,4RS)-(E)-3-{4-[7-hydroxy-3-(4-hydroxyphenyl)thiochroman-4-yl]pheny l}propene oic acid; (3′RS,4′RS)-(E)-3-{4-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]phenyl}propeneoic acid; (3′RS,4′RS)-N-[2-(4,4,5,5,5-pentafluoropentylsulfinyl)]ethyl-4-{4-[7-hydroxy-3-(4-hydryoxyphenyl)-3-methylchroman-4-yl]butyl}phenyl-N-methylamin; 6-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phe noxy}-2-(4,4,5,5,5-pentafluoropentyl)hexanoic acid; 7-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phe noxy}-2-(4,4,5,5,5-pentafluoropentyl)heptanoic acid; 8-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phe noxy}-2-(4,4,5,5,5-pentafluoropentyl)octanoic acid; 9-{4-[(3RS,4RS)-7-hydroxy-3-{-4-hydroxyphenyl)-3-methylchroman-4-yl]phe noxy}-2-(4,4,5,5,5-pentafluoropentyl)nonanoic acid; (3RS,4RS)-9-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-y-2-(4 4,5,5,5-pentafluoropentyl)nonanoic acid; (3RS,4RS)-9-(7-hydroxy-3-(4-hydroxyphenyl)-3-thiochroman-4-yl-2-(4,4,5,5, 5-pentafluoropentyl)nonanoic acid; (3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-4-{[1-carboxyl-1 1-(4,4,5, 5,5-pentafluoropentyl)]undecyl)-3-methylthiochroman; (3RS,4RS)-10-(7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid; 9-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)nonanoic acid; 8-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)octanoic acid; 7-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylthlochroman-4-yl]phenoxy)-2-(4,4,5,5,5-pentafluoropentyl)heptanoic acid; 6-{4-[(3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl}3-methylthiochroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)hexanoic acid; 5-[4-((3RS,4RS)-7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]phe noxy}-2-(4,4,5,5,5-pentafluoropentyl)pentanoic acid; 5-{4-[(3RS,4RS)-7-hydroxy-344-hydroxyphenyl)-3-methylthiochroman-4-yl]phenoxy}-2-(4,4,5,5,5-pentafluoropentyl)pentanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-4,4,5,5,5-pentafluoropentyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)undecanoic acid; (3′RS,4′RS)-12-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)dodecanoic acid; (3′RS,4′RS)-12-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)dodecanoic acid; (3′RS,4′RS)-9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)nonanoic acid; (3′RS,4′RS)-9-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-4,4,5,5,5-pentafluoropentyl)nonanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4yl]-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(3,3,4,4,4-pentafluorobutyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-3,3,4,4,4-pentafluorobutyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid;. (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-4-yl]-2-6,6,7,7,7-pentafluoroheptyl)decanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2 (3,3,4,4,4-pentafluorobutyl)undecanoic acid; (3′RS,4′-RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(3,3,4,4,4-pentafluorobutyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-methyl-2-4,4,5,5,5-pentafluoropentyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-4,4,5,5,5-pentafluoropentyl)undecanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-methyl-2-4,4,5,5,5-pentafluoropentyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-4,4,5,5,5-pentafluoropentyl)decanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(4,4,5,5,5-pentafluoropentyl)undecanoic acid; (3′RS,4′RS)-1-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(4,4,5,5,5-pentafluoropentyl)undecanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid; . (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(4,4,5,5,5-pentafluoropentyl)decanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxypbenyl)-3-methylchroman-4-yl]-2-methyl-2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid; (3′RS,4′RS)-1-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-methyl -2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-methyl-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl -2-(5,5,6,6,6-pentafluorohexyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid; (3′RS,4′RS)-11-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(6,6,7,7,7-pentafluoroheptyl)undecanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4yl]-2-methyl-2-5,5,6,6,6-pentafluorohexyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-methyl-2-6,6,7,7,7-pentafluoroheptyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4yl]-2-methyl-2-6,6,7,7,7-pentafluoroheptyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(5,5,6,6,6-pentafluorohexyl)decanoic acid; (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylchroman-4-yl]-2-ethyl-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid; and (3′RS,4′RS)-10-[7-hydroxy-3-(4-hydroxyphenyl)-3-methylthiochroman-4-yl]-2-ethyl-2-(6,6,7,7,7-pentafluoroheptyl)decanoic acid.
 4. A compound represented by the following formula (17aa):

pharmaceutically acceptable salt or stereoisomer thereof, in which X is defined as claim 1, A₁₁ is a protecting group selected from a group consisting of t-butyldimethylsilyl, triisopropylsily, triethylsilyl, t-buthyldiphenylmethylsilyl, methoxymethyl, tertahydropyrany and methyl, m₁₁ is an integer of 0 to
 10. 5. A process for preparing the compound of formula (1a):

pharmaceutically acceptable salt or stereoisomer thereof, wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂ and D¹ are defined as claim 1, characterized in that (a) a compound of formula (13):

wherein X, R₃, R₄ and m₁ are defined as claim 1, P represents a hydroxy-protecting group, and W¹ represents a leaving group, is reacted with a compound of formula (14): D³H₂  (14) wherein D¹ is defined as claim 1, to produce a compound of formula (15):

wherein X, R₃, R₄, D¹ and m₁ are defined as claim 1, and P is defined as above, the resulting compound of formula (15) is reacted with a compound of formula (16): W²—(CH₂)_(m) ₂ —R₅  (16) wherein R₅ and m₂ are defined as claim 1, and W² represents a leaving group selected from a group consisting of acyl and hydrogen, and then deprotected to produce a compound of formula (1aa):

wherein X, R₃, R₄, R₅, m₁, m₂ and D¹ are defined as claim 1, or (b) the compound of formula (13) is reacted with sodium cyanide to produce a compound of formula (17):

wherein X, R₃, R₄ and m₁ are defined as claim 1, and P is defined as above, the resulting compound of formula (17) is reacted with a compound of formula (18): H₂N—(CH₂)_(m) ₂ —R₅  (18) wherein R₅ and m₂ are defined as claim 1, in the presence of a Lewis acid to produce a compound of formula (1ab) or (1ac):

wherein X, R₃, R₄, R₅, m₁ and m₂ are defined as claim
 1. 6. A process for preparing the compound of formula (1b):

pharmaceutically acceptable salt or stereoisomer thereof, wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂ and D¹ are defined as claim 1, characterized in that a compound of formula (19):

wherein X, R₃, R₄ and m₁ are defined as claim 1, P represents a hydroxy-protecting group, and W¹ represents a leaving group, is reacted with a compound of formula (20): HD¹-(CH₂)_(m) ₂ —R₅  (20) wherein R₅, m₂ and D¹ are defined as claim 1, and then deprotected to produce a compound of formula (1ba):

wherein X, R₃, R₄, R₅, m₁, m₂ and D¹ are defined as claim
 1. 7. A process for preparing the compound of formula (1c):

pharmaceutically acceptable salt or stereoisomer thereof, wherein X R₁, R₂, R₃, R₄, R₅, m₁, m₂, m₃, n) and D¹ are defined as claim 1, characterized in that a compound of formula (21):

wherein X, R₄, m₁, m₂ and D¹ are defined as claim 1, P represents a hydroxy-protecting group, and W¹ represents a leaving group, is reacted with a compound of formula (22): W²—S—(CH₂)_(m) ₂ —R₅  (22) wherein R₅ and m₃ are defined as claim 1, and W² represents a leaving group selected from a group consisting of acyl and hydrogen, to produce a compound of formula (23):

wherein X, R₄, R₅, m₁, m₂, m₃ and D¹ are defined as claim 1, and P is defined as above, the resulting compound of formula (23) is deprotected and dehydrated to produce a compound of formula (24):

wherein X, R₄, R₅, m₁, m₂, m₃ and D¹ are defined as claim 1, which is then oxidized to produce a compound of formula (1ca):

wherein X, R₅, R₅, m₁, m₂, m₃ and D¹ are defined as claim 1, and n₁′ represents 1 or
 2. 8. A process for preparing the compound of formula (1d):

pharmaceutically acceptable salt or stereoisomer thereof, wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂, m₃, n₁, D¹ and D² are defined as claim 1, characterized in that (a) a compound of formula (13):

wherein X, R₃, R₄ and m₁ are defined as claim 1, P represents a hydroxy- protecting group, and W¹ represents a leaving group, is reacted with a compound of formula (25): HD¹-(CH₂)_(m) ₂ —S(O)_(n) ₁ —(CH₂)_(m) ₃ —R₅  (25) wherein R₅, m₂, m₃, n₁ and D¹ are defined as claim 1, and then deprotected to produce a compound of formula (1da):

wherein X, R₃, R₄, R₅, m₁, m₂, m₃, n₁ and D¹ are defined as claim 1, (b) a compound of formula (15):

wherein X, R₃, R₄, D¹ and m₁ are defined as claim 1, and P is defined as above, is reacted with a compound of formula (26):

wherein n₁ is defined as claim 1, P′ represents a hydroxy-protecting group, W² represents a leaving group selected from a group consisting of acyl and hydrogen, and D2 is the same with D², provided that 1 or 2 hydrogen atoms are excluded therefrom, to produce a compound of formula (27):

wherein X, R₃, R₄, m₁, n₁ and D¹ are defined as claim 1, and D^(7′), P and P′ are defined as above, the resulting compound of formula (27) is condensed with a compound of formula (28): HO—(CH₂)_(m) ₂ —R₅  (28) wherein R₅ and m₂ are defined as claim 1, and then deprotected to produce a compound of formula (1db):

wherein X, R₃, R₄, R₅, m₁, m₂, n₁, D¹ and D² are defined as claim 1, (c) the compound of formula (13) is reacted with a compound of formula (29): W²—S-D²-(CH₂)_(m) ₃ —R₅  (29) wherein R₅, m₃ and D² are defined as claim 1, and W² are defined as above, to produce a compound of formula (30):

wherein X, R₃, R₄, R₅, m₁, m₃ and D² are defined as claim 1, and P are defined as above, the resulting compound of formula (30) is then deprotected and oxidized to produce a compound of formula (1dc):

wherein X, R₃, R₄, R₅, m₁, m₃ and D² are -defined as claim 1, and n₁′ represents 1 or 2, (d) the compound of formula (13) is reacted with a compound of formula (29a): W²—S—D²-(CH₂)_(m) ₅ —R_(5′)—P′  (29a) wherein m₃ and D² are defined as claim 1, P′ and W² are defined as above, and R₅′ is the same with R₅, provided that 1 or 2 hydrogen atoms are excluded therefrom, to produce a compound of formula (30a):

wherein X, R₃, R₄, m₁, m₃ and D² are defined as claim 1, and P, P′ and R₅′ are defined as above, the resulting compound of formula (30a) is then deprotected and oxidized to produce the compound of formula (1dc), (e) the compound of formula (13) is reacted with sodium azide and then reduced to produce a compound of formula (31):

wherein X, R₅, R and m₁ are defined as claim 1, and P is defined as above, the resulting compound of formula (31) is reacted with a compound of formula (32): W²—SO₂—(CH₂)_(m) ₅ —R₅  (32) wherein R₅ and m₃ are defined as claim 1, and W² is defined as above, and then deprotected to produce a compound of formula (1dd):

wherein X, R₃, R₄, R, m₁ and m₃ are defined as claim 1, (f) the compound of formula (31) is reacted with a compound of formula (32a): OHC(CH₂)_(m) _(2′) —S(O)_(n) ₁ —(CH₂)_(m) ₃ —R₅  (32a) wherein R₅, m₃ and n₁ are defined as claim 1, and m₂′ equals m₂−1, and then deprotected to produce a compound of formula (1de):

wherein X, R₃, R₄, R₅, m₁, m₂, m₃ and n₁ are defined as claim 1, (g) a compound of formula (33):

wherein X, R₃, R, m₁, m₂ and D′ are defined as claim 1, and W′ and P are defined as above, is reacted with the compound of formula (22): W²—S—(CH₂)_(m) ₃ —R₅  (22) wherein R₅ and m₃ are defined as claim 1, and W² is defined as above, to produce a compound of formula (34):

wherein X, R₃, P₄, R₅, m₁, m₂, m₃ and D′ are defined as claim 1, and P is defined as above, the resulting compound of formula (34) is then deprotected and oxidized to produce a compound of formula (1df):

wherein X, R₃, R₄, R₅, m₁, m₂, m₃ and D′ are defined as claim 1, or (h) a compound of formula (35):

wherein X, R₃, R₄, m₁ and n₁ are defined as claim 1, and W′ and P are defined as above, is reacted with a compound of formula (36): P′—D²-(CH₂)_(m) ₃ —R₅  (36) wherein R₅, m₃ and D² are defined as claim 1, and P′ is defined as above, and then deprotected to produce a compound of formula (1dg):

wherein X, R₃; R₄, R₅, m₁, m₃, n₁ and D² are defined as claim
 1. 9. A process for preparing the compound of formula (1e):

pharmaceutically -acceptable salt or stereoisomer thereof, wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂, m₃, n₁ and n₂ are defined as claim 1, characterized in that a compound of formula (13):

wherein X, R₃, R₄ and m₁ are defined as claim 1, P represents a hydroxy- protecting group, and W′ represents a leaving group, is reacted with a compound of formula (37): W³S—(CH₂)m₂-S(O)n₂-(CH₂) m₂-R₅  (37) wherein R₅, m₂, m₃ and n₂ are defined as claim 1, and W³ represents acyl group, and the resulting compound is then deprotected and oxidized to produce a compound of formula (1ea):

wherein X, R₃, R₄, R₅, m₁, m₂, m₃, n₁ and n₂ are defined as claim
 1. 10. A process for preparing the compound of formula (1k):

pharmaceutically acceptable salt or stereoisomer thereof, wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂, m₃, n, and D¹ are defined as claim 1, can be prepared by a process characterized in that a compound of formula (13):

wherein X, R₃, R₄ and m₁ are defined as claim 1, P is represents a hydroxy-protecting group, and W¹ represents a leaving group, is reacted with a compound of formula (44): W³S—(CH₂)m₂-D¹-(CH₂)m₅—R₅  (44) wherein R₅, m₂, m₃ and D¹ are defined as claim 1, and W³ represents acyl group, and the resulting compound is then deprotected and oxidized to produce a compound of formula (1ka):

wherein X, R₄, R₄, R₅, m₁, m₂, m₃, n₁ and D¹ are defined as claim
 1. 11. A process for preparing the compound of formula (11):

pharmaceutically acceptable salt or stereoisomer thereof, wherein X, R₁, R₂, R₃, R₄, R₅, m₁, m₂, m₃ and D¹ are defined as claim 1, can be prepared by a process characterized in that a compound of formula (45):

wherein X, R₃, R₄, and m₁ are defined as claim 1, and P represents a hydroxy-protecting group, is reacted with a compound of formula (46): W¹(CH₂) m₂W²  (46) wherein m₂ is defined as claim 1, W¹ represents a leaving group, and W² represents a leaving group selected from a group consisting of acyl and hydrogen, to produce a compound of formula (47):

wherein X, R₃, R₄, m₁, and m₂ are defined as claim 1, and W² and P is defined as above, the resulting compound of formula (47) is reacted with a compound of formula (14): D¹H₂  (14) wherein D¹ is defined as claim 1, to produce a compound of formula (48):

wherein X, R₃, R₄, m₁, m₂ and D¹ are defined as claim 1, and P is defined as above, the resulting compound of formula (48) is reacted with a compound of formula (16a): W⁵—CH₂)m₃—R₅  (16a) wherein R₅ and m₃ are defined as claim 1, and W¹ represents a leaving group and then deprotected to produce a compound of formula (11a):

wherein X, R₃, R₄, R₅, m₁, m₂, m₃ and D¹ are defined as claim
 1. 12. An anti-estrogenic pharmaceutical composition containing as an active component the compound of formula (1), pharmaceutically acceptable salt or stereoisomer thereof according to anyone of claim 1 to 3 together with a pharmaceutically acceptable carrier.
 13. The anti-estrogenic composition of claim 12 which is used for the treatment of breast cancer. 